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Abstract
Thirteen novel Schiff base complexes have been successfully synthesised
through reactions of substituted benzophenones with different diamines in the
presence of nickel(II) acetate. These precursor complexes then were successfully
alkylated using 1-(2-choroethyl)piperidine hydrochloride to form a series of novel
nickel complexes bearing dimethylenepiperidine pendant groups. The nickel
complexes with the pendant groups were sufficiently soluble in water to enable them
to be used in DNA binding experiments. All new complexes were fully characterised
using NMR spectroscopy, Electrospray Ionisation Mass Spectrometry (ESI-MS) and
elemental microanalysis. In addition, the solid state structures of eight complexes
were determined using X-ray crystallography.

Various techniques including ESI-MS, Circular Dichroism (CD), UV-Vis
spectrophotometry, Fluorescence Indicator Displacement (FID), Fluorescence
Resonance Energy Transfer (FRET) melting assays and molecular docking were
employed to investigate the effects of structural variations amongst the nickel Schiff
base complexes on their DNA binding properties. DNA binding studies were
performed using the tetramolecular G-quadruplex Q4, the unimolecular Gquadruplexes Q1 and c-kit1, the fluorescently labelled unimolecular G-quadruplex
F21T, and the double stranded DNA molecule D2. Experiments involving Q1 were
performed after it was annealed under specific conditions to afford parallel, antiparallel and hybrid topologies. The results of DNA binding studies indicated that
varying the number of pendant groups appended to the Schiff base scaffold resulted
in the largest changes to DNA affinity and selectivity. For example, complex (89),
carrying four pendant groups exhibited strong affinities towards many kinds of Gii

quadruplex DNA, including parallel Q4 and Q1, anti-parallel Q1, c-kit1 and antiparallel F21T.

DNA binding studies performed using five isomeric nickel Schiff base
complexes containing two pendant groups in different locations also showed
significant variations in the strength of interactions with some G-quadruplexes, such
as parallel Q4, parallel c-kit1, and anti-parallel F21T. Modifying the diamine moieties
in the top half of the nickel Schiff base complexes, and introducing asymmetry into
their structures, resulted generally in smaller changes to DNA affinities and
selectivities.
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Chapter 1 : Introduction
1.1 DNA replication and cancer
According to statistics from the World Health Organisation, in 2011 the global
mortality rate from cancer had surpassed the number of heart disease victims, and is
predicted to increase to an estimated 20 million new cancer patients every year by
2025.[1] It has long been understood that cancer is a disease involving the abnormal
development of cells, which exhibit suppressed damage repair mechanisms within
the cell and stimulate genetic instability. These conditions lead to cellular
malignancy, and potentially to the onset of metastasis, whereby abnormal cells
spread away from the primary tumour and to the rest of the whole body.[2, 3] The
search for new cancer therapies faces a great number of challenges, as cancer cells
have the ability to bypass cellular senescence mechanisms, and continue to
proliferate by uncontrolled multiplication. This is in contrast to the restricted number
of division cycles that ordinary somatic cells experience.[4-6] Owing to this difference
between normal and cancer cells, many attempts have been made to remove the
mechanisms that confer immortality upon cancer cells. These studies have provided
enormous insight into the cell division and DNA replication processes.
DNA replication is a complex process by which two new DNA strands are
produced from the two complementary DNA strands in a double stranded DNA
(dsDNA) molecule. The mechanism of the DNA replication process is illustrated in
Figure 1.1. Genetic material encoded within the sequence of bases of DNA is
reproduced by a process in which the duplex DNA is first unwound by a DNA
helicase, in order to make available the nucleotides that serve as templates for
replication.[7] On each strand, the DNA primase enzyme commences replication by
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creating a short, complementary RNA primer which is aligned to the template, and
which is able to be extended by DNA polymerase. As DNA polymerase can only add
nucleotides to an existing strand of DNA in the 5´ to 3´ direction, it therefore adds
bases continuously only to what is known as the leading template strand.[8]
Synthesis of a new polynucleotide molecule that is complementary to the lagging
template strand, however, is not a continuous process. Instead the synthesis results
in short sections of newly synthesised DNA called Okazaki fragments which are
subsequently linked together by the DNA ligase enzyme in a maturation process.[7,
9] As DNA replication continues DNA primase is unable to bind to the terminus of the
lagging strand, preventing further synthesis of the complementary polynucleotide
chain.[8] With each cycle of cell division approximately 50 – 100 base pairs are
therefore lost from the lagging strand owing to this “end-replication problem”.[10]

DNA
polymerase 

DNA
polymerase 
RNA primer
DNA primase

3´
Topoisomerase

Lagging
strand

3´

5´
DNA ligase
Okazaki fragment
5´

5´

Leading
strand

Parent DNA
3´

DNA helicase

DNA polymerase 

Figure 1.1 DNA replication showing the discontinuous synthesis of new DNA on the lagging
template strand. Adapted from various references.[7-9]
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To minimize the potential loss of vital genetic information caused by the endreplication problem, the ends of eukaryotic chromosomes are comprised of repeating
DNA sequences named telomeres, which do not contain the code for any
proteins.[11, 12] Nonetheless, after a number of cell division cycles, the length of the
telomeres reaches a critical length, at which point apoptosis, or programmed cell
death is induced.[13]
However, unlike normal cells, cancer cells are believed to avoid this apoptosis
signaling mechanism, therefore rendering them effectively immortal.[14] One reason
for this is that most cancer cells over-express a ribonucleoprotein enzyme named
telomerase, which is able to extend the length of telomeric segments.[15] The
hypothesis that telomerase plays an important role in the malignancy of cancer cells
has been supported by a large number of experiments during the 1990s. These
discoveries have led to a new approach to the development of anticancer
treatments.[5]

1.2 Telomeres, telomerase and their role in cancer cell growth
Even though the role of telomeres in protecting the end of chromosomes had
been acknowledged for a long time, the mammalian telomeric sequence has only
been identified more recently.[5, 16] It is now known to consist of tandem repeats of
TTAGGG, and be 10 – 15 kilo-base pair (kbp) in length.[17] Telomeres effectively act
as a biological clock, which allows human foetal cells to divide only 40 – 70 times
during a typical lifespan.[18, 19] Telomeric DNA regions are bound to the various
shelterin protein molecules to form a stable complex that inhibits DNA repair systems
from acting on the telomere. The shelterin proteins include the Protection of
Telomeres Protein 1 (POT1) and Telomeric Repeat-binding Factor 1 (TRF1).
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Together with the other telomeric proteins, these molecules protect chromosomes
from deterioration and telomere-telomere fusion events, by forming an unusual Tloop configuration shown in Figure 1.2 a.[20] The T-loop is formed by using the
telomeric single strand overhang, which contains 150 – 200 nucleobases, to invade
the telomeric double stranded region, and create a displacement loop, or D-loop, at
the invasion site.[6] Before DNA replication occurs, this T-loop structure is opened
and the ssDNA overhang at the 3´-terminal becomes accessible for extension by
telomerase (Figure 1.2 b).[20]
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Figure 1.2 Telomere structure:(a) T-loop configuration showing different telomeric length
regulation proteins, including Telomeric Repeat-binding Factor 2 (TRF2), RepressorActivator Protein 1 (RAP1), TRF1-interacting nuclear protein 2 (TIN2) and TripeptidylPeptidase 1 (TPP1); and (b) Stretched configuration observed during telomere elongation
process, showing some of the components of telomerase including Telomerase Reverse
Transcriptase (TERT) and Telomerase RNA (TERC). Adapted from various references.[2022]
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Telomerase elongates telomeric DNA sequences,[19] and was discovered in
1985.[23] It is a protein complex consisting of two core components. These are a
catalytic subunit called Telomerase Reverse Transcriptase (TERT), and a
Telomerase RNA component (TERC) which is a non-coding RNA sequence
(AAUCCC in mammals) that serves as a template for telomere replication.[20]
Recently, cryo-electron microscopy studies have shown that the structure of
telomerase is comprised of two flexible tethered lobes. In one lobe, the RNA wraps
around TERT to form an organised tertiary structure for the catalytic core whereas
the other lobe is an H/ACA ribonucleoprotein.[24] Purification and crystallization of
telomerase has proved to be extremely challenging owing to its insolubility and low
abundance.[25] Telomerase is highly upregulated in embryonic stem cells in order to
help preserve genomic stability during a large number of cell division cycles.[20] It
has also been found in other cells which divide regularly such as sperm cells,[6]
epidermal cells and bone marrow.[26] In contrast, telomerase is inactive in most
somatic cells, which form the majority of tissues in the human body.[6] Intriguingly,
Wright and co-workers showed that transfecting human cells with a vector encoding
the hTERT protein allowed the cells to surpass their normal lifespan by at least 20
more cell division cycles.[18, 27] In addition, a correlation between overexpression of
telomerase and uncontrolled cellular growth has been observed in numerous types
of cancer cells. For example, it was reported in 1994 that telomerase was overexpressed in over 85% of cancer cell types, but in only a small proportion of
specialized, normal healthy cells.[28] These observations together suggest that
inhibition of telomerase might be a promising approach for the development of new
cancer therapeutics.
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It is a somewhat contradictory observation that normal cells with significantly
low levels or a complete absence of telomerase have telomeres that are much
longer than those in cancer cells which generally have significantly higher levels of
the enzyme. This discrepancy, however, may be explained by examining the
pathway by which malignant tumors are formed from normal cells (Figure 1.3).[19]
Depending on the living habits of different individuals, and the rate of mitosis in the
cell cycle, the length of telomeres in normal cells is gradually shortened by
approximately 15 – 28 base pairs per year. This continues until the telomeric DNA
reaches the critical length of 4 – 6 kbp. At this point, the cells enter senescence
which is called mortality stage 1 (M1) or the Hayflick limit.[5, 17, 29] The shortened
and therefore defective telomeres trigger a DNA damage response (DDR) by
activating

number

of

upstream

kinases

such

as

DNA-dependent

protein

(DNA-PKcs), Ataxia Telangiectasia Related protein (ATR) or Ataxia Telangiectasia
Mutated protein (ATM). The activity of these enzymes then leads the cell towards the

Mean telomere length (kbp)

first growth arrest stage.[20]
Healthy cells
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Figure 1.3 The role of telomere length in the development of cancer cells. Adapted from
various references.[5, 19]
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Premalignant cells, however, have acquired a number of oncogenic mutations
that enable the cells to escape the M1 checkpoint, by deactivating tumor suppressor
genes such as p53 and p16.[6, 29] The proliferation rate of premalignant cells also
decreases as their telomeres shorten, leading eventually to mortality stage M2 (the
second growth arrest or crisis stage). Entry of cells to this stage is followed by
rampant genetic instability, merging of chromosome ends and extensive cell
death.[5] As a consequence the majority of premalignant cells are restrained from
proliferating further at this point, but on some occasions a cell can bypass this
checkpoint and become effectively immortal. This generally involves the upregulation
or reactivation of telomerase, or in much rarer cases, the alternative lengthening of
telomeres

(ALT) pathway

which

involves

homologous

DNA

recombination

mechanisms.[18, 25] Irrespective of the exact mechanism, most cells which escape
the M2 crisis point have stable but short telomeres, as well as excessive telomerase
activity. These features are now considered to be the major hallmarks of cancer.[5]

1.3 Telomeres and telomerase as potential therapeutic targets for
cancer treatment
There are several telomere or telomerase based anticancer therapies currently
in different phases of development. These are illustrated in Figure 1.4, and include:
(A) direct telomerase inhibition, (B) telomerase interference, (C) TERT or TERC
promoter driven strategies, (D) telomerase-based immunotherapy and (E) telomerebased approaches.[19, 29] The following sections will discuss each of these
approaches.
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Figure 1.4 Various telomere/telomerase based strategies for killing cancer cells:(A) Direct
telomerase inhibition using an oligonucleotide (Imetelstat) to bind to the TERC template; (B)
Telomerase interference using reprogrammed telomerase to add mutant telomeric DNA that
evokes a DNA-damage response; (C) TERT promoter driven adenovirus genes in an
oncolytic virus inducing cellular lysis in cancer cells by viral replication; (D) Telomerase
vaccines inducing cytotoxic T lymphocytes; and (E) Telomere-based approach using Gquadruplex stabilisers to prevent telomerase from interacting with its 3´ overhang substrate.
Adapted from various references.[19, 20, 29]

A. Direct telomerase inhibition: This approach involves the use of small
molecules

such

as

2-[(E)-3-naphthalen-2-yl-but-2-enoylamino]-benzoic

acid

(BIBR1532) (Figure 1.5 (a)) to directly inhibit the activity of telomerase by targeting
one of its critical regions.[30] This compound had been shown previously via in vitro
and in vivo studies to exhibit a high degree of selective inhibition of telomerase in
leukemia cells, compared to normal stem cells.[30] Recently, Bryan and co-workers
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showed that BIBR1532 binds to the thumb domain of TERT, thereby obstructing
TERT-TERC assembly and inhibiting the activity of telomerase.[31] However,
despite the promising results obtained during preclinical testing, BIBR1532 has not
yet

entered

into

clinical

trials.[32]

Another

approach

involves

modified

oligonucleotides such as 5´-TAGGGTTAGACAA-3´ (GRN163L; Imetelstat, Figure
1.5 b), which was designed by Geron Corporation in 2003.[33] Imetelstat interferes
with TERC/TERT interactions, by directly binding to TERC,[33] and was found to
induce telomere shortening in vitro, resulting in DNA damage and cell death in brain,
bladder, prostate, lung, liver and breast cancer cells. This has led to clinical studies
for a range of cancer types.[29]

(a)

(b)

Figure 1.5 Examples of direct telomerase inhibition agents:(a) BIBR1532; (b) Imetelstat.

Although Imetelstat is the most promising candidate for this kind of therapeutic
approach, it has not produced notable results in phase I trials for breast cancer or
phase II trials for non-small-cell lung cancer (NSCLC).[34] Full details of the
mechanism by which Imetelstat operates are still not clearly understood, since there
is no direct or clear correlation between the response of patients in clinical trials and
the variation of telomere length in their cancer cells after treatment. The explanation
for why there is a therapeutic response in some patients whereas others do not show
a response is also not clear.[29] In addition, both small molecule and oligonucleotide
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based approaches require a long treatment period in order to induce cell death,
during which malignant tumours can continue to grow, thereby intensifying the risk of
side effects from anticancer drugs.[18]
B. Telomerase interference: This approach to cancer therapy centres on
interference with the telomerase expression process, and subsequent blocking of the
biogenesis functions of telomerase. This can be achieved through the use of altered
RNA template sequences for TERC, such as the Mutant-Template human
Telomerase 47A (MT-hTer-47A).[35, 36] In one such study, mutant TERC templates
were transfected into cancer cells using lentiviral vectors, resulting in DNA mutations
located in telomeric regions.[35, 36] As telomerase could not successfully use these
abnormal template sequences, telomere shortening occurred which triggered the
DNA damage response, and finally induced senescence and apoptosis in vitro.[35]
Even though this approach has shown a promising ability to eliminate various cancer
types in vitro, the accurate expression and introduction of mutant TERC into cancer
cells remains an enormous challenge before in vivo evaluation of this approach can
commence.[29]
C. TERT/TERC promoter driven strategies: In the majority of benign cells the
hTERT genes are inactive, since the DNA promoters initiating transcription of TERT
and TERC proteins are deactivated. However, during cancer cell development,
specific hTERT promoters are mutated, leading to increased transcription of hTERT
and overexpression of telomerase.[18] These observations highlight the potential of
therapeutic strategies that selectively target DNA promoter regions, by using either
oncolytic virus or suicide gene therapy to infect the cancer cells with engineered
adenovirus vectors. Adenovirus genes in the oncolytic virus particles directly induce
cellular lysis in cancer cells by viral replication. In comparison, in the suicide gene
10

therapy approach, an enzyme named nitroreductase is produced. This enzyme
converts prodrugs such as CB1954 into active cytotoxic molecules that have been
shown to cause cell death in different cancer cell lines.[37] The most promising
candidate to emerge from oncolytic virus therapy studies is OBP-301 which has now
entered a phase I clinical trial for hepatocellular carcinoma.[38] In contrast, suicide
gene therapy drugs are yet to reach clinical trials.
D. Telomerase-based immunotherapy: Tumor-Associated Antigens (TAAs)
are substances generated in tumor cells that stimulate an immune response in
patients. They include peptides and protein fragments derived from the degradation
of telomerase by proteasomes that are present on the cancer cell membrane. TAAs
are recognised via the human leukocyte antigen (HLA) class I pathway, leading to
the release of cytotoxic T cells which can then kill tumor cells.[18] The existence of
TAAs in some malignant cells was discovered in the early 1990s, and has now led to
a novel immunotherapeutic approach for cancer treatment.[39] Telomerase
immunotherapy could be conducted by an in vivo approach involving immune system
activation by using injectable peptides such as GV1001. Alternatively, it could be
performed using an ex vivo approach in which the dendritic cells of patients are
collected and transduced outside the body with mRNA encoding hTERT,[18] and
subsequently introduced back into patients via intradermal injections.[29] Several
promising examples of this therapeutic approach are currently being tested in clinical
trials.[18] Despite this, it must be remembered that immunotherapy approaches to
cancer treatment are generally hampered by the low concentration of telomerase
present even in cancer cells.[29, 40]
E. Telomere-based approaches: These strategies involve the use of telomere
targeting agents such as XAV939, JW55 (Figure 1.6) to interfere with telomeric
11

regions, rather than directly interrupting the activity of telomerase. Therefore, these
therapies may even be successful for cancer cells which are telomerase-negative, as
the latter can preserve telomere length through the ALT pathway.[29] One approach
of this kind involves inhibiting the activity of tankyrase, a poly-ADP ribose
polymerase (PARP) protein which plays an important role in the regulation of
telomere length. When tankyrase is over expressed in the nucleus of cells, TRF1 is
separated from the telomere, and then degraded by a ubiquitin-mediated
pathway.[41] This suggests that inhibition of tankyrase will help to maintain the
association between TRF1 and telomeres in the T-loop structure, thereby preventing
the elongation of telomeric sequences.[29]

(a)
(b)

(c)
(d)
Figure 1.6 Examples of tankyrase inhibitors:(a) XAV939; (b) JW55; (c) flavone; (d) IWR1 (R1
= H) and IWR2 (R1 = CH3).

Many small molecules such as IWR1, IWR2, and flavone shown in Figure 1.6,
have been shown to effectively inhibit tankyrase expression,[42] however, none of
them has yet produced promising results in clinical trials. These approaches also
involve transfecting malignant cells with an 11-mer oligonucleotide (T-oligo) that is
analogous to the 3´-single stranded overhang present in telomeres in order to
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simulate the telomere uncapping process, and elicit a DNA damage response
followed by cell growth arrest and apoptosis.[29]
In another example of a telomere-based approach, it has been shown that
telomerase functions most effectively when the DNA substrate is present in a double
helical or single strand DNA (ssDNA) structure.[19] In view of this observation, and
the strong correlation between telomerase activity and cancer cell growth, it is
reasonable to suggest that inducing telomeric DNA sequences to form other types of
secondary structures such as quadruplex DNA (qDNA or G-quadruplex DNA), may
prevent telomerase from interacting with its normal substrate (Figure 1.7).[15, 43]
This would remove the pathway by which cancer cells become effectively “immortal”,
thereby making them more susceptible to conventional

cancer treatment

methods.[43]
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Figure 1.7 Inhibition of telomerase activity via stabilisation of G-quadruplex DNA structures
in the enzyme’s substrate. Adapted from various references.[20, 22, 44]
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The validity of the above approach has been shown by a number of
investigations, and recently several G-quadruplex stabilising agents have emerged
as promising candidates for telomere-based therapy. Many of these compounds
show an ability to stabilise G-quadruplex structures formed from proto-oncogenes,
e.g. pyridostatin (Figure 1.8 a),[45] or downregulate the expression of oncogenes
which are involved in telomere maintenance, e.g. MM41 (Figure 1.8 b).[46] Some of
these compounds have been shown to intensify cancer cell senescence in vitro, e.g.
RHPS4 (Figure 1.8 c),[47] or induce shrinkage of xenotransplantation tumors in vivo,
e.g. quarfloxin (Figure 1.8 d).[48]

(a)

(b)

(c)

(d)

Figure 1.8 Examples of qDNA stabilising compounds:(a) pyridostatin; (b) MM41; (c) RHPS4;
(d) quarfloxin.
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To date, quarfloxin is one of the most successful G-quadruplex stabilising
compounds, and was the first such drug to enter phase I and II clinical trials for
cancer treatment.[29, 49] It should be noted that quarfloxin was originally designed
as a c-myc quadruplex stabilising agent. However, it subsequently was shown to
prefer acting on putative quadruplex sequences of ribosomal DNA (rDNA), leading to
a significant decrease in tumor cell volume in xenograft models of MIA-PACA-2
pancreatic cancer and MDAMB- 231 breast cancer.[48, 49]

1.4 Quadruplex DNA
Guanine-rich

oligonucleotide

sequences

have

been

long

known

to

self-assemble, creating various secondary structures in living organisms.[43] In
1962, Davis and co-workers found that one such structure was formed when
solutions containing either 5´-guanosine monophosphate (GMP) or 3´-GMP were
cooled.[50, 51] These DNA secondary structures were formed by stacking of
guanine tetrads (G-tetrads) on top of each other, with each tetrad consisting of a
planar arrangement of four guanine residues, linked together by eight Hoogsteen
hydrogen bonds (Figure 1.9).

Figure 1.9 The square planar structure of a G-quartet, the fundamental building block of all
G-quadruplex structures. M+ represents a stabilising monovalent cation.[52]

15

The stability of a stacked array of G-tetrads, such as those shown in
Figure 1.10, arises from electrostatic interactions between small potassium or
sodium ions,[53] which are located in the central channel in the middle of the
G-tetrads, and the carbonyl oxygen atoms of the guanines.[54] The ability of the
above cations to stabilise an array of stacked G-tetrads follows the order: K+ > Ca2+ >
Na+ > Mg2+ > Li+. This sequence suggests that K+ has the strongest propensity for
forming and stabilizing G-quadruplex structures.[55]

Figure 1.10 Schematic illustrations of different G-quadruplex topologies: (a) Tetramolecular
parallel; (b) Tetramolecular antiparallel; (c) Bimolecular parallel with external loops; (d)
Bimolecular antiparallel with lateral loops; (e) Unimolecular parallel with external loops
(propeller-type); (f) Unimolecular antiparallel with lateral loops (chair-type); (g) Unimolecular
antiparallel with lateral and diagonal loops (basket-type); (h) Unimolecular hybrid 3-1. The
arrows show the orientation of the DNA strands.[43, 50, 52, 56-59]

G-quadruplex structures occur with a diverse range of topologies, which can be
distinguished using techniques such as nuclear magnetic resonance (NMR)
spectroscopy, circular dichroism (CD) spectroscopy and X-ray crystallography.[50]
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These different topologies vary in the number of DNA strands present in the
structure, the direction of the strands and the identity of the loops connecting the
strands. For example, four equivalent G-rich DNA strands can arrange themselves to
form tetramolecular quadruplexes with either parallel or antiparallel structures
(Figure 1.10 a, b).[56, 60-63] The existence of parallel tetramolecular quadruplexes
with composition (TTGGGGGT)4 was proven in previous studies.[64] Two guaninerich DNA strands also have a capability to fold and form bimolecular G-quadruplex
structures (Figure 1.10 c, d).[56, 65, 66] Finally, there are other topologies in which a
single DNA strand containing a number of guanine-rich sequences, for example 5´AGGG(TTA GGG)3-3´, can fold to form either a parallel (Figure 1.10 e), antiparallel
(Figure 1.10 f, g) or hybrid unimolecular G-quadruplex (Figure 1.10 h).[56, 67, 68]
Guanine-rich DNA sequences are pervasive throughout the genetic material of
human beings. For example, bioinformatics studies revealed that approximately
370,000 sequences, which may form G-quadruplex structures, are present in the
human genome.[69] While many of these DNA sequences are, not surprisingly,
found in the telomeric regions of chromosomes, other G-rich regions have been
discovered in many oncogene promoter segments, which are implicated in abnormal
cell growth. This includes the vascular endothelial growth factor (VEGF),[70] cytokine
receptor (c-kit),[71] and c-myc promoters.[72] In these genetic regions, the formation
of G-quadruplexes would interfere with the interactions of telomere-binding proteins,
thus influencing their biological activities.[73]
The important role of telomerase in tumourigenesis, combined with the effects
that the presence of G-quadruplex structures in the enzyme’s substrate may have on
telomerase activity, hints at a new approach to cancer therapies. In the following
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sections the different classes of compounds that have been examined for their ability
to induce formation of, or stabilise existing G-quadruplex structures are reviewed,
together with their anti-telomerase activity.

1.5. An overview of G-quadruplex DNA binding agent
Since the potential of G-quadruplex structures as novel targets for anticancer
therapies was first identified, a large number of small molecules have been reported
to possess high affinity towards telomeric DNA and the ability to interfere with
telomere function.[46] The search for G-quadruplex binding agents began with
organic compounds, however, there has been a rapid increase in number of
publications reporting on metal compounds with these properties over the last
decade.[54] To date, the design of G-quadruplex binding agents has generally
focused on electrostatic and -stacking approaches.[46, 54, 74] The overall strength
of electrostatic interactions depends on the magnitude of the cationic charge present
on the organic compound or metal complex. One way of increasing this has been to
modify the attached ligands including introduction of N-methyl groups, or amine
substituents that can be protonated in aqueous solution.[54, 74] In order to enhance
-stacking interactions, researchers often incorporate planar, polyaromatic structures
into their G-quadruplex binding agent, whilst trying to ensure that it retains sufficient
aqueous solubility.[49, 74] Table 1.1 presents a summary of results collected from
selected studies into the G-quadruplex binding properties and telomerase inhibition
activity of a number of metal complexes and organic molecules.
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Table 1.1 G-quadruplex binding characteristics of selected compounds.[43]
Ligands

qDNA
Topology
a
studied

BRACO-19

(ii): (ref[75]);
(iii)

TMPyP4

(iv), (v), (vi):
(ref [77]); (i)

Se2SAP

(iv), (v), (vi)

Telomestatin

(iii)

(19)

(iii)

(24)

(iv), (v), (vi)

(26)

(iii)

(29)

(iv), (vi)

(30)

(v), (vi)

(42)

(i), (iii)

o

Association or
dissociation
constant with
a
qDNA

qDNA/
dsDNA
e
selectivity

Tm
a,h
(°C)

Telomerase
inhibition (EC50
n
or IC50)
(M)

Ref

-----

-----

(iii), 27.5

0.113 ± 0.001

[76]

5.1

(iii), 25
(ref [77])

8 ± 2 M
(ref [78])

[79]

38.8

-----

-----

[80]

f

~ 70 (ref
[81])

(iii),
~
37.3

0.005 (ref [82])

[83]

10,000

-----

0.580

[84]

6.8

(v), 24.8

0.23 ± 0.05

[85]

100 – 5000

-----

~ 80

[86]

> 10

-----

-----

[87]

63.6

(v), 21.3

1.52 ± 0.31

[88]

~ 800

(iii), 14

0.76

[89]

7

(i), Ka = 1.38 x 10
-1 b
M
7
(iii), Kb = 6.2 x 10
-1 b
M
-----

i

9

(48)

(iii)

(49)

(iv), (v), (vi)

(52)

(iv), (v), (vi)

(54)

(iv), (v)

(61)

(ii), (iv), (v),
(vi)

(66)

(iii)

(67)

(iv), (v), (vi)

(iii), Ka = 1 x 10
-1 b
M
(iii), Ka = 2.77 x
7
-1 b
10 M
(iii), KD = 0.002
c
M
(iii), KD = 0.4 ± 0.2
b
M
(iii), Ka = 1.94 x
6
-1 b
10 M
(iii), Ka = 9.7 ± 1.1
7
-1 d
x 10 M
----6
(iii), Ka = 1.2 x 10
-1 b
M
(iii), Ka =7.97 x
6
-1 d
10 M
(iii), Ka =1.27 x
7
-1 d
10 M
(iii), KD = 0.37 ±
b
0.04 M
(iii), Kb = 1.72 ±
5
-1 d
0.04 x 10 M
(iii), Kb = 2.16 ±
6
-1 d
0.57 x 10 M

g

j

k

l
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(iii), 15.3

-----

[90]

~3

-----

-----

[91]

118.8

(iii), 16.9

-----

[92]

1417

(iii), 29.5
± 0.4

0.14 ± 0.01
(ref [93])

[94]

11.1

(iii),~ 25

i

0.70 ± 0.04

[95]

9

-----

4.4

[96]

48.8

-----

0.2

[97]

m

a

Topologies of qDNA: (i) tetramolecular parallel, (ii) bimolecular parallel, (iii) could be any
conformations of unimolecular, (iv) unimolecular parallel, (v) unimolecular antiparallel, (vi)
unimolecular hybrid, (see the illustration of these topologies in Figure 1.10).
b
Value measured by surface plasmon resonance (SPR).
c
Value measured by fluorescence binding assay.
d
Value measured by UV-vis spectroscopy.
e
Value measured by dissociation or binding constant, otherwise indicated.
f
Value measured by polymerase stop assay.
g
Value measured by FID assay.
h
Value measured by FRET assay using 0.2 M oligonucleotide and 1M compound, otherwise
indicated.
i
Value measured by FRET assay using 0.2 M oligonucleotide and 0.5 M compound.
j
Value measured by UV thermal melting using 1 M oligonucleotide and 5 M compound.
k
Value measured by CD thermal melting using 10 M oligonucleotide and 50 M compound.
l
Value measured by UV thermal melting using 20 M oligonucleotide and 20 M compound.
m
Value measured by CD thermal melting using 5 M oligonucleotide and 10 M compound.
n
Value measured by telomeric repeat amplification protocol (TRAP) assay and its variants.
o
All values were obtained from the same reference, otherwise indicated.
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1.5.1 Organic qDNA binding agents
It has been consistently shown that effective organic G-quadruplex binding
agents share a planar aromatic framework, which enables them to participate in stacking interactions with the surface of a G-tetrad. In addition, cationic groups, such
as positively charged amino side-chains, are often present around the periphery of
the central aromatic framework.[74] This was the basic design approach employed
by Neidle et al., who prepared a variety of derivatives of fluorenone,[98]
anthraquinone,[98] acridine,[99] and acridone,[100] with the above structural
features in mind, and examined their ability to act as G-quadruplex binding agents
and telomerase inhibitors. One of the compounds examined, the trisubstitutued
acridine BRACO-19 (Figure 1.11 (a)) was reported to have an excellent ability to
inhibit telomerase activity both in vitro and in vivo.[101]

(a) BRACO-19.

(b) TMPyP4.

(c) Se2SAP.

(d) Telomestatin.

Figure 1.11 Some notable organic G-quadruplex binding molecules.[75, 80, 82, 102]
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The side arms of BRACO-19 were observed to bind within the grooves of
bimolecular parallel G-quadruplexes, and the flexible loops of the latter were
considered to be likely to alter their shape in response to the presence of the drug in
order to maximize the stability of the new DNA-drug structure.[75] This study showed
that the loops and grooves of G-quadruplex structures can play a significant role in
DNA binding interactions, and are therefore useful structural targets in the design of
new G-quadruplex-interactive agents.[43]
The

tetra-alkylated

porphyrin

derivative

5,10,15,20-tetra-(N-methyl-4-

pyridyl)porphine (TMPyP4, Figure 1.11 b) is an important example of another family
of G-quadruplex-binding organic molecules.[102] TMPyP4 exhibits a high degree of
affinity towards G-quadruplex structures, as reflected in a binding constant of Kb =
1.6 x 106 M-1 for its interaction with a tetramolecular qDNA (T4G4)4 in solutions
containing Na+ ions. [103] The high degree affinity of TMPyP4 towards G-quadruplex
DNA is due largely to its aromatic structure and its molecular size, which is similar to
that of a G-tetrad. In addition, TMPyP4 possesses cationic groups which are able to
electrostatically interact with the negatively charged phosphate backbone of
DNA.[104] A number of other molecules with structures closely related to that of
porphyrins have also been investigated for their G-quadruplex-binding potential. One
such molecule is Se2SAP, shown in Figure 1.11 c. This compound was shown to
exhibit a high degree of selectivity towards a mixed parallel/anti-parallel Pu27 c-myc
G-quadruplex in the presence of double stranded DNA, and other types of Gquadruplexes such as Tetrahymena telomeric (TetTel), thrombin-binding aptamer
(TBA) and basket-type (G2T4).[80] However, the very low-yielding synthesis of
Se2SAP is a disadvantage for further investigation of its potential medical
applications.[74]
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Some researchers have focused their attention on finding new telomerase
inhibitors amongst natural products. For examples, the compound telomestatin
(Figure 1.11 d), was isolated from Streptomyces anulatus in 2001 by Shinya et
al.[82] This polyheteroaromatic compound was shown to significantly stabilise
unimolecular G-quadruplex DNA, and showed a significant degree of selectivity (>70
fold) in favour of unimolecular antiparallel G-quadruplex DNA (basket-type) over
double stranded DNA.[105] Telomestatin also exhibited promising activity as a
telomerase inhibitor, with the half maximal inhibitory concentration, as measured by
a telomeric repeat amplification protocol (TRAP) assay, reported to be only 5 nM.[82]
It should be noted, however, that there have been inconsistencies amongst values
reported for the activity of telomestatin towards telomerase in subsequent
publications.[74] A high degree of structural compatibility is believed to exist between
telomestatin and a G-tetrad, and is proposed to be the reason for its selectivity
toward G-quadruplex DNA structures. Telomestatin has also been shown to adjust
the length and configuration of telomeres, as well as inhibit telomerase binding
proteins from interacting with their substrate, all of which contributes to its ability to
inhibit the proliferative potential of cancer cells.[74] Despite these promising
observations, there are a number of disadvantages associated with telomestatin and
its derivatives as lead anticancer agents. These arise from the exceptional
hydrophobic properties of these compounds, and the difficulty associated with their
synthesis.[106]

1.5.2 Metal complexes as G-quadruplex binding agents
There are many recent studies which have focussed on the potential
advantages of novel G-quadruplex-interactive agents based on metal complexes, as
opposed to organic molecules.[43] These have been stimulated by the many
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structural and physiochemical characteristics of metal complexes that are favourable
for the development of such agents. For example, metal complexes can exhibit
magnetic, optical, or catalytic features that are advantageous for the design and
synthesis of G-quadruplex DNA probes and cleaving agents.[54] The overall positive
charge present on many metal complexes, as well as the presence of polar
functional groups, are also conductive for forming interactions with the negatively
charged phosphate backbone of G-quadruplex molecules.[74]
In order to improve the binding of small molecules to G-quadruplex DNA, one
popular approach has been to include in the molecular design large flat aromatic ring
systems that can interact with G-tetrads via -stacking. Even though this strategy
has proven successful for many organic compounds and metal complexes, there are
several examples of the latter that are able to interact with different kinds of DNA,
including G-quadruplexes, via other binding mechanisms. One such binding mode
involves coordination to the phosphate backbone or nucleobases of DNA.[54]
1.5.2.1 Metal complexes of cisplatin derivatives
One group of compounds that can directly coordinate to DNA are platinum
complexes such as cisplatin and its derivatives. Despite the low selectivity towards
different DNA secondary structures, cisplatin is still recognised as one of the most
effective anticancer drugs in clinical use today. Inspired by its success, many
researchers have pursued the rational design of new platinum drugs that act by
specifically targeting G-quadruplexes.[107] Just as with cisplatin, many of these
complexes contain hydrolysable chloride ligands which provide coordination sites for
nucleobases to bind to the platinum centre. Whilst the majority of such complexes
are mononuclear, there have also been studies performed using dinuclear cisplatin
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analogues such as that illustrated in Figure 1.12 a.[54, 108] In another study, the
novel complex shown in Figure 1.12 b was found to exhibit an atypical preference for
binding to N7 of adenine instead of guanine, as is typically the case for most
platinum complexes. Analysis of reaction mixtures containing the platinum complex
and DNA using HPLC, indicated that the number of the Pt-qDNA adducts surpassed
that of Pt adducts involving dsDNA. These results suggested that this complex may
possess a degree of selectivity for G-quadruplexes over dsDNA.[107, 109]

(a)

(b)

(c)

(d)

Figure 1.12 Structures of some novel platinum qDNA-binding agents: (a) [{transPtCl(NH3)2}2NH2(CH2)nNH2]Cl2 (n=2 or 6); (b) Pt-ACRAMTU complex; (c) Pt-MPQ complex;
(d) Pt(II) complexes with 1-azabenzanthrone or 6-hydroxyloxoisoaporphine ligands.

Other platinum complexes have been designed to interact with G-quadruplexes
through both covalent and noncovalent binding modes. One such example is the
platinum(II) complex (PtII-MPQ, (3)) shown in Figure 1.12 c, which contains a monopara-quinacridine (MPQ) group connected via a long flexible moiety to a square
planar platinum centre already bound to an ethylenediamine and a chloride ligand.
This complex was able to interact with the G-tetrad of a G-quadruplex though 24

stacking involving the planar MPQ moiety, or via covalent binding of the platinum
centre to guanine residues.[110] Furthermore complex (3) was shown to selectively
stabilise an antiparallel topology of a 22-mer G-quadruplex DNA. This was believed
to be due, at least in part, to the disruption of the Hoogsteen hydrogen bonding
network present in the G-tetrad, as platination had occurred at one of the sites
normally involved in maintaining this network.[107, 110]

Recently, Chen and co-workers have synthesised the two platinum complexes
shown in Figure 1.12 d as part of an effort to develop improved G-quadruplexbinding agents. Both complexes contain a hydrolysable chloride ligand and a planar
aromatic moiety, as well as a DMSO ligand. These complexes were shown to
interact with G-quadruplex DNA by either platination of guanine residues or stacking with G-tetrads. It was also discovered that both complexes were more
effective than cisplatin in inhibiting the growth of NCI-H460 and HCT-8 human
tumour cells using a xenograft mouse model. Furthermore (5) was more efficient
than (4) in binding to bcl-2 and c-myc telomeric G-quadruplex. This was believed to
be a potential reason why the former complex could stimulate senescence and
apoptosis in tumour cells.[107, 111]
In addition to a large number of studies showing that cisplatin derivatives are
able to bind covalently to G-quadruplex DNA, it has also been recognised that these
interactions may disrupt the stability of this nucleic acid secondary structure.[54]
Furthermore the degree of disruption appears to vary between G-quadruplex DNA
structures formed from different base sequences. For example, studies performed
using CD spectroscopy indicated that G-quadruplex structures arising from Tel-1
(human telomere) and Tel-2 (Oxytricha telomere) were unfolded once they become
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bound to transplatin or cisplatin. In contrast, G-quadruplex structures arising from
PDGF-A and c-myc DNA remained unaffected by platinum binding.[112]
1.5.2.2 Metal complexes of porphyrin and porphyrin derivatives
When it comes to investigating -stacking interactions with G-quadruplex DNA,
metalloporphyrins are one of the most widely studied classes of metal
complexes.[113] For example, complexes of many metal ions, including main group
metals, transition metals, and lanthanides, with the porphyrin TMPyP4 have been
investigated as G-quadruplex stabilisers.[78, 107, 113] In telomerase inhibition
studies, greater activity was exhibited by the CuII complex (8) (Figure 1.13) than
those with other metal ions (e.g. (10), (14) and (15)).[78] This is most likely a result
of the preference of the later metal ions to form complexes with octahedral
coordination geometries, which would inhibit their ability to approach and bind to a
planar G-tetrad.[43]
R

M
AuII (6)

Ref
[114]

NiII (7), CuII (8), ZnII (9),
MgII (10), PtII (11),PdII
(12),CoII (13), MnIII (14),
FeIII (15), InIII (16)

[78]
[104]
[113]
[115]

CuII (17), InIII (18)

[113]

MnIII (19)

[84]

Figure 1.13 Metalloporphyrin complexes of TMPyP4 and derivatives,whose G-quadruplex
binding properties have been examined.

In contrast, the square pyramidal CuII complex of TMPyP4 has one planar face,
enabling it to approach and effectively bind to a G-tetrad. Even though the degree of
telomerase inhibition exhibited by the MnIII-TMPyP4, complex (14), was not much
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greater than that shown by the free ligand, the metal complex showed the ability to
oxidatively cleave a short DNA strand containing the guanine rich telomeric
sequence.[104]
One of the most remarkable results reported in the literature concerns the MnIII
complex (19), which involves a tetra-substituted porphyrin, shown in Figure 1.13.
This complex has an overall charge of 5+, and contains four pendant arms capable
of interacting with a G-quadruplex structure. Complex (19) was reported to show a
10,000-fold increase in selectivity for G-quadruplex over duplex DNA, in experiments
conducted using surface plasmon resonance (SPR).[74, 84] It should be noted that
this selectivity factor has not since been verified by other techniques or research
groups. TRAP studies also revealed that (19) exhibits a pronounced ability to inhibit
telomerase, with an IC50 of 580 nM.[84] It was suggested that the heteroaromatic
core

of

the

complex

and

presence

of

four

flexible,

extended

cationic

methylpyridinium sidechains was the origin of the strong bonding interactions with Gquadruplex DNA, and exceptional selectivity in favour of qDNA over dsDNA.[84]
1.5.2.3 Metal complexes of phthalocyanine and derivatives
A further class of metal complexes that have been investigated for their ability
to act as G-quadruplex binders are those with phthalocyanine and derivatised
porphyrazine ligands. These complexes feature aromatic or heteroaromatic rings
fused with the pyrrole groups of a porphyrin ring system, and are therefore able to
provide a large surface for -stacking interactions with the G-tetrads of a Gquadruplex.[54] Examples of water-soluble NiII and ZnII metallophthalocyanines
which have been shown to bind to G-quadruplexes include (20) – (25), (27) and (28),
which are illustrated in Figure 1.14. Each contains four or eight pendant groups
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which can participate in electrostatic interactions with the negative charges on the
phosphate backbones of G-quadruplexes. These metal complexes exhibited strong
telomerase inhibitory activity (IC50 < 1.65 M) and a notable level of binding affinity
as well as selectivity towards human telomeric (h-telo) G-quadruplex over
dsDNA.[54, 85, 107, 116]

M
ZnII

R

Ref
[116]

M
ZnII
(27)

[116]

ZnII
(28)

ZnII (22)
NiII (23)

[116]

ZnII (24)
NiII (25)

[85]

ZnII (26)

[86]
[117]

R

Ref
[116]
[116]

Figure 1.14 Other classes of macrocyclic complexes shown to exhibit strong binding to Gquadruplex: (a) and (b) Tetra and octa-cationic zinc phthalocyanine (ZnPc); (c) 3,4-TMPyPz
ZnII porphyrazines.[87]

The octacationic (8+) phthalocyanine complex (24) was shown by surface
plasmon resonance (SPR) to exhibit a high degree of affinity towards G-quadruplex
DNA, as reflected in its binding constant of Ka = 2.77 x 107 M-1. In addition, the
results of a TRAP assay showed it was a potent telomerase inhibitor (IC 50 = 0.23 ±
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0.05 M).[85] Experiments performed using CD spectroscopy suggested (24) could
induce a change in conformation of a unimolecular G-quadruplex from an antiparallel
to parallel topology in buffers with low concentrations of cations.[85] In contrast,
complex (29), which has an overall charge of only 4+ and features less steric
crowding around the periphery, induced formation of the antiparallel conformation of
a G-quadruplex in a process that was likened to the activity of chaperone proteins.
A number of phthalocyanine complexes with pendant guanidinium groups have
been shown to exhibit luminescence, which can be utilised to explore their
interactions in vitro with G-quadruplex using fluorescence spectroscopy. Using this
approach, complex (26) was found to exhibit higher affinity towards a G-quadruplex
structure derived from the KRAS proto-oncogene than from G-quadruplexes derived
from other sequences such as c-myc, as well as CT-DNA and tRNA.[86] Complex
(26) was also highly soluble in water, and inhibited expression of either c-myc or
KRAS in cancer cell lines at non-cytotoxic concentrations. These results suggest that
(26) is one of the best G-quadruplex DNA binding agents, and a notable anticancer
drug lead. They also highlight the important roles of planar aromatic groups and side
arms bearing positive charges in determining the strength and nature of interactions
with G-quadruplex.[54, 86, 117]
1.5.2.4 Metal complexes of corrole and derivatives
A further group of metal complexes related to those of metalloporphyrins,
whose G-quadruplex binding ability has been explored, are the tri-cationic corroles
shown in Figure 1.15. These complexes possess different geometries and electronic
characteristics compared to those of the macrocyclic complexes discussed above.
This is due to the aromatic scaffold of the corrole ring system being smaller than that
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of porphyrin. As a result, coordinated metal atoms sit slightly out of the plane formed
by the four coordinating nitrogen atoms, and the complexes exhibit an unusual
saddle shape as opposed to square planar geometry. These ligands are notable for
their ability to stabilise transition metals in unusually high oxidation states, which
could strengthen their interactions with G-quadruplexes.[54, 88, 107, 118]
R

M
MnIII (30),
CuII (31)

Ref
[88]

CuII (32)

[88]

CuII (33)

[88]

CuII (34)

[88]

CuII (35)

[88]

CuII (36)

[88]

CuII (37)

[88]

Figure 1.15 Structures of corrole complexes based on the 5,10,15-Tris(N-methyl-4-pyridyl)
corrolate ligand.[88]

During the last decade Zhou and co-workers have synthesised a number of
MnIII and CuII corrole complexes containing piperidine, pyridinium, dimethylamino or
amide pendant groups (Figure 1.15). These were reported to possess suitable
properties for acting as G-quadruplex binders and inhibitors of telomerase. For
example, the water-soluble MnIII complex (30) was reported to have a binding
constant with a G-quadruplex of 1.94 x 106 M-1, and exhibit a selectivity factor in
favour of G-quadruplex over dsDNA of 64.[88] CD spectroscopy and PCR stop
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assays showed (30) could induce adoption of the hybrid conformation of Gquadruplex DNA, and result in 50% inhibition of polymerase activity. Under the same
conditions, the CuII complex (31), which features the same ligand as (30), proved
slightly less effective than its MnIII counterpart as a G-quadruplex stabiliser. It was
also observed that replacing the MnIII metal center by CuII resulted in the complex
preferring to bind to the parallel topology of the h-telo G-quadruplex, instead of the
hybrid structure.[88]
Complexes (32) – (37) were designed with the expectation that the pendant
groups would enhance interactions with the negatively charged phosphate backbone
of G-quadruplex DNA.[107] Experiments performed using UV-Vis spectrophotometry
showed that addition of these complexes resulted in different changes to the
absorption spectrum of G-quadruplex DNA, than what was caused by addition of
(30) or (31), suggesting they exhibit different binding modes. While CD spectroscopic
studies indicated that addition of (32) or (33) caused larger increases in the melting
temperature of G-quadruplex DNA than (30) or (31), the latter showed greater
activity in PCR stop assays and higher overall qDNA affinity.[88]
1.5.2.5 Metal complexes of phenanthroline and derivatised phenanthroline
ligands
There are now many examples which show that it is not essential for a
macrocyclic ligand to be present in order for a metal complex to bind effectively to Gquadruplex structures. What is required for optimum binding, however, is that the
metal complex has a square planar geometry and at least one planar aromatic ligand
that can interact with G-tetrads through -stacking interactions.[107] One such group
of metal complexes are those containing phenanthroline or one of its derivatives
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such as phenanthroimidazole,[119] and dipyridophenazine (dppz).[89] Such
complexes have previously attracted considerable attention for their ability to interact
with dsDNA via groove binding and/or intercalative binding modes.[89, 119, 120] It is
therefore not surprising that some researchers have turned their attention to
examining the interactions of these complexes with G-quadruplexes. In one such
study, the interactions with G-quadruplex DNA of a group of related platinum
complexes including (38) and (39) (Figure 1.16) was examined using a range of
techniques including ESI-MS and CD spectroscopy.[120]

R1

R2

Ref

H (38), CH3 (39)

[120]

R

Ref

[121]
[122]

[119]
[121]

[121]
[89]

[89]

[121]

Figure 1.16 Some examples of platinum complexes of phenanthroline and related ligands,
whose interactions with G-quadruplex have been examined.[89, 119-122]
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In an effort to improve binding efficacy and selectivity, some workers have
prepared platinum complexes of derivatised phenanthroline ligands, including (44) (47). These new complexes showed high affinity towards human telomeric

(h-telo)

G-quadruplex DNA and significant levels of telomerase inhibition.[54, 121, 123] For
example, the melting temperature (Tm) of a unimolecular G-quadruplex measured by
a FRET assay increased by 18.5 and 20 °C, in the presence 1 M (44) and (47),
respectively. In contrast, addition of these metal complexes resulted in little or no
variation to Tm when experiments were conducted with dsDNA under similar
conditions.[121]
The G-quadruplex binding ability of platinum complexes of derivatised
phenanthroimidazole ligands has also been explored. It was hoped that the presence
of the aromatic side arm in the ligands might confer additional affinity on the metal
complexes towards G-quadruplexes.[107, 122] Some notable results have been
achieved with this class of metal complexes. For example, the selectivity factor for
complex (41) for G-quadruplex DNA over dsDNA was almost two orders of
magnitude.[119] In addition, complex (40) was shown to preferentially stabilise the
antiparallel G-quadruplex topology for 22AG h-telo DNA, rather than the hybrid
conformation.[122]
The importance of an extended -conjugated ring system for improving
interactions between platinum complexes bearing modified phenanthroline ligands
and G-quadruplexes has also been established.[54] For example, Che’s group
synthesised various platinum complexes, such as (42) and (43), which possess
modified dppz ligands, and exhibited intriguing optical characteristics and high
affinity towards G-quadruplexes. Notably, complex (42) exhibited a very high binding
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constant with a unimolecular G-quadruplex (Ka = 9.7 ± 1.1 x 107 M-1) and a high
degree of selectivity for qDNA over dsDNA (~800), as well as the ability to effectively
inhibit human telomerase (telIC50 = 760 nM). Photophysical and computational
experiments suggested that (42) interacts with G-quadruplex DNA via an endstacking binding mode.[89]
1.5.2.6 Metal complexes of terpyridine derivatives
Another group of metal complexes that have attracted interest as potential Gquadruplex binding agents are those with terpyridine or modified terpyridine
ligands.[54] These complexes often have simple molecular structures, and can be
readily synthesised often in just one or two simple steps.[74, 90] One example is the
CuII tolyl-terpyridine complex (48) (Figure 1.17), which was found to show a 22-fold
selectivity factor in favour of binding to G-quadruplex DNA over dsDNA.[90] In
addition, Suntharalingam et al. recently synthesised three novel PtII terpyridine
complexes, (49), (50) and (51), and investigated their affinity toward h-telo and cmyc G-quadruplex DNA structures using SPR, CD spectroscopy and Fluorescent
Indicator Displacement (FID) assays.[91]
The introduction of heterocyclic pendant groups onto the central aromatic ring
of the terpyridine ligand has been shown to result in an enhancement of binding
affinity towards a mixture of parallel and anti-parallel unimolecular G-quadruplexes.
This was suggested to be the result of additional binding interactions between the
pendant groups and the grooves of the G-quadruplex molecule.[91] As a result, this
structural feature has been introduced into other square planar complexes in an
attempt to optimise their G-quadruplex-binding potential and selectivity.[95] The
dinuclear CuII and ZnII terpyridine complexes (52) and (53) may be considered an
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extension of this approach to drug design. These complexes were found to display a
strong affinity towards a hybrid unimolecular G-quadruplex. For example, (52)
exhibited a binding constant, Ka =7.97 x 106 M-1, as well as a selectivity factor of up
to 100-fold for qDNA over dsDNA.[92]
M
CuII

R

PtII

(a)

(b)

Figure 1.17 Examples of metal complexes of derivatised terpyridine ligands whose
interactions with G-quadruplex have been examined: (a) PlatinumII terpyridine
complexes;[90, 91] (b) Dinuclear terpyridine complexes.[92]

1.5.3 Metal Schiff base complexes
One of the most widely investigated classes of compounds in coordination
chemistry is metal complexes of Schiff base ligands. In these complexes, imine
nitrogen atoms and deprotonated phenolic oxygen atoms coordinate strongly to a
variety of metal ions in a tetradentate fashion.[124, 125] In recent years, complexes
of salen (the abbreviation for salicylidene ethylenediamine) (e.g. Figure 1.18, entry 7)
and salphen (salicylidene phenylenediamine) coordinated to various transition
metals have emerged as promising G-quadruplex DNA binding agents. For example,
the nickel salphen complex (54) was shown using FRET melting assays to produce a
significant degree of stabilisation of a unimolecular G-quadruplex (Tm = 29.5 ± 0.4
o

C), while TRAP assays revealed the complex could also inhibit telomerase (IC 50 =

0.14 ± 0.01 M). These results, along with a high degree of binding selectivity in
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favour of G-quadruplex over dsDNA, were attributed to the square planar geometry
of the metal complex.[93, 94]

X

R

Position
of R
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M

Ref

1

NiII (54)
CuII (55)
ZnII (56)
VIV=O (57)

[93],
[94]
[126]

2

NiII (58)

[127]

4

3

NiII (59)

[128]

4

4

NiII (60)

[126]

4

5

NiII (61)

[95],
[129]

5

6

Niii (62)
CuII (63)

[94]

4

7

NiII (64)
CuII (65)

[130]

3

8

PtII (66)

[96]

9

NiII (67)
CuII (68)
ZnII (69)

[97]

4

4

3

Figure 1.18 Metal Schiff base complexes investigated as G-quadruplex binding agents.
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An attractive feature of this class of compounds is that the synthetic methods
used to prepare them are often simple to perform, and can be readily modified by
incorporating different starting materials to produce a wide range of potential drug
molecules. Molecular modelling and X-ray crystallographic studies have shown that
the metal ions in these square planar complexes can become aligned with the center
of a G-tetrad when binding interactions with G-quadruplexes occur (Figure 1.19).[93,
94, 96] It has been suggested that coordination of metal ions to the Schiff base
ligand would result in withdrawal of electron density from the latter, and strengthen
stacking interactions with an electron rich G-quartet.[57]

(a)

(b)

Figure 1.19 Interactions between a nickel Schiff base complex and G-quadruplex DNA:
(a) Results of a molecular docking study involving (54) and a unimolecular parallel Gquadruplex DNA (Elements are represented by the following colours: grey: carbon; green:
nickel; red: oxygen);[93] (b) Solid state structure of (55) bound to a bimolecular parallel Gquadruplex DNA as revealed by X-ray crystallography.[94]

Using as a starting point (54), Vilar and co-workers have prepared a range of
analogues in order to understand how varying the structure affects binding towards
G-quadruplexes.[93, 94, 126] In general, NiII complexes have superior Gquadruplex-binding properties compared to their CuII counterparts. However,
complex (55) has been shown to inhibit telomerase to a greater extent using the
TRAP assay (telEC50 = 3.6 M) and exhibit superior anti-proliferative effects towards
A549 lung cancer cells. These results suggest that some complexes may elicit anti37

proliferative effects by mechanism other than binding and stabilising telomeric Gquadruplexes, such as direct binding at the active site of the enzyme or targeting
other DNA sequences such as promoter regions.[94]
A number of studies have now been carried out to explore the relationship
between the G-quadruplex binding properties of Schiff base complexes involving
different metal ions and their structures.[94, 97, 126, 131] Crystallographic studies
showed that the NiII complexes examined (54), (58) – (62), (64), as well as PtII
complex (66) and CuII complexes (55), (63), (66), and (68) possess square planar
geometries. In contrast, the VIV oxo complex (57) and the ZnII complexes (56) and
(69) exhibited square pyramidal geometries.[107, 126] The results of DNA binding
studies conducted using CD spectroscopy, FID, SPR and FRET melting assays,
showed that the square planar complexes were more effective than those with other
geometries. For example, the results of FRET experiments showed that the melting
temperature of a G-quadruplex increased by 29.5 and 19.2 °C when bound to the
square planar complexes (54) and (55), respectively. In contrast, the melting
temperature only increased by 1.4 °C in the presence of the square pyramidal
complex (56).[93, 94, 126]
A number of research groups have examined the effect on G-quadruplex
affinity and selectivity of replacing the phenylenediamine group in (54) by other
moieties, resulting in the compounds shown in Figure 1.18.[93, 95, 96, 125, 126,
127, 129] These changes have in some instances resulted in significant changes to
the G-quadruplex DNA binding properties of the nickel complex. For example,
complex (59), which contains a phenanthrenediamine moiety instead of the
phenylenediamine present in (54), showed greater affinity towards dsDNA, and
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therefore a lower G-quadruplex DNA/dsDNA selecivity factor.[128] In contrast, steric
hindrance from the meso-diphenylethylenediamine group in (58) resulted in a much
lower affinity towards dsDNA, and notable selectivity for both tetramolecular and
unimolecular G-quadruplexes.[107, 127]
Each of the nickel complexes shown in Figure 1.18 contain two pendant groups
that either feature a permanent positive charge, or are likely to undergo protonation
in aqueous solution, leading to a positive charge. One of the functions of these
groups is to increase the solubility in water of the complexes. In addition, it is
believed that these pendant groups participate in additional interactions with the
loops and grooves of G-quadruplex that may affect overall affinity.[93, 94, 126, 132]
There has been significant effort devoted to optimising the G-quadruplex binding
affinity of metal Schiff base complexes through modification of these pendant
groups. This has included, for example, changing the length of the alkyl groups
present in the pendant groups,[95, 126, 127] (Figure 1.18, entry 2), or altering their
positions on the periphery of the Schiff base ligand scaffold (Figure 1.18, entry 5, 7,
9).[95, 96]
To date there have only been a small number of investigations into cellular
uptake of metal Schiff base complexes, and the effects of cellular incorporation. In
2009, Mandal and co-workers demonstrated that MnIII salen and salphen complexes
can influence cell viability and induce apoptosis in MCF7 breast cancer cells.[133]
The IC50 values of the complexes with MCF7 ranged from 12 to 55 M, which
indicated that they are only weakly cytotoxic.[133] In another study, Che et al.
designed a series of PtII salphen and salen complexes including (66), and examined
their interaction with c-myc G-quadruplex DNA. This study was motivated by the
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knowledge that suppressed transcription of c-myc is one of the hallmarks of many
types of cancers.[134] Complex (66) showed a capacity to influence the activity of
the c-myc gene promoter (IC50 = 4.4 M), as well as inhibit c-myc transcription in
human hepatocellular carcinoma (HepG2) cells (IC50 = 8.07 ± 0.11 M).[96]
Recently, Barone and co-workers synthesised a group of new Schiff base
complexes, including (67), using naphthalendiamine as one of the starting materials.
[97] This complex was shown using a PCR stop assay to induce formation of a
G-quadruplex structure by an oligonucleotide, Pu22myc, which corresponds to the
nuclease hypersensitive element (NHE) III1 region of the c-myc promoter. The
interaction between (67) and Pu22myc resulted in a significant degree of inhibition of
amplification of Pu22myc (IC50 ~ 0.2 M). In addition, the metal complex proved
cytotoxic towards MCF7 and HeLa cancer cells in a concentration dependent
manner, with Growth Inhibition 50% (GI50) values (after 48 hours) of 1.42 and 0.31
M, respectively.[97]
In contrast to the numerous investigations into the DNA binding ability of other
classes of metal complexes of ligands such as porphyrins and its analogues, there
have still only been a relatively small number of similar studies involving complexes
of Schiff base ligands. Despite this, it has already been demonstrated that the latter
are a promising class of compounds, which have the ability to bind to and stabilise
G-quadruplex structures, as well as inhibit telomerase and interfere with the
regulation of the activity of different types of oncogenes. Further exploration of the
DNA binding properties of new examples of this class of compounds is therefore
warranted. In the following sections some of the different methods which have been
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used to examine the G-quadruplex binding properties of metal complexes are
discussed.

1.6 Methods for investigating the G-quadruplex DNA binding
properties of metal complexes
1.6.1 Electrospray Ionisation Mass Spectrometry (ESI-MS)
Mass spectrometry (MS) is a quantitative technique which can be used to
determine the mass of analytes by measuring their mass-to-charge (m/z) ratio.[135]
The fundamental principles of MS were established in late 1890s, after which it
became an important method for detecting organic compounds, partially in response
to the growing needs of the oil industry in the 1940s.[136] At that time, mass
spectrometry was not a widely used method in biochemistry. This was primarily a
consequence of the ionisation processes used in mass spectrometers of the day
involving high temperatures (200 – 300 °C) and voltages (ca. 500 V). Whilst the
volatile mixtures of organic compounds typically analysed by GC-MS methods
remained stable under these conditions,[137] biomolecules such as proteins and
DNA underwent significant decomposition.[136] It was not until soft ionisation
methods such as electrospray ionisation emerged, that it became possible to
generate and transfer to the gas phase ions corresponding to biomolecules, and that
the potential for analysis of the DNA and proteins by MS methods came to be
realised.[138]
Today ESI-MS is a routine method for characterization of proteins and nucleic
acids. In addition, it is also suitable for the study of non-covalent binding interactions
between these biomolecules and other small molecules, owing to the relatively low
temperatures and voltages employed in the ESI process.[139] This has proved very
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important for enhancing our understanding of biomolecular function, as non-covalent
binding interactions with other molecules, including electrostatic, van der Waals,
hydrophobic and hydrogen bonding interactions, play important roles in their cellular
activities. For example, non-covalent interactions play a part in intermolecular
interactions with many binding partners including proteins, lipids, nucleic acids,
carbohydrates and small molecules.[138] Importantly it has been shown that noncovalent binding interactions formed between DNA and either metal complexes or
small organic molecules remain largely intact during the ESI process. [120, 139, 140]
In addition, ESI-MS also has a number of other favourable attributes for analysis of
proteins and nucleic acids, including negligible sample demand and high
sensitivity.[141]
ESI mass spectra of metal complexes are typically obtained in positive ion
mode owing to the positive charge associated with the metal centres.[142] However,
the interactions between metal complexes and DNA are usually investigated in
negative ion mode. This is due to the large negative charge on the macromolecule
resulting from the many phosphate groups that link the nucleotides which are
deprotonated under solution conditions normally used.[143] To obtain mass spectra
of solutions containing oligonucleotides it is important to use buffers that do not
contain alkali metal cations such as K+ and Na+, as these bind to varying extents to
the phosphate groups. This results in noisy ESI mass spectra owing to the method
detecting each of the many clusters of ions containing a single oligonucleotide bound
to different numbers of cations.[144] In order to avoid this problem, ESI-MS studies
involving DNA are usually performed in the presence of volatile salts such as
aqueous ammonium acetate.[127, 138, 145] This ensures that the phosphate groups
of the oligonucleotides are deprotonated and therefore able to give rise to ions in ESI
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mass spectra. However, non-covalent adduct formation with the ammonium cation is
typically minimal, except when certain G-quadruplex structures are formed. Figure
1.20 shows ESI mass spectra of solutions containing metal complexes and different
types of DNA, including two G-quadruplex topologies.

(a)

(b)

(c)

Figure 1.20 Mass spectra of solutions containing different complexes and various DNA
molecules obtained on a Q-Tof Ultima ESI-MS instrument: (a) DsDNA and a nickel Schiff
base complex;[127] (b) Parallel tetramolecular qDNA and a nickel Schiff base complex;[127]
(c) Parallel unimolecular qDNA and a ruthenium complex.[120]
= free DNA;
= {DNA +
(Ni)}; = {DNA + 2(Ni)}; {DNA + 3(Ni)}; {DNA + 4(Ni)}.

The spectra show two envelopes of ions with different overall charge states.
Within each envelope individual ions are apparent from free DNA and non-covalent
adducts containing different numbers of bound metal complex. The spectra show the
ability of ESI-MS to provide information about the number, relative amounts and
stoichiometry of non-covalent complexes present in these solutions. This can in turn
be used to provide information about the relative DNA affinities of a group of related
metal complexes or organic compounds towards different DNA molecules. When
performing these experiments it must be remembered that the topology of a
unimolecular G-quadruplex in a solution containing ammonium acetate may vary
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from that of the same G-quadruplex in a buffer containing different univalent
cations.[145-149] It is therefore essential to also use a technique such as CD
spectroscopy, which provides spectra that are highly characteristic of the specific
DNA secondary structure present in solution.

1.6.2 Circular Dichroism (CD) spectroscopy
Circular dichroism is a phenomenon that arises from the differential absorption
of left and right handed circular polarized light by optically active molecules.[150]
Today CD spectroscopy is widely used for investigating the polymorphism of
different types of DNA, including dsDNA and G-quadruplex DNA, due to its
exceptional sensitivity to stereochemical conformations, particularly amongst
biological macromolecules.[151] In addition, CD spectroscopy can be used to
explore conformational transitions for nucleic acid molecules (Figure 1.21), as well
as interactions between DNA and small molecules.[152-154]
One of the most useful aspects of CD spectroscopy is its sensitivity to
conformational polymorphism. This means distinct spectra are observed for dsDNA,
when present in different forms, such as A, B, Z and X DNA.[155] In the case of BDNA, which is the most ubiquitous form of dsDNA, the CD spectrum shows a large
positive band at 280 nm, a negative band centred at approximately 250 nm and a
small positive band at 200 – 220 nm (Figure 1.21 a). In contrast, the CD spectrum of
Z-DNA shows a broad negative band at 220 – 230 nm, a strong positive band at 260
nm and an intense negative band at 290 nm. This makes it a relatively simple task to
follow the transition from B- to Z-DNA, which can be effected by a change in solution
conditions, such as increasing the amount of trifluoroethanol (TFE) from 59 to 67% in
a solution of 1 mM sodium phosphate with 0.3 mM EDTA (Figure 1.21 b).
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Figure 1.21 CD spectra of dsDNA: (a) B-DNA; (b) B-Z transition, B-DNA (black), Z-DNA
(solid red).[153, 155]

CD spectroscopy can also distinguish between G-quadruplex DNA and dsDNA,
as well as differentiate various topologies of qDNA. The variation in polarities of
neighbouring tetrads is the origin of the specific CD spectra which then is empirically
assigned to different conformations of G-quadruplexes. For example, the CD
spectrum of a G-quadruplex when present in a parallel topology shows a strong
positive band at 260 nm and a shallow negative band at 240 nm (Figure 1.22
(a)).[155] In contrast, the CD spectra of antiparallel structures show a negative band
at 260 nm along with a positive band at 295 nm wavelength. The anti-parallel
conformation of G-quadruplex DNA can be obtained in Na+ ion solution as shown by
its CD spectrum (Figure 1.22 (b)). Addition of K+ ion to the anti-parallel G-quadruplex
can induce the transformation from anti-parallel topology to hybrid type 1 structure,
following the exchange of Na+ ions for K+ at a very fast rate.[152]
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Figure 1.22 CD spectra of different G-quadruplexes structures: (a) Parallel conformation of
c-myc qDNA in potassium phosphate (cyan); (b) Anti-parallel conformation of 22AG qDNA in
sodium phosphate + EDTA (black dashes); in sodium phosphate + NaCl (green); and in
potassium phosphate + KCl (blue). Adapted from different references.[152, 155]

45

There are also a number of different types of CD experiments that can be
performed to provide information about drug/DNA interactions. One procedure
involves monitoring the effect of adding increasing amounts of an organic compound
or metal complex on the CD spectrum of DNA alone. In these experiments the extent
to which the CD spectrum of the DNA is altered is used as an indication of the
strength of the interaction between the two binding partners (Figure 1.23 (a)).[58]
The second type of experiment takes advantage of the change in ellipticity of the CD
signal at a specific wavelength that occurs when DNA present in a folded secondary
structure, undergoes denaturation as a result of increasing temperature. This results
in a CD melting curve, the mid-point of which is the melting temperature, Tm, of the
DNA. Addition of small molecules, including metal complexes, which bind to and
stabilize either duplex or G-quadruplex DNA towards this melting phenomena,
produce a displacement of the CD melting curve that is proportional to the degree of
stabilisation.[156, 157] A typical series of CD melting curves of solutions containing
either a G-quadruplex alone, or the G-quadruplex and different organic molecules, is
shown in Figure 1.23 (b).[157]

(a)

(b)

Figure 1.23 Different methods of using CD spectra to examine DNA/drug interactions: (a)
Titration of a small molecule, in this case a nickel Schiff base complex, into a solution
containing a parallel tetramolecular G-quadruplex;[127] (b) CD melting curves produced
using solutions containing a hybrid type 1 conformation of the 22AG G-quadruplex, and
different organic ligands.[157]
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1.6.3 Absorption spectrophotometry
Absorption spectrophotometry is widely used for measuring the concentration
of DNA, RNA or protein in solutions.[158] In addition, it has been shown that adding
DNA to solutions containing metal complexes or organic molecules can cause
changes to the absorption spectra of the latter, including shifts in the position and
intensity of absorption bands.[141] An example of such experiment is shown in
Figure 1.24. The changes to the spectrum can be used to derive binding constants
(Kb) for the ligand/DNA interactions using different mathematical models.

Figure 1.24 Effect of addition of dsDNA on the visible absorption spectrum of a ruthenium
complex.[141]

This method has some disadvantages for certain systems. For example, in
some cases the change in absorbance caused by addition of DNA to the drug
molecule is not large, resulting in a significant degree of uncertainty for the
associated binding constants. Moreover, it is generally a low throughput method with
experiments often requiring comparatively large volumes (1 – 3 mL) of solutions with
high concentrations of DNA. For this reason, as well as convenience, such
experiments are often performed with calf thymus DNA rather than discrete
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oligonucleotides. Despite this inconvenience, absorption spectrophotometry can be
used to monitor changes in DNA secondary structure caused by increasing
temperature, in a similar manner to CD spectroscopy.[141, 159] A typical UV melting
profile for dsDNA is shown in Figure 1.25.

Figure 1.25 UV-Vis melting profile of dsDNA with a temperature gradient of 0.2 oC/min.[159]

The absorbance arising from the DNA bases at 260 nm is monitored in these
experiments. As the temperature increases, and the DNA duplex dissociates into
individual strands the absorbance at this wavelength increases owing to the removal
of base stacking interactions. Addition of small molecules which stabilise the double
helix to this strand dissociation process produce a displacement in the DNA melting
profile and an associated increase in the mid-point of the curve, which is known as
Tm. Similar experiments can also be performed using solutions containing Gquadruplexes.[160]
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1.6.4 Fluorescence Intercalator Displacement (FID) assays
FID assays are simple to perform as they do not require labelled
oligonucleotides or equipment that may not be available in some laboratories.[161]
They may be used to study the interactions of new compounds with either Gquadruplex or duplex DNA, by examining their ability to displace a fluorescent probe
such as thiazole orange (TO) from the nucleic acid (Figure 1.26).[126, 161, 162] In
aqueous solution TO exhibits minimal fluorescence, whereas the fluorescence
increases by a factor of up to 3000-fold once TO interacts with G-quadruplex DNA
(Ka = 3 × 106 M-1). The ability of different compounds to displace TO from a Gquadruplex may therefore be followed by monitoring the decrease in fluorescence
(Figure 1.27) and is a measure of their ability to interact with the qDNA.[126, 163]
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Figure 1.26 Schematic illustration of a G-quadruplex FID assay performed using TO and a
qDNA molecule. Adapted from various references.[126, 164, 165]

The G-quadruplex Fluorescent Intercalator Displacement (G4-FID) assay was
first introduced by Teulade-Fichou and co-workers in 2006 for studying the binding
affinity and selectivity of small ligands toward G-quadruplexes and different DNA
sequences.[165] The assay provides a quantitative measure of the affinity of a new
compound or complex towards a G-quadruplex in the form of a

G4

DC50 value, which
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is the concentration of organic compound or metal complex which causes the
intensity of fluorescence of TO to decrease by 50%.[126] The lower the value of
G4

DC50 for a given compound or complex means the higher its binding affinity

towards the G-quadruplex.
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Figure 1.27 Effect of increasing concentrations of a nickel Schiff base complex on the
fluorescence arising from TO bound to a unimolecular G-quadruplex. Adapted from various
references.[126, 166]

FID assays have been used to examine the binding ability of small molecules
with a variety of specific G-quadruplex sequences such as c-myc,[162, 167] and htelo 22AG[126, 162]. In addition, it has also been used to screen the affinity and
selectivity of compounds towards other types of DNA structures, including hairpins,
triplexes, and dsDNA sequences.[162, 168] Prior to performing an FID assay it is
important to determine whether the ligand of interest itself exhibits fluorescence
which may interfere with that arising from TO.[164]

1.6.5 Fluorescence Resonance Energy Transfer (FRET)
Förster or fluorescence resonance energy transfer (FRET) is a non-radiative
process between an excited state donor which is usually a fluorophore, and a
proximal ground state acceptor, in which energy is transferred by means of
long-range dipole-dipole interactions.[169] FRET techniques are especially useful in
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biochemistry for monitoring DNA/RNA interactions, and in nanotechnology.[170, 171]
In the field of G-quadruplex drug design, FRET assays are used to provide a
quantitative measure of the relative binding abilities of new compounds, and are
carried out using a guanine-rich oligonucleotide linked to two fluorophore probes.
The first of these is typically the fluorescence donor 6-carboxyfluorescein (FAM) at
the 5´ terminal of the oligonucleotide, and the second is tetramethyl-6carboxyrhodamine (TAMRA), which functions as the energy acceptor at the 3´ end
(Figure 1.28).[172]
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Figure 1.28 Schematic illustration of FRET involving an oligonucleotide capable of forming a
G-quadruplex structure. FAM and TAMRA are the fluorescence donor and acceptor groups,
respectively. Adapted from various references.[169, 173]

Fluorescence resonance energy transfer occurs when light of the appropriate
wavelength emitted by FAM is able to be absorbed by TAMRA, as a result of the
oligonucleotide folding into a G-quadruplex conformation that brings the two
functional groups into close proximity. Fluorescence is then restored when the donor
group becomes separated from the acceptor, as occurs during DNA melting.[173] A
plot of fluorescence intensity as a function of temperature has a sigmoidal shape, the
mid-point of which is the melting temperature, Tm (Figure 1.29). A FRET-based
melting assay was developed by Mergny et al. in which the increase in melting
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temperature of a G-quadruplex caused by addition of drug molecules was used to
evaluate their relative binding affinities.[174]

Tm

qDNA alone

qDNA + Ni complex at 10 M

Figure 1.29 Results obtained from a typical FRET assay in which increasing concentrations
of a nickel complex were added to the labelled oligonucleotide F21T.[128]

The high sensitivity of FRET assays can provide considerable insight into the
interactions of metal complexes or small organic molecules with G-quadruplex
structures. However, before performing a FRET assay with a new compound, it is
important to check that it does not quench the emission of the donor group on the
oligonucleotide. In addition, it is important to ensure that the assay does not give
misleading results owing to the G-quadruplex and metal complex forming a structure
that prevents the donor and acceptor groups from coming into close proximity and
preventing FRET from occurring.[173]

1.6.6 Molecular docking
Molecular docking is a technique employed to provide information about the
preferred binding modes of complexes with different DNA structures, as well as
discover which new compounds amongst a series are likely to be the most effective
at binding to a specific DNA molecule.[175] During the last 20 years, over 60 docking
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tools and programs have been developed for both commercial and academic
applications, including FlexX,[176] GOLD,[177] Glide,[178] ICM,[179], MOEDock,[180] DOCK,[181] LeDock,[182] rDOCK,[183] AutoDock 4 (AD4),[184] and
AutoDock Vina (AV)[184, 185]. Docking programs can be categorized by their
different sampling approaches, which include shape-based algorithms (DOCK),
incremental construction (FlexX), genetic algorithms (GOLD, AutoDock) and flexible
Monte-Carlo approaches (ICM, AutoDock Vina).[185, 186]
In general, the search algorithm of a docking program includes two
components, which are the docking process and the scoring function.[184, 187] The
docking or sampling process uses an algorithm to systematically investigate possible
binding modes and conformations of the ligands and receptors without going through
every possibility. The second component is the scoring step, which employs
equations and specific parameters to evaluate the affinity between the two binding
partners.[186] In a typical experiment, a docking program installs a ligand into
potential binding sites located on the receptor, which could be either a protein or
DNA molecule. The position and conformation of either the ligand or the receptor are
then continuously changed until the binding energy converges to a minimum
value.[185] The shape of the ligands and the receptor, as well as electrostatic
interactions, are used as variables for finding the best “matching”, also known as
binding mode or binding pose (Figure 1.30).[185, 187, 188] van der Waals
interactions, coulombic energies and hydrogen bonds also play important roles in
determining the optimum conformation and orientation of a ligand bound to its
receptor.[185]
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Binding site

(a)

(b)

(c)

Figure 1.30 Result from a docking experiment performed using the Autodock Vina 1.1.2
program: (a) G-quadruplex DNA as a receptor; (b) BRACO 19 as a ligand; (c) The best
binding mode of ligand and receptor. Adapted from [189].

In this project, Autodock Vina 1.1.2 was chosen to perform molecular docking
experiments as it has a number of advantages. First of all, Autodock Vina is able to
make use of the multiple processors of a computer, and approximately two orders of
magnitude faster than its predecessor AD4, which also was developed by The
Scripps Research Institute.[175, 184] Although the ways AD4 and Autodock Vina
perform docking experiments are similar, including the use of empirically-weighted
scoring, the latter is much faster and more accurate. For example, in one molecular
docking study involving 190 protein/ligand complexes, Autodock Vina produced a
final binding mode within 2 Å Root Mean Square Deviation (RMSD) in 78% of cases,
compared to only 49% for AD4.[190] In another study involving a large dataset of
2002 ligand/protein complexes, Autodock Vina outperformed five commercial
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docking programs (GOLD, Glide, LigandFit, Surflex-Dock and MOE-Dock), as well
as four academic counterparts (LeDock, rDock, AutoDock, and UCSF DOCK).[191]
Autodock Vina 1.1.2 has been used to examine the docking of small molecules
to G-quadruplex DNA by many research groups.[130, 175, 192-195] The success of
Autodock Vina procedures can be attributed to an efficient search algorithm that
integrates local search methods with Monte Carlo perturbations to anticipate
possible binding modes.[196] In addition, Autodock Vina has a new scoring function
which allows it to calculate ligand/receptor affinities, and docking studies can be
undertaken by taking advantage of the many cores present on modern personal
computers to accelerate the simulation process.[197] It is for these reasons that all
molecular docking studies reported in this thesis were performed using Autodock
Vina.

1.7 Thesis objectives
The work summarised earlier in this chapter showed that a number of different
classes of metal complexes exhibit properties that make them useful candidates as
selective G-quadruplex binding agents, and potential inhibitors of telomerase. Nickel
Schiff base complexes in particular have attracted attention owing to their ease of
synthesis, the ability to readily modify their structure, and their excellent Gquadruplex binding properties. One of the most notable examples of this class of
complexes is (54), which has three roughly coplanar aromatic ring systems that
facilitate -stacking interactions with G-quartets. As the number of aromatic rings in
(54) is less than the number of guanines in a G-quartet, one method for enhancing
the overall strength of binding interactions might be to increase the number of
aromatic ring systems present in the Schiff base ligand. The overarching aim of this
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thesis was therefore the development of a modular method for preparing a range of
new nickel Schiff base complexes that feature four aromatic ring systems, and
subsequently characterize those complexes and explore their G-quadruplex binding
properties. In order to achieve this goal, it was decided to adapt the method shown in
Figure 1.31 for preparing a nickel Schiff base complex featuring four aromatic ring
systems located approximately at the corners of a rectangle.[198]

Figure 1.31 Synthetic scheme for preparing
hydroxybenzophenone and 1,2-diaminopropane.

a

nickel

Schiff

base

using

2-

This led to the following specific aims of this project:
1. Prepare a range of precursor nickel Schiff base complexes using the procedure
shown in Figure 1.31, but with isomeric dihydroxybenzophenones and different
diamines. Then react the precursor nickel Schiff base complexes with 2(chloroethyl)piperidine to afford a range of alkylated derivatives that exhibit greater
solubility in water, and are therefore suitable for DNA binding studies. The structures
of all the nickel complexes prepared as part of this project are illustrated in
Figure 1.32.
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Figure 1.32 Structures of nickel Schiff base complexes prepared as part of this project.
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2. Characterise all of the above nickel complexes using microanalysis, NMR
spectroscopy, ESI-MS, and where possible or appropriate, X-ray crystallography and
CD spectroscopy.
3. Use a range of techniques, including ESI-MS, CD spectroscopy, FRET and FID
assays to explore the interactions of the alkylated nickel Schiff base complexes with
dsDNA and G-quadruplexes with varying topologies.
4. Perform molecular docking studies using Autodock Vina to examine the effect of
varying the structure of the alkylated nickel Schiff base complexes on the mode and
strength of their interactions with dsDNA and G-quadruplex DNA, as well as to
compare these results to those of DNA binding studies performed using various
spectroscopic methods.
This thesis is comprised of 8 chapters including this introductory Chapter 1. The
content of the other chapters is summarised below.
Chapter 2 provides the information about the materials and the methods used during
this project whereas chapter 3 reports the synthetic procedures used to prepare all
novel nickel Schiff base complexes and the results of their characterization.
Chapters 4 - 7 presents the results of experiments performed to examine the effect
of varying different aspects of the structures of the nickel Schiff base complexes on
their affinity and selectivity towards different types of DNA. In Chapter 4 the effect of
varying the number of pendant groups is examined, whilst in Chapter 5 the focus is
on exploring the effects of varying the location of the pendant groups amongst a
series of five isomeric nickel complexes. Chapter 6 then looks at the effect of varying
the diamine moiety in the Schiff base scaffold on the affinity and selectivity of the
benzophenone complexes towards G-quadruplex DNA over dsDNA, while Chapter 7
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investigates the DNA binding properties of some asymmetric nickel Schiff base
complexes. To conclude the thesis, Chapter 8 assesses the relative importance of
the different types of structure variations on G-quadruplex binding properties, and
presents suggestions for the future research.
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Chapter 2 : Materials and methods
2.1 Materials
2.1.1 Reagents used for synthesis
The reagents and chemicals used in this project were the highest grade
commercially available. All syntheses of nickel Schiff base complexes used
chemicals

from

Sigma

Aldrich

(Castle

Hill,

Australia)

except

2,4'-dihydroxybenzophenone was obtained from Tokyo Chemical Industry (Tokyo,
Japan). Ajax Finechem (Seven Hills, Australia) supplied methanol (MeOH), ethanol
(EtOH), anhydrous diethyl ether (Et2O), dichloromethane (DCM), chloroform (CHCl3)
and hydrochloric acid (HCl). The water used in all experiments was MilliQ TM purified
water (18.2 Mcm), obtained from Millipore (Molsheim, France).

2.1.2 Reagents used for analytical techniques
Sigma Aldrich (Castle Hill, Australia) supplied deuterated chloroform (CDCl 3),
deuterated dimethyl sulfoxide ((CD3)2SO) and deuterated DMF (DMF-d7) for use in
NMR measurements. This supplier also provided high purity DMSO (≥ 99.5%) used
in DNA-binding assays and for recrystallisation of metal complexes. The other
chemicals and solvents used in DNA purification and DNA-binding studies, namely
ammonium acetate (NH4OAc), acetic acid, ammonia, and acetonitrile (ACN) were
purchased from Ajax Finechem (Seven Hills, Australia). Thiazole orange used in
fluorescence indicator displacement (FID) assays was obtained from Chemscene
(New York, USA). Caesium iodide used for calibration of the mass spectrometer
(Waters Q-TOF UltimaTM) was purchased from Fluka (Buchs, Switzerland).
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2.2 Characterisation of metal complexes
2.2.1 General characterisation
The molecular weights of metal complexes were determined using a Waters
Quattro micro ESI mass spectrometer. Prior to measurement, non-alkylated
complexes were dissolved in 100% MeOH, while alkylated complexes were prepared
in 50:50 H2O:MeOH. All solutions containing metal complexes for molecular weight
determinations had concentrations no greater than 20 M. The solutions were
injected into the instrument at a flow rate of 20 L/min. Mass spectra of metal
complexes were obtained in positive ion mode after the operating parameters were
optimised to obtain the strongest analyte signal. Table 2.1 provides the typical
instrumental parameters used whilst obtaining mass spectra.
Table 2.1 Instrumental parameters used to obtain ESI mass spectra of metal complexes
using the Waters Quattro micro ESI mass spectrometer.
MS Parameter
Ion mode
Capillary (V)
Cone voltage (V)
RF lens energy (V)
Source block temperature (°C)
Desolvation temperature (°C)
Desolvation gas flow (L/hour)
Collision energy (V)
Acquisition mass range (m/z)
Number of acquisitions
Multiplier

Non-alkylated
complexes
+ve
3500
55-200
1-2
60
140
300
2
200-900
40
200-260

Alkylated complexes
+ve
3500
10-80
1-2
60-80
140
300
2-10
200-1200
40
170-200

Varian 500 MHz nuclear magnetic resonance (NMR) spectrometers were used
to obtain 1H and

13

C NMR spectra of metal complexes. The NMR spectra of

non-alkylated complexes were obtained using solutions prepared in (CD 3)2SO,
whereas for alkylated complexes CDCl3 was most commonly used. All chemical
shifts () are reported in ppm relative to tetramethylsilane (SiMe4). For 1H spectra,
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the internal standards were the resonances from (CD3)(CD2H)2SO and CHCl3, which
were at 2.5 and 7.26 ppm, respectively. In the case of

13

C spectra the resonances

from the two solvents at 39.5 and 77.2 ppm for (CD 3)2SO and CDCl3, respectively,
were used as internal references. In several cases where it was difficult to assign
NMR spectra of alkylated complexes owing to overlapping resonances, spectra were
also obtained using (CD3)2SO solutions, to enable comparison with the NMR spectra
of the corresponding non-alkylated precursor complex. Assignments of conventional
(1D) 1H and

13

C NMR spectra were facilitated by using two-dimensional (2D) NMR

methods including COSY, TOCSY, HSQC, HMBC and NOESY. The percentage of
C, H, N and Ni in every compound was obtained by elemental analyses in order to
assure the purity and structure of synthesised complexes. Elemental analyses were
performed by analysts of the Campbell Microanalytical Laboratory within the
Department of Chemistry, University of Otago, New Zealand.

2.2.2 Crystallographic characterisation
Since many of the complexes prepared could be obtained as high quality
crystals, their molecular structures were determined using X-ray crystallography.
These analyses were carried out at the Research School of Chemistry, Australian
National University (ANU) by Dr Anthony Willis. X-ray data was collected at 150 °K
using a SuperNova Dual EosS2 diffractometer and Cu K radiation with
= 1.54184 Å. The CrysAlis PRO program was used for data reduction and cell
refinement. Empirical absorption corrections were introduced using spherical
harmonics implemented in the SCALE3 ABSPACK scaling algorithm. SIR92[199]
was used to solve structures, which were then refined by the CRYSTALS
program[200] using the full matrix least-squares method. Molecular graphics were
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obtained using PLATON [201] while the geometric properties of the metal complexes
were analysed using the Mercury 3.6 program.
During refinement of crystallographic structures, the H atoms were initially
assigned at calculated locations and rode on the carbon atom sites to which they
were bonded, whereas H atoms located in a difference electron density map were
repositioned geometrically. At first, all H atoms were refined by soft restraints on the
bond lengths and angles to reorganise their geometry (C—H in the range
0.93–0.98 Å, O—H = 0.83 Å) with the isotropic displacement parameter Uiso(H) in the
range 1.2–1.5 times the equivalent isotropic displacement factor Ueq of the parent
atom. After this, the positions of H atoms bonded to C were refined with riding
constraints and the displacement parameters were held fixed while the positions of H
atoms bonded to O were allowed to refine freely.
Restraints were not required for complexes which had minimal disorder in the
packing of molecule. In contrast, for complex (72), which was the racemic mixture of
two enantiomers, there was disorder in the solid state arising from the methyl group
appearing to be attached to either of the two carbons of the ethylenediamine moiety.
Disorder was also observed on one side arm of the lead complex (71). For
refinement of disorder in (72), the positions of atoms in the affected regions were
firstly assigned on two sites, and the relative occupancies of the sites refined
appropriately. Restraints were then performed on the disordered areas of both
complexes in order to equalise the corresponding bond lengths so adjacent sites
would have similar displacement parameters to each other. The other steps used to
refine the crystal structures were identical to the procedures presented above.
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2.3

Preparation

of

solutions

of

metal

complexes

and

oligonucleotides for DNA-binding studies
2.3.1 Preparation of metal complex stock solutions
Five different solvents were used to prepare solutions containing DNA or metal
complexes that were used in DNA-binding experiments. The composition of these
solvents and the different types of DNA-binding experiments they were used for are
presented in Table 2.2. Stock solutions containing 1 mM metal complex were
prepared by first dissolving the required quantity of complex in 200 L MeOH, since
they did not readily dissolve in water. 10 L of 100 mM HCl solution was added to
ensure that the metal complex was fully dissolved, then 790 L of the same solvent
used to dissolve the DNA (for a selected experiment) was added. For complex (79),
100% MeOH was used to prepare the stock solution as this complex had limited
solubility in the presence of water.
Table 2.2 Composition of different solvents used to prepare stock DNA and metal complex
solutions for DNA-binding experiments.
Solvent

Composition

DNA

1

150 mM NH4OAc in MilliQTM
water, pH 7.4

Parallel structures
of Q1, c-kit1, Q4

2

100 mM NH4OAc in MilliQTM
water, pH 7.4

D2, CT-DNA

3

4
5

100 mM NaCl in MilliQTM water,
15 mM NaH2PO4, 15 mM
Na2HPO4, pH 7.4
100 mM KCl in MilliQTM water,
15 mM KH2PO4, 15 mM K2HPO4,
pH 7.4
100 mM NaCl and 10 mM
LiCaCoa in MilliQTM water, pH 7.4

Experimental
techniques
FID, MS titration,
CD titration,
CD melting,
FID, MS titration,
CD titration,
CD melting,
UV melting,
UV titration,

Q1 anti-parallel

CD titration,
CD melting

Q1 hybrid-type 1

CD titration

F21T

FRET

a

Lithium cacodylate (LiCaCo) was prepared by mixing lithium hydroxide and cacodylic acid at the
same concentrations.
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2.3.2 Purification of oligonucleotides
The sequences of oligonucleotides used in this project and their calculated
molecular masses are listed in Table 2.3. The molecular masses of DNA were
obtained using the Oligonucleotide Properties Calculator.[202] PCR grade single
stranded (ss) oligonucleotides were purchased from Sigma (New South Wales,
Australia) as ‘trityl-off’ derivatives and purified using the method reported in previous
studies.[58, 154, 203, 204] Dried samples of oligonucleotides (1 mol) were
dissolved in 1 mL of 10 mM NH4OAc solution prior to being purified by high
performance liquid chromatography (HPLC) using a Waters 1525 Binary HPLC
pump together with a C18 (octadecylsilyl) column (8 × 100 mm Waters Delta Pak
Radial Cartridge) and a Rheodyne manual injector. The column was equilibrated with
10 mM NH4OAC solution for 30 min prior to the sample being injected, and a linear
gradient of 0 – 60% aqueous acetonitrile in 10 mM NH4OAC was used to elute the
ssDNA at a flow rate of 1 mL/min over a period of 35 min. Aliquots containing
purified ssDNA were collected and combined, then freeze-dried using a Savant
SpeedVac (Selby-Biolab, Australia). The solid ssDNA was then redissolved in
MilliQTM water and stored at -20 °C prior to further use.
The concentrations of purified oligonucleotides were obtained using the
Beer-Lambert Law and the measured absorbance of aqueous solutions at 260 nm.
The extinction coefficients for each type of DNA were determined by adding the
values of the component bases, which are 15200, 8400, 12010 and 7050 M-1 cm-1
for guanine, thymine, guanine and cytosine, respectively.[202, 205] As a guide, 5
crude 1 mol samples of DNA supplied from the manufacturer yielded 1 mL ssDNA
solution of approximately 1 mM after purification and combination.
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Table 2.3 Properties of oligonucleotides used in this project.

Annealed
DNA code

Q1
F21T

c-kit1
Q4
D2

Molar
extinction
coefficient
(M-1 cm-1)
[202]

Description

Base sequence 5´- 3´

Molecular
Mass
(Da)[202]

human telomeric single
stranded qDNA

GGG(TTAGGG)3

6653.4

240120

FAM-GGG(TTAGGG)3TAMRA

na

na

GGG AGG GCG CTG GGA
GGA GGG

6698.4

248250

(TTG GGG GT)4

9986.8

85250a

GCT GCC AAA TAC CTC C
GGA GGT ATT TGG CAG C

4786.2
4977.3

159370
177370

human fluorescent
labeled oligonucleotide
21mer single stranded
qDNA
four stranded qDNA
16-mer double
stranded DNA

d2A
d2B

a

The molar extinction coefficient of Q4 was calculated using one strand of DNA, since it was present
as ssDNA at the time this measurement was performed.

2.3.3 Preparation of double stranded DNA and quadruplex DNA
The double stranded DNA (dsDNA) molecule D2 was prepared by mixing
appropriate amounts of the complimentary ssDNA sequences d2A and d2B together,
and then freeze drying the resulting mixture using a Savant SpeedVac. The required
volume of solvent 2 (Table 2.2) was then added to the dried sample to give a 1mM
solution that was then annealed by heating in a hot water bath for 15 min at 56 °C.
This temperature was selected because it is 10 °C higher than the calculated melting
temperature of D2.[58, 202] The resulting stock solution of dsDNA was then allowed
to cool gradually to room temperature overnight and stored at -20 °C.
Three ssDNA capable of forming different G-quadruplex structures (Q4, Q1 and
c-kit1) were used in this project. In order to prepare a sample of one of these DNA
molecules, the requisite amount of ssDNA was first freeze dried using the Savant
SpeedVac. The appropriate solvent (Table 2.2) was then added to the resulting solid
sample to afford a 1 mM stock solution. In order to obtain a parallel topology, the
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tetramolecular G-quadruplex Q4 was heated at 90 °C for 15 min and then allowed to
cool to 25 °C overnight.[127]
Three different G-quadruplex topologies, namely parallel, anti-parallel and
hybrid type 1, (Figure 1.10) were obtained for Q1 by using different solvent (Table
2.2) and annealing conditions. Solutions containing the ssDNA form of Q1 were first
annealed at 95 °C for 15 min, and then slowly cooled to room temperature at a rate
of 10 °C/hour in order to obtain the parallel G-quadruplex topology.[58] The
anti-parallel and hybrid forms of Q1 were obtained by annealing the DNA at 95 °C for
10 min and then cooling in ice for 30 min.[157] Due to its instability at high
temperatures, the parallel topology of c-kit1 was obtained by heating a solution of the
single stranded form of this DNA at 50 °C for 5 min, and then allowing the solution to
cool to room temperature. All annealed DNA samples were kept in a freezer at
-20 °C prior to further use.

2.4 Mass spectrometry DNA–binding experiments
The required amounts of 1 mM stock metal complex solution were mixed with
aliquots of annealed DNA solution to give mixtures with metal:DNA ratios of 1:1, 3:1,
6:1 and 9:1. In each case, the final volume of these reaction mixtures and final
concentration of DNA were 100 L and 10 M, respectively. Further details of the
volumes of the stock solutions used to prepare these reaction mixtures are provided
in Table 2.4. The reaction mixtures were allowed to equilibrate at room temperature
for at least 10 min before being injected into the mass spectrometer using a Harvard
Model 22 syringe pump (Natick, USA) at a flow rate of 10 L/min.
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Table 2.4 Guide to preparing reaction mixtures for ESI-MS DNA-binding experiments.
Ratio of metal complex:DNA
Volume of 1 mM DNA stock
solution (L)
Volume of 1 mM metal complex
stock solution (L)
Volume of solvent (L)

1:1
1

3:1
1

6:1
1

9:1
1

1

3

6

9

98

96

93

90

Mass spectra of all reaction mixtures were acquired using a Waters
extended-mass range Q-ToF UltimaTM ESI mass spectrometer (Manchester, UK).
The instrument was equipped with a Z-spray probe and a quadrupole mass analyser
with a m/z range of 32,000, which was sufficient to observe all ions with significant
abundance. Prior to use the instrument was externally calibrated using a solution of
1 mg/mL caesium iodide in MilliQTM water. Mass spectra of the reaction mixtures
were obtained in negative ion mode, since greater signal sensitivity arises as a result
of the phosphate groups losing protons.[143] The instrumental parameters used to
obtain spectra are shown in Table 2.5, and were arrived at after optimization of
values reported in previous studies.[58, 141, 154, 203] In general, each final
spectrum was obtained by combining 40 acquisition scans, performing a background
subtraction using a 11th degree polynomial with 40% of data points beneath the fitted
background curve,[203, 206] and smoothing twice using the Savitzky Golay method.
Table 2.5 Optimised Q-ToF UltimaTM parameters for obtaining ESI mass spectra of reaction
mixtures containing different types of DNA.
MS Parameter
Ion mode
Capillary (V)
Cone voltage (V)
RF lens 1 energy (V)
Source block temperature (°C)
Desolvation temperature (°C)
Desolvation gas flow (L/hour)
Collision energy (V)
Acquisition mass range (m/z)
Number of acquisitions
Multiplier (V)
Multichannel plate (V)

Q4
-ve
2000
40
40-50
25
80
300
5
5004000
40
550
1780

Q1
-ve
2100
40-50
36-45
30
80
300
5
5004000
40
550
1850

c-kit1
-ve
1400
100
25
30
80
300
5
5004000
40
550
1783

D2
-ve
2500
40
50
25
80
100
5
5003000
40
550
1800
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2.5 Circular dichroism (CD) DNA-binding experiments
Reaction mixtures for these experiments were prepared as follows. Initially a
300 L solution containing 20 M dsDNA or qDNA only in the appropriate solvent
(Table 2.2) was prepared. A second solution containing the same DNA at 20 M
concentration as well as a metal complex at 600 M, in the same solvent as the first
solution, was then prepared. Aliquots of this second solution were then added to the
first solution containing DNA only, to give reaction mixtures containing 0:1, 1:1, 3:1,
6:1 ad 9:1 ratios of metal complex:DNA. After mixing, the reaction mixtures were
transferred to a 0.1 cm pathlength quartz cell cuvette, and allowed to stand for
10 min, before their CD spectrum were recorded between 200 to 400 nm at 25 °C
using a Jasco J-810 spectropolarimeter. For each mixture, the CD spectrum of a
solution containing the same concentration of metal complex alone, acquired under
the same conditions, was then subtracted from the spectrum of the mixture in order
to obtain the final spectrum used to determine the wavelengths and ellipticity of CD
bands. The instrumental operating parameters used to perform these CD
experiments are shown in Table 2.6.
Table 2.6 Instrumental parameters for performing CD titration experiments.
Sensitivity (mdeg)
Wavelength range (nm)
Data pitch (nm)
Scanning mode
Scanning speed (nm/min)
Response (second)
Bandwidth (nm)
Number of scans
Temperature (°C)

100
200 - 400
0.1
Continuous
100
2
1
6
25

It should be noted that the signal-to-noise ratio of CD spectra is often poorer at
very low wavelengths (< 215 nm) owing to rapid increases in the high tension (HT)
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voltage applied to the photomultiplier (PMT) tube.[207] The CD spectra within the
wavelength region 200 – 215 nm have still been included in figures in this thesis as it
is believed that may be of interest to scientists who are interested in the CD spectra
of these systems at low wavelength. However, changes in the position and/or
ellipticity of CD bands in this region have not be used to analyse the interactions
between metal complexes and DNA in any of the subsequent chapters.

2.6 Absorption spectrophotometry DNA-binding experiments
2.6.1 Absorption titrations
The binding constants for interactions of nickel complexes with calf thymus
(CT) dsDNA were determined using the absorption titration method. A Varian Cary
100 UV-Vis-NIR Spectrophotometer and 1 cm pathlength quartz cuvettes were used
to perform these experiments. Prior to commencement, a stock solution containing
1 mM metal complex (Chapter 2.3.1) was diluted with solvent 2 to give a working
solution consisting of 3 mL 20 M metal complex. The absorption spectrum of the
working solution was then recorded between 200 and 500 nm. Aliquots of 3 mM
CT-DNA dissolved in solvent 2 were then added to the solution of metal complex in
the spectrophotometer. Following each addition, the spectrum was recorded again
after the reaction mixture had been allowed to equilibrate at room temperature for 10
min. This process was repeated until no significant changes were observed in the
absorption spectrum. The binding constant (Kb) for the interaction was then obtained
by use of a graphical procedure and equation 2.1 :[94, 141, 208]

70

[𝐷𝑁𝐴]
𝜀𝐹 −𝜀𝐴

=

[𝐷𝑁𝐴]
𝜀𝐹 −𝜀𝐵

+

1
𝜀𝐹 −𝜀𝐵

× 𝐾𝑏 (2.1)

In this equation, [DNA] is the concentration of CT-DNA in the reaction mixture,
and A, B and F correspond to the extinction coefficients of the solution under
investigation, the extinction coefficient of the metal complex after it has become fully
bound to DNA, and the extinction coefficient of the free metal complex, respectively.
By plotting [DNA] against [DNA]/(F – A) the binding constant for the interaction was
able to be determined from the y-intercept (Kb/(F – B)) and the slope 1/(F – B) of
the resulting line of best fit.

2.6.2 DNA melting experiments
Melting curves for solutions containing D2 alone, or solutions with a 3:1 or 6:1
ratio of nickel complex:D2, were obtained by monitoring the absorbance of the
solution at 260 nm over the temperature range 25 to 90 °C. A Varian Cary 100
UV-Vis-NIR Spectrophotometer and 1 cm pathlength quartz cuvette were used for
these experiments. The filter size for the spectrophotometer was set to 101, and data
were collected at 0.3 °C intervals, with the temperature ramping rate set to 1 °C/min.
All solutions contained 1 M DNA in 100 mM NH4OAc, pH 7.4, and were left to stand
at room temperature for 10 min prior obtaining the DNA melting curve. Experiments
were performed in triplicate and the melting temperatures (Tm) calculated using the
Thermal-UV software associated with the Cary100 instrument.

2.7 Fluorescence intercalator displacement (FID) assays
For FID assays, 1 mM solutions of parallel Q1 or Q4, or D2, dissolved in the
appropriate solvent (Table 2.2) were prepared, and then diluted using the same
solvent to afford solutions containing 25 M DNA. Thiazole Orange (TO) was initially
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dissolved in DMSO to give a 100 M stock solution. This and the 25 M DNA
solution were used to prepare a 2.8 mL working solution consisting of 0.25 M DNA
and 0.5 M TO dissolved in the same solvent as the DNA being studied.[126] A
separate solution containing metal complex (100 M), DNA (0.25 M) and TO
(0.5 M) was prepared, and aliquots added to the above working solution containing
DNA and TO only. This afforded reaction mixtures with different concentrations of
metal complex but the same concentration of DNA and TO. The reaction mixtures
were thoroughly mixed and then allowed to stand for 3 min prior to measurement of
their fluorescence spectra. These were obtained using an Agilent Cary Eclipse
fluorescence spectrophotometer and 1 cm pathlength quartz cuvette. Data were
acquired at room temperature over the wavelength range 515-750 nm using an
excitation wavelength of 501 nm.[126, 209] The excitation slit width was 5 nm, the
emission slit width 10 nm, the scan rate 120 nm/min and the detector voltage 600 V.
The maximum fluorescence intensity was measured and the percentage TO
displacement obtained using equation 2.2:[209, 210]

%𝑇𝑂 𝑑𝑖𝑠𝑝𝑙𝑎𝑐𝑒𝑚𝑒𝑛𝑡 =

𝐼𝑜 −𝐼
𝐼𝑜

× 100% (2.2)

In this equation, I and Io are fluorescence intensities collecting at the emission
wavelength (535 nm) of TO in the presence and absence of nickel complex,
respectively. The concentration of nickel complex that caused a 50% displacement
of TO (DC50) was determined by plotting the intensity data according to the SternVolmer equation:[209, 210]
𝐼𝑜
𝐼

= 1 + 𝑘𝑐 (2.3)

In this equation, c is the concentration of nickel complex and k is a constant.
Since Io/I = 2 when c = DC50, the DC50 value can be calculated from the gradient and
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y-intercept of the regression line. Experiments were performed in triplicate in order to
obtain the average value of DC50 and standard error.

2.8 Fluorescence resonance energy transfer (FRET) DNA-binding
assays
All 96-well plates and sealed films used in these experiments were
fluorescence capable and purchased from Roche Diagnostics (Australia). The
oligonucleotide F21T (HPLC purified) was tagged with fluorescent donor and
acceptor groups, and was obtained from Sigma Aldrich (Castle Hill, Australia). F21T
was initially dissolved in MilliQTM water to prepare a 100 M stock solution. This was
then diluted using 1 M NaCl, 20 mM lithium cacodylate (LiCaCo), pH 7.4, and
MilliQTM water to produce a working solution containing 0.25 M oligonucleotide,
125 mM NaCl and 12.5 mM LiCaCo.[127] The working solution was then heated for
5 min at 95 °C and cooled straight away on ice for 30 min. The 20 mM lithium
cacodylate solution was prepared by mixing 20 mM lithium chloride and 20 mM
cacodylic acid obtained from Sigma Aldrich (Castle Hill, Australia). Metal complexes
were initially prepared as 1 mM stock solutions, but were then diluted using MilliQTM
water to afford a series of intermediate solutions with concentrations of 5, 10, 20 and
25 M.
A 20 L aliquot of 0.25 M F21T was added to each well of a 96-well plate. To
each well was added 5 L of 5, 10, 20, 25 or 50 M metal complex. The only
exception to this was the control samples, where 5L of MilliQTM water was added
instead of metal complex solution. The final concentrations of nickel complex in the
wells were 0, 1, 2, 4, 5, and 10 M, while the final concentration of F21T was 0.20
M. Duplicate samples were prepared for each nickel:DNA ratio. Once all samples
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had been added, the 96-well plates were sealed using a fluorescent capable
adhesive film and centrifuged at 1000 rpm for 1 min at 20 °C. Measurements of
fluorescence emission at 515 nm were made over the temperature range 25 to 95 °C
at a ramping rate of 1 °C/min using a Lightcycler 480 quantitative Polymerase Chain
Reaction (PCR) instrument. Experiments were performed in triplicate.
The fluorescence emission data were normalised using GraphPad Prism
software 6.1 in order to fit within the range 0 – 1. The melting temperature (Tm) of the
DNA was defined as the temperature which corresponded to a normalised
fluorescence emission of 0.5.

2.9 Molecular docking experiments
Molecular docking experiments were performed using the procedure outlined in
Figure 2.1. The first step was preparing the Protein Data Bank (PDB) partial charge
(Q) and atom type (T) PDBQT format files for DNA molecules. In order to do this the
crystal structure of a unimolecular parallel G-quadruplex (PDB code 1KF1) was
obtained.[22] This has the same base sequence as the 22AG used in other DNAbinding experiments described in this thesis, and is very similar to the sequence of
the human telomeric oligonucleotide Q1. Docking experiments were also performed
using a duplex DNA (PDB code 1KBD [211]).
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Figure 2.1 Outline of the procedure used for performing Molecular Docking experiments
using AutoDock Vina.

The DNA structures were initially edited and corrected by uploading their PDB
files to Procheck (WhatIF) website (http://swift.cmbi.ru.nl/servers/html/) to detect
potential errors. The structure energy of the DNA molecules was then minimised in
Accelrys DS visualizer 2.0 software with CHARMM22 force field, using the steepest
descent algorithm (3000 steps), and other default parameters.[188, 212] The
crystallographic structures of complexes (71), (75), (81) and (89) were used as
ligands without further optimisation, whereas all other complexes were designed by
ChemDraw Professional 15.0. The latter ChemDraw structures were converted to
molfile format and hydrogen atoms added using OpenBabel 2.3.2. The 3D structures
of metal complexes were first optimised using Avogadro 1.1.1 software employing
the Universal Force Field (UFF) with Steepest Descent algorithm and the number of
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steps per update equal to 4. Density Functional Theory (DFT) calculations
implemented in the Gaussian09 program package were then applied to optimise the
metal complex structures using the B3LYP functional and the 6-31G(d,p) basis
set.[130] The calculation was conducted via a high performance computer (HPC).
The optimised results were collected in a log files format, which was then were
converted to Protein Data Bank (PDB) files using OpenBabel. The PDBQT files of
DNA molecules and metal complexes were generated by using AutoDock Tools
[130, 184] (version 1.5.6) to upload their PDB files, and then adding polar hydrogen
atoms to the receptors and assigning the rotatable bonds to the complexes.
The molecular docking experiments were performed as blind docking
experiments in which the position and size of the search spaces were carefully
selected to cover the whole receptor. The dimensions of the grid box were chosen to
be large enough for the ligands to rotate, which was no smaller than 22.5 Å, and
larger than that of the ligand by at least 15 Å, with a spacing of 0.375 Å between the
grid points.[95, 184] There was no precise instruction for limiting the size of the grid
box, however, it was recommended that the search space should be large enough
for the ligands to rotate.[213] The centre of the grid box was chosen to be at the
same position as the centre of the receptor, which was determined to be at the
middle of its dimensions along the x, y, z coordinates using VMD. A configuration file
was prepared containing all the required information along with other parameters
including the PDBQT file name of the DNA molecules and metal complexes, the
exhaustiveness of global search, the number of CPUs and the maximum number of
binding modes to generate. The configuration file and PDBQT files then were loaded
into AutoDock Vina [130, 184, 209, 212] (version 1.1.2) to perform the molecular
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docking procedure and obtain visual representations of the binding of the metal
complexes to the DNA.
The docking protocol was validated by comparing the docking results using a
Schiff base complex with the G-quadruplex DNA 3QSC to that of a solid state
structure obtained previously using the same nickel complex and 3QSC.[94] The
binding affinity of metal complexes towards the different DNA molecules was
expressed as the predicted free energy of the binding interactions in kcal/mol
(G),[184, 212] while visualisation of optimized docking configurations was
performed using PyMol 1.3 software.[114]
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Chapter 3 :

Synthesis

characterisation

of

and

nickel

structural

complexes

of

benzophenone Schiff base ligands
3.1 Introduction
Schiff base formation facilitated by the condensation of a carbonyl compound
with an amine is one of the most well-known reactions in chemistry.[214] One
example is the synthesis of metal derivatives of salphen and related ligands via the
reaction

of

1,2-phenylenediamine

and

other

diamines

with

2,4-

dihydroxybenzaldehyde.[93, 94, 127] Replacement of 2,4-dihydroxybenzaldehyde by
substituted benzophenones enables the synthesis of a range of new metal
complexes that feature additional benzene rings, but retain hydroxy groups on their
periphery that can then be used to introduce positively charged pendant groups that
may provide further interactions with G-quadruplexes. This chapter will present the
synthesis of a number of metal complexes of Schiff base ligands derived from
substituted benzophenones, together with their full characterisation. Issues that
arose during the preparation of these new Schiff base complexes are also
discussed. The structures and identities of all metal complexes were verified using
elemental analyses, NMR spectroscopy and ESI mass spectrometry. In addition,
X-ray crystallography was employed to determine the solid state structures of a
number of the novel complexes.
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3.2 Overview of synthetic procedures
3.2.1 Synthetic reactions
Most of the metal complexes of alkylated Schiff base ligands used in
DNA-binding studies for this project were synthesised using the synthetic scheme
outlined

in

Figure

3.1,

which

was

used

for

ligands

derived

from

2,4-dihydroxybenzophenone. The molar ratio of benzophenone derivative to diamine
was typically slightly greater than 2:1, to minimise production of “half ligand”
by-products via 1:1 condensation reactions. In addition, the amount of nickel acetate
used was slightly greater than what was required to complex all the Schiff base
ligand formed, in order to ensure that there was no free ligand after the reaction was
complete. The overall synthetic procedure consisted of 3 distinct steps. In the first
step, a diamine compound was dissolved in methanol and then added to a
methanolic solution containing a benzophenone derivative. In the second step,
Ni(OAc)2.4H2O was added in order to obtain the nickel complex of the initial
(non-alkylated) Schiff base ligand. The above reaction mixtures were typically stirred
for several hours to ensure the reactions went to completion. No attempts were
made to isolate the metal-free Schiff base ligands. Instead, nickel complexes of the
non-alkylated Schiff base ligands were obtained as fine powders that were easy to
separate from reaction mixtures by filtration.
The third step in the synthetic procedure was the alkylation reaction. Prior to
commencing this step, the non-alkylated complexes were dried at 60 °C until their
masses no longer changed. This drying process was conducted strictly to ensure
that all the solvents and water present in the initial products were removed, since the
presence of protic solvents could induce the alkylating reaction to take place at
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carbon instead of the desired O-alkylation occurring.[215] For the same reason, the
alkylation reactions performed using 1-(2-chloroethyl)-piperidine HCl were conducted
in anhydrous DMF.

Figure 3.1 General synthetic scheme for producing nickel complexes of derivatised Schiff
base ligands using 2,4-dihydroxybenzophenone.

The O-alkylation reaction can only occur at the 4-position, since the
2-hydroxyl groups were protected by coordination to the nickel centres.[216] An
excess of 1-(2-chloroethyl)piperidine was used to ensure both 4-OH groups were
fully alkylated. The pendant groups present in all the alkylated complexes presented
in this thesis would be expected to have pKa values roughly equal to 10.4, as this is
the pKa of 1-ethyl piperidine.[217] This would result in the piperidine groups
remaining > ~ 90% protonated under the solution conditions used for performing the
DNA binding experiments described in this thesis. The progress of alkylation
reactions was monitored by thin layer chromatography (TLC).
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3.2.2 Purification procedures
All non-alkylated complexes were easily separated from reaction mixtures using
vacuum filtration, washed with 500 mL water, and dried under vacuum overnight and
on a hot plate at 60 °C. The alkylated complexes were separated from reaction
mixtures also using vacuum filtration. The resulting crude products were washed with
20 mL DCM to selectively redissolve the nickel complexes. The filtrates from the
original reaction mixtures were combined with these DCM extracts, and the
combined solutions then evaporated carefully to give a solid residue. These were
then purified by redissolving in DCM, and washing the solution ten times with 1 L
water to remove unwanted by-products. The final DCM solution was then dried using
MgSO4, before the DCM was allowed to evaporate at room temperature to yield the
final, purified products. In most cases the above procedure was sufficient to obtain
alkylated complexes with sufficient purity for DNA-binding studies. However, in some
cases, the alkylated nickel complexes needed further purification using either column
chromatography (complex (95)) or recrystallisation (complexes (77) and (93)). The
recrystallisation method proved to be very useful for the latter nickel complexes as
they exhibited very low mobility on silica gel columns with many different eluents.

3.3 Results and discussion
3.3.1 Synthesis of nickel complexes containing different diamine
groups
These complexes were synthesised as outlined in Figure 3.1 using
2,4-dihydroxybenzophenone and different diamines. Table 3.1 shows the effect of
varying the reaction conditions for the different steps of the synthetic procedure on
the yield of products. Also included is the effect of varying the reaction conditions on
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the yield of (54_P) and (54). These complexes were included as (54) was used in
many DNA-binding studies for comparative purposes. Initial attempts at preparing
complex (70) used conditions reported in the literature.[93, 127] This included a
reaction time of only 0.5 h and 3h for the first and second steps of the reaction.
Performing the reaction under these conditions returned the desired product with a
very low yield of 7.9%. Increasing the reaction time, particularly for the alkylation
reaction, resulted in a significant improvement in yield. For example, the yield of (70)
was 78.1% after the reaction time was increased to 18 h for step 1 and 8 h for
step 2. Similarly, increasing the length of step 2 from 8 to 12 h resulted in the yield of
(72) increasing from 58.9 to 93.9%. In general, increasing the length of steps 1 and 2
afforded better yields of each of the non-alkylated complexes.
Table 3.1 Effect of changing reaction conditions on yields of nickel Schiff base complexes
prepared using different diamine groups.

Diamine
groups

Non-alkylated complexes
Length
of
Yield
Complex
step1
(%)
and 2
(h)b
(54_P)a

(70)
(72)

(76)

(74)

0.5; 3

64
53c

0.5; 3
18; 8
12; 8

8
78
59

12; 12

94

12; 12

94

12; 12

33

24; 48

96

Alkylated complexes

Complex

(54)a

(71)
(73)

(77)

(75)

Length
of step
3 (day)

Temperature
(°C)d

Yield
(%)

1.5

RT

3

RT

3

60

31
42
47c
59

3

60

82

3

RT

0

3

60

70

14

60

0

5

110

0

10
3
5
5

RT
60
110
RT

20
impure
0
66

a

Complex was synthesised using 2,4-dihydroxybenzaldehyde instead of 2,4-dihydroxybenzophenone.
Step 1 and 2 are the reaction times for preparing the non-alkylated nickel Schiff base ligands and
the corresponding nickel complexes, respectively.
c
Literature yield.[93]
d
RT indicates reactions were performed at room temperature.
b
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The alkylation reactions were also performed using different temperatures and
reaction times in an effort to improve yields. Initial attempts at preparing nickel
complexes of novel alkylated Schiff base ligands used the optimum conditions for
synthesising the closely related reference compound (54). The highest yield obtained
for this complex was 59.1%, after performing step 3 at 60 °C for 3 days. These
conditions were therefore used for performing the alkylation reactions to prepare the
novel alkylated complexes. While good yields were obtained for (70) and (72) using
these preparative conditions, this was not true for (75) and (77), which were more
effectively prepared at room temperature using longer reaction times.
Details of the synthetic procedures used to prepare individual complexes are
presented below, together with characterisation data. A comprehensive description
of how the NMR spectra for the lead complexes (70) and (71) were assigned is
provided to illustrate the procedures used with the other novel complexes. For the
remaining complexes, the discussion of their NMR spectra is focused on the unique
features and problems that were encountered, for example, as a result of
overlapping proton resonances. Once the resonances for all 1H NMR signals had
been assigned using a combination of 1D and 2D methods, the

13

C resonances were

able to be readily assigned using HSQC and HMBC spectra.
N,N′-Bis-4-(hydroxysalicylidine)phenylenediaminenickel(II) (54_P)
This reference complex was synthesised using the method reported by Reed et
al.[93] O-phenylenediamine (548 mg, 5.07 mmol) was reacted with 2,4dihydroxybenzaldehyde (1422 mg, 10.3 mmol) in 50 mL MeOH. A yellow precipitate
appeared after approximately 5 min. The reaction mixture was brought to reflux for
30 min, and then Ni(OAc)2·4H2O (2469 mg, 9.92 mmol) was added. A red solid
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appeared immediately, and heating at reflux was
continued for a further 3 h to afford the product as a red
powder. Yield: 715 mg, 64%. ESI-MS calc.: [M+Na]+ =
427.01. Found: [M+Na]+ = 426.9. 1H-NMR (500 MHz,
DMSO-d6): 6.21 (s, 2H, H10); 6.22 (d, J = 9.76 Hz, 2H, H8); 7.21 (dd, J = 2.87 and
5.56 Hz, 2H, H1); 7.41 (d, J = 8.47 Hz, 2H, H7); 7.99 (m, 2H, H2); 8.55 (s, 2H, CH=N-); 10.2 (br s, 2H, -OH).13C NMR (500 MHz, DMSO-d6):  104.14 (C10); 108.39
(C8); 115.13 (C6); 116.08 (C2); 127.03 (C1); 136.47 (C7); 143.09 (C3); 154.79 (C5);
165.01 (C9); 167.91 (C11).
N,N′-Bis-(4-((1-(2-ethyl)piperidine)oxy)salicylidine)phenylenediaminenickel(II) (54)
The alkylated version of the above reference compound
was prepared using a similar method to that reported by
Reed et al.,[93] with the exception that a higher
temperature was used. A suspension of
(468

mg,

1.15

mmol),

(54_P)

1-(2-chloroethyl)piperidine

hydrochloride (475 mg, 2.58 mmol) and K2CO3

(288

mg, 2.08 mmol) in 10 mL anhydrous DMF was stirred for
72 h under N2 at 60 °C. The crude product was collected by vacuum filtration, and
purified using the DCM/water extraction procedure reported in Chapter 3.2.2 to give
the desired complex as a red solid (220 mg, 59%). ESI-MS calc.: [M+H]+ = 627.3.
Found: [M+H]+ = 627.2. 1H-NMR (500 MHz, CDCl3,): 1.46 (m, 4H, H19); 1.62 (m,
8H, H18, H20); 2.51 (s, 8H, H17, H21); 2.78 (t, J = 5.75 Hz, 4H, H15); 4.10 (t, J =
5.77 Hz, 4H, H14); 6.29 (dd, J = 1.60 and 8.81 Hz, 2H, H8); 6.57 (s, 2H, H10); 7.10
(m, 2H, H1); 7.13 (d, J = 9.10 Hz, 2H, H7); 7.61 (dd, J = 3.29 and 5.91 Hz, 2H, H2);
7.99 (s, 2H, -CH=N-). 13C NMR (500 MHz, CDCl3,):  24.38 (C19); 26.10 (C18, C20);
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55.14 (C17, C21); 57.83 (C15); 66.14 (C14); 103.29 (C10); 109.16 (C8); 114.60
(C2); 114.87 (C6); 126.69 (C1); 134.37 (C7); 142.99 (C3); 152.40 (C5); 165.18 (C9);
168.49 (C11).
N,N′-Bis-(4-(hydroxybenzophenylidene))ethylenediaminenickel(II) (70)
This compound was synthesised using the method for
preparing (54_P) reported by Reed et al., [93] with slight
modifications. Ethylenediamine (341 mg, 5.67 mmol) in
2 mL methanol was added dropwise into a 10 mL
methanolic solution of 2,4-dihydroxybenzophenone (2869 mg, 13.4 mmol). A yellow
precipitate appeared after 4 h, after which the reaction mixture was brought to reflux
for 14 h. Upon adding Ni(OAc)2·4H2O (3022 mg, 12.1 mmol), the suspension turned
from yellow to red within 30 min. The reaction mixture was held at reflux for a further
8 h to afford the product as a red powder. Yield: 2253 mg, 78%. Microanalysis calc.
for C28H22N2NiO4·3H2O: C = 59.71%; H = 5.01%; N = 4.97%; Ni = 10.42%. Found: C
= 59.65%; H = 5.23%; N = 4.75%; Ni = 10.70%. ESI-MS calc.: [M+H]+ = 509.1,
[M+Na]+ = 531.1. Found: [M+H]+ = 509.0, [M+Na]+ = 531.0. 1H-NMR (500 MHz,
DMSO-d6): 2.71 (s, 4H, H1); 5.85 (dd, J = 2.14 and 8.99 Hz, 2H, H12); 6.12 (d, J =
2.11 Hz, 2H, H14); 6.25 (d, J = 8.98 Hz, 2H, H11); 7.15 (d, J = 6.58 Hz, 4H, H5, H9);
7.46 (m, 6H, H6, H7, H8); 9.74 (br s, 2H, -OH).

C NMR (500 MHz, DMSO-d6): 
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55.84 (C1); 104.56 (C14); 105.85 (C12); 115.86 (C10); 127.29-127.48 (C5, C9);
129.35-129.62 (3C, C6, C7, C8); 134.52 (C11); 136.08 (C4); 162.38 (C13); 167.05
(C15); 169.60 (C3).
The 1H NMR spectrum of complex (70) is shown in Figure 3.2, with particular
resonances highlighted. Each of the protons in the aromatic rings containing the OH
groups were more shielded than the other aromatic resonances, and consequently
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had chemical shifts between 5.8 and 6.3 ppm. The reasons for their greater shielding
are unclear, but may be related to the greater degree of coplanarity of the bottom
aromatic ring system with the central Schiff base moiety. The assignments for H11,
H12 and H14 were confirmed using a COSY spectrum and by comparison of the
observed coupling to the theoretical values, 4Jortho = 2.14 Hz and 3Jmeta = 8.99
Hz.[218] The most deshielded resonance was a very broad singlet located at 9.74
ppm. This was assigned to the –OH protons which were still present in this nonalkylated complex. The singlet at 2.71 ppm was assigned to the aliphatic CH 2 groups
by virtue of their relatively shielded chemical shift.
H6,7,8
H5,9

H11

H14

H12
H2O

H1

DMSO
-OH(17)

Figure 3.2 1H NMR spectrum of (70), with the atom numbering scheme shown.

N,N′-Bis-(4-((1-(2-ethyl)piperidine)oxy)benzophenylidene)ethylenediaminenickel(II)
(71)
A suspension of (70) (781 mg, 1.53 mmol), 1-(2-chloroethyl)piperidine
hydrochloride (918 mg, 4.99 mmol) and K2CO3 (1474 mg, 6.95 mmol) in 10 mL
anhydrous DMF, was stirred for 72 h under N2 at 60 °C. This yielded a solid which
was isolated by vacuum filtration and purified as described in Chapter 3.2.2 to afford
the desired complex as an orange-red solid (895 mg, 82%). Microanalysis calc. for
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C42H48N4NiO4·0.5H2O: C = 68.12%; H = 6.67%; N =
7.57%; Ni = 7.93%. Found: C = 68.32%; H = 6.20%; N
= 7.53%; Ni = 7.77%. ESI-MS calc.: [M+H]+ = 731.3.
Found: [M+H]+ = 731.2. 1H-NMR (500 MHz, CDCl3,):
1.43 (br s, 4H, H23); 1.59 (m, 8H, H22, H24); 2.47
(br s, 8H, H21, H25); 2.74 (t, J = 5.89 Hz, 4H, H19);
2.76 (s, 4H, H1); 4.07 (t, J = 5.86 Hz, 4H, H18); 5.97
(dd, J = 2.18 and 9.12 Hz, 2H, H12); 6.42 (d, J = 9.12 Hz, 2H, H11); 6.54 (d, J = 2.12
Hz, 2H, H14); 7.07 (m, 4H, H5, H9); 7.42 (m, 6H, H6, H7, H8).

13

C NMR (500 MHz,

CDCl3,):  24.23 (C23); 25.93 (C22, C24); 54.86 (C21, C25); 55.59 (C1); 57.72
(C19); 65.58 (C18); 103.44 (C14); 106.30 (C12); 115.78 (C10); 126.68 (C5, C9);
128.76 – 128.87 (C6, C7, C8); 133.47 (C11); 135.98 (C4); 162.75(C13); 167.04
(C15); 169.78 (C3).
Since complexes (70) and (71) have the same aromatic scaffold, it is not
surprising that there were strong similarities between their NMR spectra. The
additional resonances in the aliphatic region of the 1H NMR spectrum of (71) (Figure
3.3) arise from the pendant dimethylenepiperidine groups. This includes two coupled
triplets (Figure 3.4) that were assigned to the two methylene groups in each of the
side arms. The more deshielded of these triplets was at 4.07 ppm, and was assigned
to the CH2 groups adjacent to the more electronegative oxygen atom. The second
triplet was found at 2.74 ppm, and assigned to the CH2 groups adjacent to the less
electronegative nitrogen atom. The three most shielded resonances arise from the
three CH2 groups in the heterocyclic rings, and were assigned on the basis of their
relative integration and coupling patterns in a gCOSY spectrum (Figure 3.4).
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H6,7,
H5,9
8

H1
H14

H11

H12

H19

H22,24

H18
H21,25

H2O

CHCl3

H23

Figure 3.3 1H NMR spectrum of (71), with the atom numbering scheme shown.
H6,7,8

H1
H5,9 4 H11
H12

H18

H19
H22,24
H21,25
H23

Figure 3.4 Gradient-selected correlation spectroscopy (gCOSY) spectrum of (71).

The NOESY spectrum of (71) (Figure 3.5) proved especially useful for
confirming some of the above assignments. For example, the observation of a single
set of cross peaks between the

resonance for H1 and one of the aromatic

resonances, provided strong support for the latter to be assigned to H5 and H9 as
these were in closest proximity. Another set of cross peaks was observed for the
triplet at 4.07 ppm from H18, and the nearest aromatic proton (H14). Finally, the
triplet at 2.74 from H19 showed strong cross peaks with the resonance at 2.47 ppm
confirming the latter should be assigned to the nearest protons on the piperidine ring
systems (H21 and H25).
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H1

H5,9

H18
H14

H19
H21,25

H22,24

Figure 3.5 NOESY spectrum of (71) with highlighted correlations.

Most of the resonances in the

13

C NMR spectrum of (71) could be readily

assigned using the C-H cross-peaks in the HSQC spectrum (Figure 3.6 (a)), as all
proton resonances for the complex had already been assigned. For the carbon
atoms that had no C-H bonds, assignments were made with the assistance of an
HMBC spectrum (Figure 3.6 (b)), which shows correlations between carbon and
hydrogen atoms across multiple bonds. The resonance at 169.78 ppm was assigned
to C3, as it was correlated through three bonds to the chemically equivalent H5 and
H9, as well as to H1 and H11 via the same number of bonds. The resonance in the
13

C spectrum at 135.98 ppm was identified as C4 owing to its correlations with H6

and H8. Similarly, as the

13

C signal at 162.75 ppm showed correlations with H11,

and in particular with H18 on the pendant group, it was assigned to C13. This left the
two

13

C resonances at 115.78 and 167.04 ppm to be assigned to either C10 or C15.

The former resonance was assigned to C10 on the basis of its two strong
correlations with H12 and H14, both of which are three bonds distant. In contrast, the
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last remaining 13C resonance at 167.04 ppm does not show any correlation with H12.
This is consistent with assignment of the former

13

C resonance to C15, as it is

located four bonds apart from H12.
H1
H6,7,8

H14
H5,9 H11

C22,24

H19
H21,25

H18

H22,24
H23

H12

C23

C1
C19
C18

C21,25

C14
C12
C10
C5,9
H6,7,8

C11
C4

(a)
H1

H6,7,8
H5,9

H18

H14
H11
H12

C1
0
H5,9
H6,7,8

C11
C4

C13
C15
C3

(b)
Figure 3.6 HSQC and HMBC NMR spectra of (71), with selected C-H correlations

highlighted: (a) HSQC spectrum; (b) HMBC spectrum.
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N,N′-Bis-(4-(hydroxybenzophenylidene))-1,2-propylenediaminenickel(II) (72)
A racemic mixture of 1,2-diaminopropane (333 mg, 4.50
mmol) was dissolved in 3 mL methanol, and the resulting
solution slowly added to 5 mL of a methanolic solution of
2,4-dihydroxybenzophenone (2148 mg, 10.0 mmol). The
final reaction mixture was then brought to reflux for 18 h, during which time a yellow
precipitate appeared. A solution of Ni(OAc)2·4H2O (2438 mg, 9.80 mmol) in 5 mL
methanol was then added, resulting in the colour of the reaction mixture gradually
changing from pink to orange-red. The reaction mixture was then maintained at
reflux for a further 12 h. The resulting orange-red precipitate was collected and dried
under vacuum (1965 mg, 94%). Microanalysis calc. for C29H24N2NiO4·2H2O: C =
62.28%; H = 5.05%; N = 5.01%; Ni = 10.50%. Found: C = 62.34%; H = 5.04%; N =
4.84%; Ni = 10.50%. ESI-MS calc.: [M+Na]+ = 545.1. Found: [M+Na]+ = 545.0. 1HNMR (500 MHz, DMSO-d6): 1.20 (d, J = 6.40 Hz, 3H, H35); 2.19 (d, J = 13.22 Hz,
1H, H26B); 2.92 (d, J = 5.96 Hz, 1H, H1); 3.05 (dd, J = 5.20 and 13.25 Hz, 1H,
H26A); 5.84 (m, 2H, H12, H21); 6.12 (d, J = 1.79 Hz, 1H, H14); 6.13 (d, J = 1.83 Hz,
1H, H19); 6.15 (d, J = 9.08 Hz, 1H, H11); 6.25 (d, J = 8.98 Hz, 1H, H22); 7.13 (m,
3H, H9, H28, H31); 7.26 (d, J = 6.91 Hz, 1H, H5); 7.47 (m, 6H, H6, H7, H8, H29,
H30, H31); 9.74 (br s, 2H, -OH).

C NMR (500 MHz, DMSO-d6): 21.93 (C35);
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59.65 (C1); 61.16 (26); 104.71 (C14, C19); 105.87 – 105.93 (C12, C21); 115.85
(C10); 127.12 (C28, C32); 127.77 (C5, C9); 129.39 (C6, C7, C8, C29, C30, C31);
135.56 – 136.21 (C4, C27); 162.38 – 162.42 (C13, C20); 166.97 – 167.21 (C15,
C18); 168.72 – 170.53 (C3, C24).
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N,N′-Bis-(4-((1-(2-ethyl)piperidine)oxy)benzophenylidene)-1,2-propylenediamine
nickel(II) (73)
Complex (72) (420.3 mg, 0.80 mmol), was suspended
along with 1-(2-chloroethyl)piperidine hydrochloride (601
mg, 3.26 mmol) and K2CO3 (1493.5 mg, 10.8 mmol) in
DMF (anhydrous, 10 mL) and stirred for 72 h under N 2
at 60 °C. The reaction provided a crude product which
was purified as described in Chapter 3.2.2 to yield (73)
as a brown solid (420 mg, 70%). Microanalysis calc. for
C43H50N4NiO4·0.5H2O: C = 68.44%; H = 6.81%; N = 7.42%; Ni = 7.78%. Found: C =
68.46%; H = 6.65%; N = 7.35%; Ni = 7.40%. ESI-MS calc.: [M+H]+ = 745.3. Found:
[M+H]+ = 745.3. 1H-NMR (500 MHz, CDCl3,): 1.28 (d, J = 6.01 Hz, 3H, H35); 1.43
(m, 4H, H41, H49); 1.59 (m, 8H, H40, H48); 2.33 (d, J = 12.53 Hz, 1H, H26B); 2.47
(s, 8H, H39, H47); 2.74 (m, 4H, H37, H45); 2.98 (m, 2H, H1, H26A); 4.07 (t, J = 6.10
Hz, 4H, H36, H44); 5.97 (td, J = 2.38 and 9.51 Hz, 2H, H12, H21); 6.32 (d, J = 9.13
Hz, 1H, H11); 6.41 (d, J = 9.12 Hz, 1H, H22); 6.55 (d, J = 2.30 Hz, 1H, H19); 6.57 (d,
J = 2.30 Hz, 1H, H14); 7.06 (m, 3H, H9, H28, H32); 7.11 (m, 1H, H5); 7.40 (m, 6H,
H6, H7, H8, H29, H30, H31).
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C NMR (500 MHz, CDCl3):21.77 (C35); 24.42

(C41, C49); 25.98 – 26.25 (C40, C42, C48, C50); 54.72 – 55.36 (C39, C43, C47,
C51); 57.58 – 57.92 (C37, C45); 58.26 (C1); 61.07 (C26); 65.58 – 65.94 (C36, C44);
103.52 – 130.84 (C14, C19); 106.31 – 106.51 (C12, C21); 116.03 – 116.16 (C10,
C23); 126.68 – 127.64 (C5, C9, C28, C32); 128.67 – 129.45 (C6, C7, C8, C29, C30,
C31); 133.51 – 133.85 (C11, C22); 135.71 – 136.32 (C4, C27); 162.84 – 162.94
(C13, C20); 167.20 – 167.34 (C15, C18); 168.82 (C3); 170.71 (C24).
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The 1H NMR spectrum of (73) is shown in Figure 3.7, and is similar to that of
(71). However, the asymmetric structures of (72) and (73) resulted in more complex
NMR spectra than what was observed for the closely related, but symmetrical
complexes (70) and (71). For example, separate doublets were observed for H14
and H19 in the 1H NMR spectrum of (73), as a result of the lower symmetry of this
complex. This was also true for H11 and H22. In addition, the methylene groups
linking the piperidine rings to the rest of the molecule gave overlapping triplets.

H28,32, 9 (5)
H37,45

H14,19
H9 (5)

H22 H11

H36,44

H40,48

H12,21
H6,7,8,
29,30,31

H39,47

CHCl3

H35
H41,
49

H1,26A

H26B

Figure 3.7 1H NMR spectrum of (73), with the atom numbering scheme shown.

The three protons of the ethylenediamine bridge were separated into two
groups of resonances at 2.33 and 2.98 ppm. The multiplet at 2.98 ppm consists of
overlapping resonances from H1 and one of the protons on C26 (H26.A), whereas
the doublet at 2.33 ppm was assigned to H26.B, which is coupled to H26.A
(J = 12.53 Hz). Many of the resonances assigned to protons on the left side of
complex (73) were found at similar chemical shifts to the corresponding protons in
complex (71), which is not surprising in view of the close similarities between their
structures.
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N,N′-Bis-(4-(hydroxybenzophenylidene))-1,3-propylenediaminenickel(II) (74)
A solution of 1,3-diaminopropane (239 mg, 3.23 mmol)
in 3 mL methanol was slowly added to a 7 mL
methanolic

solution

of

2,4-dihydroxybenzophenone

(2074 mg, 9.68 mmol), and the resulting mixture brought
to reflux for 24 h, during which time a yellow precipitate appeared. Ni(OAc) 2·4H2O
(2130 mg, 8.56 mmol) was then added, and the reaction mixture brought to reflux for
a further 48 h, resulting in the formation of the desired product which was collected
and purified followed the procedure in Chapter 3.2.2 to give the final product as a
dark

green

precipitate.

Yield:1513

mg

(96%).

Microanalysis

calc.

for

C29H24N2NiO4·1.5H2O: C = 63.20%; H = 4.95%; N = 5.09%; Ni = 10.67%. Found: C =
63.10%; H = 4.65%; N = 4.84%; Ni = 11.00%. ESI-MS calc.: [M+Na]+ = 545.1.
Found: [M+Na]+ = 545.1. 1H-NMR (500 MHz, DMSO-d6): 1.32 (br s, 2H, H17); 3.21
(br s, 4H, H1); 5.82 (d, J = 8.14 Hz, 2H, H12); 6.10 (s, 2H, H14); 6.3 (d, J = 8.67 Hz,
2H, H11); 7.09 (br s, 4H, H5, H9); 7.45 (br s, 6H, H6, H7, H8); 9.72 (br s, 2H, -OH).
C NMR (500 MHz, DMSO-d6):  27.25 (C27); 48.71 (C1); 104.74 (C14); 105.20
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(C12); 117.78 (C10); 127.63 (C5, C9); 128.99 – 129.49 (6C, C6, C7, C8); 134.48
(C11); 136.44 (C4); 162.28 (C13); 166.58 (C15); 171.48 (C3).
N,N′-Bis-(4-((1-(2-ethyl)piperidine)oxy)benzophenylidene)-1,3-propylenediamine
nickel(II) (75)
This complex was prepared by first stirring a suspension of (74) (272.7 mg,
0.52 mmol), 1-(2-chloroethyl)piperidine hydrochloride (390 mg, 2.12 mmol) and
K2CO3 (465 mg, 3.26 mmol) in dry DMF (10 mL) for 5 days under N 2 at room
temperature. The reaction afforded a crude product which was isolated by vacuum
filtration, and subsequently purified as described in Chapter 3.2.2 to yield the desired
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complex as a brown solid (244 mg, 66%). Microanalysis
calc. for C43H50N4NiO4: C = 69.27%; H = 6.76%; N =
7.51%; Ni = 7.87%. Found: C = 68.96%; H = 6.54%; N =
7.38%; Ni = 7.76%. ESI-MS calc.: [M+H]+ = 745.3.
Found: [M+H]+ = 745.3. 1H-NMR (500 MHz, CDCl3,):
1.39 (m, J = 6.95 Hz, 2H, H17); 1.43 (m, 4H, H24);
1.59 (m, 8H, H23, H25); 2.47 (br s, 8H, H22, H26); 2.74
(t, J = 5.32 Hz, 4H, H20); 3.42 (t, J = 6.09 Hz, 4H, H1); 4.07 (t, J = 5.35 Hz, 4H,
H19); 5.96 (d, J = 8.97 Hz, 2H, H12); 6.28 (d, J = 8.98 Hz, 2H, H11); 6.53 (s, 2H,
H14); 6.99 (d, J = 6.77 Hz, 4H, H5, H9); 7.40 (m, 6H, H6, H7, H8).
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C NMR (500

MHz, CDCl3,):  24.22 (C24); 25.91 (C23, C25); 27.83 (C17); 48.65 (C1); 54.85
(C22); 57.73 (C20); 65.54 (C19); 103.24 (C14); 105.77 (C12); 117.77 (C10); 127.26
(C5, C9); 128.52-129.04 (C6, C7, C8); 133.72 (C11); 136.12 (C4); 162.83 (C13);
166.68 (C15); 171.50 (C3).
The resonances in the 1H NMR spectrum of (75) (Figure 3.8) were readily
identified through a comparison with the corresponding spectrum of complex (71),
which has a nearly identical, symmetric structure. The only difference between the
two structures is that the ethylenediamine moiety in (71) is replaced by a
1,3-propylenediamine moiety in (75). Therefore the aliphatic region of the 1H NMR
spectrum of the latter complex is slightly more complex. The triplet at 3.42 ppm was
assigned to H1 as its integration corresponded to 4 hydrogen atoms. A COSY
spectrum was then used to identify that the resonance corresponding to H17 was
located at 1.39 ppm, and overlapped with the resonance from H24 at 1.43 ppm. Both
H1 and H17 showed correlations with H5 and H9 in the NOESY spectrum of (75)
(Figure S3.1).
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Figure 3.8 1H NMR spectrum of (75), with the atom numbering scheme shown.

N,N′-Bis-(4-(hydroxybenzophenylidene))-2-hydroxy-1,3-propylenediaminenickel(II)
(76)
A solution of 1,3-diamino-2-propanol (990 mg, 10.99
mmol) in MeOH (5 mL) was slowly added to a 5 mL
methanolic

solution

of

2,4-dihydroxybenzophenone

(6840 mg, 31.9 mmol) and brought to reflux for 12 h.
Ni(OAc)2·4H2O (6746 mg, 27.1 mmol) was then added to the yellow reaction mixture,
which was maintained under reflux for a further 12 h, resulting in the formation of a
green precipitate. The solid was collected and purified using the process in Chapter
3.2.2 to give the final product. Yield: 5544 mg (94%). Crystals suitable for X-ray
diffraction were obtained by evaporating a solution of 5.4 mg (76) in 5 mL acetonitrile
at room temperature. Microanalysis calc. for C29H24N2NiO5·2.5H2O: C = 59.13%; H =
4.96%; N = 4.76%; Ni = 9.90%. Found: C = 59.47%; H = 4.79%; N = 4.33%; Ni =
9.80%. ESI-MS calc.: [M+H]+ = 539.1. Found: [M+H]+ = 539.1. 1H-NMR (500 MHz,
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DMSO-d6): 3.47 (broad m, 4H, H1, H17); 5.81 (d, J = 8.06 Hz, 2H, H12); 6.08 (s,
2H, H14); 6.10 (d, J = 8.90 Hz, 2H, H11); 7.05 (s, 2H, H5 or H9); 7.14 (d, J = 3.03
Hz, 2H, H5 or H9); 7.44 (s, 6H, H6, H7, H8).

C NMR (500 MHz, DMSO-d6):  56.70
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(C1); 66.80 (C17); 105.58 (C12); 106.11 (C14); 118.20 (C10); 127.83 (C5); 128.90 –
129.04 (C6, C7, C8); 129.52 (C9); 134.81 (C11); 137.73 (C4); 162.69 (C13); 166.58
(C15); 172.07 (C3).
N,N′-Bis-(4-((1-(2-ethyl)piperidine)oxy)benzophenylidene)-2-((1-(2-ethyl)piperidine)
oxy)-1,3-propylenediaminenickel(II) (77)
A suspension of (76) (438 mg, 0.81 mmol), 1-(2chloroethyl)piperidine hydrochloride (598 mg, 3.25
mmol) and K2CO3 (1494.5 mg, 10.8 mmol) in 15 mL dry
DMF was stirred for 10 days under N2 at room
temperature. The crude product of this reaction was
isolated by vacuum filtration and purified by the
DCM/water extraction method outlined in Chapter 3.2.2.
Final

purification

was

achieved

following

recrystallisation using 1:5 MeOH:water, which afforded
the desired complex as a brown-green powder (142 mg, 20%). Microanalysis calc.
for C50H63N5NiO5·H2O: C = 68.27%; H = 7.16%; N = 7.66%; Ni = 6.42%. Found: C =
68.28%; H = 7.13%; N = 7.30%; Ni = 6.43%. ESI-MS calc.: [M+2H]2+ = 436.7. Found:
[M+2H]2+ = 437.0. 1H-NMR (500 MHz, CDCl3): 1.37 (s, 2H, H25); 1.43 (s, 4H, H34);
1.48 (m, 4H, H24, H26); 1.58 (m, 8H, H33, H35); 2.24 (m, 4H, H23, H27); 2.47 (s,
8H, H32, H36); 2.74 (t, J = 5.77 Hz, 4H, H30); 2.95 (t, J = 5.99 Hz, 2H, H21); 3.16 (s,
1H, H17); 3.51 (m, 6H, H1, H18, H20); 4.07 (t, J = 5.70 Hz, 4H, H29); 5.95 (dt, J =
2.37, 9.02 Hz, 2H, H12); 6.26 (dd, J = 2.00, 9.12 Hz, 2H, H11); 6.52 (s, 2H, H14);
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6.93 (d, J = 7.10 Hz, 2H, H5 or H9); 7.11 (t, J = 7.24 Hz, 2H, H5 or H9); 7.39 (m, 6H,
H6, H7, H8).
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C NMR (500 MHz, CDCl3): 24.31 – 24.43 (C25, C24, C26, C34);

26.10 (C33, C35); 53.86, 56.27 (C1, C18); 55.06 – 55.29 (C32, C36); 57.93 – 58.21
(C23, C27, C30); 65.82 (C29); 67.35 (C21); 68.09 (C20); 76.17 (C17); 103.28 (C14);
106.20 – 106.30 (C12); 117.74 – 117.81 (C10); 127.35 (C5,9 or C37,38); 128.42 –
128.81 (C6, C7, C8 and C5,9 (C37,38)); 134.11 – 134.16 (C11); 136.11 (C4); 163.10
– 163.15 (C13); 166.91 (C15); 172.13 – 172.22 (C3).
The 1H NMR spectrum of (77) is shown in Figure 3.9. The presence of the
pendant group in the top half of the molecule resulted in slight differences in
chemical environment for some protons on the left and right sides of the molecule.
Therefore, whilst there was only one singlet which corresponded to both H14 in the
molecule, H11 appears as two doublets with slightly different chemical shifts at ca.
6.26 ppm. This indicates that the H11 atoms in the right and left sides of the
molecule are not chemically equivalent. In addition, while a single very broad singlet
was observed at 7.39 ppm which could be assigned to H6, H7 and H8 in both of the
upper aromatic rings, separate multiplets were observed at 6.93 and 7.11 ppm for
H5 and H9. Both of the latter resonances were clearly shown to be coupled to the
former in a COSY spectrum. Therefore the H5 and H9 atoms in the left hand
aromatic ring are in a sufficiently different chemical environment to those in the right
hand ring system to result in clearly separated resonances.
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Figure 3.9 1H NMR spectrum of (77), with the atom numbering scheme shown.

In contrast, the differences in chemical environments for the two sets of H6, H7
and H8 atoms were not as great, and gave rise to a single, very broad singlet. The
aliphatic region of the 1H NMR spectrum showed separate sets of resonances
corresponding to protons in the two bottom pendant groups, and the single top
pendant group. These were assigned on the basis of their relative integrations, and
separate coupling patterns observed in a TOCSY spectrum (Figure S3.2).

3.3.2 Synthesis of isomeric nickel complexes
In the previous section the synthetic procedure for preparing complexes (70)
and

(71),

commencing

with

the

reaction

of

ethylenediamine

with

2,4-dihydroxybenzophenone was presented. The final complex, (71), featured two
pendant ethyl piperidine groups in the bottom half of the molecule. By repeating the
above process, but using two equivalents of either 2,2´-dihydroxybenzophenone or
2,4´-dihydroxybenzophenone to react with one mole of ethylenediamine, it was
possibly to prepare the novel, symmetric complexes (78) and (80), which were then
dialkylated to afford (79) and (81), (Figure 3.10).
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Figure 3.10 Structures of complexes (78), (79), (80) and (81).

In addition, a number of novel asymmetric nickel complexes were prepared by
a modified version of the above procedure, which also involved 3 steps, the first two
of which are outlined in Figure 3.11 for complex (82). Initially, the half ligand (HL)
was prepared by reaction of 2,4-dihydroxybenzophenone with an excess of
ethylenediamine (step (i)). The half ligand then was reacted with either 2,4´dihydroxybenzophenone and Ni(OAc)2·4H2O in step 1 and 2 to form (82), or 2,2´dihydroxybenzophenone and Ni(OAc)2·4H2O to afford (84).These complexes were
then dialkylated using similar procedures to those described above in step 3 to yield
(83) and (85), respectively.

Figure 3.11 Synthetic scheme for preparing the asymmetric complex (82).
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The effect of changing synthetic conditions (temperature and time) on the yield
of the isomeric nickel complexes is shown in Table 3.2. In some instances
decreasing the length of step 2 resulted in a dramatic improvement in the yield of
non-alkylated nickel complex. Table 3.2 also shows that the temperature used for the
alkylation sometimes also had a significant effect on the outcome of the reaction. For
example, complex (81) was synthesised successfully by alkylation of (80) at room
temperature over a 3 day period, however mass spectrometric analysis showed that
unreacted (80) and the half alkylated complex were both present. The complex was
synthesised again at 60 °C over a 3 day period, which resulted in a very good yield
of (81) with high purity.
Table 3.2 Effect of synthetic conditions on the yield of isomeric nickel complexes.
Non-alkylated complex
Time of
steps 1
Yield
Complexes
and 2
(%)
(hour)a
18; 24
65
(82)
18; 10
82
18; 48
0
(78)
18; 6
93
18; 12
78
(80)
18; 24
96
(84)
18; 10
88

Alkylated complex
Complexes

(83)
(79)
(81)
(85)

Time of
step 3
(day)

Temperature
(°C)b

Yield (%)

3
14
5
5
3
3
3

60
RT
60
RT
60
RT
60

0
37
61
75
83
impure
86

a

Step 1 and 2 are the reaction time for forming the full ligands and adding Ni(OAc) 2, respectively.
b
RT The reactions were carried at room temperature.

N,N´-Bis-(4´-(hydroxybenzophenylidene))-ethylenediaminenickel(II) (78)
Ethylenediamine (46 mg, 0.76 mmol) was added to

3

mL methanol and the resulting solution slowly added to
a

2

mL

methanolic

solution

of

2,4´-

dihydroxybenzophenone (346 mg, 1.61 mmol). The
resulting reaction mixture was then brought to reflux for
18 h. During this time a yellow precipitate appeared. After 18 h a solution of
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Ni(OAc)2·4H2O (631 mg, 2.54 mmol) in 5 mL methanol was added to the reaction
mixture, resulting in it immediately changing to a brown-red colour. The mixture was
held at reflux for a further 6 h to afford a precipitate which was purified following the
process in Chapter 3.2.2, to give the final product as a brown-red powder. Yield: 358
mg (93%). Microanalysis calc. for C28H22N2NiO4: C = 66.05%; H = 4.35%; N =
5.50%; Ni = 11.53%. Found: C = 65.69%; H = 4.37%; N = 5.53%; Ni = 11.10%. ESIMS calc.: [M+Na]+ = 531.1. Found [M+Na]+ = 531.0. 1H-NMR (500 MHz, DMSO-d6):
2.89 (s, 4H, H1); 6.32 (t, 2H, H12); 6.56 (d, J = 8.06 Hz, 2H, H11); 6.76 (d, J = 8.49
Hz, 2H, H14); 6.87-6.99 (AB pattern, JAB = 8.17 Hz, 8H, H5,9; H6,8); 7.10 (t, 2H,
H13); 9.91 (br s, 2H, -OH).

C NMR (500 MHz, DMSO-d6):  56.12 (C1); 114.47
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(C12); 116.28 (C5, C9); 121.12 (C14); 122.54 (C10); 128.80 (C6, C8); 129.09 (C4);
133.10 (C11, C13); 158.49 (C7); 165.21 (C15); 171.30 (C3).
N,N´-Bis-(4´-((1-(2-ethyl)piperidine)oxy)benzophenylidene)-ethylenediamine nickel(II)
(79)
Complex

(78)

(308

mg,

0.60

mmol),

1-(2-

chloroethyl)piperidine hydrochloride (511 mg, 2.77
mmol) and K2CO3 (527 mg, 3.82 mmol) were
suspended in 10 mL anhydrous DMF and stirred for 5
days under N2 at room temperature. The reaction
afford a crude product which then was isolated by
vacuum filtration and purified as described in Chapter
3.2.2 to give the desired complex as an orange-red solid (329 mg, 75%).
Microanalysis calc. for C42H48N4NiO4: C = 68.96%; H = 6.61%; N = 7.66%; Ni =
8.02%. Found: C = 68.66%; H = 6.61%; N = 7.77%; Ni = 8.00%. ESI-MS calc.:
[M+H]+ = 731.3. Found: [M+H]+ = 731.2. 1H-NMR (500 MHz, CDCl3): 1.46 (m, 4H,
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H23); 1.61 (m, 8H, H22, H24); 2.51 (s, 8H, H21, H25); 2.79 (t, J = 5.92 Hz, 4H, H19);
2.89 (s, 4H, H1); 4.11 (t, J = 5.92 Hz, 4H, H18); 6.32 (t, J = 7.38 Hz, 2H, H12); 6.60
(d, J = 8.09 Hz, 2H, H11); 6.95-6.98 (AB pattern, JAB = 8.57 Hz, 8H, H5,9; H6,8);
7.07 (d, J = 8.40 Hz, 2H, H14); 7.12 (t, J = 7.52 Hz, 2H, H13);
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C NMR (500 MHz,

CDCl3):  24.38 (C23); 26.14 (C22, C24); 55.31 (C21, C25); 55.94 (C1); 58.06 (C19);
66.42 (C18); 114.55 (C12); 115.16 (C5, C9); 121.97 (C10); 122.39 (C14); 128.16
(C6, C8); 132.69 (C11); 132.89 (C13); 159.39 (C7); 165.34 (C15); 171.30 (C3).
The 1H NMR spectrum of (79) is shown in Figure 3.12. Aliphatic resonances in
the 1H NMR spectra of both (78) and (79) were able to be identified readily on the
basis of their relative integrations and correlations in COSY spectra. Completing the
assignments of the aromatic 1H resonances was facilitated by acquisition of HMBC
spectra. In HMBC spectra, the

13

C resonance from C3 for both (78) and (79) showed

correlations to H1, as well as two other sets of aromatic resonances. The most
deshielded of these in each case was an AB quartet at ca. 6.9 – 7.0 ppm, which
integrated to 4 hydrogen atoms, and which is assigned to H5, H6, H8 and H9. This
leaves the other set of resonances that C3 correlates with in the HMBC spectra, to
be assigned to H11. Having made these assignments, it was a simple task to use
COSY and TOCSY spectra to assign the other aromatic resonances (H12, H13 and
H14) for both complexes. Figure S3.3 shows the TOCSY spectrum of (79). For both
(78) and (79) the two most deshielded sets of aromatic resonances were assigned to
protons in the lower aromatic rings. This is consistent with assignments presented
for the novel nickel complexes in Chapter 3.2.1.
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Figure 3.12 1H NMR spectrum of (79), with the atom numbering scheme shown.

N,N´-Bis-(2´-(hydroxybenzophenylidene))-ethylenediaminenickel(II) (80)
Ethylenediamine (124 mg, 2.06 mmol) in 2 mL methanol
was added dropwise to 2 mL of a methanolic solution of
2,2´-dihydroxybenzophenone (9334 mg, 4.36 mmol),
and the resulting reaction mixture brought to reflux for
18 h to give a yellow solution. A 5 mL solution
containing Ni(OAc)2·4H2O (761 mg, 3.06 mmol) in MeOH was then added to the
reaction mixture, which was maintained at reflux for a further 24 h to afford a brownred precipitate. A fine powder was collected followed the procedure outlined in
Chapter 3.2.2 to give the desired product. Yield: 1005 mg (96%). Microanalysis calc.
for C28H22N2NiO4·0.5H2O: C = 64.90%; H = 4.47%; N = 5.41%; Ni = 11.33%. Found:
C = 64.70%; H = 4.45%; N = 5.64%; Ni = 11.70%. ESI-MS calc.: [M+H]+ = 509.1,
[M+Na]+ = 531.1. Found: [M+H]+ = 509.1, [M+Na]+ = 531.0. 1H-NMR (500 MHz,
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DMSO-d6): 2.91 (s, 2H, H1); 6.32 (t, J = 7.44 Hz, 2H, H12); 6.57 (d, J = 8.07 Hz,
2H, H11); 6.77 (d, J = 8.48 Hz, 2H, H14); 6.91 (t, J = 7.40 Hz, 2H, H8); 6.94 (d, J =
8.39 Hz, 2H, H9); 6.99 (d, J = 7.32 Hz, 2H, H6); 7.10 (t, J = 7.55 Hz, 2H, H13); 7.30
(t, J = 7.67 Hz, 2H, H7); 9.95 (br s, 2H, -OH).

C NMR (500 MHz, DMSO-d6): 
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55.67 (C1); 114.41 (C12); 116.50 (C9); 119.92 (C8); 121.04 (C14); 121.92 (C4);
122.52 (C10); 128.72 (C6); 131.49 (C7); 132.45 (C11); 132.69 (C13); 153.83 (C5);
165.10 (C15); 169.24 (C3).
N,N´-Bis-(2´-((1-(2-ethyl)piperidine)oxy)benzophenylidene)-ethylenediaminenickel(II)
(81)
Compound (80) (269.7 mg, 0.53 mmol)
was suspended in anhydrous DMF (10
mL) along with 1-(2-chloroethyl)piperidine
hydrochloride (305 mg, 1.66 mmol) and
K2CO3 (525 mg, 3.80 mmol) and stirred for
72 h under N2 at 60 °C. The reaction
yielded a crude product which was isolated by vacuum filtration, and purified using
the DCM/water extraction method described in Chapter 3.2.2 to afford (81) as a
brown-red solid (323 mg, 83%). Microanalysis calc. for C42H48N4NiO4·H2O:

C =

67.30%; H = 6.72%; N = 7.47%; Ni = 7.83%. Found: C = 67.17%; H = 6.54%; N =
7.62%; Ni = 7.73%. ESI-MS calc.: [M+H]+ = 731.3. Found: [M+H]+ = 731.2. 1H-NMR
(500 MHz, DMSO-d6): 1.27 (m, 4H, H39, H48); 1.39 (m, 8H, H38, H40 and H47,
H49); 2.35 (m, 8H, H37, H41 and H46, H50); 2.56 (m, 4H, H35, H44); 2.76 – 3.03
(m, 4H, H1, H26); 4.06 (m, 4H, H34, H43); 6.30 (m, 2H, H12, H21); 6.47 (d, J = 8.11
Hz, 1H, H11 or H22); 6.52 (d, J = 8.14 Hz, 1H, H11 or H22); 6.76 (d, J = 8.44 Hz,
2H, H14, H19); 6.98 (d, J = 7.35 Hz, 2H, H9, H28); 7.04 (t, J = 7.55 Hz, 2H, H13,
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H20); 7.09 (t, J = 7.32 Hz, 2H, H8, H29); 7.15 (m, 2H, H6, H31); 7.45 (t, J = 7.70 Hz,
2H, H7, H30).

C NMR (500 MHz, DMSO-d6):  24.51 (C39, C48); 26.30 – 26.35

13

(C38, C40 and C47, C49); 54.77 – 55.04 (C37, C41 and C46, C50); 55.32 – 55.82
(C1, C26); 57.78 (C35, C44); 66.74 – 67.39 (C34, C43); 112.97-113.26 (C9, C28);
114.41 – 114.60 (C12, C21); 121.12 (C14, C19); 121.40 – 121.66 (C8, C29); 121.80
– 121.88 (C10, C23); 124.06 – 124.27 (C4, C27); 128.54 – 128.70 (C6, C31); 131.81
(C7, C30); 132.53 (C11, C22); 133.26 (C13, C20); 154.77 (C5, C32); 165.18 (C15,
C18); 168.41 – 168.65 (C3, C24).
The 1H NMR spectrum of (81) was first obtained in CDCl3, however there was
considerable overlap of resonances, which made assignments difficult. Therefore,
the spectrum was obtained again in DMSO-d6, and is shown in Figure 3.13, along
with that of its non-alkylated precursor (80). Comparison of the two spectra reveals
that while (80) is a symmetric complex in solution, the introduction of the two
pendant groups to give (81) resulted in asymmetry that led to multiple resonances for
what were originally equivalent protons. For example, the spectrum of (80) shows
one doublet from the two chemically equivalent protons H11. In contrast, in the
spectrum of (81) these two protons are no longer equivalent (now H11 and H22) and
give rise to separate doublets. Figure S3.5 illustrates the TOCSY spectrum of (81),
which shows correlations between the doublets from H11 and H22, and all of the
remaining protons in the lower aromatic rings of the complex.
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Figure 3.13 1H NMR spectra of: (a) (80) and (b) (81).The atom numbering schemes for

both complexes are shown.
The effects of asymmetry are also apparent in the aliphatic region of the 1H
NMR spectrum. Figure 3.13 (a) shows only a sharp singlet at 2.91 ppm from the four
equivalent hydrogen atoms in (80). Figure 3.13 (b) shows a number of multiplets
between 2.76 and 3.03 ppm that when integrated together equate to four hydrogen
atoms as expected for the two CH2 groups in the ethylenediamine moiety. The
complexity of the NMR spectrum in this region is consistent with all four protons no
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longer being both chemically and magnetically equivalent, leading to 2 nd order
spectral patterns. The effects of asymmetry were also apparent in the

13

C NMR

spectra of the two complexes, with (80) showing a single imine carbon resonance,
whilst two were observed for (81).
N,N´-4,2´-Bis-(hydroxybenzophenylidene)-ethylenediaminenickel(II) (82)
The asymmetric complex (82) was prepared by a
pathway that commenced with the synthesis of the half
ligand

(HL) (Figure

3.11). This

compound

was

synthesised by slowly adding a 5 mL methanolic
solution of 2,4-dihydroxybenzophenone (2171 mg,
10.14 mmol) to a 5 mL solution of ethylenediamine (1235 mg, 20.5 mmol) in MeOH,
and bringing the reaction mixture to reflux for 16 h. A yellow precipitate appeared
after approximately 12 h, and was isolated by filtration, washed with methanol (10
mL) then water (500 mL), and finally dried under vacuum. Yield: 2467 mg (96%). HL
(410.6 mg, 1.60 mmol) was then brought to reflux with 2,4´-dihydroxybenzophenone
(433.1 mg, 2.02 mmol) in 10 mL methanol. After 18 h, Ni(OAc) 2·4H2O (623.5 mg,
2.51 mmol) was added to the reaction mixture and an orange/red precipitate
appeared immediately. The reaction mixture was held at reflux for a further 10 h to
afford a dark orange precipitate as the desired product. Yield: 666.4 mg (81.7%).
Microanalysis calc. for C28H22N2NiO4·0.5H2O: C = 64.90%; H = 4.47%; N = 5.41%;
Ni = 11.33%. Found: C = 65.02%; H = 4.30%; N = 5.80%; Ni = 11.30%. ESI-MS
calc.: [M+H]+ = 509.1. Found: [M+H]+ = 509.0. 1H-NMR (500 MHz, DMSO-d6): 2.73
(m, 2H, H26); 2.87 (m, 2H, H1); 5.85 (dd, J = 2.06 and 8.93 Hz, 1H, H21); 6.13(s,
1H, H19); 6.26 (d, J = 8.95 Hz, 1H, H22); 6.30 (t, J = 7.43 Hz, 1H, H12); 6.54 (d, J =
7.70 Hz, 1H, H11); 6.75 (d, J = 8.49 Hz, 1H, H14); 6.85 (d, J = 8.26 Hz, 2H, H5, H9);
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6.96 (d, J = 8.44 Hz, 2H, H6, H8); 7.09 (t, J = 7.43 Hz, 1H, H13); 7.16 (d, J = 7.26
Hz, 2H, H28, H32); 7.47 (m, 3H, H29, H30, H31); 9.84 (br s, 2H, -OH).
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C NMR

(500 MHz, DMSO-d6):  55.47 (C26); 56.48 (C1); 104.65 (C19); 106.00 (C21);
114.36 (C12); 115.82 (C23); 116.24 (C5, C9); 121.13 (C11); 122.58 (C10); 126.09
(C4); 127.42 (C28, C32); 128.77 (C6, C8); 129.49 (C29, C30, C31); 133.05 (C11,
C13); 134.39 (C22); 136.03 (C27); 158.43 (C7); 162.44 (C20); 165.20 (C15); 166.91
(C18); 169.62 (C24); 171.21 (1C, C3).
N,N′-4,4´-Bis-(((1-(2-ethyl)piperidine)oxy)benzophenylidene)-ethylenediamine
nickel(II) (83)
A suspension of (82) (407 mg, 0.80 mmol), 1-(2chloroethyl)piperidine hydrochloride (1217 mg, 6.61
mmol) and K2CO3 (1833 mg, 13.3 mmol) in 10 mL
anhydrous DMF was stirred for 14 days under N2 at
room temperature. The crude product of this reaction
was isolated by vacuum filtration, and purified using
DCM/water extraction as described in Chapter 3.2.2 to
afford the desired complex as a red solid (218 mg,
37%). Microanalysis calc. for C42H48N4NiO4·0.5H2O: C =
68.12%; H = 6.67%; N = 7.57%; Ni = 7.93%. Found: C = 68.09%; H = 6.45%; N =
7.69%; Ni = 7.67%. ESI-MS calc.: [M+2H]2+ = 366.2. Found: [M+2H]2+ = 366.3. 1HNMR (500 MHz, CDCl3): 1.44 (m, 4H, H39, H48); 1.60 (broad s, 8H, H38, H40 and
H47, H49); 2.47 (s, 4H, H37, H41 or H46, H50); 2.51 (s, 4H, H37,41 or H46,50); 2.74
(t, J = 5.66 Hz, 2H, H35 or H44); 2.79 (m, 4H, H26, H44 or H35); 2.89 (t, J = 6.20 Hz,
2H, H1); 4.06 (t, J = 5.70 Hz, 2H, H34 or H43); 4.11 (t, J = 5.83 Hz, 2H, H43 or H34);
5.97 (dd, J = 9.05 Hz, 1H, H21); 6.33 (t, J = 7.33 Hz, 1H, H12); 6.42 (d, J = 9.12 Hz,
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1H, H22); 6.54 (d, J = 1.45 Hz, 1H, H19); 6.60 (d, J = 8.15 Hz, 1H, H11); 6.94 (d, J =
8.43 Hz, 2H, H5, H9); 6.97 (d, J = 8.53 Hz, 2H, H6, H8); 7.07 (d, J = 7.78 Hz, 3H,
H28, H32 and H14); 7.12 (t, J = 7.51 Hz, 1H, H13); 7.41 (m, 3H, H29, H30, H31).
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C

NMR (500 MHz, CDCl3):  24.38 (C39, C48); 25.94 – 26.22 (C38, C40, C47, C49);
54.73 – 55.05 (C37, C41, C46, C50); 55.43 (C1); 55.98 – 56.35 (C26, C44); 58.02
(C35); 65.76 – 66.46 (C34, C43); 103.44 (C19); 106.48 (C21); 114.62 (C12); 115.17
(C5, C9); 115.92 (C23); 122.03 (C10); 122.58 (C14); 126.72 (C28, C32); 128.05 (C6,
C8); 129.33 – 129.86 (C29, C30, C31); 132.63 (C11); 132.86 (C13); 133.79 (C22);
136.13 (C27); 159.29 (C7); 162.98 (C20); 165.27 (C15); 167.19 (C18); 170.05 (C24);
171.21 (C3).
The 1H NMR of spectra of (82) and (83) were both complex patterns of
resonances, as expected for complexes with asymmetric structures. For example,
Figure 3.14 shows the 1H NMR spectrum of (83). Despite the complexity of the NMR
spectra of both complexes, it was possible to completely assign all resonances with
the assistance of 1D and 2D NMR methods, as well as knowledge gained from
analysing previous spectra.
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Figure 3.14 1H NMR spectrum of (83), with the atom numbering scheme shown.

The asymmetric structure of (83) manifests itself in a number of ways in the
spectrum shown in Figure 3.14. This includes separate pairs of triplet resonances for
the dimethylene groups linking the two piperidine ring systems to the remainder of
the Schiff base ligand. In addition, the ethylenediamine moiety does not give rise to a
singlet, as it did for the symmetric complex (79), but instead affords two coupled
multiplets. These are most likely both triplets, however as the more shielded multiplet
overlaps with resonances from the piperidine groups, this cannot be determined with
certainty. In contrast to the above, the proton resonances for the top and the bottom
piperidine ring systems generally appeared almost at the same chemical shifts. For
example, a single broad singlet was observed at 1.60 ppm, which corresponds to
H38, H40, H47 and H49. This was not unexpected, as the piperidine rings are well
isolated from the rest of the metal complex and attached via flexible linker groups.
In the downfield region of the spectrum, four groups of resonances were
identified corresponding to the different aromatic ring systems. Assignment of these
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resonances was facilitated by the TOCSY spectrum shown in Figure S3.6, which
showed strong coupling patterns within the individual ring systems. For example, the
only para substituted aromatic ring in the complex gave an AB pattern centred at
6.96 ppm, which corresponded to H5, H6, H8 and H9.
N,N′-4,2´-Bis-(hydroxybenzophenylidene)-ethylenediaminenickel(II) (84)
To a suspension of the half ligand (HL) (411 mg, 1.60
mmol)

in

10

mL

methanol

was

added

2,2´-

dihydroxybenzophenone (378 mg, 1.76 mmol), and the
reaction mixture brought to reflux for 18 h. After this
time, the colour of the reaction mixture had turned to light orange. Ni(OAc) 2·4H2O
(634 mg, 2.55 mmol) was added to the reaction mixture, which was maintained at
reflux for a further 10 h, resulting in the formation of a dark red precipitate as the
desired product. Yield: 750 mg (92%). Microanalysis calc. for C28H22N2NiO4·H2O: C
= 63.79%; H = 4.59%; N = 5.31%; Ni = 11.13%. Found: C = 63.86%; H = 4.63%; N =
5.40%; Ni = 10.80%. ESI-MS calc.: [M+Na]+ = 531.1. Found: [M+Na]+ = 531.0. 1HNMR (500 MHz, DMSO-d6): 2.74 (m, 2H, H26); 2.88 (m, 2H, H1); 5.86 (d, J = 8.61
Hz, 1H, H21); 6.14(s, 1H, H19); 6.25 (d, J = 7.08 Hz, 1H, H22); 6.30 (t, J = 7.17 Hz,
1H, H12); 6.56 (d, J = 8.10 Hz, 1H, H11); 6.76 (d, J = 8.44 Hz, 1H, H14); 6.92 (m,
3H, H6, H8, H9); 7.08 (t, J = 7.49 Hz, 1H, H13); 7.16 (d, J = 6.59 Hz, 1H, H28); 7.20
(d, J = 7.47 Hz, 1H, H32); 7.29 (t, J = 7.48 Hz, 1H, H7); 7.47 (m, 3H, H29, H30,
H31); 9.80 (br s, 2H, -OH).

C NMR (500 MHz, DMSO-d6):  55.31 (C26); 55.75
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(C1); 104.39 (19); 105.80 (C21); 114.20 (C12); 115.57 (1C, C23); 116.33 (C9);
119.71 (C8); 120.89 (C14); 121.74 (C10); 122.32 (C4); 127.16-127.21 (C28, C32);
128.34 (C6); 129.28 (C29, C30, C31); 131.03 (C7); 132.33 (C11); 132.79 (C13);
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134.26 (C22); 135.84 (C27); 153.57 (C5); 162.20 (C20); 164.92 (C15); 166.74 (C18);
168.89 (C3); 169.44 (C24).
N,N′-4,2´-Bis-(((1-(2-ethyl)piperidine)oxy)benzophenylidene)-ethylenediamine
nickel(II) (85)
In 10 mL anhydrous DMF, complex (84) (504 mg, 0.99
mmol), 1-(2-chloroethyl)piperidine hydrochloride (580
mg, 3.15 mmol) and K2CO3 (874 mg, 6.32 mmol) were
suspended and stirred for 3 days under N2 at 60 °C. The
reaction provided a solid which was purified using the
DCM/water extraction method outlined in Chapter 3.2.2
to yield the alkylated complex as a dark red solid (619
mg, 85%). Microanalysis calc. for C42H48N4NiO4·H2O: C
= 68.12%; H = 6.67%; N = 7.57%; Ni = 7.93%. Found: C = 67.93%; H = 6.54%; N =
7.86%; Ni = 7.75%. ESI-MS calc.: [M+H]+ = 731.3. Found: [M+H]+ = 731.2. 1H-NMR
(500 MHz, DMSO-d6): 1.29 (m, 4H, H39, H48); 1.39 (m, 4H, H47, H49); 1.46 (m,
4H, H38, H40); 2.36 (m, 8H, H37, H41 and H46, H50); 2.55 (m, 2H, H44); 2.60 (t, J =
5.7 Hz, 2H, H35); 2.68-2.94 (m, 4H, H1, H26); 4.01 (t, J = 5.5 Hz, 2H, H34); 4.06 (m,
2H, H43); 5.96 (d, J = 9.14 Hz, 1H, H21); 6.24 – 6.35 (m, 3H, H22, H12, H19); 6.49
(d, J = 8.06 Hz, 1H, H11); 6.74 (d, J = 8.58 Hz, 1H, H14); 7.01 – 7.11 (m, 3H, H13,
H8, H6); 7.11 – 7.21 (m, 3H, H28, H32, H9); 7.44 (m, 1H, H7); 7.49 (m, 3H, H29,
H30, H31).

C NMR (500 MHz, DMSO-d6):  24.33 – 24.39 (C39, C48); 26.01 –
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26.15 (C38, C40 and C47, C49); 54.79 (C37, C41 and C46, C50); 55.55 – 55.77
(C1, C26); 57.54 – 57.64 (C35, C44); 65.90 (C34); 66.73 (C43); 102.54 (C19);
105.76 (C21); 112.85 (C9); 114.22 (C12); 115.95 (C23); 120.79 (C14); 121.14 (C8);
126.91-127.17 (C28, C32); 128.32 (C6); 129.32-129.44 (C29, C30, C31); 131.32
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(C7); 132.16 (C11); 132.84 (C13); 133.76 (C22); 135.69 (C27); 154.48 (C5); 162.77
(C20); 164.91 (C15); 121.68 (C10); 123.93 (C4); 166.85 (C18); 168.26 (C3); 169.55
(C24).
Both (84) and (85) are asymmetric structures that gave complex NMR spectra.
This is illustrated by the complex multiplets between 2.68 and 2.94 ppm which can
only be assigned to the protons of the ethylenediamine moiety. Assigning the spectra
of these complexes was assisted by comparing with the corresponding spectra of
(71) and (81), each of which resembles one half of the structure of (85).
One notable difference between the spectrum of (85) shown in Figure 3.15 and
those of the other alkylated complexes described above concerns the resonances
assigned to the dimethylene groups linking the piperidine rings to the rest of the
molecule. In all previous complexes each methylene in one of these linker groups
gave rise to sharp triplets that were coupled to each other. Figure 3.15 shows one
such set of coupled triplets at 2.60 and 4.01 ppm. The latter was assigned to H34 as
it showed a correlation with H19 in the NOESY spectrum of the complex. Therefore
the other triplet at 2.60 ppm was assigned to H35 since both were shown to be
coupled to each other in a COSY spectrum. In contrast, the resonances adjoining
these two triplets, which are assigned to the other dimethylene protons (H43 and
H44), are not triplets. Instead both resonances appear to resemble 1:3:3:1 quartets,
suggesting both sets of protons are coupling to three equivalent protons. A more
probable explanation is that the dimethylene protons constitute an AA’BB’ spin
system, which would be expected to resemble two AB patterns. The lack of magnetic
equivalence between protons attached to the same carbon atom may reflect a
barrier to rotation around the C-C bond in the dimethylene group involving C43 and
C44, which is not present in the other linker group.
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Figure 3.15 1H NMR spectrum of (85), with the atom numbering scheme shown.

3.3.3 Synthesis of nickel complexes with different numbers of
pendant groups
The synthesis of nickel complexes with 2 and 3 pendant groups, (71) and (77),
respectively was reported in Chapter 3.2.1. In order to undertake a systematic
investigation into the effect of the number of pendant groups on DNA-binding
properties it was necessary to also prepare and study the corresponding complexes
with one and four pendant groups. The synthetic procedures for preparing the nonalkylated precursors of these complexes, (86) and (88), both involved two steps, and
are shown in Figure 3.16. Once these complexes were prepared the pendant groups
were attached using the same procedure outlined in Chapter 3.2.1 and used for all
other alkylation reactions. The non-alkylated complex (86) was prepared by reacting
(HL) with an excess of 2-hydroxybenzophenone, since the latter dissolves readily in
MeOH and the excess can therefore be easily separated from the final product,
which was obtained as a precipitate.
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Figure 3.16 Outline of synthetic pathways to non-alkylated nickel Schiff base complexes with
one and four pendant groups.

The synthesis of (88) was carried out by reacting an excess of 2,4,4´trihydroxybenzophenone with ethylenediamine. The excess of the derivatised
benzophenone was easily separated from the desired product as the former is very
soluble in MeOH. However, care must be taken when washing (88) with methanol,
as it is also soluble in this solvent. To maximise the yield of purified product it was
found advantageous to perform the synthesis using a limited volume of MeOH (ca.
10 mL), and to subsequently wash the crude material with a small amount of this
solvent (ca. 2 mL). The highest yield of (88) was obtained using reaction times of 18
and 24 h for steps 1 and 2, respectively. The first attempt to synthesise (89) from
(88) was performed by stirring the reactants at room temperature for 4 days, and
only afforded a yield of 37%. The yield of (89) improved slightly to 48% when the
reaction was performed at room temperature for 10 days.
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(4-(hydroxybenzophenylidene))-(4-(hydroxysalicylidine))-ethylenediaminenickel(II)
(86)
This complex was synthesised using the half ligand (HL)
which was described earlier. A suspension of HL (513
mg, 2.00 mmol) and 2-hydroxybenzaldehyde (487 mg,
2.46 mmol) in 15 mL methanol was stirred and brought
to reflux for 20 h to give a yellow precipitate. Ni(OAc)2·4H2O (1046 mg, 4.20 mmol)
was then added and the reaction mixture maintained at reflux for a further 24 h,
resulting in a dark red precipitate as the final product. This was isolated using the
process described in Chapter 3.2.2 to give the desired complex. Yield 801 mg (81%).
Microanalysis calc. for C28H22N2NiO3·1.5H2O: C = 64.65%; H = 4.84%; N = 5.39%;
Ni = 11.28%. Found: C = 64.34%; H = 4.67%; N = 5.50%; Ni = 11.30%. ESI-MS
calc.: [M+H]+ = 493.1, [M+Na]+ = 515.1. Found: [M+H]+ = 493.1, [M+Na]+ = 515.0.
H-NMR (500 MHz, DMSO-d6): 2.74 (t, J = 8.75 Hz, 2H, H26); 2.83 (t, J = 11.81,

1

2H, H1); 5.85 (t, J = 7.88 Hz, 1H, H21); 6.13 (d, J = 5.36 Hz, 1H, H19); 6.25 (d, J =
8.80 Hz, 1H, H22); 6.30 (dd, J = 6.31 and 14.31 Hz, 1H, H12); 6.43 (d, J = 7.98 Hz,
1H, H11); 6.78 (d, J = 8.33 Hz, 1H, H14); 7.11 (t, J = 7.28 Hz, 1H, H13); 7.15 (t, J =
6.92 Hz, 2H, H28, H32); 7.20 (d, J = 6.60 Hz, 2H, H5, H9); 7.48 (m, 6H, H6, H7, H8,
H29, H30, H31); 9.80 (br s, 2H, -OH). 13C NMR (500 MHz, DMSO-d6):  55.53 (C26);
56.54 (C1); 104.47 (C19); 105.97 (C21); 114.62 (C12); 121.13 (C14); 127.07 –
127.54 (C5, C9, C28, C32); 129.18 – 129.79 (C6, C7, C8, C29, C30, C31); 132.78
(C11); 133.28 (C13); 134.58 (C22); 115.82 (C23); 122.13 (C10); 136.01 (C4, C27);
162.40 (C20); 165.22 (C15); 167.00 (C18); 169.66 (C24); 170.68 (C3).
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N-(4-((1-(2-ethyl)piperidine)oxy)benzophenylidene)-N′-(4-((1-(2-ethyl)piperidine)oxy)
salicylidine)-ethylenediamine nickel(II) (87)
Complex (86) (345.9 mg, 0.70 mmol) was suspended in
10

mL

anhydrous

DMF

along

with

1-(2-

chloroethyl)piperidine hydrochloride (325 mg, 1.76
mmol) and K2CO3 (417 mg, 3.02 mmol), and then stirred
for 3 days under N2 at room temperature. This yielded a
crude product which was isolated and then purified
using the DCM/water extraction procedure described in
Chapter 3.2.2 to afford an orange-red solid as the final product (301 mg, 71%).
Microanalysis calc. for C35H35N3NiO3·0.5H2O: C = 68.54%; H = 5.92%; N = 6.85%;
Ni = 9.57%. Found: C = 68.21%; H = 6.11%; N = 7.12%; Ni = 9.12%. ESI-MS calc.:
[M+H]+ = 604.2. Found: [M+H]+ = 604.1. 1H-NMR (500 MHz, CDCl3): 1.44 (m, 2H,
H39); 1.59 (m, 4H, H38, H40); 2.47 (s, 2H, H37, H41); 2.74 (t, J = 5.85 Hz, 2H, H35);
2.78 (t, J = 6.96 Hz, 2H, H26); 2.85 (t, J = 6.92 Hz, 2H, H1); 4.07 (t, J = 5.80 Hz, 2H,
H34); 5.98 (dd, J = 2.30 and 8.99 Hz, 1H, H21); 6.33 (t, J = 7.23 Hz, 1H, H12); 6.42
(dd, J = 3.24 and 9.10 Hz, 1H, H22); 6.54 (s, 1H, H11); 6.56 (s, 1H, H19); 7.06 (s,
1H, H14); 7.08 (d, J = 7.64 Hz, 4H, H5, H28, H32); 7.13 (t, J = 7.23 Hz, 1H, H13);
7.41 (m, 6H, H6, H7, H8, H29, H30, H31).

C NMR (500 MHz, CDCl3):  24.43
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(C39, C48); 26.13(C38, C40); 55.05 (C37, C41); 55.45 – 55.80 (C26, C1); 57.92
(C35); 65.78 (C34); 103.59 (C19); 106.64 (C21); 114.56 (C12); 115.90 (C23); 122.51
(C10); 122.51 (C14); 126.77 – 126.88 (C5, C9, C28, C32); 128.97 – 129.16 (C6, C7,
C8, C29, C30, C31); 132.61 (C11); 132.93 (C13); 133.68 (C22); 136.12 – 136.17
(C4, C27); 162.94 (C20); 165.31 (C15); 167.23 (C18); 170.08 (C24); 171.11 (C3).
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Completing the assignment of proton signals in the 1H NMR spectrum of (86)
and (87) (Figure 3.17) was facilitated by a comparison with the corresponding
spectra of (71) and (79). H6-8,29-31 and H5,9,28,32 in (87) were assigned to
complex multiplets at 7.41 and 7.06 ppm, with relative integrations of 6 and 4
protons, respectively. The protons on the two lower aromatic rings, H11-14 and
H19,21,22 were easy recognised by the expected strong coupling patterns in the
TOCSY spectrum of this complex. In the aliphatic region, the two familiar triplets at
4.07 and 2.74 ppm were assigned to H34 and H35 of the sole dimethylene group
linking the Schiff base to a piperidine ring. The resonances from the piperidine ring
were similar to those seen in the spectrum of (71), and could be assigned through a
comparison to the spectrum in Figure 3.3.
H35
H1
H5,9,28,
32

H26

H14
H19
H13

H6-8,29-31

H11

H22

H12

H21
H34
H38,40
H37,41
H40

CHCl3
H2O

Figure 3.17 1H NMR spectrum of (87), with the atom numbering scheme shown.
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N,N´-Bis-(4,4´-(dihydroxybenzophenylidene))-ethylenediaminenickel(II) (88)
A solution of ethylenediamine (74 mg, 1.23 mmol) in 3
mL methanol was added dropwise to a 7 mL methanolic
solution of 2,4,4´-trihydroxybenzophenone (601 mg, 2.61
mmol), and the resulting reaction mixture brought to
reflux for 18 h. A dark yellow precipitate appeared after
10 h. Ni(OAc)2·4H2O (1041.6 mg, 4.19 mmol) was then added to the yellow reaction
mixture resulting in the immediate formation of a dark red precipitate. The reaction
mixture was held at reflux for a further 24 h, and then filtered to collect the final
product as a red precipitate, which was washed with methanol (2 mL), water (500
mL) and diethyl ether (50 mL). Yield: 433 mg (65%). Microanalysis calc. for
C28H22N2NiO6: C = 62.14%; H = 4.10%; N = 5.18%; Ni = 10.85%. Found: C =
61.94%; H = 4.05%; N = 5.09%; Ni = 10.70%. ESI-MS calc.: [M+H]+ = 541.1,
[M+Na]+ = 563.1. Found: [M+H]+ = 541.0, [M+Na]+ = 563.0. 1H-NMR (500 MHz,
DMSO-d6): 2.74 (s, 4H, H1); 5.84 (dd, J = 2.04 and 8.98 Hz, 2H, H12); 6.09 (d, J =
2.01 Hz, 2H, H14); 6.36 (d, J = 8.96 Hz, 2H, H11); 6.83-6.92 (AB pattern, JAB = 8.34
Hz, 8H, H5,9; H6,8); 9.74 (br s, 4H, -OH).

C NMR (500 MHz, DMSO-d6):  55.75
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(C1); 104.72 (C14); 105.57 (C12); 116.14 (C10); 116.28 (C5, C9); 126.38 (C4);
128.84 (C6, C8); 134.79 (C11); 158.24 (C7); 162.20 (C13); 167.04 (C15); 170.05
(C3).
N,N′-Bis-(4,4´-(di(1-(2-ethyl)piperidine)oxy)benzophenylidene)-ethylenediamine
nickel(II) (89)
A suspension of (88) (319 mg, 0.59 mmol), 1-(2-chloroethyl)piperidine hydrochloride
(673 mg, 3.66 mmol) and K2CO3 (1570 mg, 11.4 mmol) in dry DMF (10 mL) was
stirred for 10 days under N2 at room temperature. The reaction provided a crude
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product which was isolated by vacuum filtration and
purified using the DCM/water extraction procedure
outlined in Chapter 3.2.2 to give the target complex as
an orange-red solid (281 mg, 47%). Microanalysis calc.
for C56H74N6NiO6·H2O: C = 66.99%; H = 7.63%; N =
8.37%; Ni = 5.85%. Found: C = 66.97%; H = 7.51%; N =
8.29%; Ni = 5.60%. ESI-MS calc.: [M+H]+ = 985.5.
Found: [M+H]+ = 985.4. 1H-NMR (500 MHz, CDCl3):
1.44 (s, 8H, H23, 32); 1.60 (m, 16H, H22, H24, H31,
H33); 2.47 (s, 8H, H21,25 or H30,34); 2.50 (s, 8H,
H30,34 or H21,25); 2.74 (t, J = 5.84 Hz, 4H, H28); 2.78 (t, J = 5.95 Hz, 4H, H19);
2.80 (s, 4H, H1); 4.06 (t, J = 5.85 Hz, 4H, H27); 4.11 (t, J = 5.93 Hz, 4H, H18); 5.97
(dd, J = 2.23 and 9.11 Hz, 2H, H12); 6.47 (d, J = 9.11 Hz, 2H, H11); 6.53 (d, J = 2.18
Hz, 2H, H14); 6.93-6.96 (AB pattern, JAB = 7.56 Hz, 8H, H5,9; H6,8).
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C NMR (500

MHz, CDCl3):  24.40 (C23, C32); 26.15 (C22, C24, C31, C33); 54.80 – 55.06 (C21,
C25, C30, C34); 55.74 (C1); 57.81 – 58.23 (C19, C28); 65.77 – 65.96 (C27); 66.32
– 66.51 (C18); 103.54 (C14); 106.24 (C12); 115.78 (C10); 115.05 (C5, C9); 128.18
(C6, C8); 133.66 (C11); 159.20 (C7); 162.84 (C13); 167.24 (C15); 170.01 (C3).
The 1H NMR spectra of (88) and (89) both reflected the symmetric structure of
these complexes. The spectrum of (89) in Figure 3.18 contained a similar pattern of
multiplets from H11, H12 and H14 to what was seen in the spectrum of (71),
whereas H5,6,8 and 9 gave an AB pattern strongly resembling that arising from the
same protons in the spectrum of (79). The dimethylene units in the top and bottom
linker groups gave rise to distinct, tightly coupled pairs of triplets. 2D NMR
measurements were required to finalise assignment of these resonances owing to
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overlap of the triplet from H19 with the singlet from H1. The triplet at 4.06 ppm was
assigned to H27 as it showed a strong correlation with H14 as well as H28 in a
NOESY spectrum (Figure S3.7). The other triplet at 4.11 ppm showed a strong
correlation in the NOESY spectrum with H6 and H8, and was therefore assigned to
H18.

H1
H14

H11
H19

H5,9, 6,8

H28

H12

H18 H27

H22,24
H31,33
H21,25
H30,34

H23,32

CHCl3
H2O

Figure 3.18 1H NMR spectrum of (89), with the atom numbering scheme shown.

3.3.4 Synthesis of nickel complexes with asymmetric structures
During the course of this project a number of asymmetric nickel complexes,
whose structures are shown in the following sections were prepared. The method for
synthesising these complexes was the same as that outlined in Figure 3.16, which
involved reactions between (HL) and another aromatic compound. Table 3.3 shows
the yields obtained of three asymmetric non-alkylated nickel Schiff base complexes,
and their alkylated analogues. The first attempt to synthesise (90) was not
122

successful, since the ligand obtained after benzaldehyde had reacted only with (HL)
was very insoluble and precipitated quickly in the form of lumps that did not react
further when nickel acetate was added. This problem was overcome by ensuring the
half ligand (HL) was present in sufficient MeOH to enable it to remain totally
dissolved prior to the addition of benzaldehyde, which was then was slowly added.
Complex (92) was prepared via the reaction of (HL) with naphthaldehyde for 10 h,
after which Ni(OAc)2.4H2O was added and the reaction continued for a further 5 h.
Although these reaction times were less than what was employed during the
synthesis of (90), an even higher yield of 92% was obtained. The synthesis of
complex (94) was performed using a small volume of MeOH (8 mL) since the
product was very soluble in this solvent.
Table 3.3 Effect of temperature and reaction time on yield of asymmetric nickel complexes.
Non-alkylated complexes
Length of
Yield
Complexes steps 1 and
(%)
2 (h)a
(90)

(92)

(94)
a
b

12; 12

10; 5

12; 24

71

92

97

Complexes

Alkylated complexes
Length of
Temperature
step 3
(°C)b
(day)

Yield
(%)

3

RT

0

3

60

65

3

RT

impure

3

60

31

3

60

impure

7

RT

23

(91)

(93)

(95)

Steps 1 and 2 are the reaction times for forming the full ligands and adding Ni(OAc) 2, respectively.
RT = the reaction was performed at room temperature.

When the alkylation reaction was performed with either (90) or (92) at room
temperature the desired products were not obtained. Carrying out the reactions at 60
˚C, however, resulted in low to moderate yields of alkylated nickel complexes. When
the alkylation reaction was first performed using (94) it was carried out at 60 °C over
a 3 day period. This afforded a small amount of impure (95) that could not be used in
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DNA-binding studies. Subsequently the reaction was performed at room temperature
for a length of time that was more than twice as long as that of the initial reaction.
After purification including column chromatography, a small amount of (95) of
sufficient purity for DNA binding studies was obtained.
N-(4-(hydroxybenzophenylidene))-N´-salicylidine-ethylenediaminenickel(II) (90)
This asymmetric complex was synthesised by adding
dropwise

a

2

mL

methanolic

solution

of

2,2´-

dihydroxybenzophenone (357 mg, 2.92 mmol) to a
suspension of the half ligand (HL) (516 mg, 2.02 mmol),
which had been prepared previously using 40 mL of
MeOH solvent. After bringing the reaction mixture to reflux for 12 h, it changed to a
yellow colour. A 20 mL solution containing Ni(OAc)2·4H2O (789 mg, 3.17 mmol,
dissolved in methanol) was then added, and the reaction mixture held at reflux for a
further 12 h, resulting in formation of a dark orange precipitate. This solid was
isolated by vacuum filtration, and purified by the process described in Chapter 3.2.2
to give the final product. Yield: 596 mg (71%). Crystals for X-ray diffraction were
prepared by suspending 20.1 mg of the complex in 5 mL H 2O, and then slowly
adding DMSO with stirring on a hot plate until the solid just became dissolved.
Crystals were obtained from the solution after two weeks. Microanalysis calc. for
C22H18N2NiO3·0.5H2O: C = 62.01%; H = 4.49%; N = 6.57%; Ni = 13.77%. Found: C =
62.22%; H = 4.31%; N = 6.76%; Ni = 13.60%. ESI-MS calc.: [M+H]+ = 417.1,
[M+Na]+ = 439.1. Found: [M+H]+ = 417.0, [M+Na]+ = 439.0. 1H-NMR (500 MHz,
DMSO-d6): 2.84 (t, J = 6.54 Hz, 2H, H21); 3.26 (t, J = 6.40 Hz, 2H, H1); 5.86 (dd, J
= 2.18 and 9.02 Hz, 1H, H16); 6.11 (d, J = 2.15 Hz, 1H, H13); 6.28 (d, J = 9.02 Hz,
1H, H17); 6.49 (t, J = 7.33 Hz, 1H, H6); 6.72 (d, J = 8.55 Hz, 1H, H5); 7.16 (t, J =
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7.71 Hz, 1H, H7); 7.22 (m, 3H, H23, H27, H8); 7.51 (m, 3H, H24, H25, H26); 7.82 (s,
1H,-CH=N-) 9.77 (br s, 1H, -OH).

C NMR (500 MHz, DMSO-d6):  55.88 (C21);
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58.82 (C1); 104.51 (13); 105.96 (C16); 114.74 (C6); 115.57 (C18); 120.34 (C5);
127.16 (C23, C27); 129.27 – 129.79 (C24, C25, C26); 121.02 (C4); 133.09 (C8);
134.24 (C7); 134.72 (C17); 136.31 (C22); 162.47-162.90 (C3, C14); 162.63 (C14);
164.64 (C9); 166.89 (C12); 170.05 (C19).
N-(4-((1-(2-ethyl)piperidine)oxy)benzophenylidene)-N′-(salicylidine)-ethylenediamine
nickel(II) (91)
This compound was synthesised by suspending (90)
(419 mg, 1.00 mmol) in 10 mL anhydrous DMF along
with 1-(2-chloroethyl)piperidine hydrochloride (294 mg,
1.60 mmol) and K2CO3 (450 mg, 3.25 mmol), and
stirring for 3 days under N2 at 60 °C. The reaction
provided a crude product which was isolated by
vacuum filtration and purified using the DCM/water
extraction method outlined in Chapter 3.2.2 to yield the desired compound as brownred solid (329 mg, 75%). Microanalysis calc. for C29H31N3NiO3·0.5H2O: C = 64.83%;
H = 6.00%; N = 7.82%; Ni = 10.92%. Found: C = 64.63%; H = 5.90%; N = 7.95%; Ni
= 10.80%. ESI-MS calc.: [M+H]+ = 528.2. Found: [M+H]+ = 528.2. 1H-NMR (500
MHz, CDCl3): 1.43 (broad s, 2H, H33); 1.59 (dt, J = 5.54 and 11.10 Hz, 4H, H32,
H34); 2.46 (broad s, 4H, H31, H35); 2.73 (t, J = 5.85 Hz, 2H, H29); 2.96 (t, J = 6.57
Hz, 2H, H20); 3.24 (t, J = 6.46 Hz, 2H, H1); 4.05 (t, J = 5.87 Hz, 2H, H28); 5.97 (dd,
J = 2.34 and 9.15 Hz, 1H, H15); 6.40 (d, J = 9.16 Hz, 1H, H16); 6.51 (m, 2H, H6,
H13); 7.03 (m, 2H, H5,8); 7.08 (m, 2H, H22,26); 7.19 (m, 1H, H7); 7.41 (s, 1H, CH=N-); 7.44 (m, 3H, H23,24,25).

C NMR (500 MHz, CDCl3):  24.40 (C33); 26.10
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(C32, C34); 55.05 (C31, C35); 55.56 (C20); 57.89 (C27); 59.06 (C1); 65.77 (C28);
103.59 (C13); 106.66 (C15); 115.12 (C6); 115.94 (C7); 120.24 (C4); 122.06 (C5);
126.90 (C22,26); 129.06 – 129.17 (C3, C23,24,25); 132.25 (C8); 133.91 (C7, C16);
136.24 (C21); 161.55 (C3); 163.04 (C14); 165.15 (C9); 167.12 (C12); 170.58 (C18).
The 1H NMR spectrum of (91) is shown in Figure 3.19. The absence of one
benzene ring in the top right hand corner of the structure of the complex resulted in
the appearance of a strong singlet at 7.41 ppm which could be assigned to the imine
proton (-N=CH-). This is a similar chemical shift to what has been reported
previously for imine proton resonances in nickel Schiff base complexes such as
(54_P) and (54).[93, 127] The resonances from H15 and H16 were well separated
from other aromatic signals, and found at 5.97 and 6.40 ppm, respectively. These
assignments were based on the integration of the resonances, the absence of any
coupling to other aromatic protons, and their similarity to the chemical shifts that
were observed for the corresponding proton resonances in the spectrum of (71).
Many other aromatic protons, however, were found to give overlapping resonances.
For example, the doublet corresponding to H13 overlapped with the triplet from H6 at
ca. 6.51 ppm. All aromatic resonances were able to be assigned based on their
relative integrations and coupling patterns observed in a TOCSY spectrum (Figure
S3.8). Due to the asymmetric structure of the complex, the protons of the
ethylenediamine moiety were chemically inequivalent and gave two triplets at 3.24
ppm (H1) and 2.96 ppm (H20). These were assigned using the observed correlations
of H1 with H3 in TOCSY and NOESY spectra. The protons in the piperidine ring
system were assigned through comparison with the spectrum of (71).
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H23,24,25
H3

H22,26
H5,8
H7

H6,13
H16
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H32,34

H20 H29
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H1

H33
H2O
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Figure 3.19 1H NMR spectrum of (91), with the atom numbering scheme shown.

N-(4-(hydroxybenzophenylidene))-N´-(naphthalidine)-ethylenediaminenickel(II) (92)
A solution of 2-hydroxy-1-naphthaldehyde (836 mg,
4.86 mmol) in 15 mL methanol was added dropwise
to a suspension of (HL) (755 mg, 2.95 mmol)
prepared previously in 15 mL MeOH. After the
reaction mixture had been brought to reflux for 10 h, it had changed to a dark yellow
colour. Ni(OAc)2·4H2O (1512 mg, 6.08 mmol) was then added, and the reaction
mixture maintained at reflux for 5 h, forming a dark orange precipitate. This solid was
isolated by the procedure outlined in Chapter 3.2.2 to give the final product. Yield:
1260 mg (92%). Microanalysis calc. for C26H20N2NiO3·0.5H2O: C = 65.58%; H =
4.44%; N = 5.88%; Ni = 12.33%. Found: C = 65.32%; H = 4.22%; N = 5.34%; Ni =
12.10%. ESI-MS calc.: [M+H]+ = 467.1. Found: [M+H]+ = 467.1. 1H-NMR (500 MHz,
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DMSO-d6): 2.88 (m, 2H, H24); 3.42 (m, 2H, H1); 5.87 (d, J = 8.92 Hz, 1H, H19);
6.13(s, 1H, H17); 6.29 (d, J = 8.96 Hz, 1H, H20); 6.97 (d, J = 9.10 Hz, 1H, H11); 7.21
(m, 3H, H26, H30, H8); 7.42 (t, J = 7.49 Hz, 1H, H7); 7.52 (m, 3H, H27, H28, H29);
7.67 (d, J = 9.22 Hz, 1H, H12); 7.70 (d, J = 7.96 Hz, 1H, H9); 8.05 (d, J = 8.33 Hz,
1H, H6); 8.65 (s, 1H, -CH=N-); 9.78 (br s, 1H, -OH).
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C NMR (500 MHz, DMSO-d6):

 56.05 (C26); 59.19 (C1); 104.48 (C17); 106.06 (C19); 120.18 (C6); 111.19 (C5);
122.71 (C8); 123.68 (C11); 127.37 (C26, C30); 128.00 (C7); 129.23 (C9); 115.79
(C21); 126.51 (C4); 129.48 – 129.59 (C27, C28, C29); 134.28 (C12); 134.64 (C20);
157.62 (C3); 133.90 (C10); 136.31 (C25); 162.52 (C18); 165.38 (C13); 170.04 (C22).
N-(4-((1-(2-ethyl)piperidine)oxy)benzophenylidene)-N′-(naphthalidine)ethylenediaminenickel(II) (93)
To a suspension of (92) (458 mg, 0.98 mmol) in 10
mL dry DMF was added 1-(2-chloroethyl)piperidine
hydrochloride (277 mg, 1.51 mmol) and K2CO3 (787
mg, 5.70 mmol). The reaction mixture was stirred
under N2 at 60 °C for 3 days. The crude product of
the reaction was isolated by vacuum filtration and
purified first by DCM/water extraction as described in Chapter 3.2.2, and then by
recrystallisation from 1:1 MeOH:water. This afforded the desired compound as a
brown-red powder. Yield: 178 mg (31%). Microanalysis calc. for C33H33N3NiO3: C =
68.53%; H = 5.75%; N = 7.26%; Ni = 10.15%. Found: C = 68.23%; H = 5.88%; N =
7.16%; Ni = 8.93%. ESI-MS calc.: [M+H]+ = 578.2. Found: [M+H]+ = 578.2. 1H NMR
(500 MHz, CDCl3): 1.43 (s, 2H, H38); 1.59 (m, 4H, H37, H39); 2.46 (s, 4H, H36,
H40); 2.74 (t, J = 5.62 Hz, 2H, H33); 2.97 (t, J = 6.39 Hz, 2H, H24); 3.24 (t, J = 6.34
Hz, 2H, H1); 4.06 (t, J = 5.65 Hz, 2H, H32); 5.98 (d, J = 9.12 Hz, 1H, H19); 6.43 (d, J
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= 9.14 Hz, 1H, H20); 6.52 (s, 1H, H17); 7.11 (d, J = 7.02 Hz, 2H, H26, H30); 7.20 (m,
2H, H11, H8); 7.37 (t, J = 7.58 Hz, 1H, H7); 7.47 (m, 3H, H27, H28, H29); 7.57 (d, J
= 9.23 Hz, 1H, H9); 7.62 (d, J = 7.87 Hz, 1H, H12); 7.74 (d, J = 8.41 Hz, 1H, H6);
8.26 (s, 1H, -CH=N-);

C NMR (500 MHz, CDCl3):  24.41 (C38); 26.12 (C37, C39);
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55.05 (C36, C40); 55.71 (C24); 57.89 (C33); 59.64 (C1); 66.85 (C32); 103.63 (C17);
106.65 (C19); 118.72 (C6); 110.75 (C5); 116.00 (C21); 122.43 (C8); 124.77 (C11);
126.80 – 126.93 (C26, C30, or C4); 127.45 (C7); 129.05 – 129.17 (C28, C29, C9);
133.25 – 134.06 (C20 or C10, C12); 163.16 (C18); 166.45 (C13); 167.19 (C16);
170.57 (C22).
The 1H NMR spectrum of (93) is shown in Figure 3.20. Initial assignments of a
number of resonances could be made through a comparison with the spectra of (71)
and (91). These assignments were then confirmed through analysis of 2D NMR
spectra of the complex, which also showed a number of similarities to that of its
precursor (90). For example, the three most shielded aromatic resonances in both
spectra were a pair of coupled doublets and a singlet assigned to H17, H19 and
H20. The doublet at 7.74 ppm was assigned to H6 as it showed a correlation with H3
at 8.26 ppm in the NOESY spectrum of the complex (Figure S3.9). The latter also
showed a correlation with H1 that enabled it to be distinguished from H24. Since H6
only coupled to the triplet at 7.37 ppm in the gCOSY spectrum, the latter was
assigned to H7. Further analysis of the COSY spectrum enabled the remaining two
protons in the same aromatic ring, H8 and H9, to be assigned. The protons in the
aliphatic region of the spectrum were identified through a comparison with the
spectra of (71) and (91).
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Figure 3.20 1H NMR spectrum of (93), with the atom numbering scheme shown.

N-(4-(hydroxybenzophenylidene))-N´-(4-(hydroxysalicylidine))-ethylenediamine
nickel(II) (94)
A suspension of (HL) (408 mg, 1.59 mmol) and 2,4dihydroxybenzaldehyde (301 mg, 2.18 mmol) in 8 mL
methanol was stirred and brought to reflux for 12 h.
Ni(OAc)2·4H2O (693 mg, 2.79 mmol) was then added
and the reaction mixture maintained at reflux for a
further 24 h, resulting in a colour change to red. The desired complex was obtained
by slowly evaporating the solvent at 60 °C, which yielded a dark red precipitate. The
solid was filtered and washed with water only (500 mL) to give the final product as a
dark

orange

powder.

Yield:

669

mg

(97%).

Microanalysis

calc.

for

C22H18N2NiO4·2H2O: C = 56.33%; H = 4.73%; N = 5.97%; Ni = 12.51%. Found: C =
55.91%; H = 4.66%; N = 6.23%; Ni = 12.60%. ESI-MS calc.: [M+Na]+ = 455.1.
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Found: [M+Na]+ = 455.0. 1H NMR (500 MHz, DMSO-d6): 2.81 (t, J = 6.52 Hz, 2H,
H20); 3.16 (t, J = 6.52 Hz, 2H, H1); 5.84 (dd, J = 2.01 and 9.01 Hz, 1H, H15); 6.03
(dd, J = 1.77 and 8.53 Hz, 1H, H6); 6.09 (d, J = 1.90 Hz, 1H, H8); 6.10 (d, J = 2.12
Hz, 1H, H13); 6.26 (d, J = 9.00 Hz, 1H, H16); 7.04 (d, J = 8.56 Hz, 1H, H5); 7.19 (d,
J = 6.77 Hz, 2H, H22, H26); 7.50 (m, 3H, H23, H24, H25); 7.56 (s, 1H, H3) 9.73 (br
s, 2H, -OH).

C NMR (500 MHz, DMSO-d6):  56.15 (C20); 58.21 (C1); 104.24-
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104.79 (C8, C13); 106.10 (C15); 106.29 (C6); 114.72 (C4); 115.84 (C17); 127.24
(C22, C26); 129.41 – 129.67 (C23, C24, C25); 134.46 (C16); 134.66 (C5); 136.39
(C21); 161.13 (C3); 162.39 – 163.21 (C7, C14); 166.48 – 167.03 (C9, C12); 169.98
(C18).
N-(4-((1-(2-ethyl)piperidine)oxy)benzophenylidene)-N′-(4-((1-(2-ethyl)piperidine)oxy)
salicylidine)ethylenediaminenickel(II) (95)
This complex was synthesised by suspending 434 mg of
(94) (1.00 mmol) in 20 mL anhydrous DMF along with 1(2-chloroethyl)piperidine hydrochloride (1500 mg, 8.15
mmol) and K2CO3 (1394 mg, 10.1 mmol), and stirring
the reaction mixture for 7 days under N2 at room
temperature. The crude product of this reaction was
isolated and subsequently purified by DCM/water
extraction as described in Chapter 3.2.2, and column chromatography using initially
an eluent consisting of 1:9 DCM:MeOH, and then 1:5 CHCl3:MeOH. The second
fraction collected contained (95). Yield: 148 mg (23%). Microanalysis calc. for
C36H44N4NiO4·H2O: C = 64.20%; H = 6.88%; N = 8.32%; Ni = 8.72%. Found: C =
64.40%; H = 6.54%; N = 8.33%; Ni = 8.67%. ESI-MS calc.: [M+H]+ = 655.3. Found:
[M+H]+ = 655.2. 1H-NMR (500 MHz, CDCl3): 1.44 (s, 4H, H33,42); 1.59 (s, 8H,
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H32,34, H41,43); 2.47 (s, 8H, H31,35, H40,44); 2.74 (m, J = 5.79 Hz, 4H, H29,38);
2.93 (t, J = 6.44 Hz, 2H, H20); 3.16 (t, J = 6.32 Hz, 2H, H1); 4.06 (m, J = 6.07 Hz,
4H, H28,37); 5.97 (dd, J = 1.83 and 9.08 Hz, 1H, H15); 6.18 (dd, J = 1.54 and 8.59
Hz, 1H, H6); 6.41 (d, J = 9.15 Hz, 1H, H16); 6.52 (s, 2H, H8 and H13); 6.93 (d, J =
8.69 Hz, 1H, H5); 7.10 (d, J = 5.91 Hz, 2H, H22,26); 7.29 (s, 1H, H3); 7.46 (m, 3H,
H23,24,25).

C NMR (500 MHz, CDCl3):  24.42 (C33, C42); 25.98 – 26.25 (C32,
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C34, C41, C43); 54.79 – 55.44 (C31, C35, C40, C44); 55.83 (C20); 57.62 – 57.24
(C29, C38); 58.57 (C1); 65.79-65.96 (C28, C37); 103.53 – 103.78 (C8, C13); 106.51
(C15); 107.09 (C6); 114.51 (C4); 115.99 (C17); 126.73 – 127.04 (C22, C26); 128.96
– 129.38 (C23, C24, C25); 132.95 (C5); 133.73 (C16); 136.33 (C21); 159.94 (C3);
163.02 – 163.93 (C7, C14); 167.10 – 167.19 (C9, C12); 170.48 (C18).
The 1H NMR spectrum of (95) is shown in Figure 3.21. The imine proton H3
gave rise to a singlet at 7.29 ppm. In the NOESY spectrum of the complex (Figure
S3.10), H3 showed correlations to H1 and H5 that were used to assign these protons
to resonances at 3.16 and 6.93 ppm, respectively. The NMR spectrum showed some
effects of the asymmetric structure of the complex. For example, the dimethylene
linker groups on both sides of the complex gave separate pairs of coupled triplets.
However, there was very little difference in the chemical environments between, for
example, H29 and H38. As a result, the resonances from these different protons
overlapped, resulting in the observed multiplets.
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H23,24,25

H8,13

H29,38

H22,26
H3
CHCl3
H5

H16 H6 H15

Acetone H32,34,
41,43
H31,35,
40,44
H2O

H28,37
H1 H20

H33,42

Figure 3.21 1H NMR spectrum of (95), with the atom numbering scheme shown.

3.4 X-ray crystallographic characterisation of nickel complexes
3.4.1 Solid-state structures of non-alkylated nickel complexes
Crystals of non-alkylated nickel Schiff base complexes suitable for X-ray
crystallographic investigation were obtained by slowly adding DMSO to suspensions
of the complexes in small volumes (~ 2 mL) of solvents that they had limited
solubility in, such as MeOH or water (Table 3.4). The suspensions were stirred at
room temperature on a hot plate until sufficient DMSO had been added so that the
nickel complexes dissolved. High quality crystals were obtained from the solutions by
allowing them to slowly evaporate over a period of several days at room
temperature.
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Table 3.4 Conditions used to obtain crystals of non-alkylated nickel Schiff base complexes
suitable for X-ray crystallography.
Complex
(72)
(74)
(80)
(94)

Mass of
complex used
(mg)
21.2
21.8
20.3
25.5

Solvent(s) used to
crystallise the nickel
complex
MeOH/DMSO
MeOH/DMSO
MeOH/DMSO
MeOH/DMSO

Time of
crystallisation
(days)
7
14
14
19

Table 3.5 summarises the results of data collection and structure refinement
processes performed on four complexes. Figure 3.22 presents ORTEPs for each of
the complexes, and shows the atom numbering schemes used, while Table 3.6
shows selected bond lengths and bond angles. Solvent molecules were observed in
the unit cells of each complex. Complexes (74) and (94) crystallised in the
monoclinic crystal system and were assigned to the P21/n space group. In contrast,
while (80) also gave monoclinic crystals, its space group was P21/c, and (72)
crystallised in the triclinic crystal system, and was found to belong to the space
group P1. All complexes crystallised in an asymmetric unit with four molecules per
unit cell (Z = 4), with the exception of complex (72), for which Z = 2.
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Table 3.5 Crystallographic data for non-alkylated nickel Schiff base complexes.
(72)
C29H24N2NiO4.
2(C2H6OS).H2O
697.52
Triclinic
Orange
P1
9.9443 (2)
10.8213 (2)
15.0907 (3)
90.9180 (16)
95.2472 (16)
94.9377 (15)
1610.64 (5)
1.438
2
-11<h<12
-13<k<13
-17<l<18

(74)
C29H24N2NiO4.
(C2H6OS).3H2O
655.41
Monoclinic
Green
P21/n
12.8742 (1)
9.3175 (1)
25.5985 (2)
---98.4790 (7)
---3037.11 (5)
1.433
4
-16<h<15
-11<k<11
-31<l<28

Number of unique
reflections

6529

Refinement

Rint = 0.019
R[F2 > 2σ(F2)] = 0.038

Formula
Mr
Crystal system
Crystal colour
Space group
a (Å)
b (Å)
c (Å)



V (Å3)
Dx (Mg m-3)
Z
(h,k,l)

(80)

(94)

C28H22N2NiO4.2(C2H6OS)

C22H18N2NiO4.2(H2O)

665.47
Monoclinic
Orange
P21/c
13.1465 (1)
14.9679 (1)
16.4141 (2)
---107.3576 (11)
---3082.81 (5)
1.434
4
-16<h<16
-18<k<18
-20<l<16

469.14
Monoclinic
Orange
P21/n
7.9887 (1)
20.7141 (2)
12.4586 (2)
---98.920 (1)
---2036.70 (5)
1.530
4
-9<h<9
-25<k<25
-15<l<15

6155

6213

4095

Rint = 0.027
R[F2 > 2σ(F2)] = 0.030

Rint = 0.037
R[F2 > 2σ(F2)] = 0.036

Rint = 0.032
R[F2 > 2σ(F2)] = 0.038
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(74)
(72)

(80)

(94)

Figure 3.22 Molecular structures of (72), (74), (80) and (94),with anisotropic displacement ellipsoids drawn at the 30% probability level. Colours:
white = hydrogen, black = carbon, blue = nitrogen, red = oxygen, green = nickel. The dotted line for (72) shows the position of atoms for the
enantiomeric complex.
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The nickel atom in all four complexes adopted a square planar coordination
geometry, with Ni–O and Ni–N bond distances and bond angles subtended at the
metal centre generally close to expected values and those reported previously for
similar complexes.[126, 127, 130] The one exception to this was for (74), which
exhibited two O-Ni-N angles of ~ 172°, and slightly longer Ni–N bond distances.
These differences may be the reason for the green colour of (74), which contrasts
with the red or orange colours of most other non-alkylated complexes, and may be a
consequence of (74) being the only complex in Figure 3.22 to feature a diamine
moiety that is part of a six-membered chelate ring.
One aspect of the structures of all novel complexes that was of particular
interest was the degree of co-planarity between the different aromatic ring systems.
This was because it was expected that alkylated complexes which show a high
degree of co-planarity might be able to -stack more effectively onto G-tetrads of Gquadruplex structures. In order to examine this further, the ring notation system
illustrated in Figure 3.23 was used. This enabled the coplanar angles for different
pairs of aromatic rings also included in Table 3.6 to be determined. Inspection of the
data obtained shows that there was, as expected, a high degree of coplanarity
between each of the ring systems in the bottom parts of the molecules. For example,
the largest coplanar angle of this type was that observed between rings A and B in
complex (80), which was 21.30°. For all of the other complexes in Table 3.6 the Ring
A/Ring B coplanar angle ranged from 4.14° to 12.27°. In addition, aromatic rings C
and D were found to exhibit a high degree of coplanarity with rings A and B,
respectively, with the coplanar angles all < 11°.
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Figure 3.23 Structures of complexes (71) and (80) illustrating the lettering system (A-F) used
to discuss the degree of coplanarity of different rings in the solid state structures of the
complexes.

In contrast to the above, Table 3.6 shows the aromatic rings in the top halves of
the complexes (E and F) did not show a high degree of coplanarity with those in the
bottom halves (C and D).
Table 3.6 Selected bond lengths (Å), bond angles (°) and coplanar ring angles (°) for (72),
(74), (80) and (84).
Geometric
parameters
Ni1–O1 (Å)
Ni1–O2 (Å)
Ni1–N1 (Å)
Ni1–N2 (Å)
O1–Ni1–O2 (°)
O2–Ni1–N2 (°)
O1–Ni1–N2 (°)
O2–Ni1–N1 (°)
O1–Ni1–N1 (°)
N1–Ni1–N2 (°)
N1—C8—C9—N2 (°)
Ring A/Ring B (°)
Ring A/Ring C (°)
Ring B/Ring D (°)
Ring C/Ring E (°)
Ring D/Ring F (°)

(72)
1.8434 (12)
1.8232 (13)
1.8563 (17)
1.8541 (16)
83.37 (6)
95.00 (6)
178.33 (6)
177.62 (7)
94.55 (6)
87.09 (7)
52.1 (4)
4.14
3.07
1.59
86.49
87.34

Nickel complexes
(74)
(80)
1.8385 (9)
1.8352 (12)
1.8313 (9)
1.8357 (12)
1.8761 (11)
1.8564 (14)
1.8944 (12)
1.8543 (14)
82.72 (4)
85.25 (5)
92.48 (5)
93.87 (6)
171.65 (5)
175.57 (6)
171.67 (5)
175.46 (6)
92.46 (5)
93.83 (6)
93.08 (5)
87.38 (6)
---36.63 (17)
13.27
21.30
9.83
7.84
10.13
5.67
79.65
81.59
73.68
84.18

(94)
1.8536 (14)
1.8313 (14)
1.8396 (17)
1.8602 (17)
84.37 (6)
94.10 (7)
178.22 (7)
178.07 (8)
94.57 (7)
86.99 (8)
41.7 (2)
6.65
5.51
5.56
87.86
----

138

The crystal lattices of all four non-alkylated complexes were composed of
molecules assembled in pairs, with three of the complexes ((72), (74) and (94))
possessing a crystallographic inversion centre. Only in the case of (72) were pairs of
molecules packed in a slipped co-facial configuration, resulting in a separation of
4.535 Å between the average planes of the pairs (Figure 3.24). The crystal lattices of
(72), (74) and (94) were supported by hydrogen bonds between the protons of water
molecules and the oxygen atoms of the complexes, or between the H atoms of the
OH groups on the complexes and the oxygens of water molecules. The interatomic
O–H⋯O distances ranged from 1.76 to 2.32 Å. Since (80) had no water molecules in
its crystal lattice, the hydrogen bond present instead involved the H atoms of the OH
groups of one molecule of the complex, and O atoms of neighbouring (CH 3)2SO
molecules.

4.535 Å

Figure 3.24 Packing of molecules of (72) in the crystal lattice.

139

3.4.2 Solid-state structures of alkylated nickel complexes
Four alkylated nickel Schiff base complexes were crystallised by slow
evaporation of solvent from saturated solutions. The latter were prepared by initially
suspending a small amount of complex in a solvent in which it had limited solubility,
such as acetone, methanol or hexane. A second solvent that the complexes were
very soluble in, such as DCM, was then slowly added until the complex just
dissolved. In contrast to the above procedure, crystals of (81) suitable for
crystallographic examination were collected from a solution of the complex in DMSOd6 in an NMR tube. Table 3.7 summarises the solvents used to obtain crystals of
complexes for determining their solid-state structures.
Table 3.7 Conditions used to obtains crystals of alkylated nickel Schiff base complexes
suitable for X-ray crystallography.
Complexes
(71)
(75)
(81)
(89)

Mass (mg)
19.6
20.1
11.3
12.5

Solvents
Acetone/DCM
Acetone/DCM
DMSO-d6
MeOH/DCM

Time (days)
13
15
21
4

Most of the unit cells of the complexes contained only the alkylated molecules.
The one exception to this was (75), which also had one molecule of DCM in the unit
cell. Information obtained during crystallographic data acquisition and refinement is
shown in Table 3.8, while ORTEPs for the complexes are shown in Figure 3.25, and
selected bond lengths, bond angles and coplanar ring angles in Table 3.9.
Complexes (71) and (75) crystallised in the monoclinic space group P21/c, and each
had an asymmetric unit cell that contained four nickel molecules. The unit cells of
(89) and (81) were also asymmetric, but belonged to the triclinic system. These
complexes were found to have the space group P1, and their unit cells contained two
and eight molecules of complex, respectively.
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Table 3.8 Crystallographic data for alkylated nickel Schiff base complexes.
(71)
C42H48N4NiO4
731.56
Monoclinic
Orange
P21/c
15.6742 (16)
9.0717 (8)
26.436 (3)
---94.398 (9)
---3747.9 (7)
1.296
4
-19<h<18
-7<k<11
-32<l<29

(75)
C43H50N4NiO4.(CH2Cl2)
830.54
Monoclinic
Green yellow
P21/c
14.6486 (1)
8.8879 (1)
31.2974 (3)
---91.8126 (8)
---4072.74 (7)
1.354
4
-18<h<18
-11<k<8
-38<l<38

(81)
C42H48N4NiO4
731.56
Triclinic
Orange
P1
10.6471 (4)
26.9276 (13)
28.5309 (16)
65.563 (5)
84.047 (4)
83.883 (3)
7388.6 (7)
1.315
8
-12<h<9
-32<k<33
-35<l<33

(89)
C56H74N6NiO6
985.94
Triclinic
Orange
P1
10.5477 (5)
15.4745 (6)
16.5986 (8)
88.093 (3)
83.802 (4)
70.576 (4)
2540.1 (2)
1.289
2
-12<h<11
-19<k<18
-20<l<20

Number of unique
reflections

7203

8211

27960

9968

Refinement

Rint = 0.074
R[F2 > 2σ(F2)] = 0.081

Rint = 0.032
R[F2 > 2σ(F2)] = 0.052

Rint = 0.056
R[F2 > 2σ(F2)] = 0.097

Rint = 0.054, wR(F2) =
0.177,
R[F2 > 2σ(F2)] = 0.064

Formula
Mr
Crystal system
Crystal colour
Space group
a (Å)
b (Å)
c (Å)
(o)
(o)
(o)
V (Å3)
Dx (Mg m-3)
Z
(h,k,l)
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(71)

(75)

(89)

(81)

Figure

3.25

Molecular

structures

for

(71),

(75),

(81)

and

(89),

with

ellipsoids

drawn

at

the

30%

probability

level.
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The nickel atoms in all four alkylated complexes also possessed the square
planar coordination geometry exhibited by their non-alkylated analogues, and
showed similar Ni–O and Ni–N bond distances and bond angles to other nickel Schiff
base complexes previously reported.[126, 127, 130] The largest deviations were
observed for complex (75) which exhibited an atypical green colour, and features a
diamine moiety that forms a six-membered chelate ring with the nickel ion.
Table 3.9 Selected bond length (Å), angles (°) and separation (Å) for alkylated
benzophenone derivatives complexes.
Geometric
parameters
Ni1–O1 (Å)
Ni1–O2 (Å)
Ni1–N1 (Å)
Ni1–N2 (Å)
O1–Ni1–O2 (°)
O2–Ni1–N2 (°)
O1–Ni1–N2 (°)
O2–Ni1–N1 (°)
O1–Ni1–N1 (°)
N1–Ni1–N2 (°)
N1—C8—C9—N2 (°)
Ring A/Ring B (°)
Ring A/Ring C (°)
Ring B/Ring D (°)
Ring C/Ring E (°)
Ring D/Ring F (°)

(71)
1.834 (3)
1.818 (4)
1.846 (4)
1.851 (4)
84.03 (15)
94.10 (17)
176.16 (18)
176.26 (18)
94.42 (16)
87.64 (18)
35.9 (5)
15.90
4.23
4.27
82.91
89.54

Nickel complexes
(75)
(81)
1.8372 (15)
1.833 (5)
1.8625 (14)
1.827 (5)
1.8909 (17)
1.860 (5)
1.8716 (17)
1.853 (5)
85.87 (6)
84.3 (2)
91.54 (7)
93.9 (2)
166.18 (7)
176.4 (2)
167.03 (7)
175.1 (2)
94.23 (7)
93.3 (2)
91.31 (7)
88.7 (2)
---39.7 (7)
24.90
5.62
15.84
4.50
5.51
1.92
83.20
79.37
87.01
75.22

(89)
1.822 (2)
1.829 (2)
1.854 (3)
1.850 (3)
84.18 (9)
93.49 (10)
177.67 (10)
178.39 (12)
94.40 (10)
87.92 (11)
40.1 (3)
11.28
1.59
8.32
79.85
61.48

The solid-state structures shown in Figure 3.25 confirm that the alkylation
reactions were successful, including for (89), which features four pendant groups. In
the case of (81), one pendant group is orientated above the coordination sphere of
the metal ion, while the second is located beneath (Figure 3.26 (b)). This
configuration appears to have had the effect of inducing a greater degree of
coplanarity between the two bottom aromatic rings in (81) (coplanar angle for rings A
and B = 5.62°) compared to its non-alkylated analogue (80), for which the
corresponding angle was 21.30°, (Table 3.6 and Figure 3.26 (a)). In contrast, the
corresponding coplanar angle for rings A and B in the alkylated complex (75), which
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features two pendant groups located below the metal ion’s coordination sphere, was
24.90°, which was larger than what was found for its non-alkylated analogue (74)
(coplanar angle for rings A and B = 13.27°).

(a)

(b)

Figure 3.26 Molecular structures of nickel Schiff base complexes viewed parallel to the
coordination sphere of the metal ion: (a) (80) and (b) (81).

Similar to what was observed with the non-alkylated complexes, there was
typically a much higher degree of coplanarity between ring systems located solely in
the bottom half of the molecules, than between those located in the top and bottom
halves. This is exemplified by the coplanar ring angles for rings C and E, and
between rings D and F, varying from 61.48° to 89.54°, (Table 3.9). In contrast, all
other coplanar ring angles were < 25°. The lack of coplanarity between ring systems
in the top and bottom halves of the molecule could inhibit -stacking interactions with
G-tetrads, which is usually the most important binding mode for this class of
complexes with G-quadruplexes. It must be noted, however, that there is free
rotation around the C-C bonds connecting the upper aromatic rings to those in the
bottom halves of the complexes, which may mean that alternative conformations to
those observed in the solid state may occur in solution, and which are more suitable
for binding to G-quadruplexes.
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The crystal lattices of (71), (89) and (75) consisted of molecules arranged in
pairs around crystallographic inversion centres. In the case of (71) and (89) the
molecules were packed in a slipped co-facial arrangement, with separations of 4.647
Å and 4.254 Å, respectively between the mean molecular planes calculated
excluding the pendant groups. This packing arrangement is illustrated for (89) in
Figure 3.27. In contrast to the solid-state structures of the non-alkylated complexes,
there were no hydrogen bonds between the metal complexes and solvent molecules,
as the former lack free hydroxyl groups and the latter were generally absent from the
structures.

(a)

4.254 Å

(b)

Figure 3.27 Different views of the packing of molecules of (89) in the crystal lattice: (a) two
molecules of (89) in the unit cell; and (b) the view parallel to the molecular planes, showing
the separation between the molecules (side arms omitted for clarity).
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Chapter 4 : Effect of varying the number of
pendant groups on DNA binding properties
4.1 Introduction and scope
Previous studies have recognised the important role in G-quadruplex binding
that can be played by pendant groups attached to organic compounds or ligands
present in metal complexes.[74, 76, 84, 129, 219] In many instances these pendant
groups are able to bind electrostatically to the phosphate backbone of the DNA,
owing to their polarity, or by virtue of having permanent positive charges or being
able to undergo protonation under physiological pH conditions.[74] One prominent
example of such a compound is BRACO-19 (Figure 1.11 (a)), which is a
trisubstituted acridine that has shown excellent G-quadruplex binding properties in a
FRET assay (T1/2 = 27 °C), and notable levels of telomerase inhibition via a TRAP
assay (IC50 = 113 nM).[76] The interactions between a G-quadruplex and nickel
Schiff base complexes with three side arms, such as (61) (Figure 1.18), has also
been investigated by Lecarme and co-workers.[95, 129] This complex exhibited a
high degree of affinity towards a G-quadruplex, and telomerase inhibition
(IC50 = 70 nM) in a TRAP assay. In addition, a binding constant (K a) of 4 × 107 M-1
was measured by surface plasmon resonance (SPR) for its interaction with the
tetramolecular G-quadruplex d[TTAGGGT]4.
A number of research groups have also shown that small molecules containing
four pendant groups exhibit notable affinity towards G-quadruplexes and biological
activities.[46, 84, 219-221] For example, complex (19) was shown by SPR to exhibit
a selectivity factor of 10,000 in favour of a G-quadruplex over dsDNA.[84] Another
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example centres on the compound MM41 (Figure 1.8 (b)), which showed notable
anticancer activity towards a pancreatic cancer cell line.[46]
With the above results in mind, it was decided to systematically investigate the
interactions between different DNA molecules and nickel Schiff base complexes
containing different numbers of pendant groups capable of undergoing protonation.
The structures of the nickel complexes examined are shown in Figure 4.1. The
literature complex (54) was also included in this study, because it is one of the
strongest G-quadruplex binding metal complexes known, and has also been showed
to inhibit telomerase. Furthermore, many of the structural features inherent in
complex (54) which result its notable G-quadruplex binding properties, are also
present in the novel complexes reported for the first time in this thesis. These include
the “salen” framework shared by both (54) and the novel complexes, and which
contains two approximately co-planar aromatic rings. DNA binding studies in this
chapter were carried out using a variety of different techniques including ESI-MS, CD
and UV-Vis spectroscopy, a FID assay, FRET melting assay and molecular docking.

Figure 4.1 Structures of nickel complexes containing different numbers of pendant groups
used in DNA binding studies. Complex (54) was included for comparative purposes.
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4.2 Results and discussion
4.2.1 DNA binding studies performed using ESI mass spectrometry
ESI-MS was first used to compare the affinity of nickel complexes with different
numbers of pendant groups towards the tetramolecular G-quadruplex Q4,
unimolecular G-quadruplex Q1 and dsDNA D2. This technique has been previously
used to obtain information about the number, stoichiometry and relative amounts of
non-covalent adducts formed between metal complexes and G-quadruplex or
dsDNA.[120, 127, 141, 222, 223] Stock solutions of Q1 and Q4 used in these ESIMS experiments were annealed under conditions which ensured that they were
present in parallel conformations (Chapter 2.3.3). Figure 4.2 shows the negative ion
ESI mass spectra of free Q4, and solutions containing a 3:1 ratio of nickel Schiff
base complexes and Q4. Each spectrum shows ions of medium or high abundance
at m/z 1675.2 and 2010.4, which are assigned to [Q4 + 4NH4 – 10H]6- and [Q4 +
4NH4 – 9H]5-, respectively. These ions arise from Q4 molecules with a total of four
ammonium ions bound, as expected for a quadruplex structure consisting of five
tetrads and one monovalent cation located in between each tetrad.[127]
The results of the mass spectral study indicate that the affinity of the new nickel
Schiff base complexes towards Q4 generally increased with the number of pendant
groups. In the case of complex (87), which contains only one pendant group, the
mass spectrum (Figure 4.2 (c)) only showed ions from free Q4. In contrast, when the
nickel complex contained either two or three pendant groups (complexes (71) and
(77), respectively), ions from non-covalent complexes consisting of one nickel
molecule bound to Q4 were also present in low to medium abundance (Figures 4.2
(d) and (e)).
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Figure 4.2 Negative ion ESI mass spectra of solutions containing free Q4 or different nickel
Schiff base complexes and Q4 at a 3:1 ratio. (a) free Q4; (b) Q4 + (54); (c) Q4 + (87);
(d) Q4 + (71); (e) Q4 + (77) and (f) Q4 + (89). = free Q4; = {Q4 + (Ni)}; = {Q4 + 2(Ni)}.

In the case of (71), these ions were at m/z 1797.2 and 2156.8, and are
assigned to [Q4 + (71) + 4NH4 – 12H]6- and [Q4 + (71) + 4NH4 – 11H]5-, respectively.
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When the nickel complex used was (77), the corresponding ions were observed at
m/z 1820.5 and 2184.8. The above ions and adduct(s) will hereafter be referred to
collectively as {Q4 + (71)} and {Q4 + (77)}, and this terminology will be used in future
to describe non-covalent adducts consisting of one or more of the other novel nickel
Schiff base complexes and different DNA molecules. Complex (89), with four
pendant groups, exhibited the highest affinity towards Q4. This is supported by
Figure 4.2 (f), which shows no ions from free Q4, but does contain ions of high, and
low to medium abundance, from {Q4 + (89)} and {Q4 + 2 (89)}, respectively. The
prevalence of ions from {Q4 + (89)} in the Figure 4.2 (f) supports the hypothesis that
Q4 may have one high affinity binding site for this nickel complex. In contrast, Figure
4.2 (b) shows that under the same conditions the literature complex (54) formed noncovalent complexes consisting of one or two nickel molecules bound to Q4 in roughly
equal amounts. This suggests that Q4 has two binding sites for (54) with similar
affinities.
Analogous DNA binding experiments were conducted by ESI-MS using the
parallel unimolecular G-quadruplex Q1 and dsDNA D2. Figure 4.3 shows how the
relative abundances of ions varied in ESI mass spectra of solutions containing a 3:1
ratio of one of the new nickel complexes, or (54), and Q1, Q4 or D2. Relative
abundances were obtained by adding the abundances of all ions arising from either
free DNA or non-covalent adducts containing a specific number of bound nickel
molecules, and dividing by the total abundance of all ions in the spectrum, and
converting the results to percentage values.[128] The results obtained show that the
nickel complex with one pendant group, (87), did not form non-covalent ions with any
of the three types of DNA investigated. When the [Ni]:[DNA] ratio was increased to
6:1, the resulting mass spectra still did not show any ions from {Q1 + (87)} or {D2 +
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(87)}, whilst the relative abundances of ions from {Q4 + (87)} was very low (Figure
S4.1). This confirms that (87) has a very low affinity towards DNA in general, and
suggests that the low overall charge of the complex may limit its DNA binding
capability.

Figure 4.3 Relative abundances of ions in ESI mass spectra of solutions containing a 3:1
ratio of nickel Schiff base complexes and dsDNA (D2), unimolecular qDNA (Q1) or
tetramolecular qDNA (Q4): (a) solutions containing (54); (b) solutions containing (87);
(c) solutions containing (71); (d) solutions containing (77) and (e) solutions containing (89).

Complex (71), which contains two pendant groups, was shown previously to
interact with Q4. In contrast, Figure 4.3 (c) shows that mass spectra of solutions
containing this nickel complex and either Q1 or D2 did not contain ions of significant
abundance from non-covalent complexes. Complex (77), with three pendant groups,
also did not show an ability to form non-covalent complexes with D2, but unlike (71)
did produce ions of low abundance from {Q1 + (77)}. In contrast to all of the above
nickel complexes, (89) did form significant amounts of non-covalent complexes with
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Q1, whilst still exhibiting a relatively low degree of affinity towards D2. This
observation suggests that the number of pendant groups in these metal complexes
can have a major effect on their ability to bind to G-quadruplexes.

Inspection of Figure 4.3 shows that increasing the number of pendant groups in
the new class of nickel Schiff base complexes did not greatly increase their ability to
interact with the dsDNA D2. In contrast, the literature complex (54) did show
evidence of binding to D2, which was more notable in solutions containing a 6:1 ratio
of [Ni]:[DNA] (Figure S4.1 (a)). It is also noteworthy that (89), with four pendant
groups, did not bind as strongly to D2 as (54). This conclusion is supported by the
greater percentage of ions from free DNA in the spectrum containing the former
nickel complex (Figure 4.3 (e)), and is also evident in the data obtained from spectra
of solutions containing a higher [Ni]:[DNA] ratio (Figure S4.1 (e)). Figure 4.3 also
shows that the abundances of ions from free DNA was lower in the case of spectra
containing (89) and either Q1 or Q4, than for the corresponding spectra of solutions
with (54) present. Taken together, the results presented above suggest that the
affinity of (89) towards Q1 and Q4, and its selectivity for these DNA molecules over
D2, is at least comparable to, if not greater than that exhibited by (54).

4.2.2 DNA binding studies performed using CD spectroscopy
4.2.2.1 CD titrations using parallel tetramolecular Q4
The results of ESI-MS experiments presented in the previous section suggest
that (89) has a significant affinity and selectivity towards G-quadruplex DNA over
dsDNA. In order to investigate this possibility further, circular dichroism (CD)
experiments were performed using the novel nickel Schiff base complexes
containing varying numbers of pendant groups, and different types of DNA. Circular
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dichroism spectroscopy is a well-known and sensitive technique for investigating
chiral molecules such as DNA. When achiral organic molecules or metal complexes
bind to DNA the secondary structure of the latter is altered, resulting in changes to its
CD spectrum which can provide information about the strength and nature of the
binding interactions.[224, 225] Small molecules which have larger effects on the CD
spectra of a nucleic acid are generally believed to participate in stronger interactions
with the DNA. The experiments presented here were carried out using the parallel
tetramolecular

G-quadruplex

Q4,

unimolecular

G-quadruplex

Q1,

parallel

unimolecular G-quadruplex c-kit1, and dsDNA D2. Experiments involving Q1 were
performed using this DNA annealed under different conditions, in order to vary its
topology from parallel to anti-parallel and hybrid conformations. Figure 4.4 shows the
effect of increasing amounts of nickel Schiff base complexes with different numbers
of pendant groups on the CD spectrum of parallel Q4. Also included for comparison
purposes is the effect of increasing amounts of (54). The CD spectrum of a solution
containing Q4 alone displayed two positive CD bands at 208 and 263 nm, along with
a weak negative CD band centred near 242 nm. These observations are consistent
with Q4 being present in a parallel conformation.[127, 128, 152, 226-228] Table 4.1
illustrates the effect of the nickel complexes on the wavelength and maximum
ellipticity of the CD bands. The percentage change in ellipticity ((%)) of the CD
bands was calculated according to equation 4.1:
∆𝜀(%) =

𝜀1 − 𝜀0
𝜀0

× 100 (4.1)

In this equation, 0 and 1 are the maximum ellipticities of the CD bands of
solutions containing DNA alone, and a 9:1 ratio of nickel complex:DNA, respectively.
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(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 4.4 CD spectra of solutions containing different ratios of nickel Schiff base complexes
with different numbers of pendant groups and parallel Q4: (a) Q4 + (54); (b) Q4 + (87);
(c) Q4 + (71); (d) Q4 + (77) and (e) Q4 + (89). The HT voltage observed during the course of
obtaining the CD spectra of Fig 4.4 a, b, c, d exceeded 400 V, at wavelengths < 215 nm.

Inspection of Table 4.1 shows that none of the nickel complexes had a
significant effect on the position of the CD bands, however some resulted in notable
changes to their ellipticity. In some instances there was consistency between relative
DNA binding affinities based on CD and ESI-MS results. For example, complex (87)
failed to induce significant changes to the CD spectrum of Q4. This suggests this
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nickel complex does not interact strongly with Q4, in agreement with its inability to
form non-covalent adducts detectable by ESI-MS. The reference complex (54) had
the biggest effect on the CD spectrum of Q4, and was one of two nickel complexes
to exhibit a pronounced ability to generate ions from non-covalent complexes in
ESI-MS experiments. The other complex which showed a notable ability to form
non-covalent complexes with Q4 in ESI-MS experiments, (89), did not have as
dramatic an effect on the CD spectrum of Q4 as (54). It is also somewhat surprising
that (77), which showed a comparable ability to (71) to form non-covalent adducts
with Q4 in ESI-MS experiments, had a smaller influence on the CD spectrum of the
nucleic acid. These variations hint at subtle differences in the binding mechanisms
used by the nickel complexes to interact with the nucleic acid molecule, and also
perhaps varying sensitivities of the CD technique to differences in binding modes.
Table 4.1 Effect of addition of nickel Schiff base complexes with different numbers of
pendant groups on the CD spectrum of parallel Q4.
Complexes
(54)
(87)
(71)
(77)
(89)

Negative CD band at 242 nm
max (nm)*
(%)*
0.7
31
0.1
8
0.1
14
0.0
14
0.1
25

Positive CD band at 263 nm
max (nm)*
(%)*
0.3
-58
0.1
-6
0.1
-36
-0.3
-11
0.1
-26

*max and (%) were calculated using solutions containing free Q4 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and Q4.

4.2.2.2 CD titrations using parallel unimolecular Q1
The topology of a unimolecular G-quadruplex can be varied from parallel to
anti-parallel or hybrid conformation, by altering the composition and pH of the
surrounding solution, and the annealing conditions.[152, 157, 229, 230] Optimised
conditions for obtaining each of the above three topologies for unimolecular Q1 were
established by systematically exploring the effect of varying the solution and
annealing conditions on the appearance of its CD spectrum. These optimised
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conditions were presented in Chapter 2.3.3, while Figure 4.5 illustrates the variation
between the CD spectra of these different G-quadruplex topologies. The CD
spectrum of parallel Q1 was essentially identical to that of parallel Q4, and other
parallel G-quadruplexes reported previously.[127, 128] Two positive CD bands with
large ellipticities were observed at 207 and 263 nm, along with a much weaker
negative CD band centred at 241 nm.

Figure 4.5 CD spectra of different topologies of the unimolecular G-quadruplex Q1. The
parallel conformation was obtained in 150 mM NH4OAc, pH 7.4, while the anti-parallel
conformation predominated in 100 mM NaCl, 15 mM NaH2PO4, 15 mM Na2HPO4, pH 7.4.
The hybrid conformation was observed in solutions containing 100 mM KCl, 15 mM KH2PO4,
15 mM K2HPO4, pH 7.4.

Figure 4.6 shows the effect of adding increasing amounts of the nickel
complexes on the CD spectrum of parallel Q1, while Table 4.2 summarises the
changes observed to the position and ellipticity of the CD bands. The results
obtained show (54) and (89) both strongly affected the CD spectrum of parallel Q1,
in agreement with the notable levels of non-covalent complex formation evident in
ESI mass spectra of these systems. Comparison of Tables 4.1 and 4.2 shows that all
nickel complexes had a more pronounced effect on the CD spectrum of parallel Q1,
than on Q4. This perhaps reflects the loops, which are only present in the
unimolecular G-quadruplex, are playing a significant role in the mode of binding, and
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especially those interactions which lead to alterations to the chirality of the nucleic
acid.

(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 4.6 CD spectra of solutions containing different ratios of nickel Schiff base complexes
with different numbers of pendant groups and parallel unimolecular Q1: (a) Q1 + (54);
(b) Q1 + (87); (c) Q1 + (71); (d) Q1 + (77) and (e) Q1 + (89). The HT voltage observed
during the course of obtaining all CD spectra illustrated here exceeded 400 V, at
wavelengths < 215 nm.

One of the biggest differences in results obtained between the two nucleic
acids was observed with (71). This complex caused a reduction in ellipticity of 36%
for the positive CD band at 263 nm in the spectrum of Q4, however the change in
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ellipticity was more than twice as great when the DNA examined was Q1.
Intriguingly, ESI mass spectra of solutions containing (71) and Q1 did not show
appreciable amounts of ions from non-covalent adducts. This apparent anomaly may
be explained by postulating that non-covalent adducts are actually formed between
the nickel complex and DNA molecule, but have insufficient stability to withstand the
ESI process. In contrast to the other nickel complexes, (87) and (77) had relatively
small effects on the CD spectrum of parallel Q1, which is consistent with the low
abundances of ions in ESI mass spectra of these systems.
Table 4.2 Effect of addition of nickel Schiff base complexes with different numbers of
pendant groups on the CD spectrum of parallel unimolecular Q1.
Complexes
(54)
(87)
(71)
(77)
(89)

Negative CD band at 241 nm
max (nm)*
(%)*
3.5
51
-1.6
58
1.0
89
-0.1
43
2.1
69

Positive CD band at 263 nm
max (nm)*
(%)*
16
-78
-1.0
-36
-1.0
-77
-0.2
-22
1.0
-58

*max and (%) were calculated using solutions containing free parallel Q1 alone, and solutions
containing a 9:1 ratio of nickel Schiff base complex and parallel Q1.

4.2.2.3 CD titrations using anti-parallel unimolecular Q1
In order to investigate the ability of metal complexes to distinguish different
conformations of unimolecular G-quadruplexes, CD titration experiments were also
performed using Q1 present in the anti-parallel topology. Figure 4.5 shows the CD
spectrum of anti-parallel Q1 has positive CD bands with maximum ellipticity at 245
and 296 nm, as well as a negative CD band with maximum ellipticity at 265 nm.
These features are similar to those of CD spectra published by Mergny and
co-workers for another anti-parallel, unimolecular G-quadruplex.[157] The origin of
the variations between the CD spectra of the different conformations of unimolecular
G-quadruplexes has been discussed previously, and depends on the conformations
of the glycosidic bonds and the relative polarity of successive G-tetrads.[226, 231,
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232] The polarity of a G-tetrad refers to the directionality of the hydrogen bond donor
and acceptor groups that are involved in forming the Hoogsteen hydrogen bonds
which hold the structure together. In parallel G-quadruplex structures all guanines in
the G-tetrads have anti-conformations for their glycosidic bonds, and successive
G-tetrads have the same polarity. In contrast, for anti-parallel topologies the
glycosidic bonds alternate between syn- and anti-conformations, and G-tetrads can
exhibit opposite polarities.[226]
The effect of adding increasing amounts of nickel complexes with different
numbers of pendant groups on the CD spectrum of anti-parallel Q1 is presented in
Figure 4.7, while Table 4.3 compiles the changes to both the position and maximum
ellipticity of the CD bands observed in these experiments. Inspection of the data
obtained shows that the nickel complexes with one, two or three pendant groups
only had a small effect on the CD spectrum of antiparallel Q1. In contrast, the
literature complex (54), and the novel nickel complex with four pendant groups (89),
both induced significant alterations to all bands in the CD spectrum of the nucleic
acid. For example, (54) and (89) decreased the ellipticity of the positive CD band at
296 nm by 58% and 46%, respectively, (Table 4.3). This suggests that both of these
complexes exhibit a significant degree of affinity towards anti-parallel Q1, but also
little selectivity towards this nucleic acid in its different conformations. Unfortunately,
owing to incompatibility between the solvent system required for annealing Q1 in
order to force it to adopt the anti-parallel conformation, and conditions required for
performing ESI-MS experiments, it was not possible to use the latter technique to try
and verify this conclusion.

159

(a)

(b)
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(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 4.7 CD spectra of solutions containing different ratios of nickel Schiff base complexes
with different numbers of pendant groups and anti-parallel unimolecular qDNA Q1:
(a) Q1 + (54); (b) Q1 + (87); (c) Q1 + (71); (d) Q1 + (77) and (e) Q1 + (89). The HT voltage
observed during the course of obtaining all CD spectra illustrated here exceeded 400 V, at
wavelengths < 215 nm.
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Table 4.3 Effect of addition of nickel Schiff base complexes with different numbers of
pendant groups on the CD spectrum of anti-parallel Q1.
Complexes
(54)
(87)
(71)
(77)
(89)

Negative CD band at 265 nm
max (nm)*
(%)*
-5.0
95
0.2
3
-1.0
12
0.6
27
-4.3
65

Positive CD band at 296 nm
max (nm)*
(%)*
2.7
-58
0.3
3
0.2
-9
-0.6
-4
-0.3
-46

*max and (%) were calculated using solutions containing free Q1 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and Q1.

4.2.2.4 CD titrations using hybrid unimolecular Q1
The hybrid conformation of a unimolecular G-quadruplex consists of 3 parallel
DNA strands and one anti-parallel strand (Figure 1.10 h).[231, 233, 234] This
topology results in a CD spectrum that shows two broad positive peaks centred at
208 and 291 nm, with the latter having shoulders at 255 and 269 nm. A small
negative CD band is also present at 233 nm. The CD spectrum reported here for Q1
after it was annealed under conditions designed to force it to adopt a hybrid
conformation is shown in Figure 4.5. This spectrum resembles strongly that reported
for the hybrid conformation of the h-telo qDNA 22AG, which was prepared using very
similar solution and annealing conditions.[157]
CD spectroscopy was also used to investigate the effects of varying the number
of pendant groups in the novel nickel Schiff base complexes on the CD spectrum of
the hybrid conformation of unimolecular Q1. These results are presented in Figure
4.8, while Table 4.4 illustrates the changes to both the position and maximum
ellipticity of the CD bands observed in these experiments. Of all the complexes
examined, the literature complex (54) exhibited the strongest ability to interact with
hybrid Q1. This is supported by the significant changes to the position of the CD
bands of hybrid Q1 caused by (54), as well as reductions in ellipticity that were more
than twice as large as those caused by any of the other novel nickel complexes
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(Table 4.4). Since the results of CD experiments indicate (54) interacts strongly with
all three topologies of unimolecular Q1, it would appear this complex exhibits little
binding selectivity towards G-quadruplexes.

(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 4.8 CD spectra of solutions containing different ratios of nickel Schiff base complexes
with different numbers of pendant groups and hybrid unimolecular qDNA Q1: (a) Q1 + (54);
(b) Q1 + (87); (c) Q1 + (71); (d) Q1 + (77) and (e) Q1 + (89). The HT voltage observed
during the course of obtaining CD spectra illustrated in Fig 4.8 (e) exceeded 400 V, at
wavelengths < 215 nm.
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Table 4.4 Effect of addition of nickel Schiff base complexes with different numbers of
pendant groups on the CD spectrum of hybrid Q1.
Complexes
(54)
(87)
(71)
(77)
(89)

Positive CD band at 208 nm
max (nm)*
(%)*
-1.8
-70
2.2
-2
0.1
-35
1.6
-4
-2.3
-26

Positive CD band at 291 nm
max (nm)*
(%)*
4.7
-62
1.3
-1
0.7
-22
-0.7
-10
1.5
-9

*max and (%) were calculated using solutions containing free Q1 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and Q1.

Of the novel nickel Schiff base complexes, those with one and three pendant
groups ((87) and (77), respectively) had the smallest impact on the spectrum of
hybrid Q1, suggesting that they display the lowest binding affinities. Both of these
nickel complexes exhibited a negligible ability to affect the CD spectrum of
anti-parallel Q1, and only had a small effect on the corresponding spectrum of the
nucleic acid when it was present in the parallel topology. Overall these complexes
therefore appear to have a limited ability to interact with any of the different
topologies of unimolecular Q1.
In contrast, both (71) and (89) showed a significant ability to alter the CD
spectrum of hybrid Q1, although these changes were much smaller than those
elicited by (54). Complex (89) was also shown previously to exhibit a notable ability
to alter the CD spectrum of Q1 when present in either of the two alternative
topologies investigated. This suggests that while the complex with four pendant
groups might exhibit a notable ability to interact with G-quadruplex DNA structures, it
may not necessarily display a high degree of selectivity in its binding interactions
with different conformations of unimolecular qDNA.
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4.2.2.5 CD titrations using parallel unimolecular c-kit1
The CD and ESI-MS results presented earlier in this chapter indicate that (89),
and to a slightly lesser extent (71), display a significant ability to bind to a variety of
G-quadruplex structures. It was of interest to see if these or other members of this
new class of nickel Schiff base complexes also show similar results in CD
experiments

performed

using

a

different

unimolecular

G-quadruplex.

One

oligonucleotide that is also known to form a parallel unimolecular G-quadruplex
structure is the 21-mer c-kit1, with the sequence 5´-GGG AGG GCG CTG GGA GGA
GGG-3´. The proto-oncogene c-kit1 is found in promoter regions and overexpressed
in over 80% of cancers including ovarian, gastrointestinal and breast cancer.[235]
Owing to the ability of this DNA sequence to form a parallel quadruplex
conformation, it has been investigated as a potential target for several G-quadruplex
binding agents.[195, 235, 236] The CD spectrum of parallel c-kit1 showed two
positive CD bands with large ellipticities at 207 and 262 nm, along with a negative
CD band with much smaller ellipticity at 240 nm (Figure 4.9). The CD spectrum was
therefore very similar to that of other G-quadruplex structures reported in the
literature,[195, 235, 236] as well as that of parallel Q1 discussed in Chapter 4.2.2.2
(Figure 4.5). The results obtained from CD experiments performed by adding
increasing amounts of nickel complexes with different numbers of pendant groups to
parallel c-kit1 are shown in Figure 4.9, while Table 4.5 quantifies the maximum
effects on the position and ellipticity of the CD bands.
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DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 4.9 CD spectra of solutions containing different ratios of nickel Schiff base complexes
and c-kit1: (a) c-kit1 + (54); (b) c-kit1 + (87); (c) c-kit1 + (71); (d) c-kit1 + (77) and
(e) c-kit1 + (89). The HT voltage observed during the course of obtaining all CD spectra
illustrated here exceeded 400 V, at wavelengths < 215 nm.
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Table 4.5 Effect of addition of nickel Schiff base complexes with different numbers of
pendant groups on the CD spectrum of c-kit1.
Complexes
(54)
(87)
(71)
(77)
(89)

Negative CD band at 240 nm
max (nm)*
(%)*
3.6
58
0.0
61
-0.9
52
-0.1
48
0.9
42

Positive CD band at 262 nm
max (nm)*
(%)*
4.6
-74
-0.9
-39
-0.2
-31
0.1
-30
3.3
-56

*max and (%) were calculated using solutions containing free c-kit1 alone, and solutions
containing a 9:1 ratio of nickel Schiff base complex and c-kit1.

The results obtained show that (54) and (89) had the strongest influence on the
CD spectrum of parallel c-kit1. These two complexes also caused large changes to
the ellipticity of parallel Q1, suggesting that they are able to consistently recognise
and interact with this type of G-quadruplex structure. Complex (71), on the other
hand, did not affect the CD spectrum of parallel c-kit1 as much as it did the spectrum
of Q1 in a parallel conformation, hinting at some degree of selective structure
recognition. It is also notable that (87) was able to interact with c-kit1 to a significant
extent, as shown by it causing the third largest reduction in ellipticity of the positive
CD band of the DNA molecule (Table 4.5). The only other G-quadruplex whose CD
spectrum was significantly affected by the nickel complex with a single pendant
group was Q1 when present in a parallel conformation. For all other types of
G-quadruplexes (87) changed the CD spectrum to only a very minor extent. This
suggests that whilst (87) may not display a high degree of affinity towards parallel,
unimolecular G-quadruplexes, it may bind to them with some selectivity over other
types of DNA molecules.
4.2.2.6 CD titrations using double stranded DNA D2
It is imperative that any small molecule that is designed to be a therapeutic
agent that acts through binding to G-quadruplex structures, does not also interact
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strongly with the much larger amount of dsDNA present in cells. The results obtained
from experiments performed using ESI-MS suggested that each of the novel nickel
complexes exhibit very low affinities towards the dsDNA molecule D2, highlighting
that some members of this class of molecules may exhibit the desired binding
selectivity. In order to explore this further, it was decided to use CD spectroscopy to
also examine the binding interactions of the nickel complexes with D2. CD
spectroscopy has been widely used previously to study the topology of dsDNA and
its interactions with small molecules, some of which result in transitions from B-form
DNA to different conformations.[128, 155, 229, 237, 238]
The effects of addition of the nickel complexes on the CD spectrum of D2 are
shown in Figure 4.10, while Table 4.6 illustrates the maximum changes observed to
the position and ellipticity of the principal CD bands. As expected, the spectrum of
free D2 showed a positive CD band with large ellipticity at 282 nm, a smaller,
positive CD band at 219 nm, and a large, negative CD band with maximum ellipticity
at 249 nm. These spectral features are in agreement with those reported previously
for B-form DNA.[229] Addition of (87) or (77) resulted only in very small changes to
the CD spectrum of the nucleic acid. This is consistent with the results of the mass
spectrometric study, and provides further evidence that (87), in particular, may
function as a selective binding agent for parallel, unimolecular G-quadruplexes.
Complexes (54) and (71) also only induced relatively minor changes to the CD
spectrum of D2, apart from a significant decrease in the ellipticity of the negative CD
band cause by (54). Overall these observations are also consistent with the low
abundance of ions in ESI mass spectra of these systems.
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Table 4.6 Effect of addition of nickel Schiff base complexes with different numbers of
pendant groups on the CD spectrum of dsDNA D2.
Complexes
(54)
(87)
(71)
(77)
(89)

Negative CD band at 248 nm
max (nm)*
(%)*
-0.5
49
0.0
4
0.7
5
0.3
10
7.1
69

Positive CD band at 282 nm
max (nm)*
(%)*
-1.8
-6
0.0
-9
3.6
-35
0.0
-5
-17.3
-114

*max and (%) were calculated using solutions containing free D2 alone, and solutions containing
a 9:1 ratio of nickel Schiff base complex and D2.

In view of the low abundance of ions observed in ESI mass spectra of solutions
containing (89) and D2, it was surprising that this nickel complex induced dramatic
alterations to the CD spectrum of the same nucleic acid. These include the complete
disappearance of prominent bands that are typical of B-form duplex DNA, and
replacement by new CD signals. Such dramatic changes may indicate that the
binding of (89) to this nucleic acid molecule is stronger that what is expected based
on the mass spectrometry study of the same system. Furthermore, the changes to
the CD spectrum may reflect a change in conformation, or loss of secondary
structure of the nucleic acid, as a result of the metal binding event. It is currently
unclear what the origin is of the dramatic changes to the CD spectrum shown in
Figure 4.10 (e).
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Figure 4.10 CD spectra of solutions containing different ratios of nickel Schiff base
complexes and dsDNA D2: (a) D2 + (54); (b) D2 + (87); (c) D2 + (71); (d) D2 + (77) and
(e) D2 + (89). The HT voltage observed during the course of obtaining CD spectra illustrated
in Fig 4.10 (a), (e) exceeded 400 V, at wavelengths < 215 nm.

4.2.3 DNA binding studies performed using UV-Vis spectroscopy
4.2.3.1 Absorption titration method
Ultraviolet-Visible (UV-Vis) absorption spectrophotometry is one of the most
frequently used techniques to study the interactions between small molecules and
DNA. A number of different individual methods can be used with this particular
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technique. One of the most widely used is the determination of an overall binding
constant for drug/DNA interactions by monitoring the effect of adding increasing
amounts of DNA on the absorption spectrum of solutions containing drug
molecules.[94, 141, 239] For this thesis project, UV-Vis titration experiments were
performed in order to determine overall binding constants for the interactions of the
nickel complexes with dsDNA. As such experiments can use large quantities of DNA,
the studies were carried out using 100 mM NH4OAc solutions containing CT-DNA.
Experiments were performed by monitoring the change in absorbance of an intense
band at 280 – 300 nm, and a broad band centred around 380 nm, in the spectra of
the nickel complexes. These absorption bands have been assigned to intraligand (IL)
electronic  transitions and metal to ligand charge transfer (MLCT) transitions,
respectively.[94, 97, 239]
The above experiments were performed to provide an indication of the overall
strength of binding interactions between the novel nickel complexes and dsDNA, as
well as the relative strengths of these binding interactions amongst the nickel
complexes. It was hoped that the binding constants obtained might help answer
questions arising from differences in binding affinity noted earlier for some
complexes, based on results obtained from ESI-MS and CD experiments. The
method used to perform the UV-Vis absorption titrations is described in
Chapter 2.6.1. The results obtained from a typical absorption titration experiment
involving (89) are shown in Figure 4.11, S4.3, whereas those obtained from
experiments performed using the other nickel complexes can be found in Figure
S4.2, S4.3.
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Figure 4.11 Effect of addition of 3 mM CT-DNA on the absorption spectrum of 20 M
(89).The inset shows the resulting binding isotherm. The arrows indicate the direction of
change in absorbance upon addition of CT-DNA.

Adding CT-DNA to solutions containing the nickel complexes resulted in
significant hypochromicity for the MLCT bands of every complex and, in some
instances, notable changes to the position of the absorption bands (Table 4.7). This
absorption band was used for determining binding constants in view of the proximity
of the IL band to the absorption band of CT-DNA. The data obtained from these
experiments were analysed using Equation 2.1 to provide the binding constants also
presented in Table 4.7. The binding constants for the novel nickel complexes with
different numbers of pendant groups, and (54), were all very small, and similar to
each other. These results therefore suggest that each of these complexes has a
relatively low affinity towards dsDNA. This conclusion is consistent with the very low
abundances of ions observed in ESI-MS experiments performed using these
complexes and D2, as well the relatively small changes to the CD spectrum of D2
observed on most occasions when the metal complexes were added.
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Table 4.7 Results obtained from absorption titration experiments performed using nickel
Schiff base complexes with different numbers of pendant groups and CT-DNA.
Complexes
(54)
(87)
(71)
(77)
(89)
a

max for
MLCT
band (nm)
366.7
382.2
380.3
377.8
385.3

max for
MLCT
band (nm)
15.5
-4.7
-2.2
0.0
9.2

Extinction coefficient
of complexes (A ×
104 (M-1 cm-1))
2.0 ± 0.3
0.7 ± 0.2
0.8 ± 0.1
1.7 ± 0.4
0.8 ± 0.2

A for
MLCT
band (%)
-54.8
-47.3
-19.4
-24.8
-25.2

Mean binding
constant (Kb ×
104 (M-1)) a
24.0 ± 1
6.7 ± 0.1
5.3 ± 0.3
1.8 ± 0.1
2.8 ± 0.2

-1

Mean binding constants (units = M(base pairs) ) were obtained from three absorption titration
experiments, and are presented here together with standard errors.

It is important to look closely at the results obtained for (89), in view of the
unexpectedly dramatic changes to the CD spectrum of D2 caused by addition of this
nickel complex, which were noted in Chapter 4.2.2.6. Whilst the MLCT band of (89)
did shift significantly to lower energy when CT-DNA was added, the hypochromicity
caused by the binding interaction and the overall binding constant were both
relatively minor. Therefore the CD results obtained for this complex in the previous
section of this chapter appear to not be consistent with all other evidence concerning
the strength of the binding interaction for (89) with duplex DNA. Taking the ESI-MS
results presented earlier in this chapter also into consideration, it would appear that
(89) has a relatively low affinity towards dsDNA molecules. Of the remaining nickel
complexes, the literature compound (54) exhibited the largest hypochromicity and
binding constant. The energy of its MLCT band was also the most dramatically
affected by addition of CT-DNA. Furthermore, whilst ESI mass spectra of solutions
containing (54) and D2 contained ions attributable to non-covalent complexes that
were only of low abundance, they were present in greater relative amounts than in
spectra of solutions containing the other nickel complexes. This reinforces the view
that whilst the binding of (54) to dsDNA may be relatively weak, it is perhaps still
slightly stronger than that exhibited by the novel nickel complexes.
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4.2.3.2 DNA melting studies
It has been well documented that the binding affinity of small molecules
towards dsDNA or qDNA can be investigated by using UV spectrophotometry to
examine the effect on the thermal behaviour of secondary DNA structures.[127, 141,
239, 240] This technique relies upon the change in absorbance at 260 nm (A260)
from the DNA bases, which occurs when dsDNA or G-quadruplex structures
denature, or “melt”, as a result of an increase in temperature. Plots of A260 as a
function of temperature are often referred to as DNA melting curves, and have a
sigmoidal appearance, with the temperature at which 50% of the dsDNA has
undergone strand separation being referred to as the melting temperature (Tm).[241]
Small molecules that can bind to and stabilise dsDNA or G-quadruplexes towards
this melting process cause a shift in the DNA melting curve to higher temperatures,
resulting in an increase in Tm. The magnitude of the change in Tm, referred to as
Tm, is proportional to the ability of the small molecule to bind to and stabilise the
DNA secondary structure. Therefore, small molecules which have stronger and/or
more effective binding interactions result in higher Tm values. For example, it has
been shown that metal complexes that interact with dsDNA via an intercalative
binding mode enhance the stability of the double helix and significantly increase
Tm.[242, 243] Representative DNA melting profiles for solutions containing D2 alone,
or D2 and (71), are shown in Figure 4.12. Figure 4.13 illustrates the effect on Tm of
D2 of adding 3 or 6 equivalents of nickel complexes with different numbers of
pendant groups, or (54).
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Figure 4.12 Melting curves for solutions containing 1M dsDNA D2 alone, and a 6:1 ratio of
(71) and 1M D2.

Melting temperature experiments were performed using solutions containing a
3:1 or 6:1 ratio of one of the nickel complexes and D2. The melting temperature, Tm,
of D2 alone was determined to be 62.6 ± 0.2 °C. Figure 4.13 shows that the Tm of D2
decreased by 1 – 3 °C in the presence of the four novel nickel Schiff base
complexes. These results are therefore in accord with the low binding constants
reported for the interaction of the nickel complexes and CT-DNA in Chapter 4.2.3.1,
and the low abundances of ions observed in ESI mass spectra of solutions
containing the nickel complexes and D2 (Chapter 4.2.1). The results obtained from
the DNA melting studies not only provide further evidence that the novel nickel Schiff
base complexes have a low affinity towards dsDNA, they also suggest that their
interactions with the nucleic acid may lead to destabilisation of its secondary
structure.
In contrast to the novel nickel Schiff base complexes which are the focus of this
chapter, (54) caused a small increase in the Tm of D2 of 2.1 °C under the same
conditions. This result is also consistent with those obtained from the absorption
titration experiments in particular, as these showed that the overall binding constant
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for interactions between (54) and CT-DNA was slightly larger than for any of the
other nickel complexes.
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Nickel complexes
Figure 4.13 Effect of addition of nickel complexes with different numbers of pendant groups
on the melting temperature, Tm, of D2. The experiments were performed in triplicate with the
error bars showing standard errors. For each nickel complex the left hand value of Tm was
obtained from a solution containing a 3:1 ratio of nickel complex:D2. The right hand values
were obtained from solutions containing a 6:1 ratio of nickel complex:D2.

4.2.4 DNA binding studies performed using FRET melting assays
The effects of varying the number of pendant groups present in the nickel
complexes on their ability to interact with a unimolecular G-quadruplex was also
investigated using Fluorescence Resonance Energy Transfer (FRET) melting
assays.

These

experiments

were

performed

using

the

oligonucleotide

5´-FAM-G3(TTAG3)3-TAMRA-3´, which contains a fluorophore and a quencher group
at opposite ends, and features the same base sequence as that found in human
telomeric DNA. It has been shown previously by NMR spectroscopy that F21T
adopts an anti-parallel structure under the conditions used for the FRET melting
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assay.[244] FRET melting profiles showing the effects of increasing amounts of the
nickel complexes on the melting curve of F21T are presented in Figure 4.14, while
the changes in Tm are summarised in Figure 4.15.

Figure 4.14 Results obtained from FRET melting assays performed using F21T and different
nickel complexes: (a) Complex (54); (b) Complex (87); (c) Complex (71); (d) Complex (77)
and (e) Complex (89).

The results presented in Figures 4.14 and 4.15 show that the nickel complexes
with one, two or three pendant groups had almost no effect on the T m of F21T,
except at the highest concentration examined, which was 10 M. In contrast,
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addition of (89), which contains four pendant groups, or the literature complex (54),
had notable effects on Tm even at low concentrations of added nickel complex.
These results are consistent with those obtained from CD studies performed using
Q1 present in its anti-parallel conformation (Chapter 4.2.2.3). Addition of nickel
complexes with between one and three pendant groups had relatively small effects
on the position and ellipticity of the principal negative and positive CD bands of the
nucleic acid. Complex (89), however, had a much greater effect on the CD spectrum,
which was only overshadowed by that caused by the literature complex (54).
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Figure 4.15 Effect of different concentrations of nickel complexes on Tm of F21T measured
by a FRET assay. The experiments were repeated six times with the error bars showing
standard errors.

Figures 4.14 and 4.15 suggest there may be a correlation between the variation
in Tm for F21T, and the number of pendant groups amongst the novel nickel Schiff
base complexes. Of these complexes (87), which contains only one pendant group,
had the smallest influence on Tm at all nickel concentrations. Addition of nickel
complexes with two and three pendant groups ((71) and (77)) resulted in slightly
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larger increases in Tm, whereas the greatest changes to the melting temperature of
F21T were obtained with (89), which has four pendant groups. For example,
solutions containing 10 M (89) were shown to increase the Tm of F21T by 31.4 °C,
which was more double the change caused by any of other new nickel Schiff base
complexes. This finding along with the results of ESI-MS and CD experiments
presented earlier in this chapter, further demonstrates that (89) has a significant
ability to interact with a wide range of G-quadruplex structures.

4.2.5 DNA binding studies performed using FID assays
The effects of varying the number of pendant groups amongst the new nickel
Schiff base complexes on the strength of their interactions with parallel
G-quadruplexes (Q4, Q1) and dsDNA D2 was also investigated using Fluorescent
Indicator Displacement (FID) assays. This technique is easy to perform and, unlike
FRET melting assays, does not require modified oligonucleotides.[164] FID assays
previously have been used by many research groups to study the binding ability of
various compounds with G-quadruplexes.[94, 126, 164, 245] The assays provide a
quantitative measure of binding ability in the form of DC50 values, which are the
concentrations of the molecules of interest required to cause a 50% decrease in
fluorescence from thiazole orange (TO) which is bound tightly to the DNA. It is
important to remember when performing these assays, that comparison amongst
results obtained using a suite of new drug molecules and different kinds of DNA
should be made with care. This is because the mechanism of binding of TO to
different types of DNA may vary.[163] However, for a specific type of DNA, a lower
value of DC50 for one drug molecule compared to another, can generally be used to
indicate a higher affinity of the former molecule for that particular type of DNA.
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The experiments were performed by adding increasing amounts of the nickel
complexes to solutions containing DNA and TO, as described in Chapter 2.7 and in
previous studies.[94, 126, 164, 245] Representative results obtained from FID
assays performed using parallel Q1 are shown in Figure 4.16 and Figure S4.4.
Table 4.8 presents the DC50 values obtained from the assays, with lower values of
this parameter being attributed to a stronger DNA binding affinity for the nickel
complex.

Figure 4.16 Results obtained from an FID assay performed using (89) and parallel Q1. The
Stern-Volmer plot [245] derived from the results is shown in the inset.

Inspection of the data in Table 4.8 shows that the literature complex (54) had
the smallest DC50 values with each of the three types of DNA examined, and
therefore exhibited the strongest binding affinity. Complex (89) showed the next
lowest values of DC50 with parallel Q1 and Q4, however its DC50 values with D2
were greater than that for both (71) and (87). These observations further reinforce
the view that (89) exhibits a significant ability to bind to G-quadruplex structures.
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Table 4.8 Results obtained from FID assays performed using different DNA molecules and
nickel complexes.
Complexes
(54)
(87)
(71)
(77)
(89)

Parallel Q1
0.10 ± 0.01
0.35 ± 0.02
0.30 ± 0.03
0.40 ± 0.02
0.23 ± 0.01

DC50 (M)
Parallel Q4
0.13 ± 0.01
0.88 ± 0.06
0.75 ± 0.06
0.88 ± 0.04
0.26 ± 0.01

DsDNA D2
0.20 ± 0.03
0.34 ± 0.05
0.29 ± 0.04
0.60 ± 0.05
0.39 ± 0.00

It is also very noteworthy that the value of DC50 obtained for (89) in
experiments with D2 was the second largest measured, which indicates that this
nickel complex exhibits a low affinity towards dsDNA. This result is consistent with
the limited ability of (89) to form non-covalent adducts in ESI-MS experiments
performed with D2, as well as the low binding constant determined from UV-Vis
titration experiments performed with CT-DNA, and the inability to stabilise D2
revealed by DNA melting experiments. Overall, it appears that (89) may exhibit a
more pronounced selectivity for binding to G-quadruplex structures in preference to
dsDNA than any the other new nickel Schiff base complexes, as well as the literature
complex (54). The high DC50 value obtained in studies performed using (89) and D2
also suggests that the unusual effects this complex had on the CD spectrum of D2
do not reflect the formation of stable non-covalent adducts.

4.2.6 DNA binding studies performed using molecular docking
While the techniques described above were able to afford information about the
relative DNA binding affinities of the nickel complexes, they do not provide
information about their preferred binding modes. Computational docking techniques
were therefore used to determine possible binding modes and minimum binding
energies (G) for the interactions of the nickel complexes with both a parallel
unimolecular G-quadruplex and dsDNA. Docking studies were performed using
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Autodock Vina 1.1.2 as described in Chapter 2, and following similar procedures to
those used by other workers.[130, 212] These experiments were performed using
reported crystal structures for the parallel, unimolecular G-quadruplex 22AG (protein
data bank (PDB) ID: 1KF1; [246]) and a 16-mer dsDNA (PDB ID: 1KBD; [211]). The
sequence of 1KF1 is AGGG(TTA GGG)3 whereas that of 1KBD is (5´- CTG GGG
ACT TTC CAGG -3´)/(5´- CCT GGA AAG TCC CCAG -3´). The DNA base sequence
and/or the number of DNA bases for 1KF1 and 1KBD resembled those for Q1
(GGG(TTA GGG)3 ) and D2 ((5´- GCT GCC AAA TAC CTCC -3´)/(5´- GGA GGT
ATT TGG CAGC -3´)) used in the other experiments reported in this thesis.

The top and bottom views of the solid state structure of 1KF1 are shown in
Figure 4.17 as line and surface cartoons. The phosphate backbone of the DNA is
represented by the dark orange lines in Figures 4.17 (a) and (c). The first
nucleobase in the sequence of 1KF1 is A1 at the 5´-terminus, while G22 occupies
the 3´ terminus. In the surface cartoon images (Figures 4.17 (b) and (d)), the
G-tetrads are easy to recognise as the square areas in the middle of the
G-quadruplex structures, while the TTA regions are located outside the rest of the
qDNA structure. The TTA sequences form three propeller-like loops and large
grooves at the corners of the G-quadruplex, which in conjunction with the G-tetrads
provide potential binding sites for drug molecules. The nickel complexes can bind to
either the top or bottom G-tetrad surfaces by -stacking interactions, and/or to the
grooves as well as loops of a G-quadruplex by a combination of electrostatic
mechanisms.
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Figure 4.17 Cartoon depictions of the structure of the parallel unimolecular G-quadruplex 5´AGGG(TTAGGG)3-3´ generated from the crystal structure 1KF1 using PyMOL software:
(a) Line cartoon of top view; (b) Surface cartoon of top view; (c) Line cartoon of bottom view
and (d) Surface cartoon of bottom view. The arrows show the direction from 5´ to 3´.
Elements in the line cartoons are represented by the following colours: green: carbon; blue:
nitrogen; red: oxygen; orange: phosphorus.

Figure 4.18 displays one binding mode generated from the top docking score
for each combination of nickel complex and DNA, while Table 4.9 presents the
minimum binding energies (G) for interactions between each pair of partners.
Docking studies were performed using each of the four novel nickel Schiff base
complexes with different numbers of pendant groups, as well as the literature
complex (54) for comparison purposes. Inspection of Figure 4.18 reveals a number
of similarities amongst the binding modes used by the various nickel complexes with
both types of DNA, but also some important differences. Docking experiments have
previously shown that (54) binds to a G-tetrad of 1KF1 via stacking interactions
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with three of the four guanine bases, and by intermolecular interactions involving the
positively

charged

pendant

groups

and

the

loops

and

grooves

of

the

G-quadruplex.[93] A feature of the results from this previous literature study
(Figure 1.19 (a)) was that it demonstrated there was good overlap between aromatic
groups present in both binding partners, in part as a result of the nickel ion in the
metal complex being located near the centre of the G-tetrad. Figure 4.18 (a) provides
a similar overall view of the interactions between (54) and 1KF1 obtained as part of
the present study, including showing that the nickel ion is located roughly above the
centre of the G-tetrad.

Figure 4.18 Results of molecular docking investigations performed using nickel complexes
containing different numbers of pendant groups, or (54), and either the G-quadruplex 1KF1
(top row) or dsDNA 1KBD (bottom row): (a) (54); (b) (87); (c) (71); (d) (77) and (e) (89).

In contrast, the docking results illustrated in Figure 4.18 for the novel nickel
complexes with one, two and three pendant groups, and 1KF1, are very different. In
each case the aromatic rings in the bottom half of the molecules are lying flat on the
G-tetrad to facilitate -stacking interactions. However, these are not optimised as the
nickel ion is not located centrally above the G-tetrads, resulting in one of the lower
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aromatic rings being positioned towards the edge of the guanine residues. The upper
aromatic ring systems of the nickel complexes are roughly orthogonal to the
G-tetrad, and therefore not able to participate in effective -stacking interactions, and
may even weaken the overall interaction. The displacement of the nickel ions away
from above the centre of the G-tetrads may be in response to this, as well as a
measure to maximise stabilising interactions between the pendant groups of the new
nickel complexes and the grooves and loops of the G-quadruplex.
Figure 4.18 suggests that the interactions between (89) and 1KF1 are very
different to those involving the other novel nickel complexes, and more reminiscent
of those involving the literature complex (54). The nickel ion of (89) is located above
roughly the centre of the G-tetrad, with all four aromatic rings of the complex nearly
coplanar with each other, and therefore able to participate in -stacking interactions
with guanine residues of the G-tetrad. The coplanar angles of rings C/E and D/F of
(89) after binding to 1KF1 obtained by molecular docking were 2.6° and 0.6°,
respectively. These values are much smaller than those observed in the solid state
of (89), which were 79.9° and 61.5°, (Chapter 3.4.2). Furthermore, the pendant
groups in (89) are positioned so that they can participate in favourable intermolecular
interactions with the loops and/or grooves of the G-quadruplex to optimise overall
binding.

Table 4.9 provides further evidence that the binding interactions between

(89) and 1KF1 are different to those involving the other novel nickel Schiff base
complexes, and even (54). Most of the minimum binding energies were distributed
over a very narrow range from -8.44 to -9.54 kcal/mol. The one exception to this was
(89), which had a minimum binding energy of -14.32 kcal/mol. This result suggests
that the overall strength of binding interactions between (89) and 1KF1 is greater. In
view of this result it is perhaps not surprising that (89) consistently proved to interact
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more extensively with various G-quadruplex structures in spectroscopic studies
described earlier in this chapter.
In the case of docking studies involving the dsDNA 1KBD, Figure 4.18 shows
that again most of the novel nickel Schiff base complexes, and (54), participate in
very similar binding interactions. In each case the most favourable binding mode with
1KBD involved the minor groove of the nucleic acid. The two pendant groups in the
bottom half of the nickel complexes and the two associated benzene rings were
typically positioned in the minor groove in order to optimise favourable intermolecular
interactions. Simultaneously, the two additional aromatic rings in the top halves of
the novel nickel complexes were positioned so that they were orientated away from
the minor groove, perhaps in an attempt to avoid unfavourable steric interactions.
Figure 4.18 (e) again shows that (89), however, participates in a very different
binding mode. The entire nickel molecule, including all four pendant groups, can be
seen to be interacting with functional groups located within the major groove. The
distinctive nature of this binding mode does not, however, result in a very different
minimum binding energy for (89) (Table 4.9). All of the minimum binding energies
were found within a narrow distribution of energies, between -8.5 and -11.2 kcal/mol.
The similarity of the minimum binding energy for (89) to each of the other novel
nickel Schiff base complexes is consistent with the general lack of interactions noted
for all of these complexes in spectroscopic studies involving various dsDNA
molecules. However, the observation that the binding energy for (89) was larger than
for any of the other novel complexes, together with the novel docking mode evident
in Figure 4.18, may provide clues as to why the CD spectrum of a solution containing
D2 was so dramatically changed when this nickel complex was present.
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Table 4.9 Binding free energies obtained from docking studies performed using nickel
complexes containing different numbers of pendant groups, or (54), and either 1KF1 or
1KBD.
qDNA 1KF1
dsDNA 1KBD
Complexes
Binding modes
Binding modes
G (kcal/mol)a
G (kcal/mol)a
(54)
-9.54 ± 0.02
Top, groove
-10.1 ± 0.1
Minor groove
(87)
-8.44 ± 0.04
Top, groove
-8.7 ± 0.1
Minor groove
(71)
-8.82 ± 0.06
Bottom, groove
-9.4 ± 0.1
Minor groove
(77)
-8.84 ± 0.02
Bottom, groove
-8.5 ± 0.1
Minor groove
(89)
-14.32 ± 0.07
Top, groove
-11.2 ± 0.1
Major groove
a

Average values of G with standard errors obtained from the top five docking scores.

4.3 Summary
This chapter presented the results of DNA binding studies performed using a
number of different analytical techniques and nickel Schiff base complexes with
varying numbers of pendant groups. Overall the data obtained showed that changing
the number of pendant groups can have significant effects on both DNA affinity and
selectivity. For example, complex (87), which contains only one pendant group,
exhibited little tendency to bind to dsDNA or any of the G-quadruplex structures
examined. The only evidence to the contrary was provided by CD studies involving
the parallel unimolecular G-quadruplexes Q1 and c-kit1, where small changes to the
ellipticity of the positive CD band of the nucleic acid were observed. In contrast, the
complex (89), with four pendant groups, was consistently found to bind to a variety of
G-quadruplexes, whilst showing little inclination to interact with dsDNA. Since the
piperidine moieties are expected to protonate in aqueous solution, the greater
G-quadruplex binding ability of (89) may in part be a result of electrostatic forces
making a significant contribution to the overall DNA binding interactions of this
complex.
In view of the superior G-quadruplex DNA binding ability exhibited by (89), it is
worth considering further the potential of this complex as a pharmaceutical.
Normally, polycationic compounds such as (89) would not be considered an ideal
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drug candidate. One of the reasons is that its high overall charge would be expected
to adversely affect its lipophilicity and therefore its ability to pass across cell
membranes. On the other hand, despite its large molecular mass (986 Da), the high
overall charge makes (89) soluble in water, which is a desirable property for a new
pharmaceutical. It has also been suggested that compounds that are highly charged
may not exhibit sufficient selectivity in their binding interactions to be useful as drug
molecules.[247-249] Overall, however, it is believed that this will not be a major issue
for complex (89). This is in part because recently an organic compound with a very
similar molecular mass, and four pendant groups capable of undergoing protonation,
was shown not only to be an effective G-quadruplex binding agent, but also to be
effective in in vivo studies against a mouse pancreatic cancer xenograft model, and
to accumulate in cell nuclei.[219] In addition, the metal complex BBR3464, which
also has an overall charge of 4+, has been shown to effective against several tumour
types and has undergone phase 1 and 2 clinical trials.[250, 251] These examples
therefore support the belief that there is not a barrier to (89) having the right
combination of pharmacological properties to potentially be effective as a drug.
The above hypothesis is supported by the results of the molecular docking
study, which showed that the four pendant groups of (89) were favourably positioned
in order to be able to participate in electrostatic interactions with the loops and
grooves of a unimolecular G-quadruplex. Another important result obtained from the
molecular docking study involving (89) was that all four aromatic rings of the nickel
complex were able to stack favourably onto a G-tetrad. Such a binding mode would
not be possible if the solid state structure of this complex, in which the two aromatic
rings in the top half of the molecule are not coplanar with those in the bottom half,
were retained in solution. This suggests that when the overall energetics of the nickel
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complex/DNA interaction are sufficiently favourable, it is possible for all four aromatic
rings present in these complexes to adopt a roughly coplanar orientation, suitable for
binding to a G-tetrad. This process was only observed with (89), although
theoretically it could also occur with any of the other novel nickel Schiff base
complexes, as the top aromatic rings are in each case connected to the rest of the
molecule by C-C single bonds.
While most of the other novel nickel Schiff base complexes generally did not
show much affinity for any of the G-quadruplexes examined, they also showed a
similar or even lower level of interaction with dsDNA. This may suggest that the
basic structural motif of this class of nickel complexes, the four aromatic rings
arranged in a roughly rectangular fashion, may generally prohibit strong interactions
with dsDNA. Evidence in support of this again comes from the results of the
molecular docking investigation, which suggests that the nickel complexes are forced
to adopt a conformation to ensure that the two aromatic ring systems in the top
halves of the molecules are orientated away from the dsDNA minor groove.
Therefore future research should be directed towards determining what other
structural features, in addition to a large number of pendant groups, could be
introduced into this class of nickel molecules to enhance their G-quadruplex affinity,
without adversely affecting their inherently poor dsDNA binding characteristics.
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Chapter 5 : Effect of varying the positions of
pendant groups on DNA binding properties
5.1 Introduction and scope
Most metal Schiff base complexes that have been developed as potential
G-quadruplex binding agents have usually contained pendant groups consisting of
piperidine rings attached to the bottom aromatic rings of the ligand. A typical
example is (54) shown in Figure 1.18. In the previous chapter it was shown that
varying the number of piperidine pendant groups can have a dramatic effect on the
DNA binding properties of nickel Schiff base complexes. Prior to now there has been
limited study into the effects of changing the position of pendant groups around the
periphery of these complexes on their ability to interact with different types of DNA,
with most investigations involving complexes with ligands prepared through
condensation reactions involving dihydroxybenzaldehyde.[95, 128, 129] In addition,
most of these prior reports only used complexes in which the pendant groups were
symmetrically arranged on both of the bottom aromatic rings of the ligands. There is
therefore a gap in our knowledge about the effects of asymmetrically distributing
pendant groups in similar complexes on their ability to interact more strongly and
with greater selectivity for G-quadruplex structures over dsDNA.
In this chapter, the results of a systematic investigation of the DNA binding
properties of five isomeric nickel Schiff base complexes, each containing two
identical piperidine pendant groups, is presented. The synthesis and characterisation
of these five complexes was presented in Chapter 3, and their structures are shown
in Figure 5.1. The isomers include symmetric complexes (79) and (71), which feature
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two pendant groups bound to either the two top or two bottom aromatic rings,
respectively. Also included are the asymmetric complexes (81), (83) and (85). The
asymmetric structure of (81) was characterised by both NMR spectroscopy and Xray crystallography in Chapter 3.
The same DNA molecules used in the various binding studies described in
Chapter 4 were also used in the investigations with the nickel complexes shown in
Figure 5.1. A range of different techniques was once again used to perform these
investigations, including ESI-MS, CD spectroscopy, UV-Vis spectroscopy, FRET
melting assays, FID assays and molecular docking. Whilst experiments performed
using complex (71) were reported in the previous chapter, the results of those
studies are included here again as well for comparison purposes.

Figure 5.1 Structures of isomeric nickel Schiff base complexes containing two pendant
groups.
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5.2 Results and discussion
5.2.1 DNA binding studies performed using ESI mass spectrometry
ESI-MS experiments were initially performed to compare the affinities of the five
isomeric nickel Schiff base complexes towards the parallel tetramolecular
G-quadruplex Q4. Figure 5.2 shows the mass spectra obtained of solutions
containing a 3:1 ratio of Ni:Q4. In each case ions from free DNA were observed at
m/z 1674.9 and 2010.9. Since the five nickel complexes used were isomers, ions
arising from non-covalent complexes with DNA occur at the same m/z values. For
example, ions at m/z 1797.2 and 2156.8 in each spectrum in Figure 5.2 are
attributable to [Q4 + (Ni) + 4NH4 – 12H]6- and [Q4 + (Ni) + 4NH4 – 11H]5-,
respectively, which will hereafter be referred to collectively as {Q4 + Ni}. In addition,
the mass spectra of solutions containing (79) or (83) also contained ions from
{Q4 + 2Ni} at m/z 1919.1 and 2303.1.
Comparison of the spectra in Figure 5.2 indicates that (81) has the lowest
affinity of the isomeric nickel complexes towards Q4. This is reflected in ions of only
very low abundance from {Q4 + Ni} being present in Figure 5.2 (d). A possible
explanation for the very low affinity of (81) towards Q4 is provided by the solid state
structure of the complex, which was described in Chapter 3.4.2 (Figure 3.25). This
showed that the two pendant groups were located roughly above and below the
square planar coordination sphere of the nickel ion. Such an arrangement would be
expected to hinder the approach of the nickel complex to a planar G-tetrad in a
G-quadruplex structure, and therefore inhibit -stacking interactions. In addition,
because (81) has a more globular shape than any of its isomers, or the nickel
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complexes discussed in Chapter 4, it is unlikely to be capable of functioning
effectively as a groove binding agent.

Figure 5.2 Negative ion ESI mass spectra of solutions containing free Q4 or a 3:1 ratio of
different isomeric nickel Schiff base complexes and Q4: (a) free Q4; (b) Q4 + (71);
(c) Q4 + (79); (d) Q4 + (81); (e) Q4 + (83) and (f) Q4 + (85). = free Q4; = {Q4 + (Ni)};
= {Q4 + 2(Ni)}.
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As none of the isomers of (81) had a similar structure as a result of the location
of their pendant groups, it was expected that there would be less steric hindrance to
binding interactions with Q4. This proved to be correct, with ESI mass spectra of
solutions containing either (71) or (85), and Q4, now containing ions of low to
medium abundance from {Q4 + Ni} (Figure 5.2 (b) and (f), respectively). The affinity
of (79) towards Q4 was perhaps marginally greater than that of the above
complexes, as the mass spectrum of a solution containing this nickel complex and
Q4 (Figure 5.2 (c)) also contained ions of low abundance from {Q4 + 2Ni}. The
highest binding affinity of the isomeric nickel complexes towards Q4 was exhibited
by (83). This is shown by the results presented in Figure 5.2 (e). This was the only
spectrum in which the abundances of ions from {Q4 + Ni} were greater than that of
ions from free DNA. Furthermore, this spectrum also contained ions from {Q4 + 2Ni}
with greater relative abundances than in any of the other spectra.
Similar ESI-MS experiments to those described above were performed with the
isomeric nickel complexes and both parallel Q1 and D2. The results of experiments
carried out with all three DNA molecules are presented in the form of relative
abundances in Figure 5.3 (see Chapter 4.2.1 for how to calculate relative
abundances). In contrast to the ESI-MS experiments performed using Q4, most of
the nickel complexes did not show any ability to interact with parallel Q1, when the
ratio of Ni:DNA was 3:1. The one exception to this was (83), which still showed a
very poor ability to form non-covalent adducts with this nucleic acid. In order to
explore the binding affinity of the isomeric nickel complexes towards Q1 further, ESI
mass spectra were also obtained using solutions containing a 6:1 ratio of Ni:DNA
(Figure S5.1). Ions from {Q1 + Ni} remained at very low abundances in all of these
spectra with the exception of that of a solution containing (71), in which these ions
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were completely absent. This experiment therefore further suggests that each of the
nickel complexes exhibits a very limited ability to interact with this unimolecular
G-quadruplex.

Figure 5.3 Relative abundances of ions in ESI mass spectra of solutions containing a 3:1
ratio of isomeric nickel Schiff base complexes containing two pendant groups, and dsDNA
(D2), unimolecular qDNA (Q1) or tetramolecular qDNA (Q4): (a) solutions containing (71);
(b) solutions containing (79); (c) solutions containing (81); (d) solutions containing (83) and
(e) solutions containing (85).

The results presented in Chapter 4 showed that changing the number of
pendant groups did not result in any of the nickel Schiff base complexes displaying a
notable ability to interact with the dsDNA D2. Inspection of Figure 5.3 reveals that
changing the location of the pendant groups in the nickel complexes also had a
negligible effect on affinity towards duplex DNA. When the ESI-MS experiments
were repeated using solutions containing a 6:1 ratio of Ni:D2, the nickel complexes
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were again found to have a negligible ability to bind to and form stable non-covalent
complexes with this nucleic acid (Figure S5.1). This most likely reflects the absence
of any structural feature capable of endowing upon the complexes the ability to bind
to dsDNA via an intercalative mechanism, as well as overall shapes which do not
facilitate binding interactions with the DNA minor groove. In order to gain further
insights into the mechanism(s) by which the nickel complexes interact with each of
the three types of DNA examined in this chapter, molecular modelling studies were
carried out. The results of these investigations are presented in Chapter 5.2.6.

5.2.2 DNA binding studies using CD spectroscopy
5.2.2.1 CD titrations using parallel tetramolecular Q4
The results of experiments presented in Chapter 4 showed that some nickel
Schiff base complexes were able to form significant amounts of non-covalent
complexes with different G-quadruplexes. On occasion, however, the mass spectra
of solutions containing nickel complexes and DNA did not contain abundant ions
from non-covalent adducts formed between the binding partners. This either reflects
that non-covalent adducts were not formed at all, or alternatively they were formed,
but were not sufficiently stable to survive the ESI process. In contrast, CD
spectroscopy is very sensitive to binding interactions between metal complexes and
DNA, but is carried out under conditions that are unlikely to result in their
decomposition. In view of the different characteristics of CD spectroscopy and ESIMS, the former technique was also used to investigate the effect of varying the
positions of pendant groups in nickel Schiff base complexes on binding to different
DNA molecules. The results of experiments in which the effects of increasing
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amounts of isomeric nickel complexes on the CD spectrum of parallel Q4 were
investigated are shown in Figure 5.4, and Table 5.1.

(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 5.4 CD spectra of solutions containing different ratios of isomeric nickel Schiff base
complexes and parallel Q4: (a) Q4 + (71); (b) Q4 + (79); (c) Q4 + (81); (d) Q4 + (83) and
(e) Q4 + (85). The HT voltage observed during the course of obtaining all the CD spectra
illustrated here exceeded 400 V, at wavelengths < 215 nm.

Inspection of the results shows that the results of the CD experiments are in
many instances consistent with those obtained from the ESI-MS study presented in
the previous section of this chapter. For example, (81) had the least effect on the CD
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spectrum of Q4, and also showed the lowest ability to form non-covalent complexes
that could be detected by ESI-MS. Complex (85) also had a relatively minor
influence on the CD spectrum of Q4, which mirrors the low abundance of ions from
{Q1 + Ni} and high abundance of ions from free Q4 in Figure 5.2 (f).
Table 5.1 Effect of addition of isomeric nickel Schiff base complexes on the CD spectrum of
parallel Q4.
Complexes
(71)
(79)
(81)
(83)
(85)

Positive CD band at 263 nm
max (nm)*
(%)*
0.1
-36
-0.6
-33
0.0
-7
-0.3
-19
-0.4
-12

*max and (%) were calculated using solutions containing free Q4 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and Q4.

Complexes (71) and (79) had greater effects on the CD band of parallel Q4
than those of the above nickel complexes, but these were not as great as those
observed when the literature complex (54) was present, (Figure 4.4 (a)).Therefore,
the results of CD experiments performed with (71) and (79) are consistent with those
derived from the ESI-MS study, where ions of only relatively low abundance from
{Q4 + Ni} were detected. In contrast, complex (83) did not affect the CD band of Q4
as much as (71) and (79), however ESI mass spectra of solutions containing the
former complex and this DNA molecule showed the highest abundances of ions from
non-covalent complexes. This observation may be rationalised by considering the
very different natures of these two techniques, including the conditions under which
they are performed.
5.2.2.2 CD titrations using parallel unimolecular Q1
CD experiments were carried out using the parallel topology of Q1 in an
attempt to find evidence for strong interactions with any of the isomeric nickel
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complexes. The results of these experiments are presented in Figure 5.5 and Table
5.2. Complexes (81), (83) and (85) each had only a very minor influence on the CD
spectrum of parallel Q1, except in some instances at the highest Ni:DNA ratios
examined. These observations are consistent with the inability of these three nickel
complexes to form non-covalent complexes with Q1 that could be detected by
ESI-MS (Figure 5.3).

(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 5.5 CD spectra of solutions containing different ratios of isomeric nickel Schiff base
complexes and parallel unimolecular Q1: (a) Q1 + (71); (b) Q1 + (79); (c) Q1 + (81);
(d) Q1 + (83) and (e) Q1 + (85). The HT voltage observed during the course of obtaining all
the CD spectra illustrated in Fig 5.5 b, c, d, e exceeded 400 V, at wavelengths < 215 nm.
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Surprisingly, whilst (71) and (79) shared the same inability to form stable
non-covalent complexes such as {Q1 + Ni}, which could be detected in significant
amounts in ESI-MS experiments, they both had dramatic effects on the CD spectrum
of the nucleic acid. For example, addition of (79) resulted in a decrease of 59% in
ellipticity for the major positive CD band at 263 nm. The lack of correlation between
the results obtained for these two complexes with parallel Q1 most likely again
reflects differences between the two techniques, and provides further evidence of the
need to apply a variety of methods to studying these systems, before drawing
conclusions regarding relative binding affinities and/or mechanisms of binding.
Table 5.2 Effect of addition of isomeric nickel Schiff base complexes on the CD spectrum of
parallel unimolecular Q1.
Complexes
(71)
(79)
(81)
(83)
(85)

Negative CD band at 241 nm
max (nm)*
(%)*
1.0
89
-1.1
55
-0.6
58
-1.0
20
-0.2
81

Positive CD band at 263 nm
max (nm)*
(%)*
-1.0
-77
0.4
-59
-2.3
-23
-0.1
-19
-2.0
-40

*max and (%) were calculated using solutions containing free Q1 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and Q1.

Inspection of the quantitative effects of the nickel complexes on  for the
larger positive CD band (Table 5.2) suggests that their overall binding affinities
towards parallel Q1 follow the sequence: (71) > (79) > (85) > (81) > (83). This
sequence is similar to that derived from experiments performed using parallel Q4,
with the exception that (83) had the smallest affinity towards Q1. It must be noted,
however, that the data presented in Table 5.2 was determined using results obtained
from experiments performed using a Ni:DNA ratio of 9:1. In the case of complexes
(81) and (83), the change in  was comparable to or smaller than what was
observed with (85), at lower Ni:DNA ratios. When the ratio was increased to 9:1, the
ellipticity only changed slightly in the case of (83), whereas more notable decreases
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were observed with the other two nickel complexes. Therefore there was little
difference between the effects of the nickel complexes on the CD spectra of the two
parallel G-quadruplexes.
5.2.2.3 CD titrations using anti-parallel unimolecular Q1
In order to investigate the influence of the position of pendant groups in the
nickel Schiff base complexes on their interactions with different conformations of a
unimolecular G-quadruplex, CD experiments were also carried out with anti-parallel
Q1. The results of these experiments are presented in Figure 5.6 andTable 5.3. All
five isomeric nickel complexes had less impact on the CD spectrum of anti-parallel
Q1 than they did on the corresponding parallel structure. Of the complexes
examined, (79) had the largest effect on the spectrum of the nucleic acid, including
67 and 27% reductions in ellipticity for the major negative and positive CD bands,
respectively. Comparison with the results presented in Chapter 5.2.2.2 suggests that
(79) may interact strongly with both the parallel and anti-parallel conformations of
Q1. In contrast, (71) had little effect on the CD spectrum of anti-parallel Q1, but had
the largest impact of the isomeric nickel complexes on the spectrum of the parallel
conformation of the same nucleic acid. Inspection of Figure 5.6 andTable 5.3 shows
that (81), (83) and (85) had much smaller effects on the CD spectrum of anti-parallel
Q1, similar to what was observed with the parallel topology. Overall the results
presented here suggest that (71), with two pendant groups appended to its bottom
aromatic rings, may exhibit some selectivity in its binding interactions with
unimolecular G-quadruplexes.
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(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 5.6 CD spectra of solutions containing different ratios of isomeric nickel Schiff base
complexes and anti-parallel unimolecular Q1: (a) Q1 + (71); (b) Q1 + (79); (c) Q1 + (81);
(d) Q1 + (83) and (e) Q1 + (85). The HT voltage observed during the course of obtaining all
the CD spectra illustrated here exceeded 400 V, at wavelengths < 215 nm.
Table 5.3 Effect of addition of isomeric nickel Schiff base complexes on the CD spectrum of
anti-parallel Q1.
Complexes
(71)
(79)
(81)
(83)
(85)

Negative CD band at 265 nm
max (nm)*
(%)*
-1.0
12
-1.5
67
-0.1
-4
-1.2
40
0.3
20

Positive CD band at 296 nm
max (nm)*
(%)*
0.2
-9
2.0
-27
0.6
3
1.6
-9
-1.0
~0

*max and (%) were calculated using solutions containing free Q1 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and Q1.
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5.2.2.4 CD titrations using hybrid unimolecular Q1
The effects of the five isomeric nickel complexes on the CD spectrum of hybrid
Q1 are presented in Figure 5.7 and Table 5.4. Once again, possibly as a result of
unfavourable steric interactions resulting from the locations of their two pendant
groups, (81) and (85) showed little evidence of interaction, as addition of these
complexes resulted in only very small changes to the CD spectrum of hybrid Q1.
This result mirrors observations made during experiments performed with these
nickel complexes and both the parallel and anti-parallel forms of this nucleic acid. In
contrast, addition of (71), (79) and (83) resulted in greater changes to the CD
spectrum of hybrid Q1, although these were less dramatic than those elicited through
addition of (54) shown in Figure 4.8.
Whilst it therefore does not appear that any of the isomeric nickel complexes
interact strongly with hybrid Q1, it was found that addition of (83) resulted in a
different pattern of changes to the CD spectrum of this nucleic acid topology. Upon
first introducing the nickel complex, so that the ratio of Ni:DNA was 1:1 or 3:1,
increases in ellipticity of the two positive CD bands were observed. At higher ratios
the ellipticity of these two peaks decreased. In contrast, inspection of the
corresponding CD spectra obtained when either (71) or (79) was added reveals a
uniform overall decrease in ellipticity for these CD bands, as was also observed
when (54) was used. The different behaviour observed when (83) was added to the
nucleic acid is worth noting since as a result of the high concentration of K + in living
cells, the hybrid conformation is considered to be predominant form of a
unimolecular G-quadruplex such as Q1.[252]
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(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 5.7 CD spectra of solutions containing different ratios of isomeric nickel Schiff base
complexes and hybrid unimolecular Q1: (a) Q1 + (71); (b) Q1 + (79); (c) Q1 + (81);
(d) Q1 + (83) and (e) Q1 + (85).
Table 5.4 Effect of addition of isomeric nickel Schiff base complexes on the CD spectrum of
hybrid Q1.
Complexes
(71)
(79)
(81)
(83)
(85)

Positive CD band at 208 nm
max (nm)*
(%)*
0.1
-35
-0.2
-16
-1.9
2
-1.4
-17
-0.4
-2

Positive CD band at 291 nm
max (nm)*
(%)*
0.7
-22
0.9
-14
-1.5
6
0.9
-6
0.5
~0

*max and (%) were calculated using solutions containing free Q1 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and Q1.
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5.2.2.5 CD titrations using parallel unimolecular c-kit1
Even though it contains the same number of nucleobases as the human
telomeric DNA model Q1, the G-quadruplex formed by c-kit1 is more heterogeneous
and may therefore provide different binding sites.[195] In order to see if any of the
isomeric nickel complexes, by virtue of having pendant groups in different positions,
might interact differently with these two unimolecular G-quadruplexes, a series of
binding studies was also carried out using the CD titration method and c-kit1 present
in a parallel topology. The results of these experiments are presented in Figure 5.8
and Table 5.5.
Table 5.5 Effect of addition of isomeric nickel Schiff base complexes on the CD spectrum of
c-kit1.
Complexes
(71)
(79)
(81)
(83)
(85)

Positive CD band at 262 nm
max (nm)*
(%)*
-0.2
-31
2.3
-53
1.3
-20
1.6
-45
-0.6
-26

*max and (%) were calculated using solutions containing free c-kit1 alone, and solutions
containing a 9:1 ratio of nickel Schiff base complex and c-kit1.

Adding increasing amounts of the nickel complexes did not change the overall
appearance of CD spectrum of c-kit1, which always exhibited a positive band with
large ellipticity at 262 nm, and a negative band at 240 nm. This indicated that the
parallel structure of c-kit1 remained intact throughout the experiments.[253] In
general, the isomeric nickel complexes showed an ability to modify the CD spectrum
of parallel c-kit1 which was similar to what they exerted on parallel Q1, and greater
than their influence on the corresponding spectra of the anti-parallel and hybrid
forms of the latter G-quadruplex.

204

(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 5.8 CD spectra of solutions containing different ratios of isomeric nickel Schiff base
complexes and c-kit1: (a) c-kit1 + (71); (b) c-kit1 + (79); (c) c-kit1 + (81); (d) c-kit1 + (83) and
(e) c-kit1 + (85). The HT voltage observed during the course of obtaining all the CD spectra
illustrated here exceeded 400 V, at wavelengths < 215 nm.

Quantitative measurement of the effects on the CD spectrum of c-kit1
(Table 5.5) showed that (79), containing two pendant groups at the para- positions
on the top aromatic rings, had the strongest influence on the CD spectrum of c-kit1.
This is illustrated by the observation of a 53% decrease in ellipticity for the positive
CD band of c-kit1. Further inspection of Table 5.5 suggests that the affinity of both
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(79) and (83) towards this G-quadruplex was greater than that of all remaining nickel
complexes, including (71). This is noteworthy as the latter complex, with two pendant
groups attached to the bottom aromatic rings of the Schiff base ligand, produced the
largest changes to the CD spectrum of the parallel structure formed by the h-telo
sequence Q1.
5.2.2.6 CD titrations using double stranded DNA D2
The results of ESI-MS experiments involving the isomeric nickel complexes and
the dsDNA D2 presented in Figure 5.2, suggested that there was little interaction
between any of the binding partners. In order to verify this conclusion, CD spectra
were also obtained of these systems. The effects of adding the nickel complexes on
the CD spectrum of D2 are shown in Figure 5.9, and summarised in Table 5.6.
Complexes (81), (83) and (85) all had a negligible effect on the CD spectrum of D2,
providing strong support for the earlier conclusion based on ESI-MS experiments,
that these complexes have low affinities towards dsDNA. This could be due to steric
hindrance resulting from the arrangement of their pendant groups around the
periphery of the Schiff base ligand, preventing significant binding interactions.
Table 5.6 Effect of addition of isomeric nickel Schiff base complexes on the CD spectrum of
D2.
Complexes
(71)
(79)
(81)
(83)
(85)

Positive CD band at 219 nm
max (nm)*
(%)*
0.2
-96
0.1
-31
-0.9
-12
0.4
-31
-1.6
-10

Positive CD band at 282 nm
max (nm)*
(%)*
3.6
-35
-0.1
-25
0
-2
1.3
5
0.2
-5

*max and (%) were calculated using solutions containing free D2 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and D2.
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(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 5.9 CD spectra of solutions containing different ratios of isomeric nickel Schiff base
complexes and dsDNA D2: (a) D2 + (71); (b) D2 + (79); (c) D2 + (81); (d) D2 + (83) and
(e) D2 + (85).

The lack of interaction exhibited by (83) towards D2 is noteworthy, as this nickel
complex had previously only shown an ability to significantly modify the CD spectrum
of c-kit1 and, to a lesser extent parallel Q4. These observations suggest that (83)
may exhibit some selectivity towards several kinds of G-quadruplex structures over
dsDNA. Although complexes (71) and (79) did result in some changes to the CD
spectrum of D2, the effects were not large, and therefore still consistent with the
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conclusion that they exhibit a relatively low affinity towards dsDNA. Upon close
examination of Figure 5.9, it can be seen that (79) changed the ellipticity of both the
negative CD band at 249 nm and the positive CD band at 282 nm. In contrast, (71)
modified the ellipticity of both positive bands 219 nm and 282 nm, but did not affect
significantly the negative CD band. These different observations could derive from
different binding modes for these two complexes with dsDNA.

5.2.3 DNA binding studies performed using UV-Vis spectroscopy
5.2.3.1 Absorption titration method
Typical UV-Vis absorption spectra obtained using solutions containing one of
the isomeric nickel complexes and increasing amounts of CT-DNA are shown in
Figure 5.10, S4.2, S4.3, S5.2 and S5.3. Equation 2.1 was used to analyse the results
in order to obtain the binding constants shown in Table 5.7. Adding CT-DNA to the
isomeric nickel complexes resulted in hypochromicity of the MLCT band ranging
from 19% to 63%. In contrast, in each case there were only small variations in the
positions of the absorption bands upon addition of CT-DNA, suggesting that the
binding modes of the nickel complexes do not involve intercalation. This is because
the absorption spectra of most effective intercalators usually show significant
hyperchromicity and red shifts for their MLCT bands upon addition of dsDNA.[94,
141] In contrast, the MLCT band of (83) showed a blue shift of ~ 8 nm, which
suggests a binding mode other than intercalation is used, and also one that is
possibly different to that of the other nickel complexes. Inspection of the binding
constants presented in Table 5.7 suggests that each of the nickel complexes has a
relatively low affinity towards CT-DNA, which is consistent with the results of the ESIMS and CD studies carried out with the discrete dsDNA molecule D2. There was
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also little variation between the binding constants, suggesting that varying the
position of the pendant groups does not greatly modify binding affinity towards
dsDNA.
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Figure 5.10 Effect of addition of 3 mM CT-DNA on the absorption spectrum of 20 M (83).
The inset shows the resulting binding isotherm. The arrows indicate the change upon adding
CT-DNA.
Table 5.7 Results obtained from absorption titration experiments performed using isomeric
nickel Schiff base complexes and CT-DNA.
Complexes
(71)
(79)
(81)
(83)
(85)

max for
MLCT
band (nm)
380.3
396.2
399.2
383.2
388.3

max for
MLCT
band (nm)
-2.2
-1
0
-8
0.5

a

Extinction coefficient
of complexes (A ×
104 (M-1 cm-1))
0.8 ± 0.1
0.4 ± 0.1
0.6 ± 0.1
1.1 ± 0.1
0.9 ± 0.3

A for
MLCT
band (%)
-19.4
-62.9
-21.1
-59.4
-35.9

Mean binding
constant (Kb ×
104 (M-1)) a
5.3 ± 0.3
1.7 ± 0.1
4.4 ± 0.3
4.8 ± 0.3
1.7 ± 0.1

-1

Mean binding constants (units = M(base pairs) ) were obtained from three absorption titration
experiments, and are presented here together with standard errors.

5.2.3.2 DNA melting studies
In order to further explore the affinity of the isomeric nickel complexes towards
dsDNA, a series of DNA melting experiments were undertaken using UV-Vis
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spectroscopy and D2. The results of these experiments, which were performed using
solutions containing Ni:D2 ratios of 3:1 and 6:1, are presented in Figure 5.11. In all
cases, the melting temperature of D2 decreased by between 0.2 and 3˚C in the
presence of the nickel complexes. These results are consistent with those obtained
from ESI-MS and CD experiments, in providing evidence that the five isomeric nickel
complexes have little affinity towards and/or ability to stabilise dsDNA. Furthermore
these results, together with those presented in Figure 4.13, suggest that this new
class of novel nickel Schiff base complexes inherently display low affinities towards
duplex DNA structures. This may reflect the absence of an effective intercalating
moiety, as well as steric hindrance created by the presence of two aromatic rings in
the top halves of the molecules.

Melting temperature Tm (oC)

64.0
63.0

62.6

62.0
61.0

60.0
59.7

60.6
60.2

D2+(71)

D2+(79)

60.9
60.5

61.8
61.3

62.4
61.1

60.0

59.0
58.0
57.0
56.0
D2

D2+(83)

D2+(81)

D2+(85)

Nickel complexes
Figure 5.11 Effect of addition of isomeric nickel Schiff base complexes on the melting
temperature, Tm, of D2. The experiments were performed in triplicate with the error bars
showing standard errors. For each nickel complex the left hand value of Tm was obtained
from a solution containing a 3:1 ratio of Ni:D2. The right hand values were obtained from
solutions containing a 6:1 ratio of Ni:D2.
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5.2.4 DNA binding studies performed using FRET melting assays
FRET melting assays were performed to gain additional insight into the
interactions between the

isomeric nickel complexes and an

anti-parallel,

unimolecular G-quadruplex. These experiments were performed using the labelled
oligonucleotide F21T and the method described in Chapter 2.8 and previous
studies.[127, 128] The normalised fluorescence emission of F21T over the
temperature range 25 to 95 °C in the presence of increasing amounts of the nickel
Schiff base complexes is shown in Figure S5.3. A cursory inspection of the melting
profiles suggests that the thermal stability of F21T shows some dependency on the
positions of the pendant groups in these isomeric complexes. Further analysis of the
results was undertaken by examining the trends in Tm derived from the melting
profiles, which are presented in Figure 5.12.
Inspection of Figure 5.12 showed that both (81) and (85) had a small effect on
Tm for F21T. This is consistent with the lack of effect these complexes had on the
CD spectrum of anti-parallel Q1, and may be a result of steric hindrance preventing
either -stacking with the G-tetrads, or binding to grooves and loops of the DNA
structure, as a result of the locations of the pendant groups. Complex (71) also only
had a significant effect on Tm of F21T at the highest nickel concentration examined.
This is also consistent with the relatively small effect this complex had on the CD
spectrum of the anti-parallel form of Q1.
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Figure 5.12 Effect of different concentrations of isomeric nickel Schiff base complexes on
Tm of F21T measured by a FRET assay. The experiments were repeated six times with the
error bars showing standard errors.

In contrast, complex (79), which also only had a significant effect on Tm of
F21T at the highest nickel concentration examined, produced the largest changes in
ellipticity for the anti-parallel form of the other unimolecular G-quadruplex,
suggesting that slight changes in base sequence and structure may have a
significant effect on binding interactions. The latter point is reinforced by inspection
of the data presented in Figure 5.12 for (83). This complex has two pendant groups
located at opposite positions across the square planar coordination sphere of the
nickel ion. Addition of (83) resulted in the most significant changes in Tm in the
FRET assay, including a value of 26.3 °C when the concentration of (83) in solution
was 10 M, but did not affect the CD spectrum of anti-parallel Q1 as much as (79).

5.2.5 DNA binding studies performed using FID assays
FID assays were undertaken in order to provide a final set of data that could
shed light on the strength of interactions between the isomeric nickel Schiff base
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complexes and different kinds of DNA. The results of these investigations were also
compared with those presented earlier in this chapter, which were obtained using
other spectroscopic methods, in order to further pursue the above aim. The
procedures used to perform the FID assays were detailed in Chapter 2, and followed
methods reported in the literature.[126, 209, 210] A typical set of results obtained
from FID assays performed using the isomeric nickel Schiff base complexes and
parallel Q1 are presented in Figure 5.13, S4.4 (c) and S5.4. The ratios of Ni:DNA at
the end of the assays were found to be between 60:1 and 100:1, except in the case
of experiments performed using (81), for which the final ratio varied from 12:1 to
32:1.

Figure 5.13 Results obtained from an FID assay performed using (83) and parallel Q1.The
Stern-Volmer plot [245] derived from the results is shown in the inset.

The DC50 values obtained from FID assays performed with the various DNA
molecules are compiled in Table 5.8. Inspection of the results reveals that the largest
DC50 values for both types of G-quadruplex were obtained with (81) and (85). In
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addition, (85) exhibited the largest value of DC50 with the dsDNA D2. These
observations suggest these two nickel complexes exhibit very low affinity towards all
three types of DNA, which is consistent with the results presented earlier in this
chapter, which were obtained using other physical methods. Therefore the locations
of the pendant groups in these nickel complexes are not favourable for forming
strong interactions with G-quadruplex DNA, or dsDNA.
Inspection of the DC50 values in Table 5.8 suggests that there is not as much
variation in binding affinity towards parallel Q4, as there is with parallel Q1. The
lowest DC50 value for Q4 was obtained with (79). This complex was also suggested
by the data to have one of the stronger binding affinities towards Q1, of the
complexes examined, and one of weakest set of binding interactions with D2.
Complex (71) also gave one of the lowest DC50 values observed with both Q1 and
Q4. These results are consistent with those obtained from CD experiments
performed using different G-quadruplexes. They also suggest that positioning the
pendant groups so that they are on the same side of, and pointing away from the
Schiff base ligand, is the most suitable configuration in order for a nickel complex to
bind effectively to a G-quadruplex. The data in Table 5.8 also suggests that (83)
exhibited one of the strongest sets of binding interactions with parallel Q1. This is
consistent with the greater ability of this complex to form non-covalent adducts with
Q1, as reflected in the results of ESI-MS experiments shown in Figure 5.2. There
was also a notable correlation between the results obtained from FID assays
performed using D2, and those derived from absorption titration experiments.
Complexes (71), (81) and (83) produced the lowest DC50 values with D2, and the
largest binding constants with CT-DNA. Both sets of observations are consistent with
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the conclusion that these three nickel complexes exhibit a greater affinity towards
dsDNA than the remaining two members of the series.
Table 5.8 Results obtained from FID assays performed using different DNA molecules and
isomeric nickel Schiff base complexes.
Complexes
(71)
(79)
(81)
(83)
(85)

Parallel Q1
0.30 ± 0.03
0.28 ± 0.03
0.43 ± 0.01
0.27 ± 0.02
0.44 ± 0.01

DC50 (M)*
Parallel Q4
0.75 ± 0.06
0.32 ± 0.03
1.03 ± 0.06
0.81 ± 0.03
0.97 ± 0.06

DsDNA D2
0.29 ± 0.04
0.48 ± 0.03
0.37 ± 0.05
0.33 ± 0.03
0.58 ± 0.05

* Mean values and standard errors derived from experiments performed in triplicate.

5.2.6 DNA binding studies performed using molecular docking
In order to provide information about the mechanisms used by the isomeric
nickel complexes to bind to dsDNA and unimolecular G-quadruplexes, a series of
molecular docking simulations were performed using Autodock Vina 1.1.2, and the
method described in Chapter 2. These simulations also provided estimates of overall
binding energies, which enabled further comparisons into the relative strengths of
interactions between the binding partners. The results of the docking experiments
are presented in Figure 5.14 and Table 5.9.
Overall, the isomeric nickel complexes appeared to display a greater range of
binding interactions with both the dsDNA and G-quadruplex, than what was exhibited
by the complexes examined in the previous chapter. For example, the images
presented in Figure 5.14 show that the optimal binding modes of (79), (81) and (83)
with 1KF1 involved the top of a G-tetrad, whereas for (71) and (85) the bottom
G-tetrad of the G-quadruplex was the site of interaction. Figure 5.14 (d) shows that
the two pendant groups of (83) are bound to diagonally opposite TTA loops of 1KF1.
This binding configuration allows (83) to be orientated roughly above the middle of
the

G-quadruplex, thereby optimising opportunities for -stacking with a G-tetrad.
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The binding mode employed by (83) to interact with 1KF1 may be the reason why
this nickel complex appeared to bind more strongly to F21T in a FRET assay, and
also showed a slightly greater ability to form non-covalent complexes in ESI-MS
experiments. Furthermore, (83) often showed a greater ability to modify the CD
spectrum of a variety of DNA molecules in results presented earlier in this chapter.

Figure 5.14 Results of molecular docking investigations performed using isomeric nickel
Schiff base complexes and either the unimolecular G-quadruplex 1KF1 (top row), or dsDNA
1KBD (second row): (a) (71); (b) (79); (c) (81); (d) (83) and (e) (85).

In contrast to the binding mode described above, the pendant groups of
complex (71) can be seen to be interacting with the second and third TTA loops of
1KF1 (Figure 5.14 (a)), whereas the pendant groups of (79) instead prefer to bind to
the first and second TTA loops (Figure 5.14 (b)). These results reflect the impact that
repositioning the pendant groups around the periphery of the Schiff base ligand has
on the mode of binding. In the case of (81), the preferred binding mode illustrated
(Figure 5.14 (c)) shows there is very little overlap between the aromatic groups of the
Schiff base ligand and a G-tetrad.
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The docking results presented in Figure 5.14 for the dsDNA 1KBD provide
further evidence of the impact of varying the position of the pendant groups on
binding modes. Only (71) and (85) were found to prefer to bind to the dsDNA minor
groove. In contrast, the optimal binding interactions for the remaining nickel
complexes all involved the major groove. This is most likely a result of the location of
their pendant groups around the periphery of the Schiff base ligand resulting in
significant steric hindrance for minor groove binding modes.
Inspection of Table 5.9 shows that the binding free energies for interactions
with both 1KBD and 1KF1 fall within very narrow ranges. For example, the binding
free energies for the isomeric nickel complexes with 1KDB were distributed over the
range -7.0 to -9.4 kcal/mol. In comparison, complex (89), with four pendant groups,
was shown in the previous chapter to have an optimal binding mode which results in
a much larger binding free energy (-11.2 ± 0.1 kcal/mol) with 1KBD. Overall the
binding free energies suggest that none of the isomeric nickel complexes are able to
interact strongly with 1KBD. This is reflected in some of the binding interactions
illustrated in Figure 5.14, which do not show an optimal size match between the
nickel complex and DNA major groove, and is consistent with the results obtained
from spectroscopic studies and assays presented earlier in this chapter.
Table 5.9 Binding free energies obtained from docking studies performed using isomeric
nickel Schiff base complexes and either 1KF1 or 1KBD.
Complexes
(71)
(79)
(81)
(83)
(85)
a

qDNA 1KF1
Binding modes
G (kcal/mol)a
-8.82 ± 0.06
Bottom, loop
-7.70 ± 0.03
Top, loop
-7.62 ± 0.05
Top, loop
-9.02 ± 0.06
Top, loop
-9.22 ± 0.02
Bottom, loop

dsDNA 1KBD
Binding modes
G (kcal/mol)a
-9.4 ± 0.1
Minor groove
-7.6 ± 0.0
Major groove
-7.0 ± 0.1
Major groove
-8.5 ± 0.0
Major groove
-8.0 ± 0.0
Minor groove

Average values of G with standard errors obtained from the top five docking scores.
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The binding free energies for interactions between the nickel Schiff base
complexes and the G-quadruplex 1KF1 varied from -7.6 to -9.2 kcal/mol. This is a
much narrower range of values than what was reported in Chapter 4 for nickel
complexes with different numbers of pendant groups, and suggests that it is the
number of such groups, rather than their position, which can have the largest effect
on binding affinity. Inspection of Figure 5.14 shows that none of the binding
interactions result in all four of the aromatic groups of the Schiff base ligand being
orientated in an optimal manner for -stacking interactions with a G-tetrad. In
contrast, Figure 4.18 shows that (89) was able to adopt such a binding mode, which
perhaps played a significant role in why its binding free energy was much larger than
that for any other nickel complex investigated.

5.3 Summary
Five isomeric nickel Schiff base complexes were successfully synthesised in
which four aromatic groups were present in identical positions, but the locations of
two dimethylenepiperidine pendant groups varied. The DNA binding experiments
performed using the isomeric nickel complexes indicated that varying the position of
the pendant groups does in some instances have an influence on their affinity
towards different types of G-quadruplex structures. However, comparison of the
results of spectroscopic studies presented here with those discussed in the previous
chapter, suggests that varying the location of the pendant groups does not have as
strong an influence on binding interactions as varying the number of pendant groups.
The results of CD spectroscopic studies, as well as FID assays and ESI-MS
experiments, suggest that (79) and (83) were able to interact to a significant extent
with a variety of G-quadruplex structures. In contrast, (71) showed a degree of
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selectivity in its binding interactions, as the results of FRET assays and CD titration
studies suggest it does not interact as strongly with anti-parallel unimolecular
G-quadruplexes, as with other types of qDNA. In contrast, the results of CD and UVVis spectroscopic binding studies and assays performed using (81) and (85) showed
that these isomers typically interacted to the lowest extent with all types of DNA
examined. This indicates that the positions of the pendant groups in these nickel
complexes are far from optimal for interacting with either G-quadruplexes or dsDNA.
In general, there was a significant degree of consistency between relative
binding affinities for the isomeric nickel complexes derived using different physical
methods. On some occasions, however, the results of binding studies performed
using different analytical techniques suggested contrasting conclusions regarding
relative binding affinities of some of the complexes. For example, (79) had a
significant impact on the CD spectrum of parallel Q4, as well as those of parallel and
anti-parallel Q1, suggesting it binds in a notable manner with these G-quadruplexes.
In contrast, the evidence from ESI-MS studies with Q4, and FRET assays performed
with F21T, was that (79) does not interact strongly. These contrasting observations
may again reflect the formation of non-covalent complexes featuring relatively weak
intermolecular forces, which were not strong enough to withstand the conditions
used in the ESI-MS and FRET experiments, but could still be detected in ambient
temperature CD spectral measurements.
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Chapter 6 : Effect of varying the diamine
moiety on DNA binding properties
6.1 Introduction and scope
The effect of altering the structure of the diamine group in the top half of a
metal salphen complex on G-quadruplex binding properties has been investigated
previously.[93, 126, 127, 129, 130] In a number of instances it was found that
increasing the surface area of the aromatic ligands present in the complex enhanced
overall binding to G-quadruplexes by facilitating stronger -stacking interactions.
However, the presence of large aromatic ring systems in the diamine moieties in
these complexes does not always improve G-quadruplex binding selectivity. This is
because these structural modifications may also enhance the ability of the complex
to intercalate with dsDNA.[128] In contrast, nickel Schiff base complexes containing
non-planar diamine groups such as meso-1,2-diphenylethylenediamine have been
shown to interact weakly with dsDNA, whilst strongly binding to tetramolecular
G-quadruplexes.[127]
In view of the above results, it was decided to explore the effect of varying the
diamine moiety amongst a range of nickel benzophenone complexes on their DNA
binding properties. The results of these experiments, which were conducted using
the nickel complexes shown in Figure 6.1, are presented in this chapter. The results
obtained using complexes (71) and (77) were reported in Chapter 4, but are
reproduced here to facilitate discussion of the effects of varying the diamine moiety.
A range of different types of DNA molecules were used for the DNA binding
experiments, including the dsDNA D2, tetramolecular G-quadruplex Q4, and
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unimolecular G-quadruplexes featuring h-telo and c-kit1 sequences. Furthermore
separate binding investigations were carried out with the unimolecular G-quadruplex
Q1, after it had been annealed to be present in parallel, anti-parallel and hybrid
topologies. The techniques used to perform these binding studies were ESI-MS, CD
spectroscopy, UV-Vis spectrophotometry, FRET, FID assays and molecular docking.

Figure 6.1 Structures of nickel Schiff base complexes containing different diamine moieties
used in DNA binding studies.

6.2 Results and discussion
6.2.1 DNA binding studies performed using ESI mass spectrometry
ESI-MS experiments were performed using 3 different kinds of DNA including
the dsDNA D2, parallel tetramolecular G-quadruplex Q4 and parallel unimolecular Gquadruplex Q1. Binding experiments were carried out using solutions containing 1:1,
3:1, 6:1 and 9:1 ratios of nickel complexes and DNA. Figure 6.2 graphically
compares the relative abundances of ions from free DNA and non-covalent
complexes in the spectra of solutions containing a ratio 3:1 of one of the nickel
complexes and each of the three different kinds of DNA investigated.
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Figure 6.2 Relative abundances of ions in negative ion ESI mass spectra of solutions
containing a 3:1 ratio of nickel Schiff base complexes with different diamine moieties and
dsDNA (D2), unimolecular qDNA (Q1) or tetramolecular qDNA (Q4): (a) solutions containing
(71); (b) solutions containing (73); (c) solutions containing (75) and (d) solutions containing
(77).

The results presented in Figure 6.2 show that changing the diamine moiety
sometimes resulted in small variations to the DNA binding properties of the nickel
complexes. For example, the mass spectra of solutions containing (71) and Q4
showed ions of medium abundance from {Q4 + (71)}. In contrast, when the nickel
complex (73) was used, no ions corresponding to non-covalent adducts involving Q4
were detected. The structure of (73) differs from that of (71) only in having a methyl
group as part of the diamine moiety, however this alteration resulted in the complete
absence of any ions from non-covalent complexes. In contrast, incorporation of an
additional methylene group into the diamine moiety of (71) to give (75) had little
impact on affinity towards Q4. The impact that substituents can have on DNA binding
properties is further reinforced by consideration of the results obtained with (77). This
complex features a diamine moiety that contains both a six-membered ring system
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and a third dimethylenepiperidine substituent. Comparison of

the relative

abundances of ions present in the spectrum of a solution containing this complex
and Q4, with those of ions present in the spectrum of a solution containing (71) and
Q4, suggests that (77) may have the highest binding affinity of the four nickel
complexes for Q4. This may be a result of the ability of the third substituent to
protonate, yielding a complex with a higher overall positive charge that can therefore
participate in additional electrostatic interactions.

Inspection of Figure 6.2 shows that all of the nickel complexes exhibited low or
very low affinities towards Q1. Furthermore, the affinity of each nickel complex
towards Q1 was less than what they exhibited towards Q4. In the case of (71) and
(73), no ions were detected from non-covalent complexes in ESI mass spectra.
Although ions from {Q1 + (75)} were observed in the mass spectrum of a solution
containing these binding partners, their abundances were very low. This was also
true for the mass spectrum of a solution containing (77) and Q1, although the
abundances of ions from {Q1 + (77)} may have been slightly greater. The slightly
higher affinity of (77) towards Q1, compared to that exhibited by the other nickel
complexes, may again be a result of the dimethylenepiperidine group bound to the
diamine moiety. This additional substituent would be expected, like the identical
moieties present in the bottom part of the nickel complex, to undergo protonation in
aqueous solution. This may lead to additional favourable electrostatic interactions
with the loops or grooves of this G-quadruplex.
In order to be useful as an anticancer drug, it is crucial for nickel Schiff base
complexes to exhibit a high degree of binding selectivity, in favour of G-quadruplexes
over dsDNA. Figure 6.2 showed that none of the mass spectra obtained of solutions
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containing the nickel complexes and D2 contained ions of significant abundance
from non-covalent adducts. This is consistent with some of the nickel complexes
exhibiting a preference for binding to G-quadruplexes molecules over dsDNA. A
similar conclusion was reached after analysis of the corresponding plots of relative
abundances of ions observed in spectra of solutions containing a 6:1 ratio of nickel
complex and the different DNA molecules (Figure S6.1).

The ESI-MS experiments discussed above showed that some of the nickel
complexes examined displayed low affinity towards the two G-quadruplexes. As their
affinity towards dsDNA was even lower, it can be concluded that complexes such as
(71), (75) and (77) exhibit some selectivity in their DNA binding interactions in favour
of one or more G-quadruplex structures. Varying the diamine moiety in this particular
class of nickel Schiff base complexes did not result in high affinity for the Gquadruplex structures. However, the basic structural motif in these complexes,
namely the presence of four aromatic residues located in an approximately
rectangular arrangement, did perhaps contribute to their low affinity towards dsDNA,
which is a desirable attribute. The low affinity of the nickel complexes towards D2,
could arise from unfavourable steric interactions between the nucleic acid and the
two aromatic rings located in the top half of the Schiff base ligands. Analysis of the
solid state structures of (71) and (75), as well as those of the non-alkylated
precursors to (73) and (75) (Chapter 3.4) showed that the two aromatic rings in the
top halves of the nickel complexes are not coplanar with those in the bottom halves.
This may hinder the ability of this class of nickel complexes to intercalate between
the base pairs of dsDNA, and also interfere with binding interactions involving
different G-quadruplex molecules.

224

6.2.2 DNA binding studies performed using CD spectroscopy
6.2.2.1 CD binding studies using parallel tetramolecular Q4
It was decided to examine the effect of adding increasing amounts of the four
nickel complexes on the CD spectra of different types of DNA. These experiments
were carried out using the parallel tetramolecular G-quadruplex Q4, unimolecular
G-quadruplex Q1, unimolecular G-quadruplex c-kit1, and dsDNA D2. Figure 6.3
shows the effect of increasing concentrations of nickel complexes on the CD
spectrum of solutions containing the tetramolecular G-quadruplex Q4. The CD
spectrum of free Q4 showed two positive CD bands with large ellipticities centred at
208 and 263 nm, along with a weaker, negative CD band at 242 nm. Addition of the
nickel complexes resulted in changes to both the position and maximum ellipticity of
the CD bands (Table 6.1).
Addition of the nickel complexes generally had only a small effect on the CD
spectrum of Q4. For example, addition of 9 equivalents of the nickel complexes
changed the position of the CD bands at 242 and 263 nm by at most 0.7 nm. This is
consistent with the low abundances of ions from non-covalent complexes observed
in ESI mass spectra of these systems. Examination of Table 6.1 shows that the
changes in ellipticity of the positive and negative CD bands were generally small
(≤14%). However, addition of complex (71) resulted in a value of (%) of 36.0% for
the positive CD band. Despite this, the CD spectra also support the conclusion that
complexes (71), (73), (75) and (77) generally exhibit low binding affinities towards
Q4.
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(a)

(b)

(c)

(d)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 6.3 CD spectra of solutions containing different ratios of nickel Schiff base complexes
and parallel tetramolecular Q4: (a) Q4 + (71); (b) Q4 + (73); (c) Q4 + (75) and (d) Q4 + (77).
The HT voltage observed during the course of obtaining all the CD spectra illustrated in Fig
6.3 a, b, d exceeded 400 V, at wavelengths < 215 nm.
Table 6.1 Effect of addition of nickel Schiff base complexes on the CD spectrum of parallel
Q4.
Complexes
(71)
(73)
(75)
(77)

Negative CD band at 242 nm
max (nm)*
(%)*
0.1
14
-0.7
15
0.3
10
0.0
14

Positive CD band at 263 nm
max (nm)*
(%)*
0.1
-36
-0.3
-14
0.2
-13
-0.3
-11

*max and (%) values were calculated using solutions containing free Q4 alone, and solutions
containing a 9:1 ratio of nickel Schiff base complex and Q4.

6.2.2.2 CD binding studies using parallel unimolecular Q1
The effect of varying diamine groups on the interaction between metal
complexes and G-quadruplexes was investigated further by CD spectroscopy using
the parallel unimolecular qDNA Q1, (Figure 6.4). Comparison of the CD spectra in
Figure 6.4 with those shown in Figure 6.3 suggests that some of the nickel
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complexes may interact more strongly with parallel Q1 than they did with parallel Q4.
This is reinforced by inspection of the values of max and (%) presented in Table
6.2, which were derived by comparing the CD spectra of solutions containing a 9:1
ratio of one of the nickel complexes and parallel Q1, with that of a solution containing
Q1 alone. In general, addition of the nickel complexes did not cause large variations
in max, apart from when (73) was added, which resulted in a blue shift of 2.5 nm for
the positive CD band at 263 nm. In contrast, addition of (73) and, in particular (71),
caused dramatic changes to the ellipticity of all CD bands.
The above results therefore hint at interactions between (71) or (73), and
parallel Q1, which are sufficiently strong to significantly affect the chirality of the
nucleic acid. It might be expected that such interactions would result in ions of
medium or high abundance from non-covalent adducts in ESI mass spectra.
However, inspection of Figure 6.2 shows that the mass spectra of solutions
containing (71) or (73), and Q1, were dominated by ions from free DNA, whilst the
abundances of ions from non-covalent adducts consisting of a single nickel complex
bound to DNA were very low. It therefore appears that relatively weak binding
interactions between these nickel complexes and DNA may sometimes lead to large
changes to the chirality of the latter, and consequently its CD spectrum. Previous
studies using related series of nickel Schiff base complexes have highlighted that
orders of relative DNA binding affinity obtained using these two techniques
sometimes differ.[127, 128] These observations were attributed to inherent
differences between these two methods, with ESI-MS able to detect ions from
non-covalent metal/DNA adducts that exhibit sufficient thermal stability, and CD
spectroscopy sensitive to binding interactions which alter the chirality of DNA.
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(a)

(b)

(c)

(d)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 6.4 CD spectra of solutions containing different ratios of nickel Schiff base complexes
and parallel unimolecular Q1: (a) Q1 + (71); (b) Q1 + (73); (c) Q1 + (75) and (d) Q1 + (77).
The HT voltage observed during the course of obtaining all the CD spectra illustrated here
exceeded 400 V, at wavelengths < 215 nm.
Table 6.2 Effect of addition of nickel Schiff base complexes on the CD spectrum of parallel
Q1.
Complexes
(71)
(73)
(75)
(77)

Negative CD band at 241 nm
max (nm)*
(%)*
1.0
89
-1.2
75
-0.3
36
-0.1
43

Positive CD band at 263 nm
max (nm)*
(%)*
-1.0
-77
-2.5
-45
-0.3
-24
-0.2
-22

*max and (%) values were calculated using solutions containing free Q1 alone, and solutions
containing a 9:1 ratio of nickel Schiff base complex and Q1.

6.2.2.3 CD binding studies using anti-parallel unimolecular Q1
In view of the different abilities of some of the nickel complexes to interact with,
and consequently alter the CD spectra of parallel Q1 and Q4, it was decided to
examine whether they might also have distinctive effects on other conformations of
the former DNA molecule. CD spectra obtained after adding increasing amounts of
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the nickel complexes to anti-parallel Q1 are shown in Figure 6.5. Table 6.3 compiles
the changes to both the position and maximum ellipticity of the CD bands observed
in these experiments.
(a)

(b)

(c)

(d)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 6.5 CD spectra of solutions containing different ratios of nickel Schiff base complexes
and anti-parallel unimolecular Q1: (a) Q1 + (71); (b) Q1 + (73); (c) Q1 + (75) and
(d) Q1 + (77). The HT voltage observed during the course of obtaining all the CD spectra
illustrated here exceeded 400 V, at wavelengths < 215 nm.

Inspection of Table 6.3 shows that only (73) had a notable effect on the CD
spectrum of anti-parallel Q1, with changes in maximum ellipticity for the CD bands at
265 and 296 nm of 33% and -10%, respectively. This complex also caused
significant changes to the CD spectrum of parallel Q1, suggesting it does not
discriminate between these two unimolecular G-quadruplex topologies. In contrast,
Figure 6.5 (a) shows that complex (71) produced only very small changes to the CD
spectrum of anti-parallel Q1, whereas it caused very large changes to the CD
spectrum of the parallel topology of this G-quadruplex. This suggests that (71) may
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exhibit a notable degree of selectivity for parallel unimolecular Q1 over the antiparallel conformation.
Table 6.3 Effect of addition of nickel Schiff base complexes on the CD spectrum of
anti-parallel Q1.
Complexes
(71)
(73)
(75)
(77)

Negative CD band at 265 nm
max (nm)*
(%)*
-1.0
12
-1.6
33
-1.1
1
0.6
27

Positive CD band at 296 nm
max (nm)*
(%)*
0.2
-9
2.4
-10
0.7
-6
-0.6
-4

*max and (%) values were calculated using solutions containing anti-parallel Q1 alone, and
solutions containing a 9:1 ratio of nickel Schiff base complex and anti-parallel Q1.

6.2.2.4 CD binding studies using hybrid unimolecular Q1
CD spectroscopy also was used to investigate the effects of varying diamine
groups in nickel complexes on the hybrid conformation of unimolecular Q1. Addition
of the nickel complexes resulted in the changes to the CD spectrum of hybrid Q1
shown in Figure 6.6. As none of the complexes changed significantly the position or
ellipticity of the negative CD band, attention was focussed on their effects on the two
positive CD signals. These are summarised in Table 6.4. Complex (71) once again
appeared to interact to the greatest extent with this G-quadruplex topology, which
may reflect the fact that it resembles a parallel structure, with 3 of the 4 strands in
alignment. The maximum ellipticity of the CD bands at 208 and 291 nm decreased
by 35.2 and 22.3%, respectively. Corresponding changes to the ellipticity of the two
shoulders were also observed in the CD spectrum. These observations support the
conclusion that (71) exhibited the greatest affinity of all the nickel complexes
examined towards hybrid Q1, however the overall magnitude of this interaction is
probably not strong, as the changes to the CD spectrum are small.
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(a)

(b)

(c)

(d)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 6.6 CD spectra of solutions containing different ratios of nickel Schiff base complexes
and hybrid unimolecular Q1: (a) Q1 + (71); (b) Q1 + (73); (c) Q1 + (75) and (d) Q1 + (77).
Table 6.4 Effect of addition of nickel Schiff base complexes on the CD spectrum of hybrid
Q1.
Complexes
(71)
(73)
(75)
(77)

Positive CD band at 208 nm
max (nm)*
(%)*
0.1
-35
-0.5
-25
-0.4
-12
1.6
-4

Positive CD band at 291 nm
max (nm)*
(%)*
0.7
-22
1.7
-11
-0.6
-2
-0.7
-10

*max and (%) values were calculated using solutions containing hybrid Q1 alone, and solutions
containing a 9:1 ratio of nickel Schiff base complex and hybrid Q1.

6.2.2.5 CD binding studies using parallel unimolecular c-kit1
The studies described above showed that the largest changes to the CD
spectrum of a nucleic acid were observed when complexes (73) and (71) were
added to parallel Q1. In view of these observations, it was of interest to see if these
complexes have a similar effect on the CD spectrum of another unimolecular parallel
G-quadruplex. In order to accomplish this goal, binding experiments were also
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conducted using c-kit1. The results of these experiments are shown in Figure 6.7.
Inspection of Figure 6.7 shows that complexes (71), (73) and (77) all had similar
effects on the CD spectrum of c-kit1. In contrast, addition of (75) resulted in smaller
changes to the CD spectrum.

(a)

(b)

(c)

(d)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 6.7 CD spectra of solutions containing different ratios of nickel Schiff base complexes
and parallel c-kit1: (a) c-kit1 + (71); (b) c-kit1 + (73); (c) c-kit1 + (75) and (d) c-kit1 + (77).
The HT voltage observed during the course of obtaining all the CD spectra illustrated here
exceeded 400 V, at wavelengths < 215 nm.

Table 6.5 summarises the changes in position and ellipticity of the CD bands of
c-kit1 caused by addition of 9 equivalents of the nickel complexes. The results
presented here show that addition of (71) and (73) did have a notable effect on the
CD spectrum of a second parallel unimolecular G-quadruplex. However, the changes
to the spectrum of c-kit1 were not as great as those observed when the DNA used
was Q1. Since both G-quadruplexes have the same parallel unimolecular structure,
and the same number of nucleobases, this suggests that (71) may exhibit some
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selectivity in its binding interactions towards G-quadruplex structures with the same
topology, but different base sequences.
Table 6.5 Effect of addition of nickel Schiff base complexes on the CD spectrum of c-kit1.
Complexes
(71)
(73)
(75)
(77)

Negative CD band at 240 nm
max (nm)*
(%)*
-0.9
52
1.1
60
0.5
33
-0.1
48

Positive CD band at 262 nm
max (nm)*
(%)*
-0.2
-31
0.1
-29
1.1
-18
0.1
-30

*max and (%) values were calculated using solutions containing free parallel c-kit1 alone, and
solutions containing a 9:1 ratio of nickel Schiff base complex and parallel c-kit1.

6.2.2.6 CD binding studies using the double stranded DNA D2
The results of DNA binding experiments performed using the four nickel Schiff
base complexes and dsDNA D2 are shown in Figure 6.8, and summarised in Table
6.6. Figure 6.8 shows that only (71) resulted in any significant changes to the CD
spectrum of D2. In contrast, none of the other nickel complexes had an effect on the
CD spectrum of the nucleic acid. These results are therefore in general agreement
with the conclusions based on ESI-MS results, as none of the spectra of solutions
containing nickel complexes and D2 showed ions from non-covalent adducts.
Table 6.6 Effect of addition of nickel Schiff base complexes on the CD spectrum of dsDNA
D2.
Complexes
(71)
(73)
(75)
(77)

Positive CD band at 219 nm
max (nm)*
(%)*
0.2
96
-1.0
21
-1.0
27
0.2
2

Positive CD band at 282 nm
max (nm)*
(%)*
3.6
-35
-0.3
-6
-0.3
-6
0.0
-5

*max and (%) values were calculated using solutions containing free D2 alone, and solutions
containing a 9:1 ratio of nickel Schiff base complex and D2.
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(a)

(b)

(c)

(d)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 6.8 CD spectra of solutions containing different ratios of nickel Schiff base complexes
and the dsDNA D2: (a) D2 + (71); (b) D2 + (73); (c) D2 + (75) and (d) D2 + (77). The HT
voltage observed during the course of obtaining the CD spectra illustrated in Fig 6.8 c
exceeded 400 V, at wavelengths < 215 nm.

Previously, CD spectroscopy had been used to investigate the interactions of
D2 with ruthenium complexes such as [Ru(phen)2L]+2 (L = dipyrido[3,2-a:2′,3′c]phenazine or dipyrido[3,2-a:2′,3′-c](6,7,8,9-tetrahydro)phenazine).[141] Addition of
the ruthenium complexes resulted in very large increases in ellipticity for the positive
CD band at 280 nm, as well blue shifts of between 6 and 8 nm.[141] These effects
were attributed to strong -stacking interactions between the aromatic moieties of
the ruthenium complexes and the base pairs of the dsDNA, resulting from an
intercalative binding mode.[239] In contrast, addition of (71) to D2 resulted in a less
marked decrease in ellipticity and smaller red shift for the same positive CD band.
These changes are totally different to those elicited by the ruthenium complexes, and
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consistent with the hypothesis that the nickel complexes primarily interact with
dsDNA by a different binding mode to intercalation.

6.2.3

DNA

binding

studies

performed

using

UV-Vis

spectrophotometry
6.2.3.1 Absorption titration method

Since there were several inconsistencies between the DNA binding results
obtained by ESI-MS and CD spectroscopy, the interactions between the nickel
complexes and dsDNA were also investigated using CT-DNA and the UV-Vis
absorption titration method described in Chapter 2.6.1. The results obtained using
complex (75) are shown in Figure 6.9, S6.2 whereas those obtained using the other
complexes can be found in Figure S6.2, S6.3, S4.2 and S4.3. Addition of CT-DNA
was ceased when there were no further significant changes to the MLCT bands at
ca. 380 nm in the UV-Vis spectra. The molar ratios of [DNA]:[Ni] at the end of the
experiments were 7.5:1, 8.3:1, 10:1, 15:1 for complexes (73), (75), (71), (77),
respectively. The data from these experiments was analysed using Equation 2.1 in
order to determine overall binding constants for the interactions of the nickel
complexes with DNA. Table 6.7 presents these binding constants, along with the
maximum changes in position of the absorption bands ( Positive and negative
values of  correspond to red shifts (bathochromic) and blue shifts (hypsochromic),
respectively.
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Figure 6.9 Effect of addition of 3 mM CT-DNA on the absorption spectrum of 20 M (75).
The inset shows the resulting binding isotherm. The arrows indicate the direction of change
in absorbance upon adding CT-DNA.
Table 6.7 Results obtained from absorption titration experiments performed using nickel
Schiff base complexes with different diamine groups, and CT-DNA.
Complexes
(71)
(73)
(75)
(77)
a

max for
MLCT
band (nm)
380.3
377.7
377.8
377.8

max for
MLCT
band (nm)
-2.2
1.2
-1.3
0.0

Extinction coefficient
of complexes (A ×
104 (M-1 cm-1))
0.8 ± 0.1
2.2 ± 0.4
1.6 ± 0.2
1.7 ± 0.4

A for
MLCT
band (%)
-19.4
-21.3
-25.1
-24.8

Mean binding
constant (Kb ×
104 (M-1)) a
5.3 ± 0.3
3.7 ± 0.1
4.0 ± 0.1
1.8 ± 0.1

-1

Mean binding constants (units = M(base pairs) ) were obtained from three absorption titration
experiments, and are presented here together with standard errors.

Since addition of the nickel complexes resulted in small changes to the
absorbance of the MLCT band, it is difficult to draw conclusions as to the mechanism
of the binding interactions. Examination of Table 6.7 shows that the binding
constants for each of the nickel complexes with CT-DNA are similar in magnitude.
Furthermore the binding constants are relatively low compared to those obtained for
other metal complexes known to interact with dsDNA by intercalation. For example,
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the binding constant for interaction of [Ru(phen)2(dppz)]2+ with CT-DNA is reported
by this method to be 5.1 x 106 M-1.[254] The low binding constants reported here
may reflect the absence of an extended aromatic moiety suitable for interacting with
dsDNA via intercalation. This is, however, a desirable property for a group of
molecules that are being designed to interact selectively with G-quadruplex
structures.
6.2.3.2 DNA melting studies
Further evidence supporting the formation of non-covalent adducts between the
nickel complexes and D2 was sought using DNA melting experiments. The results
obtained from these experiments are presented in Figure 6.10. The melting
temperature experiments were performed by measuring the effect of temperature on
the absorbance at 260 nm of solutions containing 3:1 and 6:1 ratios of nickel
complexes and D2. Inspection of Figure 6.10 shows that in the presence of the
nickel complexes Tm decreased by between 1 and 3 °C. These results indicate that
the interactions between the nickel complexes and D2 are weak and/or destabilise
the nucleic acid. This is consistent with the lack of ions from non-covalent adducts
observed in ESI mass spectra for solutions containing the nickel complexes and D2,
as well as the small changes to the CD spectrum of the nucleic acid caused by the
nickel molecules. The relatively small binding constants determined for the
interactions between the nickel complexes and CT-DNA are also in alignment with
the results of the DNA melting assays presented here, and suggest any binding that
is occurring is weak and does not involve intercalating between the base pairs of the
dsDNA.
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Melting temperature Tm (oC)

63.0

62.6
61.4

62.0

60.9

61.0

60.0
59.7

60.1

D2+(71)

D2+(75)

60.8

61.8
60.8

60.0
59.0
58.0
57.0

56.0
D2

D2+(77)

D2+(73)

Nickel complexes
Figure 6.10 Effect of addition of nickel complexes on the melting temperature, Tm, of D2. The
experiments were performed in triplicate with the error bars showing standard errors. For
each nickel complex the left hand value of Tm was obtained from a solution containing a 3:1
ratio of nickel complex:D2. The right hand values were obtained from solutions containing a
6:1 ratio of nickel complex:D2.

6.2.4 DNA binding studies performed using FRET melting assays
The interactions between the four nickel complexes and unimolecular Gquadruplex was also investigated using a FRET melting assay which was described
in Chapter 2, and has been reported in the literature.[127, 128] This assay uses a
labelled oligonucleotide 5´-FAM-G3(TTAG3)3-TAMRA-3´, which like Q1 contains the
human telomeric sequence. The results obtained from FRET melting assays
performed using F21T and complexes (71), (73), (75) and (77) are presented in
Figure 6.11. The melting temperature, Tm, of a solution containing F21T alone was
determined to be 43.6 ± 0.2 °C. In general, the nickel complexes had very little effect
on the FRET melting curves, except when present at the highest concentrations
examined. This is reinforced by examination of Figure 6.12, which illustrates
graphically the effect of increasing amounts of metal complex on Tm.
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DNA alone

1 M Ni

(a)

(b)

(c)

(d)

2 M Ni

4 M Ni

5 M Ni

10 M Ni

Figure 6.11 Results obtained from FRET melting assays performed using F21T and different
nickel complexes: (a) Complex (71); (b) Complex (73); (c) Complex (75) and (d) Complex
(77).

The results presented in Figure 6.12 show that even at the highest
concentrations of metal complex used, complexes (73) and (75) only produced very
small changes in Tm of ≤ 4 °C. Furthermore, when the concentration of (71) or (77)
used was 5 M, only modest changes in Tm of ≤ 5 °C were observed. Values of
Tm indicative of significant binding interactions were only observed when the
concentrations of (71) and (77) reached 10 M. In contrast, a previous FRET melting
temperature assay involving F21T and two related nickel Schiff base complexes,
(59) and (54), gave values of Tm of 10.4 and 43.6 °C, respectively, when the metal
complexes were present at just 5 M concentration.[128] This suggests that the
binding affinities of (71), (73), (75) and (77) towards F21T are not high, which is
consistent with the results of the binding studies involving anti-parallel Q1 performed
using CD spectroscopy, and described in Chapter 6.2.2.3. The largest value of Tm
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observed was 16.5 °C, which was obtained using a 10 M concentration of (77). This
may indicate that the side arm present on the diamine group in this complex can
participate in stabilising binding interactions with F21T that are not available to the
other nickel complexes.
19.5
17.5
15.5
13.5

Tm (oC)

11.5
9.5
7.5
5.5
3.5
1.5
-0.5

2

4

5

10

Nickel complex concentration (M)
(75)

(73)

(71)

(77)

Figure 6.12 Effect of different concentrations of nickel complexes on Tm of F21T measured
by a FRET assay. The experiments were repeated six times with the error bars showing
standard errors.

6.2.5 DNA binding studies performed using FID assays
The interactions between the four new nickel complexes and D2, parallel Q1
and parallel Q4 were also investigated using FID assays. Typical results obtained
from FID assays are presented in Figure 6.13, Figure S6.4 and Figure S4.4.
Experiments were performed until the addition of further nickel complex resulted in
no further displacement of TO from the DNA, as judged by the fluorescence of the
solution no longer changing significantly. The DC50 values obtained from
Stern-Volmer plots are presented in Table 6.8.[209, 210] The DC50 values obtained
from assays performed using D2 and parallel Q1 were generally smaller than those
derived from experiments carried out with parallel Q4. This may, as noted earlier,
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reflect differences in the affinity of TO for the different DNA sequences rather than
variations in binding affinities of the nickel complexes for the nucleic acids.

Figure 6.13 Results obtained from an FID assay performed using complex (73) and parallel
Q1. The Stern-Volmer plot derived from the results is shown in the inset.

Inspection of Table 6.8 suggests there was little difference in affinity between
the nickel complexes for parallel Q1. There were slightly greater differences between
DC50 values obtained from experiments performed using parallel Q4 and D2. The
largest DC50 value was obtained with Q4 and (73), suggesting it has the lowest
affinity for this G-quadruplex. This is consistent with the observation that (73) was
the only nickel complex that did not give rise to ions from non-covalent adducts in
ESI-MS experiments involving the nickel complexes and parallel Q4. The lowest
DC50 value obtained for experiments performed with Q4 was obtained with (75). This
suggests that (75) has a notable affinity for this G-quadruplex. Consistent with this
hypothesis, ions of low abundance from non-covalent adducts were observed in ESIMS experiments involving this nickel complex and Q4. In contrast, addition of (75)
did not result in large changes to the CD spectrum of this nucleic acid.
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Table 6.8 Results obtained from FID assays performed using different DNA molecules and
nickel complexes.
Complexes
(71)
(73)
(75)
(77)

Parallel Q1
0.30 ± 0.03
0.35 ± 0.01
0.43 ± 0.01
0.40 ± 0.02

DC50 (M)
Parallel Q4
0.75 ± 0.06
1.18 ± 0.05
0.58 ± 0.02
0.88 ± 0.04

DsDNA D2
0.29 ± 0.04
0.37 ± 0.04
0.51 ± 0.05
0.60 ± 0.05

6.2.6 DNA binding studies performed using molecular docking
Computational docking simulations were performed in order to investigate
binding interactions between different DNA and the metal complexes containing
different diamine groups. The experiments used Autodock Vina 1.1.2 software to
dock the structures of the nickel complexes onto a parallel unimolecular qDNA (PDB
ID: 1KF1) and a dsDNA (PDB ID: 1KBD). The results obtained from the docking
experiments are shown in Figure 6.14 and presented in Table 6.9. Figure 6.14
illustrates one potential binding mode generated from the top docking score for each
combination of nickel complex and DNA. Most of the nickel complexes preferred to
interact via -stacking interactions with the bottom G-tetrad of the parallel
unimolecular G-quadruplex. The one exception to this trend was (75), which instead
preferred to bind to the top G-tetrad. Figure 6.14 clearly shows that only two of the
four aromatic rings of the nickel complexes are orientated parallel to, and therefore
able to -stack with, the corresponding ring systems of the G-tetrads. The remaining
two benzene rings of the metal complexes were orientated perpendicular to the
square planar coordination sphere of the nickel ions, and therefore were not able to
participate in -stacking interactions with the G-tetrads.
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Figure 6.14 Results of molecular docking investigations performed using nickel complexes
with different diamine moieties and either qDNA 1KF1 (top row) or dsDNA 1KBD (bottom
row): (a) (71); (b) (73); (c) (75) and (d) (77).

At least one piperidine ring of each nickel complex is involved in intermolecular
interactions with the grooves formed from the TTA sequences. In the case of (77),
Figure 6.14 (d) shows that all three of its dimethylenepiperidine groups are involved
in binding interactions with different grooves of 1KF1. The nickel ions in each of the
complexes that preferred to interact with the bottom G-tetrad were not positioned
exactly above the centre of the G-quartet. In contrast, the only complex that
preferred to interact with the top G-tetrad, (75), had its nickel atom positioned almost
exactly above the centre of the four guanines.
Figure 6.14 also shows that the most favourable binding interactions for all four
nickel complexes with the dsDNA 1KBD involved the minor groove. In each case the
two dimethylenepiperidine moieties in the bottom half of the metal complexes, and
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the aromatic rings they are attached to, were positioned entirely within the minor
groove. In contrast, the remaining two benzene rings were orientated away from the
minor groove towards the solvent. The docking results are consistent with those
obtained from CD spectroscopic studies, which suggested the binding mode of the
nickel complexes with dsDNA was more likely to be groove binding than
intercalation.
Inspection of Table 6.9 shows that the minimum binding energies of the four
nickel complexes with the dsDNA 1KBD were distributed over a narrow range from
-8.5 to -9.4 kcal/mol. The largest binding energies were observed with complexes
(71) and (73), suggesting they have the strongest overall binding interactions with
1KBD. In contrast, complex (77) exhibited the lowest binding energy with the dsDNA
molecule. This may be a consequence of the additional side arm on this complex,
which could hinder the minor groove binding mode (Figure 6.14). The docking results
also showed that the minimum binding energies for the four nickel complexes with
the G-quadruplex 1KF1 were almost identical to each other. This is consistent with
the results presented in Figure 6.14, which show that each of the nickel complexes
orientate themselves in a very similar fashion onto either the top or bottom G-tetrad
of the G-quadruplex.
Table 6.9 Binding free energies obtained from docking studies performed using nickel
complexes with different diamine groups and either 1KF1 or 1KBD.
Nickel complex
(71)
(73)
(75)
(77)
a

qDNA 1KF1
Binding modes
G (kcal/mol)a
-8.82 ± 0.06
Bottom, groove
-8.88 ± 0.06
Bottom, groove
-8.80 ± 0.00
Top, groove
-8.84 ± 0.02
Bottom, groove

dsDNA 1KBD
Binding modes
G (kcal/mol)a
-9.4 ± 0.1
Minor groove
-9.4 ± 0.1
Minor groove
-8.7 ± 0.2
Minor groove
-8.5 ± 0.1
Minor groove

Average values of G with standard errors were obtained from the top five docking scores.
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6.3 Summary
The results obtained from experiments presented in this chapter suggest that
complexes (71), (73), (75) and (77) probably only interact in a relatively weak fashion
with each of the different types of DNA examined. This conclusion is supported by
the absence of ions of medium or high abundance from non-covalent adducts in ESI
mass spectra, the lack of significant changes to the CD spectra of D2, parallel Q1 or
parallel Q4 in most cases after addition of the nickel complexes, and the relatively
small binding constants measured for their interactions with CT-DNA. In the case of
D2, the reduction in Tm observed for the nucleic acid when each of the nickel
complexes was added provides further evidence that binding interactions are weak
and/or have a destabilising effect. Comparison of the results obtained from FRET
studies with those obtained previously for related nickel Schiff base complexes is
also consistent with the general conclusion that binding interactions involving these
four new complexes and each of the different types of DNA are relatively weak.
The results of molecular docking studies revealed that all four nickel complexes
interact with dsDNA primarily via minor groove binding. This conclusion is supported
by the results obtained from CD and UV-Vis spectroscopic studies, as larger
changes to the CD spectra of DNA or the absorption spectra of the nickel complexes
would have been expected if the latter were interacting via an intercalating binding
mode. Furthermore the results obtained from molecular docking studies also exclude
intercalation as a binding mode, and instead indicate minor groove binding occurs
with dsDNA, whilst binding between the nickel complexes and parallel unimolecular
qDNA involve -stacking interactions with either the top or bottom G-tetrads of the Gquadruplex.
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Chapter 7 : Effect of introducing asymmetry on
DNA binding properties
7.1 Introduction and scope
Metal complexes of asymmetric Schiff base ligands have been reported to
exhibit structures in which the square planar coordination sphere of the metal ion is
deformed, as well as unusual electronic properties.[255, 256] Metal complexes with
geometries other than square planar have generally been found to not bind as
effectively to G-quadruplexes, as a result of a diminished capacity to participate in stacking interactions with G-tetrads. To investigate this further, several asymmetric
nickel complexes illustrated in Figure 7.1 were prepared, and their binding
interactions with different DNA molecules explored. The asymmetry in these
complexes stems from differences in number and location of aromatic rings, as well
as the number of pendant groups.
DNA binding studies were performed using dsDNA and different G-quadruplex
DNA molecules, and the same techniques discussed in previous chapters. The
results obtained from experiments performed using (87) were discussed previously
in Chapter 4, but are included here again for comparison purposes. Also included
here are DNA binding results obtained using another asymmetric complex, (96). The
interaction of (96) with D2, parallel Q1 and parallel Q4 have been examined
previously by a number of techniques.[58, 128] Many of these experiments were
repeated here, and a number of additional investigations undertaken using other
techniques and/or different DNA molecules, in an attempt to more deeply understand
the effects of asymmetry on DNA binding properties.
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Figure 7.1 Structures of asymmetric nickel Schiff base complexes.

7.2 Results and discussion
7.2.1 DNA binding studies performed using ESI mass spectrometry
The DNA binding properties of the asymmetric nickel Schiff base complexes
were first investigated using negative ion ESI-MS, and solutions that contained Q4,
Q1 or D2. Previously, ESI-MS and CD spectroscopy were used to examine the
binding of (96) to D2, parallel Q1 and parallel Q4.[58, 128] CD spectroscopy showed
that Q1 and Q4 were present in the parallel topology under the conditions used for
performing the ESI-MS experiments. The relative abundances of ions from free DNA
and non-covalent ions in mass spectra of solutions containing a 3:1 ratio of Ni:DNA
are shown in Figure 7.2.
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Figure 7.2 Relative abundances of ions in ESI mass spectra of solutions containing a 3:1
ratio of asymmetric nickel Schiff base complexes and dsDNA (D2), unimolecular qDNA (Q1)
or tetramolecular qDNA (Q4): (a) solutions containing (87); (b) solutions containing (91); (c)
solutions containing (93); (d) solutions containing (95) and (e) solutions containing (96). The
results of D2 shown in part (e) were obtained from references [58] and [128].

Inspection of Figure 7.2 shows that none of the solutions containing (87)
afforded mass spectra containing ions of significant abundance from non-covalent
complexes. This suggests that the structure of (87), which is the only nickel complex
that contains one pendant group, and four aromatic rings arranged in a rectangular
fashion around the nickel ion, is not suitable for interacting with dsDNA or
G-quadruplex DNA. This may be due in part to (87) not being able to participate in
strong electrostatic interactions with either type of DNA, owing to the presence of
only one protonatable pendant group. In addition, the results of a molecular docking
study performed with (87) and the unimolecular G-quadruplex 1KF1, showed that the
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two top aromatic rings of the nickel complex were not able to participate in effective
-stacking interactions with a G-tetrad (Chapter 4.2.6).
In contrast to what was observed with (87), complex (91) was able to
participate in non-covalent complex formation to a limited extent with Q1, and to a
greater extent with Q4. In the case of the latter DNA molecule, ions from both
{Q4 + (91)} and {Q4 + 2 (91)} were observed in the ESI mass spectrum of a solution
containing a 3:1 ratio of Ni:DNA. The structure of (91) differs from that of (87) in
lacking one of the two top aromatic rings that were not positioned favourably in the
former complex for -stacking interactions with G-tetrads. Therefore, the results of
the ESI-MS experiments provide further evidence of the importance of structure in
determining the

nature

and

strength of

overall binding interactions with

G-quadruplexes.
It was hoped that (93) might exhibit improved DNA binding properties relative to
(91), by virtue of having a naphthyl moiety in the bottom right-hand corner of the
molecule instead of a single aromatic ring. Inspection of Figure 7.2 shows that this
did not turn out to be the case, as the relative abundances of ions from {Q4 + (93)}
and {Q4 + 2 (93)} were not greater than what was observed for the corresponding
system involving (91). Furthermore, there was also no evidence in the mass spectral
results of (91) interacting with D2 to form non-covalent complexes. Therefore, it
appears that the naphthyl moiety does not result in additional interactions that lead to
more extensive non-covalent complex formation with any type of DNA. The literature
complex (96), which also contains a naphthyl moiety in a similar position, was also
shown previously to not interact strongly with any of these three DNA molecules
(Figure 7.2 (e)).[58, 128]
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The only complex to show any evidence of significant formation of non-covalent
complexes was (95). Figure 7.2 (d) shows that the abundances of ions from both
{Q4 + (95)} and {Q4 + 2 (95)} were greater than that of ions from free Q4. In contrast,
the relative abundances of ions from non-covalent complexes containing (95) and
either Q1 or D2 were again low. This suggests that (95) may also exhibit some
selectivity in its DNA binding interactions. One possible contributing factor to the
greater affinity of (95) for Q4, compared to all other asymmetric nickel complexes, is
that it is the only one to have two protonatable pendant groups. Electrostatic forces
may therefore play a significant role in determining the strength of binding
interactions with Q4 in particular.
The relative abundances of ions observed in ESI mass spectra of solutions
containing a 6:1 ratio of the asymmetric nickel Schiff base complexes and the
different DNA molecules are presented in Figure S7.1. Comparison with Figure 7.2
shows that the same trends in binding affinity were observed with solutions
containing the higher Ni:DNA ratio. This includes none of the nickel complexes
showing the ability to form non-covalent complexes with D2 to a significant extent,
with the exception of (95). It should be noted, however, that the relative abundance
of ions form free D2 were still greater than that from {D2 + (95)} and {D2 + 2 (95)} in
the mass spectrum of the 6:1 solution. Complex (95) also showed the greatest ability
to interact with the other two types of DNA in solutions with a Ni:DNA ratio of 6:1. Not
surprisingly, ions attributable to non-covalent complexes containing (95) and Q4
were once again of higher overall relative abundance than those from free DNA.
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7.2.2 DNA binding studies performed using CD spectroscopy
7.2.2.1 CD titrations using parallel tetramolecular Q4
The results presented in the previous section suggest that (95) is the only
asymmetric nickel complex with a significant affinity towards Q4. To investigate this
hypothesis further, the interactions between all five asymmetric nickel complexes
and Q4 was also investigated using CD spectroscopy. The effects of increasing
concentrations of nickel complexes on the CD spectrum of parallel Q4 are shown in
Figure 7.3, and summarised in Table 7.1. The results obtained using solutions
containing (87) were presented in Chapter 4.2.2.1, but are also included here to
facilitate analysis of the effects of different asymmetric structures on the nature and
strength of binding interactions.
Addition of complexes (91), (93) and (95) all affected the CD spectrum of Q4 in
the same manner, and to a moderate extent. For example, each of these complexes
caused a maximum decrease of 22 – 24 % in ellipticity for the positive CD band at
263 nm (Table 7.1). In contrast, the effects of (87) and (96) on the CD spectrum of
the nucleic acid were negligible, with maximum decreases in ellipticity for the same
CD band of only 4 – 6 %. The absence of any large changes to the CD spectrum of
Q4 is consistent with the results of the ESI-MS investigation, which suggested that
most of the nickel complexes do not have a strong tendency to form non-covalent
complexes.
In the case of complex (95), however, there is disagreement between
conclusions based on the two different physical techniques. It was suggested in
Chapter 7.2.1 that (95) may have a greater ability than the other asymmetric nickel
complexes to form non-covalent complexes with Q4. It was proposed that this may
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be because of the greater overall positive charge of (95), which would enable it to
bind more strongly to DNA via an electrostatic mechanism. Such a binding
interaction may not, however, lead to distortions of the DNA structure that
significantly affect its chirality. Therefore, addition of (95) may not necessarily lead to
large changes to the CD spectrum of Q4.

(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 7.3 CD spectra of solutions containing different ratios of asymmetric nickel Schiff
base complexes and parallel Q4: (a) Q4 + (87); (b) Q4 + (91); (c) Q4 + (93); (d) Q4 + (95)
and (e) Q4 + (96). The HT voltage observed during the course of obtaining the CD spectra
illustrated in Fig 7.3 b, c, d, e exceeded 400 V, at wavelengths < 215 nm.
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Table 7.1 Effect of addition of asymmetric nickel Schiff base complexes on the CD spectrum
of parallel Q4.
Complexes
(87)
(91)
(93)
(95)
(96)

Negative CD band at 242 nm
max (nm)*
(%)*
0.1
8
-1.9
29
-1.6
32
-1.1
24
0.6
7

Positive CD band at 263 nm
max (nm)*
(%)
0.1
-6
-0.6
-22
-0.1
-24
-0.7
-22
-0.4
-4

*max and (%) were calculated using solutions containing free Q4 alone, and solutions containing a
9:1 ratio of asymmetric nickel Schiff base complex and Q4.

7.2.2.2 CD titrations using parallel unimolecular Q1
The results of ESI-MS investigations were consistent with the conclusion that
the asymmetric nickel complexes either interacted only weakly with parallel Q1, or
formed non-covalent complexes with the nucleic acid that were too fragile to survive
the ESI process. In contrast, the results of CD studies involving the nickel complexes
and Q1 (Figure 7.4) suggest that there is a significant interaction in most instances.
This conclusion is supported by substantial decreases in ellipticity of between 35 and
55 % for the large, positive CD band at 263 nm, as well as comparable or even more
significant changes in ellipticity for the smaller, negative CD band at 241 nm (Table
7.2).
Table 7.2 Effect of addition of asymmetric nickel Schiff base complexes on the CD spectrum
of parallel unimolecular Q1.
Complexes
(87)
(91)
(93)
(95)
(96)

Negative CD band at 241 nm
max (nm)*
(%)*
-1.6
58
-0.4
39
1.7
87
1.6
63
-0.4
52

Positive CD band at 263 nm
max (nm)*
(%)*
-1
-36
-0.3
-39
-2.9
-55
-0.4
-38
-1.3
-50

*max and (%) were calculated using solutions containing free Q1 alone, and solutions containing a
9:1 ratio of asymmetric nickel Schiff base complex and Q1.
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(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 7.4 CD spectra of solutions containing different ratios of asymmetric nickel Schiff
base complexes and parallel Q1: (a) Q1 + (87); (b) Q1 + (91); (c) Q1 + (93); (d) Q1 + (95)
and (e) Q1 + (96). The HT voltage observed during the course of obtaining all the CD
spectra illustrated here exceeded 400 V, at wavelengths < 215 nm.

It was also observed that the asymmetric nickel complexes generally had a
more substantial influence on the CD spectrum of Q1 than they did on the spectrum
of Q4. This was surprising because of the lower abundances of ions from
non-covalent complexes observed in ESI mass spectra of solutions containing the
unimolecular G-quadruplex. These results therefore provide yet another example
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where these two techniques yielded different conclusions regarding binding affinities,
probably as a result of their different sensitivities to factors such as: (a) thermal
stability of non-covalent complexes; and (b) changes to the chirality of the nucleic
acid. There are very few, if any, other examples in this thesis where all the nickel
complexes examined caused large changes to the CD spectrum of a specific nucleic
acid. This suggests that the asymmetric nickel complexes may be able to interact
with Q1 via a mechanism which results in significant distortions to the chirality of the
nucleic acid, but does not result in stable non-covalent complexes.
7.2.2.3 CD titrations using anti-parallel unimolecular Q1
In contrast to what was observed with parallel Q1, when this DNA molecule
was present in its anti-parallel topology, only two of the asymmetric nickel complexes
had a notable effect on its CD spectrum. Figure 7.5 shows that the addition of (95)
and (96) had significant, but different effects on the CD spectrum of anti-parallel Q1.
A significant change to the CD spectrum occurred when (96) was added in large
amounts, however, addition of smaller quantities only had a very minor effect, similar
to that elicited by the other nickel complexes. This therefore suggests that under
most circumstances (96) does not interact strongly with anti-parallel Q1 and/or
significantly affects its chiral characteristics.
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(a)

(b)

(c)

(d)

(e)

DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 7.5 CD spectra of solutions containing different ratios of asymmetric nickel Schiff
base complexes and anti-parallel Q1: (a) Q1 + (87); (b) Q1 + (91); (c) Q1 + (93); (d) Q1 +
(95) and (e) Q1 + (96). The HT voltage observed during the course of obtaining all the CD
spectra illustrated here exceeded 400 V, at wavelengths < 215 nm.

In contrast, addition of increasing amounts of (95) affected the CD spectrum of
anti-parallel Q1 in a regular fashion. At the highest Ni:DNA ratio examined, the nickel
complex resulted only in a 14% increase in ellipticity for the positive CD band at
196 nm (Table 7.3). Even more notable, however, was the 37% increase in ellipticity
of the negative CD band at 265 nm. Addition of (87), (91) or (93) resulted in
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negligible changes to the CD spectrum of anti-parallel Q1, as illustrated by increases
in ellipticity of only 2.5 – 5.4% for the positive CD band at 296 nm. Overall it appears
these three complexes exhibit some selectivity in their interactions with the parallel
and anti-parallel topologies of a unimolecular G-quadruplex. This was most evident
in the case of (93), which had the largest effect on the CD spectrum of parallel Q1,
but had an almost negligible influence on the corresponding spectrum of the
anti-parallel form of this nucleic acid.
Table 7.3 Effect of addition of asymmetric nickel Schiff base complexes on the CD spectrum
of anti-parallel Q1.
Complexes
(87)
(91)
(93)
(95)
(96)

Negative CD band at 265 nm
max (nm)*
(%)*
0.2
3
-0.2
9
-0.9
-4
-3.3
37
-2.5
63

Positive CD band at 296 nm
max (nm)*
(%)*
0.3
2
0.4
5
-1.1
6
-1.8
14
-1.2
-36

*max and (%) were calculated using solutions containing free Q1 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and Q1.

7.2.2.4 CD titrations using hybrid unimolecular Q1
Titration experiments were also performed with Q1 present in the hybrid
conformation, to see if any of the five asymmetric nickel complexes show the ability
to selectively modify the CD spectrum of this nucleic acid. The results of these
experiments are presented in Figure 7.6 and Table 7.4. Once again (95) had the
greatest effect on the CD spectrum, as was also found to be case with Q1 present in
the anti-parallel conformation. Addition of (91) resulted in changes to the CD
spectrum similar to those elicited by (95), whereas (87), (93) and (96) had almost no
effect. Comparison of the results presented here, with those shown earlier for
experiments performed with the parallel and anti-parallel topologies of Q1, suggest
(87) and (93) exhibit selectivity in their binding interactions in favour of the parallel
conformation over the other forms of this G-quadruplex.
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DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 7.6 CD spectra of solutions containing different ratios of asymmetric nickel Schiff
base complexes and hybrid Q1: (a) Q1 + (87); (b) Q1 + (91); (c) Q1 + (93); (d) Q1 + (95) and
(e) Q1 + (96).
Table 7.4 Effect of addition of asymmetric nickel Schiff base complexes on the CD spectrum
of hybrid Q1.
Complexes
(87)
(91)
(93)
(95)
(96)

Negative CD band at 234 nm
max (nm)*
(%)*
2.6
22
-4.2
152
-0.3
51
2.2
167
-0.8
43

Positive CD band at 291 nm
max (nm)*
(%)*
1.3
-1
1.1
-9
0.9
2
0.0
9
-1.9
5

*max and (%) were calculated using solutions containing free Q1 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and Q1.

258

7.2.2.5 CD titrations using parallel unimolecular c-kit1
The results of experiments presented earlier in this chapter indicated all of the
five asymmetric nickel complexes interacted with parallel Q1 in a way that resulted in
significant changes to the CD spectrum of the nucleic acid. Several of the nickel
complexes were also found to alter the CD spectra of the anti-parallel and hybrid
conformations of Q1. In contrast, addition of (87) or (93) to solutions of anti-parallel
or hybrid Q1 acid did not result in changes to the CD spectra of the nucleic acid.
These observations suggest the latter two nickel complexes interact with
unimolecular G-quadruplexes only when they are present in a parallel topology. In
order to explore this possibility further, CD titration experiments were also performed
using each of the asymmetric nickel complexes and the G-quadruplex c-kit1, which
had been annealed in order to ensure it adopts a parallel topology. The results of
these experiments are presented in Figure 7.7 and Table 7.5.
Table 7.5 Effect of addition of asymmetric nickel Schiff base complexes on the CD spectrum
of c-kit1.
Complexes
(87)
(91)
(93)
(95)
(96)

Negative CD band at 240 nm
max (nm)*
(%)*
0.0
61
-1.2
39
0.7
50
1.7
50
0.9
38

Positive CD band at 262 nm
max (nm)*
(%)*
-0.9
-39
-0.7
-20
-0.5
-32
1.2
-47
0.9
-24

*max and (%) were calculated using solutions containing free c-kit1 alone, and solutions
containing a 9:1 ratio of nickel Schiff base complex and c-kit1.

Inspection of the results obtained show that each of the asymmetric nickel
complexes interact with parallel c-kit1. These results, together with those presented
earlier in Chapter 7.2.2.2, therefore provide evidence that (87) and (93) are generally
selective in their unimolecular G-quadruplex DNA binding behaviour, with
interactions occurring more strongly with DNA molecules when present in a parallel
conformation.
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(a)

(b)

(c)

(d)
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DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 7.7 CD spectra of solutions containing different ratios of asymmetric nickel Schiff
base complexes and c-kit1: (a) c-kit1 + (87); (b) c-kit1 + (91); (c) c-kit1 + (93); (d) c-kit1 +
(95) and (e) c-kit1 + (96). The HT voltage observed during the course of obtaining all the CD
spectra illustrated here exceeded 400 V, at wavelengths < 215 nm.

Inspection of Table 7.5 also shows that addition of (95) resulted in the largest
changes to the CD spectrum of c-kit1. For example, when the ratio of (95):Q1 was
9:1, the ellipticity of the large, positive CD band at 262 nm had decreased by 47%.
The next biggest decrease in ellipticity of this CD band was 39%, caused by addition
of (87). In contrast, previous experiments in Chapter 7.2.2.2 showed that addition of
260

(95) resulted in smaller changes to the CD spectrum of parallel Q1, than those
elicited by either (93) or (96) (Figure 7.4). This comparison suggests that the
differences in structure between these nickel complexes are sometimes sufficient to
alter selectivity for one parallel, unimolecular G-quadruplex over another.
7.2.2.6 CD titrations using double stranded DNA D2
The results of ESI-MS experiments presented in Chapter 7.2.1 suggested that
all of the asymmetric nickel complexes have very low affinities towards the dsDNA
D2. In order to investigate this further, CD spectra were obtained of solutions
containing different ratios of the various asymmetric nickel complexes and D2. These
spectra are shown in Figure 7.8, whilst the changes in wavelength and maximum
ellipticity for the principal positive and negative CD bands are summarised in Table
7.6.
Of the asymmetric nickel complexes, only (95) produced significant changes to
the CD spectrum of D2 when added to a solution of the nucleic acid. Even with this
nickel complex, the changes that were observed were not large in comparison to
those observed with some other DNA molecules. For example, the ellipticities of the
major negative and positive CD bands at 248 and 282 nm only changed by 37% and
-16%, respectively (Table 7.6). This result is therefore generally consistent with that
obtained from the ESI-MS experiments. The latter showed (95) was the only nickel
complex to form non-covalent complexes with D2 that could be detected by this
technique, but the abundances of ions from {D2 + (95)} were very small. It is possible
that this greater, albeit still quite low, affinity of (95) towards D2 could be due to it
being the only nickel complex with two pendant groups.
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(a)

(b)

(c)

(d)
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DNA alone

Ni:DNA 1:1

Ni:DNA 3:1

Ni:DNA 6:1

Ni:DNA 9:1

Figure 7.8 CD spectra of solutions containing different ratios of asymmetric nickel Schiff
base complexes and D2: (a) D2 + (87); (b) D2 + (91); (c) D2 + (93); (d) D2 + (95) and
(e) D2 + (96). The HT voltage observed during the course of obtaining the CD spectra
illustrated in Fig 7.8 (d) exceeded 400 V, at wavelengths < 215 nm.

Each of the other four asymmetric nickel complexes had a negligible effect on
the CD spectrum of D2, even at high Ni:D2 ratios. These results are also consistent
with those obtained from the earlier ESI-MS experiments, which showed that none of
these nickel complexes were able to form non-covalent complexes in detectable
amounts. The generally low affinities of these nickel complexes towards D2 is a
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potentially useful characteristic, if they also exhibit the ability to bind to one or more
types of G-quadruplex structure to a significant extent.
Table 7.6 Effect of addition of asymmetric nickel Schiff base complexes on the CD spectrum
of dsDNA D2.
Complexes
(87)
(91)
(93)
(95)
(96)

Negative CD band at 248 nm
max (nm)*
(%)*
0.0
4
0.0
4
-0.7
11
-1.0
37
1.0
1

Positive CD band at 282 nm
max (nm)*
(%)*
0.0
-9
0.4
-3
-1.1
1
-1.6
-16
1.0
-11

*max and (%) were calculated using solutions containing free D2 alone, and solutions containing a
9:1 ratio of nickel Schiff base complex and D2.

7.2.3

DNA

binding

studies

performed

using

UV-Vis

spectrophotometry
7.2.3.1 Absorption titration method
In order to further explore the strength of binding interactions between the
asymmetric nickel complexes and dsDNA, UV-Vis absorption titrations were
conducted using CT-DNA in order to afford overall binding constants. These
experiments were performed in triplicate following the procedures described in
Chapter 2.6.1. A typical set of results obtained using complex (91) is presented in
Figure 7.9, S7.3, whereas those for the other complexes are shown in Figure S7.2,
S7.3, S4.2 and S4.3. The wavelength of maximum absorption for the MLCT bands of
(87), (91) and (95) were centred at ca. 380 nm, whereas those for complexes
containing a naphthyl moiety ((93) and (96)) appeared at lower energies (360 and
375 nm, respectively). Addition of CT-DNA to solutions containing the asymmetric
nickel complexes resulted in hypochromicity for the MLCT bands of all nickel
complexes, which was then used to determine the binding constants presented in
Table 7.7.
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Figure 7.9 Effect of addition of 3 mM CT-DNA on the absorption spectrum of 20 M (91).
The arrows indicate the direction of change in absorbance upon adding CT-DNA, while the
inset shows the resulting binding isotherm.

Inspection of the binding constants reveals each of them to be smaller than
values obtained for other metal complexes capable of interacting with dsDNA via an
intercalative mechanism. For example, the binding constant for interaction of
[Ru(phen)2(dppz)]2+ and

[Ru(bpy)2(dppz)]2+ with CT-DNA has been previously

reported to be larger than 106 M-1.[254, 257, 258] The binding constants reported
here are consistent with the results obtained from binding experiments performed
using either ESI-MS or CD spectroscopy and solutions containing D2, which also
indicated that each of the asymmetric nickel complexes has a relatively low affinity
towards dsDNA.
The largest binding constant was derived using data obtained from experiments
performed with (96). However, the binding constant obtained for this complex
(12.2 ± 2.1 x 104 M-1) is not much larger than those for the other asymmetric nickel
complexes. Therefore, it was not possible to draw meaningful comparisons with
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binding affinity series derived from the earlier ESI-MS and CD experiments
performed using solutions that contained D2 instead of CT-DNA. Such comparisons
are also not meaningful because of the small changes to the CD spectrum of D2
observed in most cases, as well as the low abundances of ions from non-covalent
complexes measured in ESI mass spectra.
Table 7.7 Results obtained from absorption titration experiments performed using
asymmetric nickel Schiff base complexes and CT-DNA.
Complexes
(87)
(91)
(93)
(95)
(96)

max for
max for
MLCT
MLCT
band (nm) band (nm)
382.2
-4.7
385
-1.1
360.2
0.0
381.5
0.3
374.8
6.5

Extinction coefficient
of complexes (A ×
104 (M-1 cm-1))
0.7 ± 0.2
0.7 ± 0.1
0.9 ± 0.2
0.6 ± 0.1
0.7 ± 0.1

a

A for
Mean binding
MLCT
constant (Kb
4
-1 a
band (%) × 10 (M ))
-47.3
6.7 ± 0.1
-48.1
9.4 ± 0.1
-60.4
2.9 ± 0.1
-33.4
4.8 ± 0.1
-48.8
12.2 ± 2.1

-1

Mean binding constants (units = M(base pairs) ) were obtained from three absorption titration
experiments, and are presented here together with standard errors.

7.2.3.2 DNA melting studies
The interactions between the asymmetric nickel complexes and dsDNA were
investigated

further

by

performing

melting

experiments

using

absorption

spectrophotometry and solutions containing D2. The results of these experiments
are presented in Figure 7.10, and show that all complexes caused either a decrease
or very small increase in Tm. This indicates that the majority of the asymmetric nickel
complexes either interact weakly with D2, or in a manner which results in its
destabilisation. These results are therefore consistent with those obtained from ESIMS, CD and UV-Vis titration experiments, all of which suggest that this group of
complexes interact weakly with dsDNA. The two complexes which resulted in the
least destabilisation of D2 were those containing naphthaldehyde moieties, (93) and
(96).
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Figure 7.10 Effect of addition of asymmetric nickel Schiff base complexes on the melting
temperature, Tm, of D2. The experiments were performed in triplicate with the error bars
presenting standard errors. For each nickel complex the left hand value of Tm was obtained
from a solution containing a 3:1 ratio of Ni:D2. The right hand values were obtained from
solutions containing a 6:1 ratio of Ni:D2.

7.2.4 DNA binding studies performed using FRET melting assays
One of the most widely used techniques for obtaining information about
interactions between small molecules and DNA is the FRET melting assay.[127, 128,
174] Therefore it was decided to perform a series of FRET assays using the
fluorescently labelled oligonucleotide F21T, which had been shown previously by
NMR studies to adopt an anti-parallel structure under the experimental conditions
used.[244] The results obtained from FRET melting assays involving solutions
containing F21T and the different asymmetric nickel complexes are shown in Figure
7.11. The results reported here for complex (96) were obtained from a previous
study [58, 128] and are included here for comparison. Examination of the data shows
that all of the four new nickel complexes had only a small effect on the thermal
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stability of F21T, with complex (95), featuring two pendant groups, producing the
largest Tm of 18.4 °C when the concentration of the nickel complex was 10 M. In
contrast, the other new asymmetric nickel complexes, all of which only have one
pendant group, increased Tm by between 5.5 and 8.3 °C. Complex (95) was shown
previously to result in the greatest changes to the CD spectrum of anti-parallel Q1
(Figure 7.5).
The results of FRET melting results performed previously using solutions
containing F21T and (96) gave a maximum Tm of 31.9 °C when the concentration of
the nickel complex was 10 M.[128] This value of Tm is significantly higher than
those obtained with the new asymmetric complexes prepared as part of this thesis,
and consistent with the strong effect (96) had on the CD spectrum of Q1 (Figure 7.5)
when it was present in the same anti-parallel conformation as the F21T used in the
FRET experiments.
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Figure 7.11 Effect of different concentrations of asymmetric nickel complexes on Tm of
F21T measured by a FRET assay. The experiments were repeated six times with the error
bars showing standard errors. The results presented here for complex (96) were obtained
from references [58] and [128].
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7.2.5 DNA binding studies performed using FID assays
A series of FID assays was performed in order to provide further information
about the interactions between the new asymmetric nickel complexes and both
dsDNA and G-quadruplexes. A representative set of results obtained using (91) and
parallel Q1 is shown in Figure 7.12. Raw results obtained from experiments
performed with other asymmetric nickel complexes and Q1 are shown in Figure S7.3
and Figure S4.4 (b). A summary of the DC50 values obtained from these assays is
presented in Table 7.8. Experiments were not performed using the literature complex
(96) and any of the DNA molecules, and these experiments had not been performed
previously.

Figure 7.12 Results obtained from an FID assay performed using complex (91) and parallel
Q1. The Stern-Volmer plot derived from the results is shown in the inset.
Table 7.8 Results obtained from FID assays performed using different DNA molecules and
asymmetric nickel Schiff base complexes.
Complexes
(87)
(91)
(93)
(95)

Parallel Q1
0.35 ± 0.02
0.31 ± 0.02
0.36 ± 0.02
0.38 ± 0.02

DC50 (M)
Parallel Q4
0.88 ± 0.06
0.80 ± 0.08
0.38 ± 0.03
0.71 ± 0.05

DsDNA D2
0.34 ± 0.05
0.38 ± 0.04
0.43 ± 0.06
0.53 ± 0.02
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Of the four new asymmetric nickel complexes, (93) showed the smallest DC50
value in experiments performed with parallel Q4. This result suggests that (93)
interacts more strongly than any of the other nickel complexes with Q4. This result is
therefore at odds with that obtained from an ESI-MS study involving the nickel
complexes and Q4, which showed that (95) resulted in the most extensive formation
of non-covalent complexes. However, it is consistent with the results of CD titration
experiments performed using the same systems. The DC50 values obtained for the
four nickel complexes and both parallel Q1 and D2 were distributed over very narrow
ranges, indicating that they had very similar affinities for both of these types of DNA
molecules.

7.2.6 DNA binding studies performed using molecular docking
Owing to the unique structures of the asymmetric nickel complexes, it was
expected that they might participate in different binding modes with DNA to those
used by the nickel complexes discussed previously. In order to investigate this
hypothesis, molecular docking simulations were performed using each of the
asymmetric nickel complexes, and both a G-quadruplex DNA (PDB ID: 1KF1) and a
dsDNA (PDB ID: 1KBD). Figure 7.13 displays one binding mode corresponding to
the top docking score for each combination of binding partners, while Table 7.9
summarises the minimum binding energies for each system.
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Figure 7.13 Results of molecular docking investigations performed using asymmetric nickel
complexes and either qDNA 1KF1 (top row) or dsDNA 1KBD (bottom row): (a) (87); (b) (91);
(c) (93); (d) (95) and (e) (96).

Figure 7.13 shows the nickel complexes participate in a wide range of binding
interactions with the G-quadruplex. In no instances, however, was the complex
positioned so that the nickel ion was located above the centre of a G-tetrad. The
result obtained for (87) was discussed previously (Chapter 4.2.6), and differs
significantly from that seen with most of the other complexes in Figure 7.13. The two
complexes containing only three aromatic rings, (91) and (95), showed little evidence
of -stacking interactions, and instead interacted with 1KF1 via some of the grooves
and loops (numbers 2 and 3). In contrast, the two complexes containing naphthyl
moieties, (93) and (96), can be seen to bind to the G-quadruplex by both groove/loop
binding modes and -stacking. The extent of -stacking appeared to be most
extensive with (96), which suggests that the phenylenediamine moiety may confer an
advantage in binding to this type of DNA molecule. In the case of docking studies
performed with dsDNA, all asymmetric complexes preferred to bind to the minor
groove. This may account for the similar results obtained in binding investigations
conducted using each of the other techniques discussed earlier in this chapter.
270

Inspection of Table 7.9 shows that the minimum binding free energies were
distributed over very narrow ranges of values with both types of DNA. In the case of
the G-quadruplex 1KF1, complex (96) produced the largest binding free energy. This
perhaps reflects the greater degree of overlap between aromatic systems in this
nickel complex and G-quadruplex, noted above. The results of docking studies
performed with the dsDNA 1KDB showed that the minimum binding free energies
varied from -8.7 to just -9.5 kcal/mol. This is consistent with the results obtained from
the various spectroscopic techniques presented earlier in this chapter, which suggest
that none of the asymmetric nickel complexes exhibit a strong affinity towards
dsDNA. The largest value of binding free energy obtained from docking studies
performed with 1KBD was observed with (96). Results obtained from UV-Vis
titrations and absorption spectrophotometry melting experiments suggested this
complex may exhibit a slightly higher binding affinity towards dsDNA than the other
asymmetric nickel complexes.
Table 7.9 Binding free energies obtained from docking studies performed using asymmetric
nickel Schiff base complexes and either 1KF1 or 1KBD.
Complexes
(87)
(91)
(93)
(95)
(96)
a

qDNA 1KF1
Binding modes
G (kcal/mol)a
-8.4 ± 0.1
Top, groove
-9.1 ± 0.1
Bottom, groove
-8.9 ± 0.1
Bottom, groove
-8.7 ± 0.1
Bottom, groove
-9.9 ± 0.1
Top, groove

dsDNA 1KBD
Binding modes
G (kcal/mol)a
-8.7 ± 0.0
Minor groove
-8.7 ± 0.0
Minor groove
-9.3 ± 0.1
Minor groove
-9.0 ± 0.2
Minor groove
-9.5 ± 0.1
Minor groove

Average values of G with standard errors obtained from top five docking scores.

7.3 Summary
The results presented in this chapter show that in general the asymmetric
nickel Schiff base complexes do not interact strongly with any of the DNA molecules
investigated. Complex (95) showed a greater ability than any of the other nickel
complexes to form non-covalent complexes with Q4 in ESI-MS experiments. This
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result suggests that the number of pendant groups may play a role in determining
the strength of interactions with some classes of DNA molecules, however
supporting evidence was not obtained from experiments conducted using any of the
other techniques.
Upon addition of the nickel complexes, the CD spectra of the various DNA
molecules examined in general showed relatively small changes. These results,
along with those obtained from FID assays, all point to this particular class of nickel
molecules not having the appropriate combination of structural features to endow
them with high affinity or selectivity for any of the types of DNA examined. This
conclusion is supported by the results of experiments performed using absorption
spectrophotometry to investigate binding to dsDNA, and is also supported by the
results of molecular docking experiments performed with a G-quadruplex, none of
which showed any of the nickel complexes binding in a manner that would be
expected to result in strong binding interactions.
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Chapter 8 : Conclusions and future directions
8.1 Conclusions
The overall objective of this project was to prepare new nickel Schiff base
complexes with high affinity and selectivity towards G-quadruplex DNA. In order to
achieve this aim, the structures of the nickel complexes were systematically varied,
in order to ascertain which molecular features had the most impact on the DNA
binding characteristics of this new class of complexes. This included varying the
diamine groups used in the condensation reactions to produce the Schiff base
scaffold, as well as changing the number and positions of pendant groups around its
periphery. In addition, the effects of introducing asymmetry into the structure of the
nickel complex on its binding properties were also examined. Overall, during the
course of this project, a total of twenty-six novel nickel Schiff base complexes were
prepared. Half of these complexes contained at least one pendant group designed to
enhance solubility in water, as well as facilitate polar binding interactions with nucleic
acid molecules. All complexes were fully characterised by NMR spectroscopy,
ESI-MS and microanalysis. In addition, the solid state structures of eight nickel
complexes were determined using X-ray crystallography.
The solid state structures of the complexes revealed that in each case there
was a square planar coordination geometry around the nickel ion. In most cases, the
O-Ni-N bond angles, coplanar angles, Ni–O and Ni–N bond distances were close to
standard or expected values.[126, 127] This was not entirely true, however, in the
case of complex (75), which showed the coplanar angles of ring A/B and A/C to be
24.9° and 15.8°, respectively, whereas these two values for other complexes were
distributed over the ranges 5.6° – 15.9° and 1.6° – 4.5°, respectively. This may be
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attributable to the use of diamines during their preparation which lead to a sixmembered chelate ring in (75), as opposed to five-membered rings in all remaining
complexes. This difference in the structure of (75) may also be the reason why it
exhibited an atypical green colour. One of the most important aspects of the solid
state structures of most, if not all of the nickel complexes, was that the aromatic ring
systems in the top half of the molecule were not co-planar with those in the bottom
halves. It is possible that in many cases this structural feature may have inhibited the
ability of nickel complexes to interact extensively with either dsDNA or G-quadruplex
DNA, despite there being free rotation around the C–C bonds linking the pendant
groups to the remainder of the Schiff base ligand. However, the strong binding
properties exhibited by (89) with different G-quadruplex molecules suggested that
this structural feature was not always retained in solution. This was confirmed by a
molecular docking study performed using (89) and 1KF1, which showed all four
aromatic ring systems lying roughly co-planar with each other, and participating in
effective -stacking interactions with a G-tetrad of the G-quadruplex.
The DNA binding properties of novel nickel complexes containing pendant
groups were investigated using a variety of different spectroscopic techniques and
molecular docking simulations. Very little evidence was obtained for significant
binding interactions between any of the nickel complexes and dsDNA. This suggests
that the basic structural features in these complexes are not conducive to
intercalative or strong groove binding interactions with this type of nucleic acid
molecule. This highlighted the potential for obtaining selective G-quadruplex binding
agents amongst the type of complexes investigated, if structural features could be
incorporated which magnified affinity towards G-quadruplex DNA, whilst not affecting
the ability to interact with more common duplex form of the nucleic acid. The results
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of molecular docking studies showed that the ability of the pendant groups to
participate in electrostatic interactions with the grooves and loops of G-quadruplex
DNA may have contributed to the excellent binding results obtained in binding
experiments performed using (89).
The importance of the pendant groups was also highlighted by the results of
binding studies conducted using various spectroscopic techniques that were
presented in Chapter 4. For example, complex (87), containing only one pendant
group, exhibited a negligible ability to interact with any G-quadruplex molecule,
according to the wide range spectroscopic techniques used. In contrast, complex
(89), which features four pendant groups, showed evidence of significant interactions
towards different kinds of G-quadruplex DNA, including the tetramolecular Q4,
parallel unimolecular Q1, c-kit1 and anti-parallel F21T. Most notably, the results of
ESI-MS experiments suggested that (89) interacts to the same extent or possibly
more extensively with Q4 than the well-known literature complex (54). In contrast,
the ability of (89) to interact with dsDNA D2 was significantly less than that of (54),
highlighting the potential of the former nickel complex. The low affinity of (89)
towards dsDNA may arise from steric hindrance owing to the presence of the four
pendant groups. This is supported by the results of molecular docking studies
involving (89) and 1KBD, which showed that unlike most of the other novel nickel
complexes, it could not bind to the minor groove of the nucleic acid.
Relative DNA binding affinities derived from spectroscopic techniques and
assays performed at room temperature, such as the measurement of binding
constants through UV-Vis spectrophotometry, CD spectroscopy and FID assays,
were generally consistent with each other. Similarly, results obtained from DNA
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binding experiments conducted using methods which are applied under more
energetic conditions, such as ESI-MS, UV-Vis and FRET melting assays, were in
general agreement with each other. In contrast, on some occasions the results of
DNA binding experiments performed using techniques from each of the above
groups gave somewhat conflicting views regarding the ability of the nickel complexes
to interact with a specific DNA molecule. For example, the results of ESI-MS
experiments showed that (71) and (89) only interacted to a limited extent with
parallel Q1 and dsDNA D2, respectively, whereas addition of these complexes had a
pronounced impact upon the CD spectra of these nucleic acid molecules. Results
such as these are most likely a result of the differing sensitivities of some of the DNA
binding techniques used to different aspects of the overall interaction, such as
whether or not it affects the chirality of the nucleic acid, or the nickel complex/DNA
adduct is sufficiently thermally stable to survive the ESI process.
Whilst increasing the number of pendant groups present in a nickel complex
had the biggest impact upon ability to interact with G-quadruplex DNA, varying the
location of pendant groups was also found to have an impact on some occasions.
For example, the results of CD titration studies indicated that (79), which has two
pendant groups in the top half of the molecule, had a strong impact on the CD
spectra of both h-telo and c-kit1 G-quadruplexes. In contrast, the isomeric
complexes (71) and (83) selectively caused a big impact on CD spectra of Gquadruplexes

containing

h-telo

and

c-kit1

sequences,

respectively.

These

observations suggest it may be possible to obtain different and/or greater selectivity
in DNA binding interactions, as well as high affinity, by preparing isomers of complex
(89) with the four pendant groups located in different positions.
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Small variations to the structure of the diamine moiety in the nickel complexes
sometimes had significant effects on interactions with both G-quadruplex DNA and
dsDNA. For example, the structure of (73) differs from that of (71) only in having a
methyl group in the diamine moiety. Despite this relative small change, in ESI-MS
experiments (73) showed an inability to form non-covalent adducts with Q4, whereas
(71) formed adducts with Q4 that gave rise to ions of medium abundance.
Importantly, slight changes to the shape and steric properties of the nickel
complexes resulting from modification of the diamine moiety also affected the ability
of the nickel complexes to interact with different topologies of unimolecular Gquadruplex DNA. For example, CD experiments showed that addition of (71)
resulted in large changes to the CD spectrum of Q1, but only when it was present in
the parallel topology. In contrast, addition of (73) or (75) resulted in much smaller
changes to the CD spectrum of this DNA molecule. This further demonstrates the
potential of this class of metal complexes as drug candidates which modify gene
expression levels through interacting with only a small number of G-quadruplex
structures amongst the numerous examples that are possible in living systems.
Of all the different types of structural changes made to the nickel complexes,
introducing asymmetry had perhaps the least significant effects on DNA binding
behaviour. The results of experiments performed with asymmetric nickel complexes
also provided further evidence for the crucial role that pendant groups can play in
determining the strength and nature of DNA binding interactions. For example, the
results of binding experiments performed using (95), which was the only asymmetric
complex examined which had two protonatable pendant groups, indicated that it
interacted more extensively with a variety of DNA molecules than any of the other
asymmetric complexes bearing just one pendant group.
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8.2 Future directions
The promising results obtained from DNA binding studies performed using (89)
highlighted the importance of pendant groups in determining the nature and strength
of binding interactions with G-quadruplex DNA. It would therefore appear desirable
to synthesise and examine the DNA binding properties of additional examples of
nickel complexes bearing at least three, or preferably four pendant groups, in
different locations around the periphery of the Schiff base core. However, the results
presented here also show that synthesising nickel complexes with more than two
pendant groups is generally more difficult than preparing molecules with a smaller
number of such groups. The reasons for this are still not fully understood, and so
further experiments should be conducted in order to try and develop more effective
synthetic pathways.
While the molecular docking experiments presented here did provide some
clues as to how the nickel complexes interact with different DNA molecules,
additional simulations are required in which the effects of temperature changes and
solvent molecules are also examined in order to gain a more complete
understanding. Molecular dynamics studies should be performed in order to obtain
this above additional data along with further information concerning interactions
between the nickel complexes and DNA.
Another important question that still needs to be answered is what effects on
DNA binding would occur if the nickel centre in the complexes described here were
replaced by other metal ions that typically exhibit rigorous square planar coordination
geometries, such as palladium(II), platinum(II) or gold(III). It is also worth to
investigate the DNA binding properties of the current Schiff base complexes
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containing different functional pendant groups such as those with longer chain
piperidine or with morpholine groups. There are many other types of pendant groups
that could be considered in this context, including amino acid and short peptides,
alkyl pyrrolidines, quaternary amines, and alkyl pyridinium moieties with different
length spacer groups. Furthermore, it is possibly that the additional flexibility created
by removing the nickel ion from these complexes may prove advantageous on some
occasions for endowing DNA binding selectivity. In preliminary investigations, the
free ligand corresponding to (71) has been prepared and was shown by ESI-MS
experiments to interact just as extensively, if not more so than the nickel complex,
with Q4.
While the experiments described in this thesis provide significant insight into
the relative strength of binding interactions, only the molecular modelling studies
offered any clues as to the nature of the binding interactions themselves. In order to
further our understanding of this area, it will be necessary to use 2D NMR
spectroscopic methods to determine the solution structure of nickel complex/DNA
adducts, or X-ray crystallographic techniques to obtain their solid state structures.
The results of ESI-MS experiments suggest a number of systems such as (89)/Q4
where specific adducts appear to form in relatively high proportions, which would be
suitable for these experiments. Future work with these and related series of nickel
complexes such as (97) – (101) (Figure 8.1) will gain additional momentum if
biological assays and other techniques demonstrate that they are able to enter cells,
and are cytotoxic.
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Figure 8.1 Some of novel nickel Schiff base complexes will be studied by Ralph’s group.
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Supplementary Figures
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H17

Figure S3.1 NOESY spectrum of (75), with the atom numbering scheme shown.
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Figure S3.2 TOCSY spectrum of (77), with the atom numbering scheme shown.
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Figure S3.3 TOCSY spectrum of (79), with the atom numbering scheme shown.
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Figure S3.4 COSY spectrum of (80), with the atom numbering scheme shown.
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Figure S3.5 TOCSY spectrum of (81), with the atom numbering scheme shown.

H29-31

H14,
H28,32
H19
H13

H11

H22
H12

H21

Figure S3.6 TOCSY spectrum of (83), with the atom numbering scheme shown.
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Figure S3.7 NOESY spectrum of (89), with the atom numbering scheme shown.
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Figure S3.8 TOCSY spectrum of (91), with the atom numbering scheme shown.
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H17
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Figure S3.9 NOESY spectrum of (93) with the atom numbering scheme shown.
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Figure S3.10 NOESY spectrum of (95), with the atom numbering scheme shown.
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Figure S4.1 Relative abundances of ions in ESI mass spectra of solutions containing a 6:1
ratio of nickel Schiff base complexes and dsDNA (D2), unimolecular qDNA (Q1) or
tetramolecular qDNA (Q4): (a) solutions containing (54); (b) solutions containing (87);
(c) solutions containing (71); (d) solutions containing (77) and (e) solutions containing (89).
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Figure S4.2 Effect of addition of 3 mM CT-DNA on the absorption spectra of 20 M nickel
Schiff base complexes: (a) complex (54); (b) complex (87); (c) complex (71) and (d) complex
(77). The arrows indicate the direction of change in absorbance upon adding CT-DNA, while
the insets show the binding isotherms derived from the absorption spectra.
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Figure S4.3 Selective binding isotherms of different nickel Schiff base complexes and 3 mM
CT-DNA: (a) complex (54); (b) complex (71); (c) complex (77), (d) complex (87) and (e)
complex (89).
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Figure S4.4 Results obtained from FID assays performed using different nickel complexes
and parallel Q1: (a) complex (54); (b) complex (87); (c) complex (71) and (d) complex (77).
The Stern-Volmer plots derived from the results are shown in the insets.
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Figure S5.1 Relative abundances of ions in ESI mass spectra of solutions containing a 6:1
ratio of isomeric nickel Schiff base complexes and dsDNA (D2), unimolecular qDNA (Q1) or
tetramolecular qDNA (Q4): (a) solutions containing (71); (b) solutions containing (79);
(c) solutions containing (81); (d) solutions containing (83) and (e) solutions containing (85).
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Figure S5.2 Effect of addition of 3 mM CT-DNA on the absorption spectra of solutions
containing 20 M nickel complex: (a) complex (79), (b) complex (81) and (c) complex (85).
The insets show the resulting binding isotherms, and the arrows indicate the direction of
change in absorbance upon addition of CT-DNA.
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Figure S5.3 Selective binding isotherms of different nickel Schiff base complexes and 3 mM
CT-DNA: (a) complex (79); (b) complex (81), (c) complex (83), and (d) complex (85).
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Figure S5.4 Results obtained from FRET melting assays performed using F21T and isomeric
nickel Schiff base complexes: (a) Complex (71); (b) Complex (79); (c) Complex (81);
(d) Complex (83) and (e) Complex (85).
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Figure S5.5 Results obtained from FID assays performed using different nickel Schiff base
complexes and parallel Q1: (a) complex (79), (b) complex (81) and (c) complex (85). The
Stern-Volmer plots derived from the results are shown in the insets.
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Figure S6.1 Relative abundances of ions in negative ion ESI mass spectra of solutions
containing a 6:1 ratio of different nickel Schiff base complexes and dsDNA (D2),
unimolecular qDNA (Q1) or tetramolecular qDNA (Q4): (a) solutions containing (71);
(b) solutions containing (73); (c) solutions containing (75) and (d) solutions containing (77).
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Figure S6.2 Effect of addition of 3 mM CT-DNA on the absorption spectrum of 20 M nickel
Schiff base complex (73). The insets show the resulting binding isotherms, and the arrows
indicate the direction of change in absorbance upon addition of CT-DNA.
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Figure S6.3 Selective binding isotherms of different nickel Schiff base complexes and 3 mM
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Figure S7.1 Relative abundances of ions in ESI mass spectra of solutions containing a 6:1
ratio of asymmetric nickel Schiff base complexes and dsDNA (D2), unimolecular qDNA (Q1)
or tetramolecular qDNA (Q4): (a) solutions containing (87); (b) solutions containing (91);
(c) solutions containing (93); (d) solutions containing (95) and (e) solutions containing (96).
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Figure S7.2 Effect of addition of 3 mM CT-DNA on the absorption spectra of 20 M
asymmetric nickel Schiff base complexes: (a) complex (93), (b) complex (95) and (c)
complex (96). The arrows indicate the direction of change in absorbance upon adding CTDNA, while the insets show the binding isotherms derived from the absorption spectra.
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Figure S7.3 Selective binding isotherms of different nickel Schiff base complexes and 3 mM
CT-DNA: (a) complex (91); (b) complex (93), (c) complex (95) and (d) complex (96).
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Figure S7.4 Results obtained from FID assays performed using different asymmetric nickel
Schiff base complexes and parallel Q1: (a) complex (93) and (b) complex (95). The SternVolmer plots derived from the results are shown in the insets.
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